KR20000069297A - Nucleic Acid and Amino Acid Sequences Relating to Helicobacter pylori and Vaccine Compositions thereof - Google Patents

Abstract

The present invention relates to recombinant or substantially pure preparations of Helicobacter pylori polypeptides. Also provided are nucleic acids encoding the polypeptides. Helicobacter pylori polypeptides are useful for diagnostic and vaccine compositions, and the figure depicts the amino acid sequence sequence of the five Helicobacter pilori proteins.

Description

Nucleic Acid and Amino Acid Sequences Relating to Helicobacter pylori and Vaccine Compositions according to Helicobacter Philoly

Helicobacter pylori is an S-type aerobic Gram-negative bacteria found and cultured from human gastrointestinal biopsy specimens (Warren, JR and B. Marshall, (1983) Lancet 1: 1273-1275: and Marshall et al., (1984) Microbios Lett. 25: 83-88). Helicobacter pylori is closely related to chronic gastritis and duodenal ulcer (Rathbone et al., (1986) Gut: 635-641). There is also increasing evidence of the etiological function of Helicobacter pylori on non-ulcer dyspepsia, gastric ulcer and gastric adenocarcinoma (Blaser M.J., (1993) Trends Microbiol. 1: 255-260). Bacteria are transmitted via the oral route, and the risk of infection increases with age (Taylor, D.N. and M.J. Blaser, (1991) Epidemiol. Rev 13: 42-50). Helicobacter pylori forms colonies in the human gastric mucosa, establishing infection that generally persists for decades. Infection with Helicobacter pylori is widespread worldwide. The infection rate in adults over 20 years of age in developed countries exceeds 50% and in adults over 90% in developing countries (Hopkins R. J. and J. G. Morris (1994) Am. J. Med. 97: 265-277).

Understanding of the bacterial factors necessary for colony formation and virulence of bacteria in the gastrointestinal environment is poor. Examples suspected of virulence factors include urease that can function to neutralize gastric acid pH (Eaton et al., (1991) Infect. Immunol. 59: 2470-2475; Ferrero, RL and A. Lee (1991) Microb. Ecol. Hlth. Dis. 4: 121-134; Labigne et al., (1991) J. Bacteriol. 173: 1920-1931); Bacterial flagella protein (Hazell et al., (1986) J. Inf. Dis 153: 658-663; Leying et al., (1992) Mol. Microbiol. 6: 2863-2874; And Haas et al. (1993) Mol. Microbiol. 8: 753-760); Bacterial toxin Vac A (Schmitt, W. and R. Haas, (1994) Molecular Microbiol. 12 (2): 307-319), which induces intracellular vacuole formation in epithelial cells; And several gastric tissue specific adhesions (Boren et al., (1993) Science 262: 1892-1895; Evans et al., (1993) J. Bacteriol. 175: 674-683; and Falk et al., 91993 ) Proc. Natl. Acad. Sci. USA 90: 2035-203).

Many therapies that eradicate in vitro Helicobacter pylori infection are currently available (Huesca et al., 91993) Zbl. Bakt. 280: 244-252; Hopkins, R.J. and J. G. Morris, supra. However, many of these therapeutic agents are not optimally effective due to bacterial resistance, modified drug distribution, patient non-compliance or poor drug tolerance (Hopkins, R. J. and J. G. Morris, supra). Treatment of antibiotics in combination with bismuth is part of standard therapies used to treat Helicobacter pylori infection (Malfertheiner, P. and J.E. Dominguez-Munoz (1993) Clinical Therapeutics 15 Supp. B: 37-48). Recently, a combination of proton pump inhibitors and single antibiotics has been found to improve duodenal ulceration (Malfertheiner, P. and J. E. Dominguez-Munoz supra). However, methods using antibiotics may have the problem of the emergence of bacterial strains resistant to these antibiotics (Hopkins, R. J. and J. G. Morris, supra). These limitations demonstrate that there is a need for new effective methods of eliminating the infection of Helicobacter pylori in the body. In particular, the design of a new vaccine that can suppress infection by the bacteria is very desirable.

Summary of the Invention

The present invention relates to novel genes, such as genes encoding polypeptides such as bacterial surface proteins from Helicobacter Philoly (H. philoly), and other related genes, their products and uses thereof. Nucleic acids and peptides of the present invention have utility as diagnostic and therapeutic agents for Helicobacter pylori and other Helicobacter species. In addition, they can be used for the detection of the presence of Helicobacter pilori and other Helicobacter species in a sample, and for the screening of compounds having the ability to interfere with or inhibit Helicobacter pilori infection cycles. More specifically, a composition of nucleic acids corresponding to the entire coding sequence of Helicobacter pylori protein, including a surface or secreted protein or a portion thereof, a nucleic acid capable of binding to mRNA of Helicobacter pylori protein and blocking protein translation, and peptide synthesis And methods for producing Helicobacter pylori protein or portions thereof using recombinant DNA technology. The invention also features antibodies and nucleic acids useful as probes for detecting Helicobacter pylori infection. Also included in the scope of the present invention are vaccine compositions and methods for the prevention or treatment of Helicobacter pylori infection.

FIG. 1 shows the amino acid sequence sequence of five Helicobacter pylori proteins (shown in single letter amino acid code, indicated by amino acid sequence number; N terminus on the left and C terminus on the right).

Figure 2 depicts the N-terminal portion of three Helicobacter pylori proteins (shown in single letter amino acid code, indicated by amino acid sequence number; N terminus on the left and C terminus on the right).

In one aspect, the invention features a recombinant or substantially pure preparation of a Helicobacter pylori polypeptide of SEQ ID NO: 98. The invention also encompasses substantially pure nucleic acids encoding the Helicobacter pylori polypeptide of SEQ ID NO: 98, eg, the sequences contained in SEQ ID NO: 1. Helicobacter phyllori polypeptide sequences of the invention are described in the Sequence Listing, and nucleic acids encoding Helicobacter phyllori of the invention are described in the Sequence Listing.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 99, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 2.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having an amino acid sequence of SEQ ID NO: 100, such as a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 3.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 101, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 4.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 102, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 5.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 103, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 6.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 104, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 7.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 105, such as a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 8.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 106, such as a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 9.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 107, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 10.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 108, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 11.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 109, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 12.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 110, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 13.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 111, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 14.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 112, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 15.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 113, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 16.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO. 114, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 115, such as a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 18.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 116, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 19.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 117, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 20.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 118, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 21.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 119, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 22.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 120, such as a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 23.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 121, such as a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 24.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 122, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 25.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 123, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 26.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pilori polypeptide having the amino acid sequence of SEQ ID NO: 124, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 27.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 125, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 28.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 126, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 29.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 127, such as a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 30.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having an amino acid sequence of SEQ ID NO: 128, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 31.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 129, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 32.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 130, such as a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 33.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 131, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 34.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 132, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 35.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 133, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 36.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 134, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 37.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 135, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 38.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 136, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 39.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 137, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 40.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 138, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 41.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 139, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 42.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 140, such as a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 43.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 141, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 44.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 142, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 45.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 143, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 46.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter Philoly polypeptide having the amino acid sequence of SEQ ID NO: 144, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 47.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 145, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 48.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 146, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 49.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 147, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 50.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 148, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 51.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 149, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 52.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 150, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 53.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 151, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 54.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 152, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 55.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 153, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 56.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter Philoly polypeptide having an amino acid sequence of SEQ ID NO: 154, eg, a nucleic acid comprising a SEQ ID NO: 57 nucleotide sequence.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter Philoly polypeptide having an amino acid sequence of SEQ ID NO: 155, eg, a nucleic acid comprising a SEQ ID NO: 58 nucleotide sequence.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter Philoly polypeptide having the amino acid sequence of SEQ ID NO: 156, eg, a nucleic acid comprising a SEQ ID NO: 59 nucleotide sequence.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter Philoly polypeptide having an amino acid sequence of SEQ ID NO: 157, eg, a nucleic acid comprising a SEQ ID NO: 60 nucleotide sequence.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter Philoly polypeptide having the amino acid sequence of SEQ ID NO: 158, eg, a nucleic acid comprising a SEQ ID NO: 61 nucleotide sequence.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter Philoly polypeptide having an amino acid sequence of SEQ ID NO: 159, eg, a nucleic acid comprising a SEQ ID NO: 62 nucleotide sequence.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having an amino acid sequence of SEQ ID NO: 160, eg, a nucleic acid comprising a SEQ ID NO: 63 nucleotide sequence.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 161, eg, a nucleic acid comprising a SEQ ID NO: 64 nucleotide sequence.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 162, eg, a nucleic acid comprising a SEQ ID NO: 65 nucleotide sequence.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 163, eg, a nucleic acid comprising a SEQ ID NO: 66 nucleotide sequence.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having an amino acid sequence of SEQ ID NO: 164, eg, a nucleic acid comprising a SEQ ID NO: 67 nucleotide sequence.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 165, eg, a nucleic acid comprising a SEQ ID NO: 68 nucleotide sequence.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 166, eg, a nucleic acid comprising a SEQ ID NO: 69 nucleotide sequence.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 167, eg, a nucleic acid comprising a sequence 70 nucleotide sequence.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 168, eg, a nucleic acid comprising a SEQ ID NO: 71 nucleotide sequence.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter Philoly polypeptide having an amino acid sequence of SEQ ID NO: 169, eg, a nucleic acid comprising a SEQ ID NO: 72 nucleotide sequence.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter Philoly polypeptide having an amino acid sequence of SEQ ID NO: 170, eg, a nucleic acid comprising a SEQ ID NO: 73 nucleotide sequence.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 171, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 74.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 172, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 75.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 173, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 76.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 174, for example a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 77.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 175, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 78.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 176, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 79.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 177, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 80.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 178, for example, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 81.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 179, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 82.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 180, such as a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 83.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 181, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 84.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 182, such as a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 85.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 183, eg, a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 86.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 184, eg, a nucleic acid comprising the sequence 87 nucleotide sequence.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 185, eg, a nucleic acid comprising a SEQ ID NO: 88 nucleotide sequence.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 186, eg, a nucleic acid comprising the SEQ ID NO: 89 nucleotide sequence.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter Philoly polypeptide having the amino acid sequence of SEQ ID NO: 187, eg, a nucleic acid comprising the SEQ ID NO: 90 nucleotide sequence.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 188, eg, a nucleic acid comprising a SEQ ID NO: 91 nucleotide sequence.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter Philoly polypeptide having an amino acid sequence of SEQ ID NO: 189, eg, a nucleic acid comprising a SEQ ID NO: 92 nucleotide sequence.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pylori polypeptide having the amino acid sequence of SEQ ID NO: 190, eg, a nucleic acid comprising a SEQ ID NO: 93 nucleotide sequence.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter Philoly polypeptide having the amino acid sequence of SEQ ID NO: 191, eg, a nucleic acid comprising a SEQ ID NO: 94 nucleotide sequence.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter Philoly polypeptide having an amino acid sequence of SEQ ID NO: 192, eg, a nucleic acid comprising a SEQ ID NO: 95 nucleotide sequence.

In another aspect, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 193, eg, a nucleic acid comprising a SEQ ID NO: 96 nucleotide sequence.

In another feature, the invention features a substantially pure nucleic acid encoding a Helicobacter pili polypeptide having the amino acid sequence of SEQ ID NO: 194, eg, a nucleic acid comprising a SEQ ID NO: 97 nucleotide sequence.

In another aspect, the invention features an isolated nucleic acid having a nucleotide sequence encoding a Helicobacter pilori polypeptide that is at least about 60% homologous to an amino acid sequence selected from the group consisting of SEQ ID NOs: 98-194. In a more preferred embodiment, the isolated nucleic acid comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1 to 97 or its complement.

In another aspect, the invention features an isolated nucleic acid having a nucleotide sequence encoding a Helicobacter pilori polypeptide selected from the group consisting of SEQ ID NOs: 98-194.

In another aspect, the invention features an isolated nucleic acid encoding a Helicobacter pylori polypeptide having a nucleotide sequence that is at least about 60% homologous to a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-97.

In another aspect, the invention provides an isolated nucleic acid molecule encoding a Helicobacter pylori polypeptide or its complement having a nucleotide sequence that hybridizes to a nucleic acid molecule having a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1 to 97 under stringent hybridization conditions. It is characterized by a sieve.

In another aspect, the invention features an isolated nucleic acid or complement thereof having a nucleotide sequence of at least 8 nucleotides in length that hybridizes to a nucleic acid molecule having a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-97 under stringent hybridization conditions It is done.

SEQ ID NO: 63, 7, 8, 9, 13, 14, 23, 24, 27, 28, 50, 51, 61, 79, 80 having a nucleotide sequence encoding a Helicobacter phyllori cell envelope polypeptide or fragment thereof , 84, 85, 91, 94, 5, 11, 26, 36, 42, 52, 22, 29, 30, 65, 66, 48, 49, 17, 18, 19, 43, 44, 38, 39, 1 Especially preferred are isolated nucleic acids or complements thereof selected from the group consisting of 2, 6, 34, 35, 60, 69 and 83.

In one embodiment, the Helicobacter philoly cell envelope polypeptide or fragment thereof is a Helicobacter philoly flagella binding polypeptide or fragment thereof encoded by a nucleic acid having the nucleotide sequence of SEQ ID NO: 63 or its complement.

In another embodiment, the Helicobacter Philoly cell envelope polypeptide or fragment thereof is a Helicobacter fill encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 48, 49, 17, 18, 19, 43, 44, 38, and 39 or its complement. A lory inner membrane polypeptide or a fragment thereof.

In another embodiment, the Helicobacter Philosophy inner membrane polypeptide or fragment thereof is a Helicobacter Fill involved in transport, encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 48, 49, 17, 18, 19, 43, and 44 or its complement. Lori polypeptide or fragment thereof.

In another embodiment, the Helicobacter Philoly cell envelope polypeptide or fragment thereof is SEQ ID NO: 7, 8, 9, 13, 14, 23, 24, 27, 28, 50, 51, 61, 79, 80, 84, 85, 91, Helicobacter pylori outer membrane polypeptide or fragment thereof encoded by a nucleic acid selected from the group consisting of 94, 5, 11, 26, 36, 42, 52, 22, 29, 30, 65 and 66 or its complement.

In other embodiments, the Helicobacter pylori outer membrane polypeptide or fragment thereof is SEQ ID NO: 7, 8, 9, 11, 13, 14, 23, 24, 26, 27, 28, 36, 42, 50, 51, 52, 61, 79 Helicobacter pylori polypeptide having a terminal phenylalanine residue, or a fragment thereof, encoded by a nucleic acid selected from the group consisting of 80, 84, 85, 91, and 94 or its complement.

In another embodiment, the Helicobacter pylori outer membrane polypeptide or fragment thereof has a terminal phenylalanine residue and a C terminal tyrosine cluster, encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 11, 26, 36, 42, and 52 or its complement Helicobacter Philoly polypeptide or fragment thereof.

SEQ ID NO: 160, 104, 105, 106, 110, 111, 120, 121, 124, 125, 147, 148, 158, 176, 177, 181, having a nucleotide sequence encoding a Helicobacter phyllori cell envelope polypeptide or fragment thereof 182, 188, 191, 102, 108, 123, 133, 139, 149, 119, 126, 127, 162, 163, 145, 146, 114, 115, 116, 140, 141, 135, 136, 98, 99, Especially preferred are isolated nucleic acids selected from the group consisting of 103, 131, 132, 157, 166 and 180.

In other embodiments, the Helicobacter Philoly cell envelope polypeptide or fragment thereof is a Helicobacter Philophyllio flagella binding polypeptide or fragment thereof having the amino acid sequence of SEQ ID NO: 160.

In another embodiment, the Helicobacter Philolyll cell envelope polypeptide or fragment thereof is a Helicobacter Philolylium inner membrane polypeptide or fragment thereof selected from the group consisting of SEQ ID NOs: 145, 146, 114, 115, 116, 140, 141, 135 and 136.

In another embodiment, the Helicobacter Philolyme polypeptide or fragment thereof is a Helicobacter Philoly polypeptide or fragment thereof that is involved in transport, selected from the group consisting of SEQ ID NOs: 145, 146, 114, 115, 116, 140 and 141.

In other embodiments, the Helicobacter Philoly cell envelope polypeptide or fragment thereof is SEQ ID NO: 104, 105, 106, 110, 111, 120, 121, 124, 125, 147, 148, 158, 176, 177, 181, 182, 188, 191, 102, 108, 123, 133, 139, 149, 119, 126, 127, 162, and 163 Helicobacter Philoyl outer membrane polypeptides or fragments thereof.

In other embodiments, the Helicobacter pylori outer membrane polypeptide or fragment thereof is SEQ ID NO: 104, 105, 106, 108, 110, 111, 120, 121, 123, 124, 125, 133, 139, 147, 148, 149, 158, 176 , 177, 181, 182, 188, and 191, a Helicobacter pili polypeptide or fragment thereof having a terminal phenylalanine residue selected from the group consisting of:

In another embodiment, the Helicobacter Philoyl outer membrane polypeptide or fragment thereof is a Helicobacter Philoly polypeptide or fragment thereof having a terminal phenylalanine residue and a C terminal tyrosine cluster, selected from the group consisting of SEQ ID NOs: 108, 123, 133, 139 and 149.

Particular preference is given to isolated nucleic acids or complements thereof selected from the group consisting of SEQ ID NOs: 57, 58, 86, 87, 88, 89, 92 and 93, having nucleotide sequences encoding Helicobacter pilori cytoplasmic polypeptides or fragments thereof.

In one embodiment, the Helicobacter pilori cytoplasmic polypeptide or fragment thereof is a Helicobacter pilori polypeptide or fragment thereof that is involved in mRNA translation, encoded by an isolated nucleic acid or complement thereof selected from the group consisting of SEQ ID NOs: 57 and 58.

In one embodiment, the Helicobacter pili cytoplasmic polypeptide or fragment thereof is a Helicobacter pili involved in genome replication, transcription, recombination and repair, encoded by an isolated nucleic acid or complement thereof selected from the group consisting of SEQ ID NOs: 86 and 87 Polypeptide or fragment thereof.

Particular preference is given to isolated nucleic acids having a nucleotide sequence encoding a Helicobacter pilori cytoplasmic polypeptide or a fragment thereof selected from the group consisting of SEQ ID NOs: 154, 155, 183, 184, 185, 186, 189 and 190.

In one embodiment, the Helicobacter pilori cytoplasmic polypeptide or fragment thereof is a Helicobacter pilori polypeptide or fragment thereof that is involved in mRNA translation, selected from the group consisting of SEQ ID NOs: 154 and 155.

In another embodiment, the Helicobacter pilori cytoplasmic polypeptide or fragment thereof is a Helicobacter pilori polypeptide or fragment thereof that is involved in genomic replication, transcription, recombination and repair, selected from the group consisting of SEQ ID NOs: 183 and 184.

SEQ ID NO: 3, 4, 10, 12, 20, 25, 31, 32, 45, 46, 53, 64, 67, 70, 77, 78, 81, 82, 90, encoding a Helicobacter pilori secreting polypeptide or fragment thereof Particular preference is given to isolated nucleic acids or their complements having a nucleotide sequence selected from the group consisting of " 95 " and 97.

Helicobacter Phil selected from the group consisting of SEQ ID NOs: 100, 101, 107, 109, 117, 122, 128, 129, 142, 143, 150, 161, 164, 167, 174, 175, 178, 179, 187, 192 and 194 Particular preference is given to isolated nucleic acids having a nucleotide sequence encoding a Laurie secreting polypeptide or fragment thereof.

SEQ ID NO: 15, 16, 21, 33, 37, 40, 41, 47, 54, 55, 56, 59, 62, 68, 71, 72, 73, 74, 75, encoding Helicobacter pilori cell polypeptide or fragment thereof Especially preferred are isolated nucleic acids or complements thereof having a nucleotide sequence selected from the group consisting of 76, 96 and 96.

Helicobacter Phil selected from the group consisting of SEQ ID NOs: 112, 113, 118, 130, 134, 137, 138, 144, 151, 152, 153, 156, 159, 165, 168, 169, 170, 171, 172, 173 and 193 Particular preference is given to isolated nucleic acids having a nucleotide sequence encoding a Lori cell polypeptide or fragment thereof.

In another feature, a probe having a nucleotide sequence consisting of eight or more nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-97 is characterized.

In another aspect, the invention features an isolated Helicobacter Philopolypeptide having an amino acid sequence that is at least about 60% homologous to a Helicobacter Philolyte polypeptide selected from the group consisting of SEQ ID NOs: 98-194.

In another aspect, the invention features an isolated Helicobacter pylori polypeptide encoded by a nucleic acid having a nucleotide sequence that is at least about 60% homologous to a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-97. In one embodiment, the isolated Helicobacter pylori polypeptide is encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-97.

In another aspect, the invention features an isolated Helicobacter Philopolypeptide encoded by a nucleic acid or complement thereof thereof that hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs: 1-97 under stringent hybridization conditions.

In another feature, the invention features an isolated Helicobacter pylori polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 97 to 194.

SEQ ID NOs: 160, 104, 105, 106, 110, 111, 120, 121, 124, 125, 147, 148, 158, 176, 177, 181, 182, 188, 191, 102, 108, 123, 133, 139, 149 , 119, 126, 127, 162, 163, 145, 146, 114, 115, 116, 140, 141, 135, 136, 98, 99, 103, 131, 132, 157, 166 and 180 Particular preference is given to an isolated Helicobacter Philoly cell envelope polypeptide or fragment thereof.

In one embodiment, the Helicobacter Philoly cell envelope polypeptide or fragment thereof is a Helicobacter Philoly flagella binding polypeptide or fragment thereof having the amino acid sequence of SEQ ID NO: 160.

In another embodiment, the Helicobacter Philolyll cell envelope polypeptide or fragment thereof is a Helicobacter Philolylium inner membrane polypeptide or fragment thereof selected from the group consisting of SEQ ID NOs: 145, 146, 114, 115, 116, 140, 141, 135 and 136.

In another embodiment, the Helicobacter pilori inner polypeptide or fragment thereof is selected from the group consisting of SEQ ID NOs: 145, 146, 114, 115, 116, 140, 141, 135, and 136. to be.

In other embodiments, the Helicobacter Philoly cell envelope polypeptide or fragment thereof is SEQ ID NO: 104, 105, 106, 110, 111, 120, 121, 124, 125, 147, 148, 158, 176, 177, 181, 182, 188, 191, 102, 108, 123, 133, 139, 149, 119, 126, 127, 162, and 163 Helicobacter Philoyl outer membrane polypeptides or fragments thereof.

In other embodiments, the Helicobacter pylori outer membrane polypeptide or fragment thereof is SEQ ID NO: 104, 105, 106, 108, 110, 111, 120, 121, 123, 124, 125, 133, 139, 147, 148, 149, 158, 176 , 177, 181, 182, 188, and 191, a Helicobacter pili polypeptide or fragment thereof having a terminal phenylalanine residue selected from the group consisting of:

In another embodiment, the Helicobacter Philoyl outer membrane polypeptide or fragment thereof is a Helicobacter Philoly polypeptide or fragment thereof having a terminal phenylalanine residue and a C terminal tyrosine cluster, selected from the group consisting of SEQ ID NOs: 108, 123, 133, 139 and 149.

SEQ ID NOs: 63, 7, 8, 9, 13, 14, 23, 24, 27, 28, 50, 51, 61, 79, 80, 84, 85, 91, 94, 5, 11, 26, 36, 42, 52 , 22, 29, 30, 65, 66, 48, 49, 17, 18, 19, 43, 44, 38, 39, 1, 2, 6, 34, 35, 60, 69 and 83 Particular preference is given to isolated Helicobacter Philoly cell envelope polypeptides or fragments thereof encoded by nucleic acids.

In one embodiment, the Helicobacter philoly cell envelope polypeptide or fragment thereof is a Helicobacter phyllori flagella binding polypeptide or fragment thereof encoded by a nucleic acid having the nucleotide sequence of SEQ ID NO: 63.

In another embodiment, the Helicobacter Philolyll cell envelope polypeptide or fragment thereof is a Helicobacter Philolymella polypeptide or is encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 48, 49, 17, 18, 19, 43, 44, 38 and 39 It is a short story.

In another embodiment, the Helicobacter pilori polypeptide or fragment thereof is a Helicobacter pilori polypeptide involved in transport, encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 48, 49, 17, 18, 19, 43 and 44 or It is a fragment.

In another embodiment, the Helicobacter Philoly cell envelope polypeptide or fragment thereof is SEQ ID NO: 7, 8, 9, 13, 14, 23, 24, 27, 28, 50, 51, 61, 79, 80, 84, 85, 91, Helicobacter pylori outer membrane polypeptides or fragments thereof encoded by nucleic acids selected from the group consisting of 94, 5, 11, 26, 36, 42, 52, 22, 29, 30, 65 and 66.

In other embodiments, the Helicobacter pylori outer membrane polypeptide or fragment thereof is SEQ ID NO: 7, 8, 9, 11, 13, 14, 23, 24, 26, 27, 28, 36, 42, 50, 51, 52, 61, 79 , Helicobacter Philoly polypeptide having a terminal phenylalanine residue encoded by a nucleic acid selected from the group consisting of 80, 84, 85, 91 and 94 or a fragment thereof.

In another embodiment, the Helicobacter pilori outer membrane polypeptide or fragment thereof is a Helicobacter pilori polypeptide having a terminal phenylalanine residue and a C terminal tyrosine cluster, encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 11, 26, 36, 42 and 52 Or a fragment thereof.

Particularly preferred is an isolated Helicobacter pilori cytoplasmic polypeptide selected from the group consisting of SEQ ID NOs: 154, 155, 183, 184, 185, 186, 189 and 190 or fragments thereof.

In one embodiment, the Helicobacter pilori cytoplasmic polypeptide or fragment thereof is a Helicobacter pilori polypeptide or fragment thereof that is involved in mRNA translation, selected from the group consisting of SEQ ID NOs: 154 and 155.

In another embodiment, the Helicobacter pilori cytoplasmic polypeptide or fragment thereof is a Helicobacter pilori polypeptide or fragment thereof that is involved in genomic replication, transcription, recombination and repair, selected from the group consisting of SEQ ID NOs: 183 and 184.

Particularly preferred is an isolated Helicobacter pili cytoplasmic polypeptide encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 57, 58, 86, 87, 88, 89, 92 and 93 or fragments thereof.

In one embodiment, the Helicobacter pilori cytoplasmic polypeptide or fragment thereof is a Helicobacter pilori polypeptide or fragment thereof that is involved in mRNA translation, encoded by an isolated nucleic acid selected from the group consisting of SEQ ID NOs: 57 and 58.

In one embodiment, the Helicobacter pilori cytoplasmic polypeptide or fragment thereof is a Helicobacter pilori polypeptide or fragment thereof that is involved in genome replication, transcription, recombination and repair, encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 86 and 87.

Isolation, selected from the group consisting of SEQ ID NOs: 112, 113, 118, 130, 134, 137, 138, 144, 151, 152, 153, 156, 159, 165, 168, 169, 170, 171, 172, 173, and 193 Particularly preferred are Helicobacter pylori cell polypeptides or fragments thereof.

To a nucleic acid selected from the group consisting of SEQ ID NOs: 15, 16, 21, 33, 37, 40, 41, 47, 54, 55, 56, 59, 62, 68, 71, 72, 73, 74, 75, 76, and 96 Particularly preferred is an isolated Helicobacter Philoly cell polypeptide or fragment thereof encoded by.

Isolation selected from the group consisting of SEQ ID NOs: 100, 101, 107, 109, 117, 122, 128, 129, 142, 143, 150, 161, 164, 167, 174, 175, 178, 179, 187, 192 and 194 Particularly preferred are Helicobacter pylori secreting polypeptides or fragments thereof.

To a nucleic acid selected from the group consisting of SEQ ID NOs: 3, 4, 10, 12, 20, 25, 31, 32, 45, 46, 53, 64, 67, 70, 77, 78, 81, 82, 90, 95, and 97 Particular preference is given to an isolated Helicobacter pylori secreting polypeptide, or fragment thereof, encoded by

In another aspect, the invention features a chimera Helicobacter Philolyte polypeptide comprising at least two Helicobacter Philolyte polypeptides or fragments thereof encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 1-97.

In another aspect, the invention features a chimeric Helicobacter Philolyte polypeptide comprising at least two Helicobacter Philolyte polypeptides or fragments thereof selected from the group consisting of SEQ ID NOs: 98-194.

In another aspect, the invention features a fusion protein comprising a Helicobacter pili polypeptide, comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 98-194 linked to a non-Helicobacter pili polypeptide.

In another aspect, the invention features a vaccine formulation for the prevention or treatment of a Helicobacter pylori infection comprising an effective amount of one or more isolated nucleic acids of the invention.

In another aspect, the invention features vaccine formulations for the prevention or treatment of Helicobacter pylori infection comprising an effective amount of one or more Helicobacter pylori polypeptides of the invention.

Preferably, the vaccine of the present invention further comprises a pharmaceutically acceptable carrier. In one embodiment, the pharmaceutically acceptable carrier comprises an adjuvant. In other embodiments, the pharmaceutically acceptable carrier comprises a delivery system, such as a live vector, such as a bacterium or a virus. In other embodiments, pharmaceutically acceptable carriers include both adjuvant and delivery systems.

In another aspect, the invention features a method for treating a Helicobacter pylori infection in a subject or for reducing the risk of infection. The method comprises administering to a subject a vaccine formulation of the present invention such that treatment of a Helicobacter pylori infection or a lower risk of infection occurs.

In another aspect, the invention features a method of making a vaccine formulation of the invention. The method comprises combining the at least one isolated Helicobacter Philoly polypeptide or fragment thereof selected from the group consisting of SEQ ID NOs: 98 to 194 with a pharmaceutically acceptable carrier to prepare a vaccine formulation.

In another aspect, the invention features a method of making a vaccine formulation of the invention. The method comprises the steps of culturing the cell under conditions permitting the expression of a Helicobacter Philolyte polypeptide or fragment thereof selected from the group consisting of SEQ ID NOs: 98-194, isolating the Helicobacter Philolyte polypeptide from the cell, and at least one isolated Combining the Helicobacter pylori polypeptide or fragment thereof with a pharmaceutically acceptable carrier to prepare a vaccine formulation.

In another aspect, the invention relates to a member of each Helicobacter pylori polypeptide or nucleic acid encoding said member of said identified group of Helicobacter pilori polypeptides.

In another aspect, the invention features nucleic acids capable of binding to mRNA of Helicobacter Philophyll. Such nucleic acids can act as antisense nucleic acids that regulate the translation of mRNA of Helicobacter phyllori. In addition, the invention features nucleic acids capable of specifically binding to Helicobacter pylori nucleic acid. These nucleic acids are also referred to herein as complements and have utility as probes and capture reagents.

In another aspect, the invention features an expression system comprising an open reading frame corresponding to Helicobacter pylori nucleic acid. The nucleic acid further includes regulatory sequences compatible with the host of interest. The expression system flows into the production of polypeptides corresponding to Helicobacter pylori nucleic acid.

In another aspect, the invention features cells transformed with an expression system for producing Helicobacter pili polypeptide.

In another aspect, the invention features a method of producing an antibody that acts against a Helicobacter pili polypeptide that can specifically bind a Helicobacter pili polypeptide. The antibody has utility as a reagent for immunoassays to assess the amount and distribution of Helicobacter pylori specific antigens.

In another aspect, the invention features a method of generating a vaccine for immunizing an individual against Helicobacter pylori. Vaccine treatment methods include immunotreatment of an individual with one or more Helicobacter pylori polypeptides, eg, surface or secreted polypeptides or active fragments thereof and pharmaceutically acceptable carriers according to the invention. The vaccine has therapeutic and / or prophylactic utility.

In another aspect, the present invention provides a method of producing a vaccine comprising a denatured immunogenic Helicobacter pylori polypeptide, eg, a surface or secreted polypeptide or an active fragment thereof and a pharmaceutically acceptable carrier.

In another aspect, the invention features a method for assessing the ability of a compound, eg, a polypeptide, eg, a host cell polypeptide fragment, to bind to a Helicobacter Philoly polypeptide. The method includes contacting the candidate compound with the Helicobacter Philolyte polypeptide and determining whether the compound binds or interacts with the Helicobacter Philolyte polypeptide. Compounds that bind to Helicobacter pylori are candidates that function as active agents or inhibitors of bacterial life cycles. The assay can be performed in vitro or in vivo.

In another aspect, the invention features a method for assessing the ability of a compound, eg, a polypeptide, eg, a host cell polypeptide fragment, to bind to Helicobacter pylori nucleic acid, eg, DNA or RNA. The method includes contacting the candidate compound with Helicobacter pilori nucleic acid and determining whether the compound binds or interacts with Helicobacter pilori nucleic acid. Compounds that bind to Helicobacter pylori are candidates that function as active agents or inhibitors of bacterial life cycles. The assay can be performed in vitro or in vivo.

The present invention features a Helicobacter Philolyte polypeptide, preferably a substantially pure preparation of Helicobacter Philly polypeptide, or a recombinant Helicobacter Philly polypeptide. In a preferred embodiment, the polypeptide has a biological activity and the polypeptide is an amino acid that is at least 60%, 70%, 80%, 90%, 95%, 98% or 99% identical or homologous to the amino acid sequence of the invention described in the Sequence Listing. Having a sequence, preferably having about 65%, most preferably about 92% to about 99% sequence homology with the amino acid sequence of the invention described in the Sequence Listing, wherein the polypeptide is an amino acid sequence of the invention as listed in the Sequence Listing Having an amino acid sequence substantially equal to 5, 10, 20, 50, 100 or 150 amino acid residues in length, the polypeptide is 5, preferably 10, more preferably 20, most preferably 50, Amino acid residues of the invention as described in the list of 100 or 150 contiguous sequences. In another preferred embodiment, amino acid sequences that differ from about 7% to about 8% in sequence identity with the Helicobacter pylori amino acid sequence described in the Sequence Listing of the present invention are included within the scope of the present invention.

In a preferred embodiment, the Helicobacter pylori polypeptide is at least 60%, 70%, 80%, 90%, 95%, 98% or 99% of the nucleic acids of the invention as listed in the Sequence Listing or the nucleic acids of the invention as listed in the Sequence Listing. It is encoded by a nucleic acid having homology.

In a preferred embodiment, the Helicobacter pylori polypeptide differs in amino acid sequence at 1, 2, 3, 5, 10 or more residues from the sequence of the invention as listed in the Sequence Listing. However, this difference is such that the Helicobacter pilori polypeptide exhibits the biological activity of Helicobacter pilori, for example, the Helicobacter pilori polypeptide retains the biological activity of the native Helicobacter pilori polypeptide.

In a preferred embodiment, the polypeptide is in frame at an additional amino acid residue, preferably at a residue encoded by genomic DNA present at 5 'or 3' of the genomic DNA encoding the sequences of the invention described in the sequence listing. Or all or a fragment of an amino acid sequence of the invention as set forth in the Sequence Listing, fused thereto.

In another preferred embodiment, the Helicobacter pilori polypeptide is a recombinant fusion protein having a first Helicobacter pilori polypeptide moiety and a second polypeptide moiety, eg, a second polypeptide moiety having an amino acid sequence independent of Helicobacter pilori. The second polypeptide moiety can be, for example, glutathione-S-transferase, DNA binding domain or polymerase activating domain. In a preferred embodiment, the fusion protein can be used for 2-hybrid analysis.

Polypeptides of the invention include polypeptides that occur as a result of alternative transcription, alternative RNA splicing and alternative translational and post-detoxification events.

The invention also relates to immunogenic components comprising at least one Helicobacter Philolyte polypeptide in an immunogenic preparation, an immune response specific for Helicobacter Philolyte polypeptides, such as a humoral response, an antibody response or an immune cell that can induce a cellular response Contains original ingredients. In a preferred embodiment, the immunogenic component comprises one or more antigenic determinants from the polypeptides of the invention described in the sequence listing.

In another aspect, the present invention provides a substantially pure nucleic acid having a nucleotide sequence encoding a Helicobacter pylori polypeptide. In a preferred embodiment, the encoded polypeptide has biological activity and the encoded polypeptide is at least 60%, 70%, 80%, 90%, 95%, 98% or 99% homologous to the amino acid sequences of the invention as listed in the Sequence Listing. The polypeptide having an amino acid sequence, the polypeptide to be encoded has an amino acid sequence substantially the same as the amino acid sequence of the invention described in the Sequence Listing, and the length of the polypeptide to be encoded is 5, 10, 20, 50, 100 or 150 amino acid residues, The polypeptide to be encoded comprises the amino acids of the invention as described in the list of 5, preferably 10, more preferably 20, most preferably 50, 100 or 150 contiguous sequences.

In a preferred embodiment, the nucleic acids of the invention are those listed in the sequence listing, and the nucleic acids are at least 60%, 70%, 80%, 90%, 95%, 98% or 99% homologous to the nucleic acids of the invention listed in the sequence listing. Has

In a preferred embodiment, the Helicobacter pili polypeptide encoded is at least 1, 2, 3, 5, 10 or more residues (e.g., by amino acid substitution, addition or deletion of one or more amino acid residues) as described in the Sequence Listing. The amino acid sequences are different. However, this difference is only such that the encoded Helicobacter pili polypeptide exhibits the biological activity of Helicobacter pili, for example, the Helicobacter pili enzyme encoded retains the biological activity of native Helicobacter pili.

In a preferred embodiment, the polypeptide to be encoded is in frame at an additional amino acid residue, preferably at a residue encoded by genomic DNA present at 5 'or 3' of the genomic DNA encoding a sequence of the invention as listed in the sequence listing. Fused to all or fragments of the amino acid sequences of the invention described in the Sequence Listing.

In a preferred embodiment, the Helicobacter pilori nucleic acid is a transcriptional regulatory sequence, eg, one or more operably linked to the Helicobacter pilori gene sequence, for example, to make the Helicobacter pilori gene sequence suitable for expression in recombinant host cells. Transcriptional promoter or transcriptional enhancer sequences.

In a further preferred embodiment, the nucleic acid encoding a Helicobacter pylori polypeptide of the invention is subjected to 8, more preferably 12, even more preferably 20, even more of the invention as listed in the sequence listing under stringent hybridization conditions. Preferably, they hybridize to nucleic acid probes corresponding to 40 or more consecutive nucleotides.

In a preferred embodiment, the nucleic acid encodes a peptide that differs by at least one amino acid residue from the sequence of the invention described in the Sequence Listing.

In a preferred embodiment, the nucleic acid differs from the nucleotide sequence of the invention described in the sequence listing by one or more nucleotides, encoding the amino acids of the invention described in the sequence listing.

In another aspect, the present invention provides a method comprising the steps of culturing a cell comprising a nucleic acid encoding a Helicobacter pili polypeptide or the above described Helicobacter pili polypeptide polypeptide, a host cell transfected with the vector, and for example a cell culture medium; For example, a method for producing a recombinant Helicobacter pilori polypeptide or Helicobacter pilori polypeptide variant comprising the step of isolating a Helicobacter pilori or Helicobacter pilori polypeptide or Helicobacter pilori polypeptide variant from a cell or from a cell culture medium.

In another aspect, the invention features purified recombinant nucleic acids having at least 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% homology with the sequences of the invention as listed in the Sequence Listing. It is done.

The present invention also provides probes or primers comprising substantially purified oligonucleotides. Oligonucleotides comprise nucleotide sequence regions that hybridize to the sense or antisense sequence of at least 8 contiguous nucleotides of the invention described in the sequence listing under stringent hybridization conditions, or natural variants thereof. In a preferred embodiment, the probe or primer further comprises a labeling group attached thereto. The labeling group can be, for example, radioisotopes, fluorescent compounds, enzymes and / or enzyme cofactors. Preferably the oligonucleotide is at least 8 and less than 10, 20, 30, 50, 100 or 150 nucleotides in length.

The invention also provides an isolated Helicobacter pylori polypeptide encoded by a nucleic acid that hybridizes to the nucleic acids listed in the Sequence Listing under stringent hybridization conditions.

The invention further provides nucleic acids, eg RNA or DNA, encoding the polypeptides of the invention. These nucleic acids include double stranded nucleic acids and coding and antisense single stranded nucleic acids.

Helicobacter Philoly strains with determined geno sequences were deposited as strain HP-J99 in the American Type Culture Collection (ATCC # 55679; deposited by Genome Therapeutics Corporation, Waltham Beaver Street 100, 02154, Maryland, USA).

The present invention includes proteins encoded by DNA hybridizing to a nucleic acid encoding a polypeptide of the invention as listed in the sequence listing under allelic variants, natural mutants, induced mutants, high stringency or low stringency conditions (high stringency or For low stringency, see Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1989, 6.3.1-6.3.6 and 6.4.1-6.4.10, and Helicobacter Philoly polypeptides, which are incorporated herein by reference. Polypeptides that are specifically bound by antiserum to, in particular, by the active or binding domain of a Helicobacter pylori polypeptide. The invention also encompasses fragments, preferably biologically active fragments. These and other polypeptides are also referred to as Helicobacter pylori polypeptide analogs or variants.

The putative functions of several Helicobacter pylori polypeptides of the present invention were investigated and shown in Table 1.

Accordingly, the use of the Helicobacter pylori polypeptide of the present invention based on the functions identified above and other functions described herein are also included within the scope of the present invention.

The present invention also encompasses the Helicobacter Filho polypeptide shown in Table 1 below, including Helicobacter Filho cell envelope protein, Helicobacter Filho secretion protein, Helicobacter Filho cytoplasmic protein and Helicobacter Filho cell protein.

In Table 1, "nt" means nucleotide sequence number and "aa" means amino acid sequence number.

Justice

A "purified or isolated polypeptide or substantially pure preparation of a polypeptide" is used interchangeably herein and means a polypeptide that has been separated from other proteins, lipids, and nucleic acids that occur together in nature as used herein. Preferably, the polypeptide is also isolated from a substance such as an antibody used for its purification or from a gel matrix such as polyacrylamide. Preferably, the polypeptide is at least 10, 20, 50, 70, 80 or 95% dry weight of the tablet formulation. Preferably, the agent contains sufficient polypeptide, at least 1, 10 or 100 μg of polypeptide, at least 1, 10 or 100 mg of polypeptide to determine the protein sequence. In addition, the term purified or isolated polypeptide or substantially pure preparation of polypeptide refers to both a polypeptide obtained from nature or a polypeptide obtained from the recombinant DNA techniques described herein.

For example, an “isolated or purified protein or a biologically active portion thereof” is substantially free of cellular material or other contaminating protein from a cell or tissue source from which the Helicobacter pylori protein is derived, or is chemically synthesized in chemical synthesis. It is substantially free of precursors or other chemicals. The term “substantially free of cellular material” includes preparations of Helicobacter pylori protein in which the protein is isolated from the cellular components of the cell from which the protein is isolated or produced by recombinant methods. In one embodiment, the term “substantially free of cellular material” refers to less than about 30%, more preferably less than about 20%, even more preferably less than about 10%, most preferably less than about 5% of non-helicobacter Helicobacter pylori protein preparations with pili protein (also called contaminating protein). If the Helicobacter pylori protein or its biologically active portion is produced by recombinant methods, substantially no culture medium is present. That is, the buried medium is present in less than about 20%, preferably less than about 10%, most preferably less than about 5% of the protein preparation.

The term “substantially free of chemical precursors or other chemicals” includes preparations of Helicobacter pylori protein from which proteins are separated from chemical precursors or other chemicals involved in the synthesis of the protein. In one embodiment, "substantially free of chemical precursors or other chemicals" is less than about 30% (based on dry weight), more preferably less than about 20%, even more preferably less than about 10%, most preferably Comprises a Helicobacter pylori protein preparation having less than about 5% chemical precursor or non Helicobacter pylori chemical.

Purified preparation of cells means in vitro preparations of cells in the case of plant or animal cells, but not intact original plants or animals. For cultured cells or microbial cells, the tablet formulation consists of a formulation with at least 10% and more preferably at least 50% of the subject cells.

Purified or isolated, or substantially pure nucleic acid, for example substantially pure DNA (as is a term that may be used interchangeably herein), is the coding of both immediately contiguous with the nucleic acid in the natural genome of the organism from which the nucleic acid is derived. Nucleic acids that are not immediately contiguous with the sequence (ie, the sequence present at the 5 ′ end and the sequence present at the 3 ′ end); Or a nucleic acid substantially free of nucleic acid that occurs with the nucleic acid in an organism from which the nucleic acid is derived. For example, the term includes a separate molecule (eg, PCR or restriction endonuine) introduced into a vector, such as an autologous plasmid or virus, or into the genomic DNA of a prokaryotic or eukaryotic cell, or independent of other DNA sequences. Recombinant DNA present as cDNA or genomic DNA fragments produced by claase treatment). Substantially pure DNA also includes recombinant DNA belonging to a hybrid gene encoding additional Helicobacter pili DNA sequence.

As used herein, "contig" is a nucleic acid that represents a contiguous extension of the genomic sequence of an organism.

An "open reading frame", also referred to herein as an ORF, is a region of nucleic acid encoding a polypeptide. This region may represent a portion of the coding sequence also the total sequence and may be determined from stop codons to stop codons, or from start codons to stop codons.

As used herein, a "coding sequence" is a nucleic acid that is transcribed into messenger RNA and / or translated into a polypeptide under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by the translation start codon at the 5 'end and the translation stop codon at the 3' end. Coding sequences include, but are not limited to, messenger RNA, synthetic DNA and recombinant nucleic acid sequences.

As used herein, “complement” of an nucleic acid refers to an anti-parallel or antisense sequence that participates in Watson-Crick base confrontation with the original sequence.

A "gene product" is a protein or structural RNA that is specifically encoded by a gene.

As used herein, the term "probe" refers to a nucleic acid, peptide or other chemical that specifically binds to the molecule. Probes are often associated with or associated with labels. The label is a detectable chemical moiety. Typical labels include dyes, radioisotopes, fluorophores and chemical fluorophores, fluorophores, enzymes, precipitants, amplification sequences, and the like. Likewise, nucleic acids, peptides or other chemicals that specifically bind to and fix such molecules are referred to herein as "trapping ligands." The trapping ligand is usually associated with or associable with a support such as nitro-cellulose, glass, nylon membrane, beads, particles, and the like. The specificity of hybridization depends on the base pair composition of the nucleotides, and on conditions such as reaction temperature and salt concentration. Such conditions will be readily apparent to those skilled in the art using conventional practice.

Homologous refers to sequence similarity or sequence identity between two polypeptides or between two nucleic acid molecules. If the same base or amino acid monomer subunit occupies a specific position in both comparison sequences, for example, if adenine occupies a specific position in each of the two DNA molecules, these molecules are homologous at that position. The percent homology between two sequences is a function of the number of identical or homologous positions shared by the two sequences divided by the number of comparative positions, multiplied by 100. For example, if six of the ten positions of two sequences are identical or homologous, the two sequences are 60% homologous. For example, the DNA sequences ATTGCC and TATGGC share 50% homology. In general, comparisons are made when two sequences are aligned to provide maximum homology.

Nucleic acids can hybridize with each other if one or more strands thereof can anneal to other nucleic acids under certain stringency conditions. The stringency of hybridization is determined by (a) the temperature at which hybridization and / or washing is carried out, and (b) the ionic strength and polarity of the hybridization and washing liquid. Hybridization requires that the two nucleic acids contain complementary sequences, but that inconsistencies can be tolerated depending on the stringency of the hybridization. Typically, hybridization of two sequences at high stringency (eg 0.5 × SSC solution, 65 ° C.) requires that these sequences are essentially completely homologous. Conditions of medium stringency (eg 2 × SSC, 65 ° C.) and conditions of low stringency (eg 2 × SSC, 55 ° C.) require correspondingly less overall complementarity between hybridization sequences. (1 × SSC is 0.15 M NaCl, 0.015 M Na Citrate). Preferred non-limiting examples of stringent hybridization zone guns are performed in 6X sodium chloride / sodium citrate (SSC) at about 65 ° C, followed by one or more washes in 0.2X SSC, 0.1% SDS strain at 50-65 ° C.

The terms peptide, protein and polypeptide can be used interchangeably herein.

The term "surface protein" as used herein refers to all proteins with surface access, such as inner and outer membrane proteins, proteins that adhere to cell walls, and secreted proteins.

If the polypeptide has one, two, and preferably two or more of the following properties, the polypeptide has the biological activity of Helicobacter pili: (1) When the polypeptide is expressed during Helicobacter pili infection, May promote or mediate attachment; (2) the polypeptide has the enzymatic activity, structure, or regulatory function properties of Helicobacter pylori protein; (3) the gene encoding the polypeptide can protect against lethal mutations in the Helicobacter pili gene; Or (4) has immunogenic properties to the subject. If a particular polypeptide is an antagonist, agonist or super-agonist of a polypeptide having one of the properties described above, the polypeptide is biologically active.

Biologically active fragments or analogs include one or more in vivo or in vitro activities, such as the biological activity described herein, that are characteristic of the Helicobacter Philoly polypeptides of the invention, or other native Helicobacter Philly polypeptides, listed in the Sequence Listing. To have. Particular preference is given to fragments present in vivo, for example fragments which arise during the posttranscriptional process or resulting from the translation of alternative spliced RNA. Fragments include fragments expressed in natural or endogenous cells as well as fragments made in expression systems such as CHO cells. Peptides, such as Helicobacter pylori polypeptides often exhibit a range of physiological properties, and useful Helicobacter pilori fragments or Helicobacter pilori analogues are useful for any biological assay for Helicobacter pilori activity because such properties are attributed to different parts of the molecule. In the biological activity. Most preferably, this fragment or analogue comprises at least 10%, preferably 40%, more preferably 60%, 70%, 80%, or 90% of the Helicobacter pylori activity in either in vivo or in vitro assays. Have

An analog can be different from the native Helicobacter pylori polypeptide in that the amino acid sequence is unrelated to the sequence, or in a manner that is not, or both. Non-sequence modifications include modifications by acetylation, methylation, phosphorylation, carboxylation or glycosylation. Preferred analogues include Helicobacter pylori polypeptides that differ in sequence from the wild-type sequence by one or more conserved amino acid substitutions, or by one or more non-conserved amino acid substitutions, deletions or insertions that do not substantially eliminate the biological activity of the Helicobacter pylori polypeptide. Or biologically active fragments thereof). Conservative substitutions usually include substituting one amino acid for another amino acid having similar properties, for example, substitutions in the following groups: valine, glycine; Glycine, alanine; Valine, isoleucine, leucine; Asphalt acid, glutamic acid; Asparagine, glutamine; Serine, threonine; Lysine, arginine; And phenylalanine, tyrosine. Other conservative substitutions are also possible in light of the table below.

Conserved amino acid substituents amino acid code Replaceable amino acids Alanine A D-Ala, Gly, β-Ala, L-cys, D-Cys Arginine R D-Arg, Lys, D-Lys, Homo-Arg, D-Homo-Arg, Met, Ile, D-Met, D-Ile, Orn, D-Orn Asparagine N D-Asn, Asp, D-Asp, Glu, D-Glu, Gln, D-Gln Aspartic acid D D-Asp, D-Asn, Asn, Glu, D-Glu, Gln, D-Gln Cysteine C D-Cys, S-Me-Cys, Met, D-Met, Thr, D-Thr Glutamine Q D-Gln, Asn, D-Asn, Glu, D-Glu, Asp, D-Asp Glutamic acid E D-Glu, D-Asp, Asp, Asn D-Asn, Gln, D-Gln Glycine G Ala, D-Ala, Pro, β-Ala, Acp Isoleucine I D-Ile, Val, D-Val, Leu, D-Leu, Met, D-Met Leucine L D-Leu, Val, D-Val, Leu, D-Leu, Met, D-Met Lee Sin K D-Lys, Arg, D-Arg, Homo-Arg, D-Homo-Arg, Met, D-Met, Ile, D-Ile, Orn, D-Orn Methionine M D-Met, S-Me-Cys, Ile, D-Ile, Leu, D-Leu, Val, D-Val Phenylalanine F D-Phe, Tyr, D-Thr, L-Dopa, His, D-His, Trp, D-Trp, trans-3,4 or 5-phenylproline, cis-3,4 or 5-phenylproline Proline P D-Pro, L-I-thiazolidine-4-carboxylic acid, D- or L-1-oxazolidine-4-carboxylic acid Serine S D-Ser, Thr, D-Thr, Allo-Thr, Met, D-Met, Met (O), D-Met (O), L-Cys, D-Cys Threonine T D-Thr, Ser, D-Ser, Allo-Thr, Met, D-Met, Met (O), D-Met (O), Val, D-Val Tyrosine Y D-Tyr, Phe, D-Phe, L-Dopa, His, D-His Valine V D-Val, Leu, D-Leu, Ile, D-Ile, Met, D-Met

Other analogs within the present invention are those modified to increase peptide stability. Such analogs may contain, for example, one or more non-peptide bonds (replacement of peptide bonds) in a peptide sequence. Also included are analogs and cyclic analogs comprising residues other than natural L-amino acids, such as D-amino acids or non-natural or synthetic amino acids such as β or γ amino acids.

As used herein, the term “fragment” will usually be at least about 20 residues, more typically at least about 40 residues, preferably at least about 60 residues, as corresponds to the Helicobacter pylori analog. Fragments of Helicobacter pylori polypeptides can be prepared by methods known to those skilled in the art. The ability of a candidate fragment to exhibit the biological activity of a Helicobacter Philoly polypeptide can be assessed by methods known to those skilled in the art as described herein. Also included are Helicobacter pylori polypeptides that contain residues that are not necessary for the biological activity of the peptide or result from alternative mRNA splicing or alternative protein processing operations.

As used herein, an “immunogen component” is a component such as a Helicobacter Philoly polypeptide, analog or fragment thereof that can elicit a hormonal system and / or cellular immune response in a host animal.

As used herein, an “antigen component” is a component such as a Helicobacter pili polypeptide, analog or fragment thereof capable of binding to a specific antigen with a high enough affinity to form a detectable antigen-antibody complex.

As used herein, the term "transgene" refers to a part or all of which is heterologous to the transgenic animal or cell into which the gene is introduced, ie exogenous to, or endogenous of the transgenic animal or cell into which the gene is introduced. Homologous to the gene, but is designed to be inserted into the cell genome in a way that modifies the genome of the cell into which it is inserted (eg, inserted at a different position than the native gene or the insertion causes knockout), Or a nucleic acid to be inserted (eg, encoding one or more polypeptides). Transgenes include any other nucleic acid, such as an intron, which is essential for optimal expression of one or more transcriptional regulatory sequences and secretory nucleic acids, all operably linked to selected nucleic acids, and which may include enhancer sequences.

As used herein, the term “transformed cell” refers to a cell containing a transgene.

As used herein, a “transgenic animal” is any animal in which at least one of the cells of the animal, and preferably essentially all cells, comprises a transgene. The transgene can be introduced into the cell either directly or indirectly by introduction into the cell precursor, by deliberate genetic manipulation such as transformation of appropriate cells or by micro injection, or by infection with recombinant virus.

As used herein, the term "antibody" is intended to include fragments thereof that are specifically reactive with Helicobacter pylori polypeptide.

As used herein, the term "cell-specific promoter" refers to a DNA sequence that acts as a promoter, ie regulates the expression of a selected DNA sequence operably linked to a promoter, and performs expression of a selected DNA sequence in a particular cell of tissue. Means. The term also encompasses "leaky" promoters, which primarily regulate the expression of selected DNA in one tissue, but cause expression in another.

Misexpression as used herein refers to a non-wild type pattern of gene expression. Misexpressions include expression at non-wild-type levels, ie excessive or insufficient expression; Expression patterns that differ from the wild type in terms of time or stage of gene expression, such as increased or decreased expression (relative to wild type) in a predetermined period or stage of development; Expression patterns different from wild type in that expression is reduced (relative to wild type) in a given cell or tissue type; Expression patterns different from wild type in terms of splicing size, amino acid sequence, post-translational modification, or biological activity of the expressed polypeptide; Expression patterns different from wild type in terms of the effect of environmental or extracellular stimulation on gene expression, such as increased or decreased expression patterns (relative to wild type), under increasing or decreasing stimulus intensity.

As used herein, the term "host cell" and other terms referring to higher eukaryotic cells cultured as microorganisms or asexuals refer to cells that can be or have been used as receptors for recombinant vectors or other transfer DNA and are transfected. Progeny of blast cells are also included. Those skilled in the art will appreciate that the progeny of a single parent cell need not be identical to the genome or whole DNA from the original parent due to accidental or planned variation.

As used herein, the term "regulatory sequence" refers to a nucleic acid having a base sequence that is recognized by the host organism to effect expression of the coding sequence, wherein the regulatory sequence is ligated to the coding sequence. The nature of these regulatory sequences varies with the host organism; For prokaryotic cells such regulatory sequences generally include a promoter, ribosomal binding site, terminator, and in some cases an operator; In eukaryotes, these regulatory sequences generally include a promoter, terminator and in some cases an enhancer. The term regulatory sequence is used to encompass the minimum of all components that must be present essentially for expression and, if present, may also include disadvantageous additional components, eg, leader sequences.

As used herein, the term "operably linked" means sequences that are linked or ligated to function in a desired manner. For example, a regulatory sequence is operably linked to a coding sequence by ligation in such a manner that expression of the coding sequence is achieved under conditions compatible with the regulatory sequence and the host cell.

As used herein, metabolism refers to all aspects of the expression, function, function or regulation of a substance. Metabolism of a substance includes modifications, such as covalent or non-covalent modifications of that substance. Metabolism of one substance includes covalent or non-covalent modifications that the substance induces in another substance. Metabolism of a substance involves altering its distribution. Metabolism of one substance involves the change caused by that substance in the distribution of another substance.

As used herein, "sample" refers to a biological sample such as, for example, an individual or tissue isolated from an in vitro cell culture component, or a fluid (including plasma, serum, cerebrospinal fluid, lymph, tears, saliva, and tissue slices). As well as samples from the environment.

The practice of the present invention will use techniques of conventional chemistry, molecular biology, microbiology, recombinant DNA and immunology, unless otherwise noted, which techniques are within the skill of the art. Such techniques are explained fully in the literature. See Sambrook, Fritsch, and Maniatis, Molecular Cloning; Laboratory Manual 2nd ed. (1989); DNA Cloning, I and II (D.N. Glover ed. 1985); Oligonucleotide Synthesis (M. J. Gait ed, 1984); Nucleic Acid Hybridization (B.D. Hames & S.J. Higgins eds. 1984); Series, Methods in Enzymoloqy (Academic Press, Inc.), especially books 154 and 155 (Wu and Grossman, eds.) And PCR-A Practical Approach (McPherson, Quirke, and Taylor, eds., 1991).

I. Nucleic Acid Isolation of Helicobacter Philosophy and Uses thereof

Helicobacter Philoly Genome Sequence

The present invention provides the nucleotide sequence of the genome of Helicobacter pili, and thus includes the DNA sequence library of Helicobacter pili genomic DNA. The following detailed description provides the nucleotide sequences of Helicobacter pylori, and also describes how to obtain the sequences and how to identify ORF and protein-encoding sequences. Also described are methods of using the described Helicobacter pylori sequences in methods, including diagnostic and therapeutic uses. This library can also be used as a database for the identification and comparison of medically important sequences in Helicobacter pylori strains and other strains.

To determine the genomic sequence of Helicobacter pili, DNA was isolated from Helicobacter pili (ATCC # 55679) strain and mechanically sheared to a median size of 2 kb by atomization. After size fractionation by gel electrophoresis, the fragments were blunt-ended, ligated to adapter oligonucleotides and cloned into each of 20 different pMPX vectors (Rice et al., Meeting of Genome Mapping and Abstract, Sequencing, Cold Spring Harbor, NY, 5 / 11-5 / 15, 1994, page 225) A series of "shotgun" subclone libraries were prepared.

DNA sequencing was fundamentally performed using various sequencing methods described in Church et al. Church et al., 1988, Science 240: 185; U.S. Patent Nos. 4,942,124 and 5,149,625. DNA was extracted from the pooled cultures and subjected to chemical or enzymatic sequencing. Sequencing reactions were analyzed by electrophoresis and the product was transferred and covalently bound to the nylon membrane. Finally, the membrane was hybridized with a series of labeled oligonucleotides complementary to the "tag" sequences present in the different shotgun cloning vectors. In this way, multiple sequences could be obtained from a set of sequencing reactions. Cloning and sequencing procedures are described in more detail in the Examples.

The individual sequence readings obtained in this manner were reported by FALCON ™ (Church et al., 1994, Automated DNA Sequencing and Analysis, JC Venter, ed., Academic Press) and PHRAP (P. Green, Abstracts of DOE Human Genome Program). Assembly using Contractor-Grantee Workshop V. Jan. 1966, page 157). The average contig length was about 3-4 kb.

Various approaches were used to arrange the contigs to obtain contiguous sequences representative of the entire Helicobacter Philo genome. Synthetic oligonucleotides were designed to be complementary to the sequence at each contig end. This oligonucleotide can be hybridized to a library of Helicobacter Philo genome DNA, for example in lambda phage vectors or plasmid vectors, to identify clones containing sequences corresponding to the conjugation regions between individual contigs. This clone was then used to isolate the template DNA and use the oligonucleotides as primers in the polymerase chain reaction (PCR) to amplify the conjugate fragments and then determine their nucleotide sequences.

This Helicobacter pylori sequence was analyzed for the presence of an open reading frame (ORF) comprising 180 or more nucleotides. As a result of ORF analysis based on stop codons versus stop codon readings, it is apparent that the ORF may not correspond to the ORF of the native Helicobacter pylori polypeptide. The ORF may contain an initiation codon, which means the initiation of protein synthesis of a native Helicobacter Philoly polypeptide. Such initiation codons within the ORFs provided herein will be apparent to those of ordinary skill in the art, and the resulting ORFs and encoded Helicobacter pylori polypeptides are included within the scope of the present invention. For example, codons such as AUG or GUG (coding methionine or valine), which are part of the initiation signal of protein synthesis in the ORF, can be identified and the ORF can be modified to correspond to the native Helicobacter Philoly polypeptide. The predicted coding region was defined by evaluating the coding potential of this sequence with the program GENEMARK ™ (Borodovsky and McIninch, 1993, Comp. Chem. 17: 123).

Other Helicobacter Floride Nucleic Acid

Nucleic acids of the invention can be obtained directly from the DNA of the aforementioned Helicobacter pylori strains using polymerase chain reaction (PCR). For details of PCR, see “PCR, A Practical Approach” (McPherson, Quirke and Taylor, eds., IRL Press, Oxford, UK, 1991). Highly reliable PCR can be used to confirm reliable DNA copies prior to expression. In addition, the amplification of the amplified product can be examined by a conventional sequencing method.Clones carrying the desired sequences described in the present invention can also be screened by PCR or synthetic oligonucleotides can be obtained from library colonies. By hybridization to filter lifts or plaques known in the art, see Sambrook et al., Molecular Cloning, A Laboratory Manual 2nd edtion, 1989, Cold Spring Harbor Press, NY.

It is also possible to obtain nucleic acids encoding Helicobacter pylori from cDNA according to the protocol described herein. CDNA encoding Helicobacter pylori can be obtained by isolating whole mRNA from suitable strains. Double stranded cDNA can then be prepared from total mRNA. The cDNA can then be inserted into a suitable plasmid or viral (eg bacteriophage) vector using any of a myriad of known techniques. Genes encoding Helicobacter pilori polypeptides can be cloned using established polymerase chain reactions according to the nucleotide sequence information provided herein. The nucleic acid of the present invention may be DNA or RNA. Preferred nucleic acids of the invention are described in the sequence listing.

Nucleic acids of the invention can also be chemically synthesized using standard techniques. Various methods of chemically synthesizing polydeoxynucleotides are known, which, like peptide synthesis, include fully automated solid phase synthesis with a commercial DNA synthesizer. See, eg, Itakura et al., US Pat. No. 4,598,049; Caruthers et al., US Pat. No. 4,458,066; And Itakura US Pat. Nos. 4,401,769 and 4,373,071, which are incorporated herein by reference.

Nucleic acids isolated or synthesized in accordance with the features of the present invention are not limited, but are useful in developing expression systems for example as probes, primers, capture ligands, antisense genes, and for the synthesis of proteins and peptides corresponding to such sequences. As probes, primers, capture lagines and antisense agents, it is common for the nucleic acid to consist of all or part of the nucleic acids of the invention described in the sequence listing (about 20 or more nucleotides for the ability to form specific and stable hybridization products). . Such uses are described in more detail below.

Probe

Helicobacter phyllori can be specifically detected using nucleic acids isolated or synthesized according to the sequences of the invention described in the Sequence Listing as probes. In the sequence information described herein, 20 or more nucleotide sequences have been identified that provide the desired inclusiveness and exclusivity for Helicobacter phyllori, and are likely to encounter foreign nucleic acids during hybridization conditions. More preferably, this sequence will comprise at least 20 to 30 nucleotides to deliver stability to the hybridization product formed between the probe and the desired target molecule.

Sequences longer than 1000 nucleotides in length are difficult to synthesize, but can be produced by recombinant DNA techniques. Those skilled in the art will readily appreciate that nucleic acids useful as probes can be provided with a label to facilitate detection of hybridization products.

Isolated and synthesized nucleic acids according to the sequences of the invention described in the Sequence Listing are also useful as probes for detecting homologous regions (particularly homologous genes) of other Helicobacter species using the appropriate stringency hybridization conditions described herein.

Capture ligands

When used as a capture ligand, nucleic acids selected in the manner described above for probes can be easily associated with a support. Methods of associating nucleic acids with a support are known. Nucleic acids having 20 or more nucleotides of the sequences of the invention described in the Sequence Listing are useful for separating Helicobacter pylori nucleic acids from nucleic acids of each other and other organisms. Nucleic acids having 20 or more nucleotides of the sequences of the invention listed in the Sequence Listing are also useful for separating different Helicobacter species, or other Helicobacter species from different organisms. Preferably, this sequence comprises at least 20 nucleotides to deliver stability to the hybridization product formed between the probe and the desired target molecule. Sequences longer than 1000 nucleotides in length are difficult to synthesize but can be produced by recombinant DNA techniques.

primer

Nucleic acids isolated or synthesized according to the sequences described herein are useful as primers for the amplification of Helicobacter pylori nucleic acids. This nucleic acid is also useful as a primer for the amplification of nucleic acids in other Helicobacter species. In polymerase chain reaction (PCR) techniques, the nucleic acid sequences of the 10-15 or more nucleotides of the invention described in the Sequence Listing are useful for making copies of Helicobacter pylori nucleic acids with suitable enzymes and reagents. More preferably, this sequence comprises at least 20 nucleotides to transfer stability to the hybridization product formed between the primer and the desired target molecule. Binding conditions of primers greater than 100 nucleotides are more difficult to control to have specificity. High reliability PCR can be used to confirm reliable DNA copies prior to expression. In addition, the amplified product can be examined by conventional sequencing methods.

This copy can be used in diagnostic assays to detect specific sequences, including genes from Helicobacter pili and / or other Helicobacter spp. This copy may be introduced into a cloning and expression vector to generate a polypeptide corresponding to the nucleic acid synthesized by PCR, as described in more detail herein.

Antisense

Nucleic acids or nucleic acid-hybridized derivatives isolated or synthesized according to the sequences described herein are useful for preventing the expression of the Helicobacter pili gene as an antisense factor. This sequence is also useful as an antisense factor in preventing gene expression of other Helicobacter species.

In one example, derivatives corresponding to nucleic acids or Helicobacter pylori nucleic acids are loaded into a suitable carrier such as liposomes or bacteriophages for introduction into bacterial cells. For example, nucleic acids having 20 or more nucleotides can bind to bacterial nucleic acids or bacterial messenger RNA. It is preferred that the antisense nucleic acid comprises at least 20 nucleotides in order to provide the necessary stability of the hybridization product of the non-natural nucleic acid and bacterial nucleic acid and / or bacterial messenger RNA. Nucleic acids having sequences longer than 1000 nucleotides in length are difficult to synthesize but can be produced by recombinant DNA techniques. Methods of loading antisense nucleic acids into liposomes are known in the art, for example in US Pat. No. 4,241,046, issued December 23, 1980 to Papahadjopoulos et al.

II. Expression of Helicobacter Floriri Nucleic Acid

Nucleic acids isolated or purified according to the sequences described herein are useful for polypeptide production. Fragments of such nucleic acids encoding the active portions of the nucleic acids or Helicobacter phyllori of the invention exemplified in the Sequence Listing can be cloned into suitable vectors or used to isolate nucleic acids. Isolated nucleic acid is cloned into a suitable vector in combination with a suitable DNA linker.

The function of a specific gene or operon can be confirmed by expression in a bacterial strain under conditions that can specifically measure the activity of the gene or gene product specified by that operon. Alternatively, gene products can be mass produced in expression strains for industrial reagents as antigens and for structural studies. Such expression can be performed in variant strains lacking the activity of the gene being tested, or in strains that do not produce the same gene product. This includes other Helicobacter strains. E. coli, Norcardia, Corynebacterium, Campylobacter and Streptomyces species, but are not limited to these. In some cases, the expression host uses a native Helicobacter promoter, while in other cases with a promoter sequence derived from the expressing organism (eg, the E. coli beta-galactosidase promoter when expressed in E. coli). It is essential to operate the gene.

The following procedure can be used to express gene products using a native Helicobacter Philoly promoter. Restriction fragments containing the genes of interest, along with their native promoter factors and regulatory sequences (identified using DNA sequence data), are cloned into appropriate recombinant plasmids having a replication initiation functioning in the host organism and appropriate selectable markers. . This can be done using a myriad of procedures known to those skilled in the art. Most preferably, the plasmids and fragments to be cloned are cut with the above restriction enzymes to produce suitable ends capable of linking the two fragments together by ligation. This recombinant plasmid was introduced into the host cell using, for example, electroporation, and the cell containing the recombinant plasmid was identified by selecting as a marker for the plasmid. Expression of the desired gene product is detected using assays specific for the gene product.

For genes that require different promoters, the gene bodies (coding sequences) are specifically cleaved and cloned into appropriate expression plasmids. This subcloning can be accomplished by several methods, most likely by PCR amplification of specific fragments and treatment of this PCR product with restriction enzymes or exonucleases followed by ligation into the expression plasmid to make ends suitable for cloning. It is easily carried out.

Suitable host cells for the expression of a gene can be any prokaryotic or eukaryotic cell. For example, helicobacter pylori. It can be expressed in bacterial cells such as E. coli, insect cells (baculovirus), yeast, or mammalian cells such as Chinese hamster oocytes (CHO). Other suitable host cells are also known in the art.

Expression in eukaryotic cells such as mammalian, yeast or insect cells can result in partial or total glycosylation and / or formation of interchain or interchain disulfide bonds that are involved in the recombinant peptide product. Yeast, S. Examples of vectors for expression in S. cervisae include pYepSec1 (Baldari, et al., (1987) Embo J. 6: 229-234), pMFa (Kurjan and Herskowitz, (1982) Cell 30: 933-943), pJRY88 (Schultz et al., (1987) Gene 54: 113-123), and pYES2 (Invitrogen Corporation, San Diego, Calif.). Baculovirus vectors that can be used for protein expression in cultured insect cells (SF9 cells) include pAc-based (Smith et al., (1983) Mol. Cell Biol. 3: 2156-2165) and pVL-based (Lucklow, VA, and Summers, MD, (1989) Virology 170: 31-39. In general, COS cells (Gluzman, Y., (1981) Cell 23: 175-182) are described in pCDM 8 (Aruffo, A. and Seed, B., (1987) Proc. Natl. Acad. Sci. USA 84: 8573-8577) and are used for amplification / expression in mammals, while CHO (Chinese hamster oocytes) cells can be used with pMT2PC (Kaufman et al. (1987), ENBO J. 6: 187-195) Used with the same vector for stable amplification / expression in mammalian cells. Vector DNA can be introduced into mammalian cells through conventional techniques such as calcium phosphate or calcium chloride coprecipitation, DEAED-dextran-mediated transfection, or electroporation. Suitable host cell transformation methods can be found in Sambrook's literature and other laboratory data. Sambrook et al. (Molecular Cloning: A laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989)).

Expression in prokaryotic cells is most often accompanied by E. coli with a fusion or non-fusion inducible expression vector. Performed in coli. Fusion vectors usually add multiple NH ₂ terminal amino acids to the expressed target gene. Such NH ₂ terminal amino acids are often called reporter groups. Such reporter groups are commonly used for two purposes: 1) to increase the solubility of the target recombinant protein, and 2) to help purify the target recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, cleavage sites by proteolytic enzymes are introduced at the junction of the reporter group with the target recombinant protein to allow purification of the fusion protein followed by separation of the target recombinant protein from the reporter group. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Common fusion expression vectors include pGEX (Amrad Corp., Melbourne, Australia), pMAL (New England Biolabs, Beverly, Mass.) And pRIT5 (Pharmacia, Piscataway, NJ), and these vectors include glutathione S in the target recombinant protein. -Transfer the transferase, maltose E binding protein, or protein A, respectively. Preferred reporter groups are poly (His) and can be fused to the amino or carboxy terminus of the protein, by which the recombinant fusion protein can be readily purified by metal chelate chromatography.

Inducible non-fusion expression vectors include pTrc (Amann et al., (1988) Gene 69: 301-315) and pET11d (Studier et al., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California ( 1990) 60-89). While target gene expression depends on host RNA polymerase transcription from the hybrid trp-lac fusion promoter in pTrc, expression of the target gene inserted into pET11d is mediated by T7 gn10 mediated by RNA polymerase (T7 gnl) of the simultaneously expressed virus. depends on transcription from the -lac 0 fusion promoter. This viral polymerase is supplied by host strain BL21 (DE3) or HMS174 (DE3) from an intrinsic lambda propage with T7 gnl under the transcriptional control of the lacUV5 promoter.

For example, host cells transfected with a nucleic acid vector that directs the expression of a nucleotide sequence encoding Helicobacter phyllori can be cultured under appropriate conditions that result in expression of this polypeptide. This polypeptide can be secreted and isolated from a mixture of cells and medium containing it. Alternatively, the polypeptide may be retained cytoplasmically, and the cells may be harvested and lysed to isolate the protein. Cell cultures include host cells, media and other byproducts. Suitable media for cell culture are known in the art. Polypeptides of the invention can be isolated from cell culture medium, host cells or both using protein purification techniques known in the art. Such purification techniques include ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and immunoaffinity purification using antibodies specific for the polypeptide. In addition, in many situations polypeptides can be produced by chemical cleavage of natural proteins (eg, by trypsin) and the cleavage products can be purified by standard techniques.

In the case of membrane binding proteins, protein fragments associated with the membrane can be isolated from the host cell by contact with a detergent to form a solubilized complex, wherein the protein associated with the membrane is no longer fully embedded in the membrane fragment and at least Isolation from membrane fragments by chromatography is dissolved to the extent possible. Several different criteria are used to select suitable detergents for dissolving such complexes. For example, one property to be considered is a detergent that dissolves Helicobacter pylori protein in membrane fragments with minimal denaturation of the protein associated with the membrane to restore the activity or function of the protein associated with the membrane upon protein reconstitution. Is the ability. Another property to be considered when selecting a detergent is that the detergent selected as the critical micelle concentration (CMC) of the cleaner preferably has a high CMC value to facilitate removal after reconstitution. The third property to be considered when selecting a cleaner is the hydrophobicity of the cleaner. Typically, proteins associated with membranes are very hydrophobic and therefore also hydrophobic, for example triton based detergents will be useful for dissolution of hydrophobic proteins. Another important property for detergents is their ability to remove Helicobacter pylori protein with minimal protein-protein interactions to facilitate further purification. The fifth property of a cleaner to be considered is the charge of the cleaner. For example, if it is desired to use an ion exchange resin in the purification process, the cleaner should be a charge free cleaner. Chromatography techniques that can be used in the final purification step are known in the art and include hydrophobic interactions, lectin affinity, ion exchange, dye affinity and immunoaffinity.

this. One strategy for maximizing expression of recombinant Helicobacter phyllori in E. coli is to express the protein in a host bacterium impaired in its ability to cleave the recombinant protein by proteolytic enzymes. (Gottesman, S., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to express a nucleic acid encoding a Helicobacter pili peptide that is to be inserted into an expression vector with a highly expressed individual codon for each amino acid. The E. coli protein is changed to be the first to use. (Wada et al., (1992) Nuc.Acids Res. 20: 2111-2118). Such nucleic acid alterations of the invention can be carried out by standard DNA synthesis techniques.

Nucleic acids of the invention can also be chemically synthesized using standard techniques. Various methods of chemical synthesis of polydeoxynucleotides are known, including solid phase synthesis, which is fully automated with commercially available DNA synthesizers like peptide synthesis (e.g., herein by reference). See US Pat. No. 4,598,049 to Itakura et al., US Pat. Nos. 4,458,066 to Carruthers et al., And US Pat. Nos. 4,401,796 and 4,373,071 to Atakura, cited.

III. Helicobacter Philolyte Polypeptide

The present invention includes isolated Helicobacter Philosophy encoded by the published Helicobacter Philosophy genomic sequence, including the polypeptides of the invention described in the Sequence Listing. The polypeptide of the invention is preferably at least 5 amino acid residues in length. Using the DNA sequence information provided herein, the amino acid sequence of a polypeptide included in the present invention can be inferred by methods known in the art. Of course, the sequence of the entire nucleic acid encoding Helicobacter phyllori can be isolated and identified based on an ORF encoding only a fragment of the cognate protein-coding region. This can be accomplished, for example, by using an isolated nucleic acid encoding an ORF, or as a fragment thereof, to initiate a polymerase chain reaction with genomic Helicobacter pili DNA as a template and then sequence the amplified product.

Polypeptides of the invention can be isolated from wild-type or variant Helicobacter pili cells expressing and expressed from Helicobacter pili nucleic acid or from heterologous organisms or cells (including bacteria, yeasts, insects, plants and mammalian cells, etc.). In addition, the polypeptide may be part of a recombinant fusion protein.

The Helicobacter pylori polypeptide of the invention can be chemically synthesized using commercial automated methods such as those recited herein.

In addition, the Helicobacter pylori polypeptide of the present invention includes the chimeric protein and truncated protein described herein.

Chimeric Helicobacter Philolyte Protein

Helicobacter philolychimeric polypeptides comprise one or more Helicobacter phyllori polypeptides fused together. This combination sequence comprises two or more genes, or sequences encoding two or more polypeptides, or one or more genes and one or more polypeptide coding sequences, followed by sequential expression of the encoded sequences by conventional molecular biological techniques. It can manufacture by. Combination nucleotide sequences may consist of a combination of a full length Helicobacter Philoly nucleotide sequence or a fragment of the sequence, eg, a fragment containing an immunologically relevant portion of the Helicobacter Philly protein encoded. These chimeric Helicobacter pilori proteins contain the vaccine efficacy of the combined or synergistic effect of each Helicobacter pili protein sequence and can be used in the vaccine formulations of the invention.

Truncated gene expression and protein production

In addition, the Helicobacter pylori protein encoded by a given nucleotide sequence can be used in truncated biologically active form. Such truncation can be generated, for example, by removal of the 5 'and / or 3' region of the coding nucleotide sequence. Such truncation may affect recombinant expression of the protein to be encoded and / or subsequent purification of the protein. For example, the truncation of the nucleotide sequence encoding the expected export sequence of a particular protein can alter the expression of the protein. Alternatively, C-terminal truncation of the Helicobacter Philoly polypeptide by removal of the 3 'end of the nucleic acid coding region can also improve protein expression and subsequent purification and use as outlined in Example VIII. Deletion of the nucleic acid region encoding the internal Helicobacter pylori protein region may improve protein expression, purification and / or efficacy as a vaccine candidate.

IV. Identification of Vaccine Components and Targets for Nucleic Acids Effective against Helicobacter Philoly

The described Helicobacter pylori genomic sequence includes segments that direct the synthesis of ribonucleic acid and polypeptides, as well as the origin of replication, promoters, other types of regulatory sequences and endogenous nucleic acids. The present invention encompasses nucleic acids encoding immunogenic components of vaccines and targets for factors that are effective against Helicobacter phyllori. Identification of such immunogen components is involved in determining the function of the described sequences and can be performed using a variety of approaches. Non-limiting examples of this approach are briefly described below.

Homology to Known Sequences: Computer-assisted comparison of the described Helicobacter Philoly sequences with already reported sequences present in a commercial database is useful for identifying functional Helicobacter Philolylic nucleic acid and polypeptide sequences. For example, protein coding sequences can be compared entirely, and if the sequence homology between the two proteins at the amino acid level is high (eg greater than 80 to 90%) then the two proteins also have some degree of functional homology, for example It is also meant to have homology, such as enzymes involved in metabolism, DNA synthesis, or cell wall synthesis, and proteins involved in transport, cell division, and the like. In addition, many structural properties of certain protein classes have been identified, which include, for example, binding domains for nucleotides, DNA, metal ions and other small molecules; Covalent modification denaturing sites such as phosphorylation, acylation, etc .; Correlated with specific consensus sequences such as protein: protein interaction sites and the like. This consensus sequence is very short and will therefore represent only one fragment of the entire protein coding sequence. Therefore, identifying these features in the Helicobacter Philoly sequence is useful for determining the function of the encoded protein and for identifying useful targets of antimicrobial drugs.

A particular relevance of the present invention is the structural features common to secretion, transmembrane and surface proteins, including secretory signal peptides and hydrophobic transmembrane domains. Helicobacter phylloprotein, which is estimated to contain a signal sequence and / or a transmembrane domain, is useful as an immunogenic component of a vaccine.

Identification of essential genes: Nucleic acids encoding proteins essential for the proliferation or survival of Helicobacter Philophyll are preferred drug targets. Techniques known to those skilled in the art can be used to test the biological relevance of the Helicobacter pili gene to an organism by investigating the effect of deleting and / or destroying the gene, ie the so-called gene "knockout". In this way, essential genes can be identified.

Strain-Specific Sequences: Because of the evolutionary relationship between different Helicobacter Philophyllium strains, it is contemplated that the currently published Helicobacter Philolyll sequences are useful for identification and / or identification between known and novel Helicobacter pylori strains. It is contemplated that other Helicobacter pylori strains will exhibit at least 70% sequence homology with the currently published sequence. Systematic and routine analysis of DNA sequences derived from samples containing Helicobacter pylori strains, as well as sequences that can be used for strain identification through comparison with existing sequences, can also identify sequences common to all Helicobacter pili strains. Do. In one example, the present invention provides nucleic acids, peptides and polypeptides, including probes, which can identify different Helicobacter pili strains. Strain specific components can also be functionally identified by their ability to elicit or react with antibodies that selectively recognize one or more Helicobacter pylori strains.

In another example, the present invention provides nucleic acids, including peptides and polypeptide sequences, including probes common to all Helicobacter pylori strains, but not found in other bacterial species.

Embodiments: Determination of Candidate Protein Antigens for Antibody and Vaccine Development

The selection of candidate protein antigens for vaccine development can result from nucleic acids encoding Helicobacter pylori polypeptides. First, ORFs were analyzed for other known exported and membrane proteins and for homology using Klein, et al., An identifier assay described by Klein, et al. (Klein, P., Kanehsia, M., and DeLisi, C. (1985) Biochimica et Biophysica Acta 815, 468-476).

Homology searches were performed using the BLAST algorithm contained in the Wisconsin sequencing package (Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711) with all sequences present in the current GenBank, SWISS-PROT, and PIR databases. Each predicted ORF amino acid sequence can be compared. BLAST retrieves the local arrangement between the ORF and the databank sequence and represents a likelihood score that indicates the likelihood of accidentally finding this sequence in the data database. ORFs with significant homology to the membrane or excretory protein (eg, likelihood of ¹ × 10 ⁻⁶ or less due to homology only due to random opportunities) represent protein antigens for vaccine development. Based on sequence homology to genes cloned in other organisms, appropriate functions can be provided to the Helicobacter pili gene.

Discriminant analysis (Klein, et al., Supra) can be used to examine the ORF amino acid sequence. This algorithm uses the unique information contained in the ORF amino acid sequence and compares it with information derived from the properties of known membranes and excreted proteins. This comparison can infer whether the protein is an excretory protein, a protein associated with the membrane, or a cytoplasmic protein. The ORF amino acid sequence determined to be excreted or membrane associated protein by this algorithm appears to be the protein antigen for vaccine development.

The outer membrane protein exposed to the surface is believed to present the best antigen that provides a protective immune response against Helicobacter Philophyll. Algorithms that can be used in predicting the outer membrane protein include the presence of an amphoteric beta-sheet region at its C terminus. Such regions detected in a large number of outer membrane proteins of Gram-negative bacteria are often characterized by hydrophobic residues (Phe or Tyr) clustered at alternating positions from the C terminus (eg block F in FIG. 5; see block E in FIG. 7). ). Importantly, these sequences are not detected at the C terminus of the periplasmic protein so that these types of proteins can be distinguished based on primary sequence data. This phenomenon is described by Struyve et al., J. Biol. 218: 141-148, 1991).

1 also illustrates additional amino acid sequence motifs found in many outer membrane proteins of Helicobacter Philophyll. In Fig. 5, the amino acid sequence sequence shows a part of the sequence of five Helicobacter phyllori (indicated by the one letter amino acid code) shown by its amino acid sequence number and shown from left to right and from N to C terminals. 5 or 6 distinct blocks of similar amino acid residues (A through to), including distinct hydrophobic residues (Phe or Tyr; F or Y according to the one letter code of amino acid residues) often found at positions near the C terminus of the outer membrane protein. Represented by E or F). The presence of several covalent motifs clearly establishes similarities between members of the proteins of this group.

In addition, outer membrane proteins isolated from Helicobacter phyllori often share a motif near the mature N terminus (ie, after processing for removal of the secretion signal), as indicated by the block in FIG. 2. Figure 2 depicts the N terminus of three Helicobacter pylori proteins (denoted by amino acid sequence number, the N terminus on the left and the C terminus on the right).

Those skilled in the art will appreciate that these covalent sequence motifs are very important and establish similarities between proteins of this group.

Rarely, it is not possible to identify a large number of nucleic acids that may be at a given position in the nucleic acid sequence. In this case, ambiguity is indicated by the extended alphabet as follows.

The following is the official IUPAC-IUB single letter base code.

Code Base Description

G guanine

A adenine

T thymine

C cytosine

R purine (A or G)

Y pyrimidine (C or T or U)

M amino (A or C)

K ketone (G or T)

S strong interaction (C or G)

W weak interaction (A or T)

Not H G (A or C or T)

Not B A (C or G or T)

Not V T (not U) (A or C or G)

Not D C (A or G or T)

N any base (A or C or G or T)

The amino acid translation of the present invention makes the nucleic acid unambiguous by deciphering the obscure codon of the letter “X”. In all cases, acceptable amino acid residues at specific positions are evident by examining the nucleic acid sequence based on the standard genetic code.

V. Production of Fragments and Analogs of Helicobacter Philoyl Nucleic Acids and Polypeptides

Based on the discovery of the Helicobacter pilori gene product of the present invention provided in the Sequence Listing, those skilled in the art will be able to alter the published structure (of the Helicobacter pilori gene), for example by producing fragments or analogs, and to modify the activity of the newly produced construct. Can be tested Examples of techniques known to those skilled in the art that can produce and test fragments and analogs are discussed below. Such or similar methods can be used to screen a library of polypeptides, such as libraries of random peptides or libraries of fragments or analogs of cytoplasmic proteins, to bind the Helicobacter Philoly polypeptide. Such screens are useful for identifying inhibitors of Helicobacter pylori.

Preparation of Fragments

Fragments of proteins can be produced in several ways, for example by recombination, proteolytic digestion, or chemical synthesis. Internal or terminal fragments of a polypeptide can be prepared by removing one or more nucleotides from one terminal (for terminal fragments) or sock end (for internal fragments) of the nucleic acid encoding the polypeptide. Expression of the mutated DNA produces polypeptide fragments. Thus, cleavage with an "end-nibbling" endonuclease can produce DNA encoding a row of fragments. DNA encoding a fragment of the protein may also be prepared by random shearing, restriction truncation or a combination of the methods discussed above.

The fragments may also be chemically synthesized using techniques known in the art, such as conventional Merrifield solid phase f-Moc or t-Boc chemistry. For example, the peptides of the present invention may optionally be divided into fragments of desired length without overlapping fragments or divided into overlapping fragments of desired length.

Alteration of Nucleic Acids and Polypeptides: a Random Method

Amino acid variants of a protein can be prepared by random mutations in the DNA encoding the protein or specific domains or regions of the protein. Useful methods include PCR mutagenesis and saturation mutagenesis. Libraries of random amino acid sequence variants can also be prepared by synthesis of a set of denatured oligonucleotide sequences (methods of screening proteins in variant libraries are described elsewhere herein).

(A) PCR mutagenesis

In PCR mutagenesis, low-reliability Taq polymerase is used to introduce random mutations into cloned fragments of DNA (Leung et al., 1989, Technique 1: 11-15). DNA region to be mutated using polymerase chain reaction (PCR), for example using a dGTP / dATP ratio of 5 and adding Mn ²⁺ to the PCR reaction, thereby lowering the reliability of DNA synthesis by Taq DNA polymerase. Amplified under conditions. A pool of amplified DNA fragments is inserted into a suitable cloning vector to obtain a random variant library.

(B) Saturation mutagenesis

It is possible to rapidly introduce multiple monobase substitutions into cloned DNA fragments through saturation mutagenesis (Mayers et al., 1985, Science 229: 242). This technique includes, for example, the generation of mutations by chemical treatment or irradiation of single stranded DNA ex vivo. The frequency of variation can be adjusted by adjusting the severity of the treatment and essentially all possible base substitutions can be obtained. Since this procedure does not involve genetic selection for variant fragments, both neutral substitutions and substitutions with altered functions are obtained. The distribution of point mutations is not biased towards conserved sequence elements.

(C) denatured oligonucleotides

Mammalian libraries can also be prepared from a set of denatured oligonucleotide sequences. Chemical synthesis of the denatured sequences can be performed with an automated DNA synthesizer and then the synthetic genes can be ligated into a suitable expression vector. Synthesis of denatured oligonucleotides is known in the art (eg, Narang, SA (1983) Tetrahedron 39: 3; Itakura et al. (1981) Recombinant DNA, Proc 3rd Cleveland Sympos. Macromolecules, ed. AG Walton, Amsterdam See Elsevier pp 273-289; Itakura et al. (1984) Annu. Rev, Biochem. 53: 323; Itakura et al. (1984) Science 198: 1056; Ike et al, (1983) Nucleic Acid Res. 11: 477 ). This technique is also used to alter the manipulation of other proteins. (See, eg, Scott et al. (1990) Science 249: 386-390; Roberts et al. (1992) PNAS 89: 2429-2433; Devlin et al. (1990) Science 249: 404-406; Cwirla et al. (1990) PNAS 87: 6378-6382; and US Pat. Nos. 5,223,409, 5,198,346 and 5,096,815).

Alteration of Nucleic Acids and Polypeptides: Directed Mutagenesis Methods

Manipulation or directed mutagenesis techniques can be used to provide specific sequences or variations in specific regions. Such techniques can be used to prepare variants in which, for example, residues of known amino acid sequences of a protein have been deleted, inserted or substituted. Variation sites may be substituted, for example, by (1) conservative amino acid first and then by more fundamental selection, depending on the results obtained, (2) deleting target residues, or (3) the same or different classes adjacent to the site located Residues can be inserted or modified in series or individually by any combination of 1-3.

(A) Alanine scanning mutations

Alanine injection mutagenesis is a useful method for identifying specific residues or regions of the desired protein that are preferred positions or domains for mutagenesis (Cunningham and Well, Science 244: 1081-1085, 1989). Upon alanine injection, target residues or groups of residues are identified (eg, charged residues such as Arg, Asp, His, Lys and Glu) to neutral or negatively charged amino acids (most preferably alanine or polyalanine). Replace. Substitution of amino acids may affect the interaction of the amino acid sequences with the aqueous environment around the cell or extracellular side. Then, by introducing additional or other variants at or about the site of substitution, the domains exhibiting functional sensitivity to substitution are improved. Thus, amino acid sequence variation introduction sites are predetermined, but the mutation nature itself does not need to be determined in advance. For example, to optimize mutation performance at designated sites, alanine injection or random mutagenesis can be performed at the target codon or region and the desired protein subunit variants expressed are screened for the optimal combination of desired activities.

(B) oligonucleotide-mediated mutagenesis

Oligonucleotide-mediated mutagenesis is a useful method for preparing substitution, deletion and insertion variants of DNA. See, eg, Adelman et al., (DNA 2: 183, 1983). Briefly, oligonucleotides encoding mutations are hybridized to a DNA template to alter the desired DNA, where the template is a single stranded form of plasmid or bacteriophage containing the unmodified or native DNA sequence of the desired protein. After hybridization, DNA polymerase will be used to synthesize the entire first complementary strand of this template, thereby introducing oligonucleotide primers and encoding the selected alterations in the desired protein DNA. Generally oligonucleotides of 25 nucleotides or more in length are used. Optimal oligonucleotides have 12 to 15 nucleotides and are completely complementary to the template on both sides of the nucleotide encoding the mutation. This confirms that the oligonucleotides hybridize appropriately to single stranded DNA template molecules. Oligonucleotides are readily synthesized using techniques known in the art as described by Crea et al. (Proc. Natl. Acad. Sci. USA, 75: 5765 [1978]).

(C) cassette mutagenesis

Another variant preparation method, cassette mutagenesis, is based on the technique of Wells et al. (Gene, 34: 315 (1985)) The starting material is a plasmid (or other vector) containing the protein subunit DNA to be mutated. Identify the codons of this protein subunit DNA to be mutated There will be a unique restriction endonuclease site on each side of the identified mutation site If no such restriction site is present, the oligonucleotide-mediated mutation described above Induction methods can be used to introduce restriction sites at appropriate positions in the desired protein subunit DNA After introduction of the restriction sites into the plasmid, these plasmids are cleaved and linearized. Double-stranded oligonucleotides encoding but containing the desired mutations are synthesized using standard procedures. The strands are synthesized separately and then hybridized together using standard techniques This double stranded oligonucleotide is called a cassette, which is compatible with both ends of the linearized plasmid so that it can be directly ligated to the plasmid and Designed to have a 5 'end This plasmid now contains the desired protein subunit DNA sequence that has been modified.

(D) combination mutations

In addition, variants can be prepared using combination mutagenesis (Ladner et al., WO 88/06630). In this way, the amino acid sequences for groups of moieties or other related proteins are aligned to facilitate the highest homology. All amino acids appearing at a given position in the aligned sequence can be selected to make a denatured set of combination sequences. A changed library of variants is made by combinatorial mutagenesis at the nucleic acid level, which is encoded by various genetic libraries. For example, a mixture of synthetic oligonucleotides can be ligated with an enzyme in a gene sequence to render it possible to express a denatured set of possible sequences as individual peptides or alternatively as a larger set of fusion proteins containing a set of denatured sequences. You can.

Helicobacter pylori nucleic acid and other denaturation of polypeptide

It is possible to modify the structure of a Helicobacter pylori polypeptide for purposes such as enhancing solubility, improving stability (eg, in vitro shelf life and resistance to degradation by proteolytic enzymes in vivo). Denatured Helicobacter pylori protein or peptides with altered amino acid sequences, such as by amino acid substitutions, deletions or additions described herein, can be prepared.

In addition, it can be modified by substitution of cysteine-based residues, preferably alanine, serine, threonine, leucine or glutamic acid residues to minimize dimerization via disulfide bonds. In addition, the amino acid side chains of fragments of the proteins of the invention can also be chemically modified. Another method of denaturation is cyclization of the peptide.

To improve stability and / or responsiveness, Helicobacter Philo may be modified to introduce one or more polymorphisms in the amino acid sequence of a protein resulting from any natural allelic variation. In addition, D-amino acids, non-natural amino acids, or non-amino acid analogs may also be substituted or added to produce denatured proteins within the scope of the present invention. In addition, helicobacter pylori polypeptides were identified as A. Polyethylene glycol (PEG) can be used to denature the PEG-conjugated protein according to the method of divorce and collaborators (Wie at al., Supra). PEG can also be added during chemical synthesis of the protein. Other denaturation methods of Helicobacter pylori include reduction / alkylation (Tarr, Methods of Protein Microcharacterization, J. E. Silver ed., Humana Press, Clifton NJ 155-194 (1986)); Acylation (Tarr, former book); Chemical coupling to a suitable carrier (Mishell and Shiigi, eds. Selected Methods in Cellular immunology, WH Freeman, San Francisco, CA (1980), US Pat. No. 4,939,239) or mild formalin treatment (Marsh (1971) Int, Arch of Allergy and Appl. Immunol., 41: 199-215).

It is also possible to add amino acid fusion residues to the peptide backbone to facilitate purification of the Helicobacter pylori protein or peptide and to increase solubility. For example, hexa-histidine can be added to the protein for purification by fixed metal ion affinity chromatography (Hochuli, E. et al., (1988) Bio / Technology, 6: 1321-1325). In addition, a specific endoprotease cleavage site may be introduced between the fusion moiety and the peptide sequence to facilitate the isolation of peptides without irrelevant sequences.

In order to effectively assist in proper antigen processing of epitopes in a Helicobacter pylori polypeptide, the canonical protease sensitive sites can be engineered between regions comprising one or more epitopes, respectively, by recombinant or synthetic methods. For example, charged amino acid pairs, such as KK or RR, can be introduced between regions within a protein or fragment during recombinant production. The resulting peptides are susceptible to cleavage by capesin and / or other trypsin-like enzymes that produce portions of the protein containing one or more epitopes. In addition, these charged amino acid residues can result in increased solubility of the peptide.

Primary Methods for Screening Polypeptides and Analogs

Various techniques for screening the resulting variant gene products are known in the art. Techniques for screening large gene libraries include cloning the gene library into replicable expression vectors, transforming the appropriate cells with the generated vector library, and detecting the desired activity, for example in this case a Helicobacter Philoly polypeptide or interaction. Detection of binding activity to a protein involves expressing the gene under conditions that can relatively easily isolate the vector encoding the gene whose product is to be detected. Each technique described below is a high throughput assay for screening a large number of sequences made, which can be corrected for example by random variation techniques.

(A) 2 hybrid systems

Randomly generated cytoplasmic protein that binds to a polypeptide, eg, a natural Helicobacter pilori polypeptide, such as a Helicobacter pilori protein, using two hybrid assays (such as other screening methods described herein), such as the system described above. Fragments or analogs of the polypeptides can be identified. (Helicobacter pilori is used as bait protein and the library of variants is expressed as fish fashion protein). In a similar manner, two hybrid assays (as in other screening methods described herein) can be used to find a polypeptide that binds a Helicobacter pilori polypeptide.

(B) display library

In one approach of screening assays, the ability to display candidate peptides on the surface of a cell or virus particle and bind the specific cell or virus particle to the appropriate receptor protein through the displayed product is referred to as a "panning assay". Detect. For example, gene libraries are cloned into genes for the surface membrane proteins of bacterial cells and the resulting fusion proteins are detected by panning (Ladner et al., WO88 / 06630; Fuchs et al. (1991) Bio / Technology 9: 1370-1371 and Goward et al. (1992) TIBS 18: 136-140). In a similar manner, detectable labeled ligands are used to score for potentially functional peptide analogs. Ligands labeled with fluorophores, such as receptors, can be used to detect homologues with ligand-binding activity. The use of ligands labeled with fluorophores allows the cells to be visually irradiated and separated by fluorescence microscopy, or may be separated by a fluorescence-activated cell shorter, if the morphology of the cells permits.

The gene library can be expressed as a fusion protein on the surface of the viral particles. For example, a filamentous phage system can express foreign peptide sequences on the surface of an infectious phage, providing two important advantages. First, these phages can be applied to affinity matrices at concentrations well above 10 ¹³ phages per ml, so that multiple phages can be screened at once. Secondly, because each infective phage displays a gene product on its surface, once a particular phage is recovered from the affinity matrix in low yield, it can be amplified by another infectious cycle. Almost the same teeth. Phage filament M13, fd and fl groups on coli filaments are most commonly used in phage display libraries. Either phage gIII or gVIII coat protein can be used to generate the fusion protein without destroying the ultimate packaging of the viral particles. Foreign epitopes can be expressed at the NH ₂ -terminus of pIII, and phage with epitopes can be recovered from excess phage without this epitope. (Ladner et al. PCT published WO90 / 02909; Garrard et al., PCT published WO 92/09690; Marks et al. (1992) J. Biol. Chem. 267: 6007-16010; Griffiths et al. (1993) EMBO J 12: 725-734; Clackson et al. (1991) Nature 352: 624-628; and Barbas et al. (1992) PNAS 89: 4457-4461).

As a common approach, E. coli as a peptide fusion partner. E. coli maltose receptors (external membrane protein, LamB) are used. (Charbit et al. (1986) EMBO 5, 3029-3037). Oligonucleotides are inserted into plasmids encoding the LamB gene to produce peptides fused to one of the extracellular loops of the protein. This peptide can bind a ligand, eg an antibody, and can induce an immune response when the cells are administered to an animal. Other cell surface proteins such as OmpA (Schorr et al (1991) Vaccines 91, pp. 387-392), PhoE (Agterberg, et al. (1990) Gene 88, 37-45) and PAL (Fuchs et al. (1991) Bio / Tech 9, 1369-1372) and large bacterial surface structures served as vehicles for peptide display. Peptides can be fused to pilin, a protein that polymerizes to form a pyrus-a tube for genetic information exchange in bacteria. (Thiry et al. (1989) Appl. Environ. Microbiol. 55, 984-993). Because of their role in interaction with other cells, this pyrus provides a useful support for the release of peptides into the extracellular environment. Another large surface structure used for peptide display is flagella, a bacterial motor organ. Fusion of peptides to subunit protein flagella gives a dense array of many peptide copies in the host cell. (Kuwajima et al. (1988) Bio / Tech. 6, 1080-1083). Surface proteins of other bacterial species have also been used as peptide fusion partners. Examples include Staphylococcus protein A and outer membrane IgA protease from Neisseria (Hansson et al. (1992) J. Bacteriol. 174, 4239-4245 and Klauser et al. (1990) EMBO J. 9, 1991-1999).

In the filamentous phage system and LamB system described above, the physical linkage between the peptide and the DNA encoding it occurs by blocking the DNA in particles (cells or phages) having the peptide on the surface. Peptide capture traps DNA inside these particles. An alternative method is to form a linkage between the peptide and the DNA using the DNA-binding protein LacI (Culle t al. (1992) PNAS USA 89: 1865-1869). This system uses a plasmid containing the LacI gene and an oligonucleotide cloning site at its 3 'end. Under induction control by arabinose, LacI-peptide fusion proteins are produced. This fusion retains LacI's unique ability to bind to short DNA sequences known as LacO operators (LacO). By placing two copies of LacO in the expression plasmid, the LacI-peptide fusion binds strongly to the plasmid encoding it. Since the plasmid in each cell contains only a single oligonucleotide sequence, and each cell expresses only a single peptide sequence, the peptide is specifically stably associated with the DNA sequence that directs its synthesis. Cells in this library are gently lysed and the peptide-DNA complex is exposed to the matrix of the fixed receptor to recover the complex containing the active peptide. The associated plasmid DNA was then reintroduced into cells for amplification and DNA sequencing to determine the identity of the peptide ligands. As a judgment on the practical utility of this method, a large random library of dodecapeptides was made and selected with monoclonal antibodies raised against opioid peptide dynopin B. A group of peptides was recovered and all involved a consensus sequence corresponding to the six residue portions of dynopin B. (Cull et al. (1992) Proc. Natl. Acad. Sci. U.S.A. 89-1869).

Sometimes called peptide-on-plasmids, this method differs from phage display in two important ways. First, the peptide attaches to the C-terminus of the fusion protein, resulting in the display of library members as peptides with free carboxy termini. The filamentous phage coat proteins, pIII and pVIII, are both anchored to phage through their C-terminus, and the guest peptide is disposed in the outwardly extending N-terminal domain. In some designs the peptide displayed by phage is to the right of the amino terminus of the fusion protein (Cwirla, et al. (1990) Proc. Natl. Acad. Sci. U.S.A. 87, 6378-6382). The second difference is the set of biological biases that affect the number of peptides actually present in the library. LacI fusion molecules are limited to the cytoplasm of host cells. Phage coat fusions are simply exposed to the cytoplasm during detoxification but rapidly secreted through the inner membrane into the periplasm compartment, waiting for the C-terminal hydrophobic domain to be assembled into the phage particles while anchored to the membrane by an N-terminal containing peptide. It protrudes from this periplasm. Peptides in LacI and phage libraries will be quite different because they have been exposed to different proteolytic activity. This phage coat protein requires transmembrane transport and signal peptidase processing prior to introduction into phage. Certain peptides adversely affect this process and appear less in this library (Gallop et al. (1994) J. Med. Chem. 37 (9): 1233-1251). These specific bias factors are not a factor in the LacI display system.

The number of sopeptides in the recombinant random library is myriad. Libraries of 10 ⁷ to 10 ⁹ independent clones are routinely prepared. As many libraries as 10 ¹¹ recombinants are made, these sizes are at the practical limit of clone libraries. This library size limitation arises from transforming random segments containing DNA into host bacterial cells. To avoid this limitation, in vitro systems based on peptide display of generators in polysome complexes have recently been developed. This display library method has the ability to produce three to six powers of the library than currently used phage / phagemid or plasmid libraries. In addition, preparation of the library, expression and screening of the peptides are carried out in a completely acellular manner.

As an example of this method (Gallop et al. (1994) J. Med. Chem. 37 (9): 1233-1251), a molecular DNA library encoding 10 ¹² decapeptide was prepared and produced. Expressed in E. coli S30 with an in vitro coupled electron / detoxification system. The conditions for placing the ribosome on the mRNA are chosen to accumulate the actual population of RNA in the polysome and to obtain a complex containing the peptide of the generator still linked to the coding RNA. This polysome is considered sufficient for substitutional purification on a fixed receptor in the same way that more conventional recombinant peptide display libraries are screened. RNA is recovered from the binding complex, converted to cDNA and amplified by PCR to produce a template for the next round of synthesis and screening. This polysome display method can be combined with a phage display system. After several screenings, cDNA from the rich pool of polysomes was cloned into phagemid vector. This vector functions as a peptide expression vector displaying a peptide fused to a coat protein and also serves as a DNA sequencing vector for peptide identification. By expressing polysomal-derived peptides in phage, the affinity selection procedure can be continued in this format or peptides for each clone can be analyzed for binding activity with phage ELISA, or binding specificity with complete phage ELISA (Barret, et al. (1992) Anal.Biochem 204, 357-364). The DNA produced by the phagemid host was sequenced to confirm the sequence of the active peptide.

Secondary Screening of Polypeptides and Analogs

For example, secondary screens can be performed following the high throughput assay described above to further identify biological activity so that those skilled in the art can separate agonists from antagonists. The type of use of the secondary string depends on the desired activity to be tested. For example, an assay can be developed that identifies antagonists from a group of peptide fragments isolated from one of the primary screens using the ability to inhibit the interaction between the protein and each of its ligands.

Thus, methods for preparing fragments and analogs and testing their activity are known in the art. Once the core sequence has been identified, obtaining analogs and fragments is routine for those skilled in the art.

Peptide Mimetics of Helicobacter Philolyte Polypeptides

The present invention also provides mimetics such as peptide or non-peptide preparations by reducing the protein binding domain of the subject Helicobacter pylori polypeptide. This peptide mimetic can interfere with the binding of the polypeptide to its counter ligand, eg, to the natural ligand in the case of Helicobacter Philophyll. It is possible to determine the important residues of a subject Helicobacter pili polypeptide involved in molecular recognition of the polypeptide, and use the residues to mimic a Helicobacter pili derived peptide that competitively or non-competitively inhibits the binding of the interacting polypeptide with the Helicobacter pili polypeptide. Sieves can be prepared. (See, for example, European patent applications EP-412,762A and EP-B31,080A).

For example, injection mutagenesis can be used to map the amino acid residues of a particular Helicobacter pili polypeptide that participates in interacting polypeptide binding and mimic the residue in binding to the interacting polypeptide and thus to the interacting polypeptide. It is possible to produce peptide mimetic compounds (eg diazepine or isoquinoline derivatives) that inhibit the binding of Helicobacter pylori polypeptides and thereby impair the function of Helicobacter pylori. For example, non-hydrolyzable peptide analogues of the residues may be selected from benzodiazepines (e.g. Freidinger et al. In Peptides: Chemistry and Biology, GR Marshall ed., ESCOM Publisher: Leiden, Netherlands. 1988), azepines (e.g. For example, Huffman et al., In Peptides: Chemistry and Biology, GR Marshall ed., ESCOM Publisher: Leiden, Netherlands. 1988), substituted gamma lactam rings (Garvey, in Peptides: Chemistry and Biology, GR Marshall ed., ESCOM Publisher: Leiden, Netherlands.1988, Keto-methylene pseudopeptide (Ewenson et al. (1986) J med Chem 29: 295; and Ewenson et al. In Peptides: Structure and Function (Proceedings of the 9th Amercan Peptide Symposium) Pierce Chemical Co. Rockland, IL, 1985), β-Turn Dipeptide Cores (Nagai et al. (1985) Tetrahedron Lett 26: 647; and Sato et al. (1986) J Chem Soc Perkin Trans 1: 1231), β- Aminoalcohols (Gordon et al. (1985) Biochem Biophys Res Commun 126: 419; and Dann et al (1986) Biochem Biophys Res Commun 1234: 71) It can manufacture.

VI. Vaccine Preparations for Helicobacter Philoyl Nucleic Acids and Polypeptides

The invention also features a vaccine composition or formulation, which can be used interchangeably, for the protection against infection with Helicobacter pylori or for the treatment of Helicobacter pylori infection. The term “treatment of a Helicobacter Philolylic infection” means present or therapeutic treatment of a chronic Helicobacter Philly infection. The term "defense against Helicobacter pylori infection" or "prophylactic treatment" refers to the use of a Helicobacter pylori vaccine formulation that reduces or inhibits the infection risk of a subject at risk of Helicobacter pylori infection. In one embodiment, the vaccine composition contains one or more immunogen components or portions thereof, such as surface proteins isolated from Helicobacter Philophyll, and pharmaceutically acceptable carriers. For example, in one embodiment the vaccine formulation of the present invention contains one or more Helicobacter pylori polypeptides or combinations, such as surface proteins isolated from the same or different Helicobacter pilori antigens. Nucleic acids and Helicobacter pili polypeptides used in the formulations of the present invention include nucleic acids and polypeptides shown in the sequence listing, preferably Helicobacter pili nucleic acids and surface proteins or fragments thereof that encode surface proteins. For example, preferred nucleic acid and Helicobacter Philoly polypeptides for use in the vaccine compositions of the invention are selected from nucleic acids and Helicobacter Philolyll cell envelope proteins encoding the cellular envelope proteins shown in Table 1. However, any nucleic acid encoding an immunogenic Helicobacter pili protein or part thereof that can be expressed in a cell can be used in the present invention. This vaccine has utility in treatment and / or prophylaxis.

One aspect of the invention provides a vaccine composition for protection against infection by Helicobacter pylori, comprising at least one immunogen fragment of Helicobacter pylori protein and a pharmaceutically acceptable carrier. Preferred fragments include peptides of about 10 or more amino acid residues in length, preferably about 10 to 20 amino acid residues, more preferably about 12 to 16 amino acid residues.

Immunogen components of the present invention can be obtained, for example, by screening recombinantly produced polypeptides from corresponding fragments of nucleic acids encoding full length Helicobacter pili protein. In addition, fragments may be chemically synthesized using techniques known in the art, such as conventional Merrifield solid phase f-MOC or t-BOC chemistry.

In one embodiment, the immunogen component can be identified by the peptide's T cell stimulating ability. Peptides that stimulate T cells are defined herein as containing at least one T cell epitope since they can be determined, for example, by T cell proliferation or cytokine secretion. T cell epitopes are thought to be associated with the initiation and preservation of an immune response to allergen proteins, which are the cause of clinical symptoms of allergy. It is believed that this T cell epitope initiates early work at the T helper cell level by binding the appropriate HLA molecules to the surface of the cells in which the antigen is present, thereby stimulating a T cell subpopulation with the relevant T cell receptor for the epitope. This work results in T cell proliferation, lymphokine secretion, local inflammatory responses, supplementation of additional immune cells to antigen / T cell interaction sites, and activation of B cell cascades to produce antibodies. . T cell epitopes are the smallest recognition unit by a basic element or T cell receptor, where the epitopes comprise amino acids (eg, about 6 or 7 amino acid residues) essential for receptor recognition. Amino acid sequences that mimic the sequences of T cell epitopes are also within the scope of the present invention.

In another embodiment, immunogen components of the invention are identified through genomic vaccine treatment. The basic protocol is based on the idea that an expression library consisting of all or part of a pathogen genome, such as the Helicobacter Philo genome, may provide a defense when used in immune processing of genetic hosts. This expression library immunotreatment (ELI) is similar to expression cloning and involves reducing the introduction of a genome expression library of pathogens, such as Helicobacter Philo, into plasmids that can act as gene vaccines. In addition, the plasmid can work well intracellularly and extracellularly by introducing a gene aid that can greatly stimulate the humoral response.

This is a new method for the production of vaccines with many benefits of live / attenuated pathogens and a low risk of infection. An expression library of pathogen DNA is used to immunize a host thereby generating the antigen presenting effect of a live vaccine without risk. For example, in the present invention, a host may be immunized with a PCR product from a gene identified by genomic sequencing and random fragments from the Helicobacter pylori genome or cosmid or plasmid clone. The feasibility of the method has been demonstrated using Mycoplasma pulmonis (Barry et al., Nature 377: 632-635, 1995), where a partial expression library of Mycoplasma Fulmonis, a natural pathogen of rodents Protection provided for the pathogen challenge.

Because ELI uses the immune system to screen candidate genes, it is a technology that can produce a multi-part, non-infectious vaccine even if you are not familiar with the biology of the pathogen. Once isolated, these genes can be used as gene vaccines or for the development of recombinant protein vaccines. Thus, ELI can produce vaccines in a systematic, mainly mechanical manner.

Screening of immunogen components can be performed using one or more of several different assays. For example, ex vivo peptide T cell stimulatory activity is assayed by contacting a peptide that is determined or presumed immunogen with a cell in which an antigen is present, which provides the appropriate MHC molecule during T cell culture. Providing immunogenic Helicobacter Philolyte peptides with appropriate MHC molecules to T cells with the necessary co-stimulation delivers signals to T cells, thereby increasing the level of production of cytokines, especially Interleukin-2 and Interleukin-4. Culture supernatants can be obtained and analyzed for interleukin-2 or other known cytokines. For example, any of several conventional interleukin-2 assays can be used. For example, Proc. natl. Acad. The assay described in Sci USA, 86: 1333 (1989) can be used. Analytical kits for the production of interferon are also available from Genzyme Corporation (Cambridge, Mass.).

Alternatively, a general assay for T cell proliferation involves measuring triple thymidine incorporation. The proliferation of T cells can be measured in vitro by determining the amount of ³ H-labeled thymidine introduced into the replicating DNA of the cultured cells. Thus, DNA synthesis rate and cell division rate can be quantified.

Vaccine compositions of the invention containing at least one immunogen component (eg, a Helicobacter Philoly polypeptide or fragment thereof or a nucleic acid encoding Helicobacter Philoly polypeptide or fragment thereof) preferably comprise a pharmaceutically acceptable carrier. . The term "pharmaceutically acceptable carrier" is intended to include all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, suitable for pharmaceutical administration. Suitable pharmaceutically acceptable carriers are, for example, one or more types of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and combinations thereof. Pharmaceutically acceptable carriers may contain minor amounts of auxiliary substances, such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effects of Helicobacter pylori nucleic acid or polypeptide. In the vaccine formulation of the present invention containing Helicobacter pylori, the polypeptide may be co-administered with a suitable adjuvant and / or delivery system.

Those skilled in the art will appreciate that a therapeutically effective amount of a DNA or protein of the invention may be administered on a schedule of administration, unit dose of Helicobacter pylori nucleic acid or polypeptide administered, whether the protein or DNA is administered with other therapeutic agents, the immune status and health of the patient. And will depend on the therapeutic activity of the particular protein or DNA.

Vaccine compositions are usually administered by parenteral, eg, subcutaneous or intramuscular injection. Intramuscular immune treatment methods are described in the literature. Wolf et al. (1990) Science 247: 1465-1468 and Sedegah et al. (1994) Immunology 91: 9866-9870. Other methods of administration include oral and pulmonary preparations, suppositories, and skin-coated forms. Oral immunotherapy is preferred over parenteral methods in inducing defense against infection by Helicobacter pylori. Czinn et al., (1993) Vaccine 11: 637-642. Oral formulations include commonly used excipients and include, for example, pharmaceutical grade mannitol, lactose, starch, magnesium stearate, sodium sodium saccharin, cellulose, magnesium carbonate and the like.

The vaccine composition of the present invention may include adjuvant, and examples thereof include aluminum hydroxide; N-acetyl-muramil-L-threonyl-D-isoglutamine (thr-MDP); N-acetyl-nor-muramil-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP); N-Acetylmuryl-L-alanyl-D-isoglutaminyl-L-alanine-2- (1 ', 2'-dipalmitoyl-sn-glycero-3-hydroxyproporyloxy)- Ethylamine (CGP 19835A, referred to as MTP-PE); RIBI (containing three components from bacteria); Monophosphoryl lipid A; Trehalose dimycorroate; Cell wall backbone (MPL + TDM + CWS) in 2% squalene / twin 80 emulsion; And cholera toxins. Others that may be used include non-toxic derivatives of cholera toxin and / or cholera toxin or conjugates or genetically engineered fusions of cholera toxin or Helicobacter pylori polypeptides, procollagegenoids, Shoo, including B subunits. Fungal polysaccharides including jophyllan, muramyl dipeptides, muramyl dipeptiide derivatives, phorbol esters, E. Unstable toxins of E. coli, non-Helicobacter pylori lysates, block polymers or saponins.

In another embodiment, the vaccine formulation comprises a delivery system as a pharmaceutically acceptable carrier. Delivery systems suitable for use in the backsand formulations of the invention include biodegradable microcapsules or immuno-stimulatory complexes (ISCOM), cochelates, or genetically engineered attenuated live vectors, such as liposomes, viruses or bacteria, and recombinant ( Chimeric) virus-like particles such as bluetongue. In another embodiment of the invention, the vaccine formulation comprises both a delivery system and adjuvant.

Delivery systems in humans may include a hindered release capsule that protects the antigen from the acidic environment of the stomach, including the insoluble form of Helicobacter pylori polypeptide as a fusion protein. Suitable carriers for the vaccines of the invention are enteric shell capsules and polylactide-glycolide microspheres. Suitable dilutions are 0.2N NaHCO ₃ and / or brine.

The vaccine of the present invention is administered to adults or children as a primary prophylactic agent, after successful elimination of Helicobacter pylori in an infected host, as a second prophylaxis, or as a therapeutic agent for the purpose of eliciting an immune response in a host susceptible to Helicobacter pylori. can do. The vaccine of the present invention is administered in an amount readily determined by one of ordinary skill in the art. Thus, suitable doses for adults range from 10 μg to 1 g, preferably from 10 μg to 100 mg, for example from 50 μg to 50 mg. Suitable dosages for adults are also from 5 μg to 500 mg. Similar dosage ranges apply to children.

The amount of supplement used depends on the type of supplement used. For example, if the mucosal adjuvant is cholera toxin, it is appropriate to use an amount of 5 μg to 50 μg, for example 10 μg to 35 μg. When used in the form of microcapsules, the amount used depends on the amount used in the matrix of the microcapsules to achieve the desired dosage. Such amounts will be determined by those skilled in the art.

Those skilled in the art will appreciate that the optimal dosage may depend somewhat on the patient's weight, disease, route of administration and other factors. Those skilled in the art will also appreciate that appropriate dosage levels are obtained based on the results for known oral vaccines. For vaccines based on E. coli lysates, the total daily dose is between 6 mg and 540 mg. E. coli purified antigen is administered four times 1 mg (Schulaman et al., J. Urol. 150: 917-921 (1993); Boedecker et al., American Gastroenterological Assoc. 999; A-222 (1993)). The number of doses depends on the efficacy data of the disease, agent, and clinical trial. While not wishing to be bound by any course of treatment, treatment may be by three to eight doses during the first immunotherapy schedule over a month. Boedeker, American Gastroenterological Assoc. 888: A-222 (1993).

In a preferred embodiment, the vaccine composition of the present invention comprises dead whole E. coli with immunogenic fragments of the Helicobacter Philolyli protein of the invention expressed on the surface. Toothpaste based on E. coli preparations, or dead teeth. E. coli functions as a carrier or adjuvant. E. coli lysate may also be used as a main component.

Some of the vaccine compositions of the present invention are useful only in preventing Helicobacter pylori infection, some are only useful in treating Helicobacter pilori infection, and some are useful in both prevention and treatment of Helicobacter pilori infection. It will be obvious to them. In a preferred embodiment, the vaccine composition of the present invention defends against Helicobacter pilori infection by hormone and / or cell-mediated immunity against Helicobacter pilori. Improving any symptom of Helicobacter pylori infection, including reducing the dose of drug used to treat a disease caused by Helicobacter pylori infection, or increasing antibody production in the serum or mucosa of a patient, is a desired clinical goal. Of course.

VII. Antibodies Reactive with Helicobacter Philoly polypeptide

The invention also includes antibodies that are specifically reactive with the subject Helicobacter Philoly polypeptide. Anti-protein / anti-peptide antiserum or monoclonal antibodies can be prepared by standard protocols. See, for example, the following references. Antibodies: A Laboratory Manual ed. by Harlow and lane (Cold Spring Harbor Press: 1988). Mammals such as mice, hamsters or rabbits can be immunotreated in the form of immunogens of peptides. Techniques for conferring immunogenicity for proteins or peptides include conjugation to a carrier or other techniques well known in the art. Immunogen doses of the subject Helicobacter pylori polypeptide can be administered in the presence of the adjuvant. Progress in immunotherapy can be monitored by detecting antibody titers in plasma or serum. Standard ELISA or other immunoassays can be used with the immunogen as antigen to assess the level of the antibody.

In a preferred embodiment, the subject antibody is an antigenic determinant of a Helicobacter pylori polypeptide of the invention, eg, an antigenic determinant of a polypeptide of the invention as listed in the Sequence Listing, or a closely related human or non-human mammal homolog (eg For example, 90% homology, more preferably at least 95% homology). In another preferred embodiment of the invention, the anti-Helicobacter pilori antibody does not substantially cross react with (ie, does not specifically react with) proteins that are less than 80% homologous to, for example, the sequences of the invention described in the sequence table. Do). "Substantially non-reacting" means a non-homologous protein whose antibody is less than 10%, preferably less than 5%, more preferably less than 1% of the binding affinity for a particular protein of the invention as listed in the Sequence Listing. It has a binding affinity for. In the most preferred embodiment, there is no cross reactivity between the bacterial and mammalian antigens.

As used herein, the term antibody is used to include fragments thereof that are also specifically reactive with Helicobacter pylori polypeptides. Antibodies can be fragmented using conventional techniques and can screen fragments in the same manner as described above for all antibodies. For example, F (ab ') ₂ fragments can be made by treating the antibody with pepsin. The disulfide bridges in the resulting F (ab ') ₂ fragments can be reduced to produce Fab' fragments. Antibodies of the invention are also used to include bispecific and chimeric molecules with anti-Helicobacter pili moieties.

Monoclonal and polyclonal antibodies directed against the Helicobacter pilori polypeptide or Helicobacter pilori variants and antibody fragments such as Fab 'and F (ab') 2 can be used to mask the action of the Helicobacter pilori polypeptide, The study of the role of certain Helicobacter Philopolypeptides of the invention and normal cell function of Helicobacter Philosophy in the event of aberrant or unwanted signals is possible by the micro-injection of the anti-Helicobacter phyllori antibodies of the invention.

Antibodies that specifically bind to Helicobacter pylori epitopes can also be used for immunohistochemical staining of tissue samples to assess the expression amount and pattern of Helicobacter pylori antigen. Anti-Helicobacter pilori polypeptide antibodies can be used for diagnosis by immuno-precipitation and immuno-blotting to test and evaluate Helicobacter pilori levels in tissues or body fluids as clinical trial procedures. Likewise, the ability to monitor Helicobacter pylori polypeptide levels in an individual can determine the efficacy of a given mode of treatment for an individual suffering from such a disease. The level of Helicobacter pylori polypeptide can be measured in cells in body fluids, such as a urine sample, or can be measured in tissue as made by gastrointestinal biodetection. Diagnostic assays using anti-Helicobacter pilori antibodies also include immunoassays designed to help early diagnosis of, for example, Helicobacter pilori infection. The present invention can also be used as a method of detecting an antibody contained in a sample from an individual infected with the bacterium by using a specific Helicobacter pilori antigen.

Another application of the anti-helicobacter phyllori antibodies of the invention is in immunological screening of cDNA libraries made from expression vectors such as λgt11, λgt18-23, λZAP and λORF8. This type of messenger library with coding sequences and orientations inserted in the correct translation frame can produce fusion proteins. For example, [lambda] gt11 can produce a fusion protein whose amino terminus is the β-calactosidase amino acid sequence and the carboxy terminus consists of a foreign polypeptide. The antigenic epitope of the Helicobacter Philolyte polypeptide of interest can then be detected by reacting an antibody, such as a nitrocellulose filter moved from an infected plate, with an anti Helicobacter Philoly polypeptide antibody. Phage scored with this assay can then be isolated from the infection plate. Thus, the Helicobacter Philolyli gene homolog can be detected and cloned from other species, and alternative analogs (including splicing variants) can be detected and cloned.

VIII. Kits Containing Nucleic Acids, Polypeptides, or Antibodies of the Invention

The nucleic acids, polypeptides, and antibodies of the invention can be combined with other reagents and articles to form kits. Diagnostic kits typically consist of nucleic acids, polypeptides or antibodies in vials or other suitable containers. Kits typically include other reagents for performing hybridization reactions, polymerase chain reaction (PCR), or redissolution of lyophilized components, such as aqueous media, salts, buffers and the like. The kit may also include reagents for sample processing, such as detergents, chaotropic agents, and the like. The kit may also include securing means such as particles, supports, walls, dipsticks, and the like. The kit may also include labeling means such as dyes, developing agents, radioisotopes, luminescent agents, fluorescent or chemifluorescent agents, enzymes, intercalating agents and the like. For the nucleic acid and amino acid sequences provided herein, those skilled in the art will be able to readily assemble the kit for a particular purpose. You can also include instructions for use in the kit.

IX. Drug Screening Analysis Using Helicobacter Philolyte Polypeptide

By making available purified and recombinant Helicobacter Philolyte polypeptides, the present invention provides assays that can be used to screen for drugs that are agonists or antagonists of normal cytoplasmic function, or action in intercellular signals, of the subject Helicobacter Philoly polypeptide. . Such inhibitors or agonists will be useful as novel therapeutics in the treatment of human Helicobacter pylori infection. Various assays will be satisfactory and will be understood by those skilled in the art in light of the present invention.

In many drug screening programs that test libraries of compounds and natural extracts, high throughput assays are preferred to maximize the number of compounds carried over a period of time. "Primary" screens that can be prepared to allow rapid development and relatively easy detection of changes in molecular targets mediated by test compounds can be performed with assays carried out in cell-free systems, such as can be derived from purified or semi-purified proteins Often preferred. In addition, the effects and / or bioavailability of the cytotoxicity of the test compound may generally be ignored in an ex vivo system, and instead the assay may appear in changes in the enzymatic properties of the molecular target or in the binding affinity with other proteins. As can be seen, the main focus is on the effect of the drug on molecular targets. Thus, in the experimental screening assays of the present invention, the compounds are contacted with isolated and purified Helicobacter pylori polypeptides.

Screening assays are made in vitro with purified Helicobacter pylori or fragments thereof, such as Helicobacter pylori polypeptide, having an enzymatic activity such that the activity of the polypeptide produces a detectable reaction product. The efficacy of a compound can be assessed by creating a dose response curve from data obtained using various concentrations of the test compound. In addition, a control analysis can be performed to provide a baseline for comparison. Suitable products include those with specific absorbance, fluorescence, chemi-luminescent properties, for example, because they can be readily and automatically detected. Various synthetic or natural compounds can be tested for this assay to see if it inhibits or enhances the activity of the Helicobacter pylori polypeptide. Some of these active compounds can be chemically altered either directly or to promote membrane permeability or solubility to inhibit or enhance the same activity (eg, enzymatic activity) as the whole Helicobacter pylori cells as a whole.

Although the invention is further illustrated by the following examples, the invention is not so limited. All references and published patent applications mentioned herein are incorporated herein by reference.

I. Cloning and Sequencing of Helicobacter Philoyl DNA

Helicobacter pylori chromosomal DNA was isolated according to a slightly modified basic DNA protocol, outlined in the following document. Schleif RF and Wensink PC, Practical Methods in Molecular Biology, p. 98, Springer-Verlag, NY., 1981. Briefly, cells are pelleted, resuspended in TE (10 mL Tis, 1 mM EDTA, pH 7.6) and GES lysis buffer (5.1 M guanidium thiocyanate, 0.1 M EDTA, pH 8.0, 0.5% N Lauryl sarcosine). The suspension was cooled and ammonium acetate (NH ₄ Ac) was added at a final concentration of 2.0 M. DNA was first extracted with chloroform, then phenol-chloroform and reextracted with chloroform. DNA was precipitated with isopropanol, washed twice with 70% EtOH, dried and resuspended in TE.

After isolation, whole genomic Helicobacter Philoyl DNA was sprayed to a medium size of 2000 bp (Bodenteich et al., Automated DNA Sequencing and Analysis (J. C. Venter, ed), Academic Press, 1994). After spraying, the DNA was concentrated and separated on a standard 1% Sepharose gel. Several fractions corresponding to about size 900-1300 bp, 1300-1700 bp, 1700-2200 bp, 2200-2700 bp were cut from the gel and purified by GeneClean procedure (Bio 101, Inc.).

Purified DNA fragments were then blunt ended using T4 DNA polymerase. The treated DNA was then ligation to 100 to 1000 fold molar excess of specific BstXI-Linker adapters. This linker is complementary to the BstXI-cleaved pMPX vector and the overhang is not self complementary. Thus, these linkers are themselves truncation-vectors that easily reorganize. Linker-adopted inserts were separated from uninserted linkers on 1% agarose gels and purified using GeneClean. This linker-adopted insert was ligated to each of the 20 pMPX vectors to produce a series of “shotgun” subclone libraries. This vector contains the lacZ gene of the out-of-frame at the cloning site that is in-frame when the adapter-dimer is cloned to prevent blue.

All subsequent steps were based on multiple DNA sequencing protocols outlined in the literature. Church G.M. And Kieffer-Higgins S., Science 240: 185-188, 1988]. I would like to highlight only the main variants of the protocol. Briefly, each 20 vectors were transformed into appropriate cells of DH5α (Gibco / BRL, DH5α transformation protocol). This library was evaluated by applying on antibiotic plates containing ampicillin, methicillin and IPTG / Xgal. Plates were incubated overnight at 37 ° C. Successful transformants were then used for implantation of the clones and pooling into multiple pools. Clones were taken and pooled in 40 ml growth medium. Media was grown overnight at 37 ° C. DNA was purified using Qiagen Midi-pre kit and Tip-100 column (produced by Qiagen, Inc.). In this way, 100 μg of DNA per pool was obtained. 15 DNA 96-well plates were made to obtain 5-10 fold sequence duplications with an average read length of 250-300 bases.

This purified DNA sample was subjected to multiple DNA sequencing (Church GM and Kieffer-Higgins S., Science 240: 185-188, 1988) based on chemical digestion methods, or Sequitrem (Epicenter Technologies) dideoxy sequencing protocol Sequence was determined by. Sequencing reactions were electrophoresed and nylon membranes were obtained by mobile electrophoresis directly from a 40 cm gel (Richterich P. and Church GM, Methods in Enzymology 218: 187-222, 1993) or by electroblotting (Church, supra). Moved to phase. 24 samples were run per gel. 45 successful membranes were produced by chemical sequencing and 8 were produced by dideoxy sequencing. DNA was covalently attached to the membrane by exposure to ultraviolet light and hybridized with labeled oligonucleotides complementary to the tag sequence of the vector (Church, supra). This membrane was washed to rinse non-specifically bound probes and to expose each sequence ladder by exposure to X-ray film. After autoradiographing, hybridized probes were removed by incubation at 65 ° C. and the hybridization cycle was repeated with other tag sequences until the membrane was probed 38 times for chemical sequencing membranes and 10 times for dideoxy sequencing membranes. . Thus, each gel produced a very large number of films, each containing new sequencing information. Whenever a new blotting proceeded, it was initially probed into an internal standard sequence added to each pool.

Digital images of the films were made using a laser scanning densitometer (Molecular Dynamics, Sunnyvale, Calif.). Digitized images were processed on a computer workstation (VaxStation 4000's) using the program REPLICA ™ (Church et al., Automated DNA Sequencing and Analysis (J.C. Venter, ed.), Academic Press, 1994). Image processing includes straightening lanes, adjusting contrast to reduce density differences, and enhancing resolution by repeating Gaussian delineation. This sequence was then automatically picked up by REPLICA and displayed for mutual calibration before being stored in the project database. The correction was made by modifying the basecall by clicking the mouse on a high speed visual scan of the film image followed by a mouse on the band of the displayed image. Many sequence errors can be detected and corrected because multiple sequence reads covering the same portion of genomic DNA provide adequate sequence duplication for editing. Each sequence is automatically assigned a confirmation number (the confirmation number corresponds to the microtyper plate, probe information and lane set number). This number is used as a permanent identification of the sequence so that it is possible to identify the source of any particular sequence without depending on the particular database.

Conventional assembly of Helicobacter pylori sequences was performed using the program FALCON (Church, Church et al., Automated DNA Sequencing and Analysis (J.C. Venter, ed.), Academic Press, 1994). The program turns out to be fast and reliable for most sequences. Assembled contigs were displayed using a revised version of GelAssemble developed by Genetics Computer Group (GCG) (Devereux et al., Nucleic Acid Res. 12: 387-95, 1984) interacting with REPLICA ™. This provided an integrated editor capable of simultaneously importing multiple sequence gel images from a REPLICA ™ database and displaying them for the correct scanning of gel traces with differences between different sequence reads in assemblies and for the rapid injection of contigs did.

II. Identification, Cloning and Expression of Recombinant Helicobacter Philosophy DNA Sequences

In order to facilitate cloning, expression and purification of membrane and secretory proteins from Helicobacter Philophyll, a powerful gene expression system, E. coli. The pET system (Novagen) was selected for cloning and expression of recombinant proteins in E. coli. In addition, to facilitate purification of the recombinant protein product, a DNA sequence encoding a peptide tag, His-Tag, was fused to the 3 'end of the DNA sequence. The 3 'end was selected for fusion to avoid replacement of any 5' end signal sequence. The exception is ppiB, a cloned gene used as a control in expression studies. In this study, the sequence of Helicobacter pylori ppiB contains a DNA sequence encoding His-Tag fused to the 5 'end of the full length gene because the protein product of this gene is expressed as a cytosolic protein rather than a signal sequence. do.

PCR amplification and cloning of DNA sequences containing ORFs for membrane and secreted proteins from J99 strain of Helicobacter pylori

Sequences selected for cloning (from the list of DNA sequences of the present invention) from the J99 strain of Helicobacter pylori were prepared by polymerase chain reaction (PCR) for amplification cloning. Synthetic oligonucleotide primers (Table 4) specific for the 5 'and 3' ends of the open reading frame (ORF) were designed and purchased (GibcoBRL Life Technologies, Gaithersburg, MD, USA). All forward primers (specific for the 5 'end of the sequence) are designed to contain an NcoI cloning site at the outermost 5' end, provided HpSeq. In case of 4821082 (SEQ ID NO: 820), NdeI was used. These primers were designed to allow the initiation of protein translation in the coding sequence for the methionine residues, followed by valine novel and the rest of the native Helicobacter Philoyl DNA. The exception is Helicobacter Philoyl 4821082 (SEQ ID NO: 82), which has the rest of the natural Helicobacter Philoyl DNA sequence immediately following the initiator methionine. All reverse primers (specific for the 3 'end of any Helicobacter Philoly ORF) comprise an EcoRI site at the outermost 5' end so that it is possible to clone each Helicobacter Philoly sequence into the reading frame of pET-28b. The pET-28B vector contains six histidine residues (outer C-terminus), including His-Tag, as well as an additional 20 carboxy terminal amino acids (only 19 amino acids are HpSeq. 26380138 (SEQ ID NO: 658) and HpSeq. 14640637 (SEQ ID NO: 447) is provided. As noted earlier, this is an exception to the vector preparation of the ppiB gene. Synthetic oligonucleotides specific for the 5 'end of the ppiB gene encoded the BamHI site at the outermost 5' end and the 3 'end of the ppiB gene encoded the Xhol site at the outermost 5' end.

Genomic DNA prepared from J99 strain of Helicobacter Philoly (ATCC # 55679) was used as a template DNA source for PCR amplification reactions (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). To amplify DNA sequences containing Helicobacter Philoly ORF, genomic DNA (50 nanograms) 1 mM synthetic oligonucleotide primer (forward or reverse primer) complementary and flanking ₂ mM MgCl ₂ , defined Helicobacter Philly ORF 0.2 mM each deoxynucleotide triphosphate; dATP, dGTP, dCTP, dTTP and 2.5 units of thermostable DNA polymerase (Amplitaq, Roche Molecular Systems, Inc. Branchburg, NJ, USA) were introduced into a reaction vial containing 100 mL final volume. The following thermal cycling conditions were used to obtain amplified DNA products for each ORF using a Perkin Elmer Cetus / GeneAmp PCR System 9600 thermal cycler.

Protein 26054702, protein 7116626, protein 29479681, protein 30100332 and protein 4821082;

Denaturation at 94 ℃ for 2 minutes,

2 cycles of 15 seconds at 94 ° C., 15 seconds at 30 ° C. and 1.5 minutes at 72 ° C.

23 cycles of 15 seconds at 94 ° C., 15 seconds at 55 ° C. and 1.5 minutes at 72 ° C.

The reaction was terminated at 72 ° C. for 6 minutes.

Protein 16225006;

Denaturation at 94 ° C. for 2 minutes.

25 cycles of 15 seconds at 95 ° C., 15 seconds at 55 ° C. and 1.5 minutes at 72 ° C.

The reaction was terminated at 72 ° C. for 6 minutes.

Protein 4721061;

Denaturation at 94 ° C. for 2 minutes.

2 cycles of 15 seconds at 94 ° C., 15 seconds at 36 ° C. and 1.5 minutes at 72 ° C.

23 cycles of 15 seconds at 94 ° C., 15 seconds at 60 ° C. and 1.5 minutes at 72 ° C.

The reaction was terminated at 72 ° C. for 6 minutes.

Protein 26380318;

Denaturation at 94 ° C. for 2 minutes.

2 cycles of 15 seconds at 94 ° C., 15 seconds at 38 ° C. and 1.5 minutes at 72 ° C.

23 cycles of 15 seconds at 94 ° C., 15 seconds at 62 ° C. and 1.5 minutes at 72 ° C.

The reaction was terminated at 72 ° C. for 6 minutes.

Protein 14640637;

Denaturation at 94 ° C. for 2 minutes.

2 cycles of 15 seconds at 94 ° C., 15 seconds at 33 ° C. and 1.5 minutes at 72 ° C.

30 cycles of 15 seconds at 94 ° C, 15 seconds at 55 ° C and 1.5 minutes at 72 ° C

The reaction was terminated at 72 ° C. for 6 minutes.

Amplification conditions of Helicobacter pylori ppiB;

Denaturation at 94 ° C. for 2 minutes.

2 cycles of 15 seconds at 94 ° C., 15 seconds at 32 ° C. and 1.5 minutes at 72 ° C.

25 cycles of 15 seconds at 94 ° C, 15 seconds at 56 ° C and 1.5 minutes at 72 ° C

The reaction was terminated at 72 ° C. for 6 minutes.

After termination of the thermal cycling reaction, each sample of amplified DNA was washed and purified using a Qiaquick Spin PCR purification kit (Qiagen Gaithersburg, MD, USA). All amplified DNA samples were restricted to the enzymes NcoI and EcoRI, or HpSeq. 4821082 (SEQ ID NO: 1309) was cleaved with NdeI and EcoRI (Current Protocols in Molecular Biology, John wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). DNA samples were then electrophoresed on 1.0% NuSeive (FMC BioProducts, Rockland, ME USA) agarose gel. DNA was visualized by exposure to ethidium bromide and long wavelength uv radiation. DNA contained in the slice isolated from this agarose gel was purified using the Bio 101 GeneClean Kit protocol (Bio 101 Vista, CA, USA).

Cloning of Helicobacter Philoly Sequence into pET-28b Prokaryotic Expression Vector

pET-28b with restriction enzymes NcoI and EcoRI, or HpSeq. For 4821082 (SEQ ID NO: 820) it was prepared for cloning by cleavage with NdeI and EcoRI (Current Protocols in Molecular Biology, John wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). In the case of ppiB cloning, a cloning site for cloning with the ppiB gene was made by cleaving with BamHI and XhoI restriction enzymes using a pET-28a vector encoding His-Tag that can be fused to the 5 'end of the inserted gene. .

After cleavage, the DNA insert was cloned into a pre-cleaved pET-28b expression vector (Current Protocols in Molecular Biology, John wiley and Sons, Inc., F. Ausubel et al., Eds., 1994), with the exception of ppiB. Amplification inserts were cloned into pET-28a. As described above using the product of the ligation reaction. Strains of E. coli were transformed (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994).

Transformation of Receptive Bacteria Using Recombinant Plasmids

In accordance with standard methods, appropriate bacteria, ie. E. coli BL21 strain, or two. E. coli BL21 (DE3) strains were transformed with recombinant pET expression plasmids containing cloned Helicobacter phyllori (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994) . Briefly, one microliter of ligation reactant is mixed with 50 microliters of electropermissive cells and subjected to a high voltage pulse, after which the sample is 0.45 milliliters of SOC medium (0.5% yeast extract, 2.0% tryptone, 10 Mm NaCl, 2.5 mM KCl). , 10 mM MgCl ₂ , 10 mM MgSO ₄ and 20 mM glucose) was incubated for 1 hour when stirred at 37 ° C. Samples were then plated on LB agar plates containing 25 μg / ml kanamycin sulfate and grown overnight. Next, transformed colonies of BL21 were taken and analyzed for cloned inserts as described below.

Identification of Recombinant pET Expression Plasmids with Helicobacter Philo Sequence

Each BL21 clone transformed with pET-28b-Helicobacter Philoyl ORF was used for the original PCR amplification cloning reaction, and the insert cloned using the same forward and reverse primers specific for each Helicobacter Philo sequence Analysis by PCR amplification. Successful amplification results confirmed the incorporation of the Helicobacter pili sequence into the expression vector (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994).

Isolation and Purification of Plasmid DNA from BL21 Transformants

Each clone of the recombinant pET-28b vector containing the appropriately cloned Helicobacter pylori ORF was taken and incubated overnight in 5 ml of LB broth and 25 μg / ml kanamycin sulfate. The next day, plasmid DNA was isolated and purified using the Qiagen plasmid purification protocol (Qiagen Inc., Chatsworth, CA, USA).

this. Expression of Recombinant Helicobacter Philoly Sequence in E. Coli

The pET vector can be extracted from any E. coli for cloning or plasmid preparation. E. coli K-12 strains such as HMS174, HB101, JM109, DH5 and the like can be spread. Expression hosts include E. coli containing chromosomal copies of T7 RNA polymerase. E. coli strains are included. These hosts are lambda derivatives containing the genes for the lacI gene, the lcaUV5 promoter and the T7 RNA polymerase as the lysogen of bacteriophage DE3. T7 RNA polymerase is caused by the addition of isopropyl-B-D-thiogalactosidase (IPTG), and T7 RNA polymerase transcribes any target plasmid such as pET-28b containing the T7 promoter and the gene of interest. Use strains include BL21 (DE3) (Studier, F.W., Rosenberg, A.H., Dunn, J.J., and Dubendorff, J.W. (1990) Meth. Enzymol. 185, 60-89).

To express the recombinant Helicobacter pylori sequence, transform the appropriate BL21 (DE3) bacteria (supplied by Novagen as part of the PET expression kit) as described above using 50 nanograms of plasmid DNA isolated as described above. I was. The lacZ gene (beta-galactosidase) was expressed in the pET-system as described for the preparation of Helicobacter pylori recombinant. Transformed cells were incubated for 1 hour in SOC medium, and the cultures were then plated onto LB plates containing 25 μg / ml kanamycin sulfate. The next day, bacterial clonies were pooled and 0.5 to 1.0 O.D. at 600 nM in LB medium containing kanamycin sulfate. Proliferate to the optical density of the unit, at which time 1 mM IPTG is added to the medium for 3 hours to induce gene expression of the Helicobacter pylori recombinant DNA preparation.

After inducing gene expression with IPTG, the bacteria were pelleted by centrifugation with a Sorvall RC-3B centrifuge at 3500xg for 15 minutes at 4 ° C. The pellet was resuspended in 50 ml of cold 10 mM Tris-HCl, pH 8.0, 0.1 M NaCl and 0.1 mM EDTA (STE buffer). The cells were then centrifuged at 2000xg for 20 minutes at 4 ° C. The wet pellets were weighed and frozen at -80 ° C until used for protein purification.

III. this. Recombinant Protein Purification from E. coli

Analytical Method

The concentration of purified protein preparation was quantified by spectrophotometric method using an extinction coefficient calculated from the amino acid content (Perkins, S.J. 1986 Eur. J. Biochem. 157, 169-180). See also Bradford method (MM (1976) Anal. Biochem. 72, 248-254), and Lowry method, (OH, Rosebrough, N., Farr, AL & Randall, RJ (1951) using bovine serum albumin as standard. J. Biol. Chem. 193, pp. 265-275).

SDS-polyacrylamide gels (12% or 4.0-25% acrylamide gradient gels) were purchased from BioRad (Hercules, CA, USA) and stained with Coomassie Blue. Molecular weight markers include rabbit skeletal muscle myosin (200 kDa), E. E. coli galactosidase (116 kDa), rabbit muscle phosphorylase B (97.4 kDa), bovine serum albumin (66.2 kDa), ovalbumin (45 kDa), small carbon anhydride (31 kDa), soybean trypsin inhibitor ( 21.5 kDa), egg white lysozyme (14.4 kDa) and bovine aprotinin (6.5 kDa).

1. Purification of Soluble Proteins

All steps were performed at 4 ° C. Freeze cells were thawed and 5 fold volume of lysis buffer (20 mM Tris, pH 7.9, 0.5 M NaCl, 5 mM imidazole and 10% glycerol, 0.1% 2-mercaptoethanol, 200 μg / ml lysozyme, 1 mM phenyl Methylsulfonyl fluoride (PMSF) and lupeptin, aprotinin, pepstatin, L-1-chloro-3- [4-tosylamido] -7-amino-2-heptanone (TLCK) at 10 μg / ml each ), L-1-chloro-3- [4-tosylamido] -4-phenyl-2-butanone (TPCK), and soybean trypsin inhibitor) and resuspended in small volume microfluidizer (Model M- Burst through several passes through 110S, Microfluidics International Corporation, Newton, Mass.). The resulting 0.1% Brij 35 was made and centrifuged at 100,000 × g for 1 hour to obtain a clear supernatant (crude extract).

After filtration through a 0.8 μm support filter (Gelman Sciences, FRG), the crude extract was pre-equilibrated with Ni ^{2+ in} a lysis buffer containing 10% glycerol, 0.1% Brij 35 and 1 mM PMSF in a 5 ml bed volume. Direct dropping onto nitrotriacetate-agarose (NTA) (Hochuli, E., Dbeli, H., and Schacheer, A. (1987) J. Chromatography 411, 177-184). The column was washed with 250 ml of lysis buffer containing 50% of 10% glycerol, 0.1% Brij 35, followed by 10% glycerol, 0.05% Brij 35, 1 mM PMSF and 20, 100, 200 And lysis buffer containing 500 mM amidazole. Fractions were monitored by absorbance at OD ₂₈₀ nm and peak fractions were analyzed by SDS-PAGE. Fractions containing recombinant protein were eluted with 100 mM imidazole.

Recombinant protein 14640637 and protein, beta-galactosidase (lacZ) and peptidyl-prolyl cis-trans isomerase (ppiB)

Fractions containing the recombinant protein from the Ni ²⁺ -NTA agarose column were pooled and then concentrated to about 5 ml by centrifugal filtration (Centriprep-10, Amicon, Mass.) And buffer A (10 mm Hepes, pH 7.5, Dropped directly onto 180 ml column (1.6 × 91 cm) of Sephacryl S-100 HR gel filtration medium equilibrated with 150 mM NaCl, 0.1 mm EGTA) and flowed at 10 ml / h in Buffer A. Fractions containing recombinant protein were confirmed by absorbance at 280 nm and analyzed by SDS-PAGE. Fractions were pooled and concentrated by centrifugal filtration.

Recombinant Protein 7116626

The fractions containing the recombinant protein from the Ni ²⁺ -NTA agarose column were pooled and overnight for 1 liter of dialysis buffer (10 mM MOPS, pH 6.5, 50 mM naCl, 0.1 mM EGTA, 0.02% Brij and 1 mM PMSF). He was dialyzed. The next morning, the fine white precipitate was removed by centrifugation and the resulting supernatant was equilibrated in 8 ml (8x75 mm) mono S in Buffer B (10 mM MOPS, pH 6.5, 0.1 mM EGTA) containing 50 mM NaCl. It was loaded onto a high performance liquid chromatography column (Pharmacia Biotechnology, Inc., Piscataway, NJ, USA). The column was washed with 10 times buffer volume B of 50 mM NaCl and developed 50 ml of NaCl with increasing gradient (50-500 mM). Recombinant protein 7116626 (SEQ ID NO: 865) eluted as a sharp peak in 300 mM NaCl.

2. Purification of Soluble Protein from Inclusion Body

The next step was carried out at 4 ° C. Cell pellets were resuspended in lysis buffer with 200 μg / ml lysozyme, 5 mM EDTA, 1 mM PMSF and 0.1% -mercaptoethanol in 10% glycerol. After passing through the cell mill, the resulting homogenate was made up to 0.2% deoxycholate, stirred for 10 minutes and centrifuged at 20,000 xg for 30 minutes. The pellet was washed with lysis buffer containing 10% glycerol, 10 mM EDTA, 1% Triton X-100, 1 mM PMSF and 0.1% mercaptoethanol, followed by 1 M urea, 1 mM PMSF and 0.1% 2-mercapto. Wash with lysis buffer containing ethanol. The resulting white pellets contained mainly inclusion bodies without pulverized cells and membrane material.

Recombinant Protein 26054702, 16225006, 30100332, 4721061

The following steps were performed at room temperature. Tablet inclusion bodies were dissolved in 20 ml of 8.0 M urea in lysis buffer with 1 mM PMSF and 0.1% 2-mercaptoethanol and incubated for 1 hour at room temperature. Undissolved material was removed by centrifugation. The filtered clear supernatant was added dropwise onto a Ni ²⁺ -NTA agarose column previously equilibrated with a 8.0 M urea solution in lysis buffer. The column was washed with 250 ml (50 times the bed volume) lysis buffer containing 8 M urea, 1.0 mM PMSF and 0.1% 2-mercaptoethanol, 8 M urea, 1 mM PMSF, 0.1% 2-mercapto The subsequent development of lysis buffer containing ethanol and 20, 100, 200 and 500 mM amidazole was continued in succession. Fractions were monitored by absorbance at OD ₂₈₀ nm and peak fractions were analyzed by SDS-PAGE. Fractions containing recombinant protein were eluted at 100 mM imidazole.

Recombinant Protein 29479681, 26380318

Pellets containing inclusion bodies were dissolved in Buffer B containing 8 M urea, 1 mM PMSF and 0.1% 2-mercaptoethanol and incubated for 1 hour at room temperature. Insoluble material was removed by centrifugation at 20,000 × g for 30 minutes and the clear supernatant was pre-equilibrated with 15 ml (1.6 × 7.5) with Buffer B containing 6 M urea, 1 mM PMSF, 0.1% 2-mercaptoethanol cm) Dropped onto SP-Sepharose column. The column was washed with 10 times the bed volume and the column developed with a linear gradient from 0 to 500 mM NaCl.

Dialysis and Concentration of Protein Samples

Tris-buffered saline (TBS; 10 mM Tris pH 8.0, 150 mM NaCl) containing 0.5% deoxycholate (DOC) with urea concentrations sequentially reduced to 6M, 4M, 3M, 2M, 1M, 0.5M, and Finally urea was slowly removed from the protein by dialysis against urea-free TBS. Each dialysis step was performed for at least 4 hours at room temperature.

After dialysis, samples were concentrated by pressure filtration using Amicon-stirred cells. Perkins (1986) Eur. J. Biochem. 157, 169-180), Bradford (1976), Anal. Biochem. 72, 248-254 and Lowy (1951), J. Biol. Chem. 193, pp. 265-275).

Recombinant proteins purified by the methods described above are summarized in Table 4 below.

IV. Analysis of Helicobacter Philoly Protein as a Vaccine Candidate

In order to analyze the Helicobacter pilori protein for use in the vaccine formulations of the invention, several Helicobacter pilori protein were expressed, immunologically characterized and tested in the animal efficacy studies described below. Specifically, the immunomodulatory effects of Helicobacter pilori protein were investigated in a mouse / Helicobacter pilori model that mimics human Helicobacter pili infection. In this study, the effect of oral immune treatment of selected Helicobacter Philolyte polypeptides on mice infected with Helicobacter Philolyte polypeptide was investigated.

Identification, Cloning and Expression of Recombinant Helicobacter Philo Sequence

To facilitate cloning, expression and purification of membranes and / or secreted proteins from Helicobacter pylori, E. coli. The pET gene system (Novagen) was selected for cloning and expression of recombinant proteins in E. coli. In addition, for a protein having a signal sequence at its amino terminus, a DNA sequence encoding a peptide tag (His-tag) was fused to the 5 'end of the target Helicobacter pylori DNA sequence to facilitate purification of the recombinant protein product. .

PCR amplification and cloning of DNA sequences containing ORFs for membrane and secreted proteins from J99 strain of Helicobacter pylori

Sequences selected from the J99 strain of Helicobacter Philoly (from the list of DNA sequences of the present invention) were prepared by polymerase chain reaction (PCR) for amplification cloning. All selected sequences encode Helicobacter pylori membrane proteins with sequences vac9 (SEQ ID NO: 125), vac10 (SEQ ID NO: 147), vac22 (SEQ ID NO: 121), and vac41 (SEQ ID NO: 176) that share both terminal phenylalanine residues and tyrosine clusters at the C terminus. do. Synthetic oligonucleotide primers (Table 5) were designed and purchased for each desired ORF, specific to the expected mature 5 'end of the open reading frame (ORF) and downstream of the expected translation stop codon (3') (Table 5). GibcoBRL Life Technologies, Gaithersburg, MD, USA). All forward primers (specific for the 5 'end of the region of the objective OFR) were designed to include BamIII restriction sites, followed by NdeI restriction sites. These primers initiate protein translation at methionine residues (which produce recombinant, non-His tagged) coding within the NdeI restriction site sequence or encode His tags followed by the remaining coding sequence of native Helicobacter pylori DNA. The DNA sequence was designed to fuse in frame. All reverse oligonucleotide primers (specific to the downstream of the expected translation termination codon of the ORF (3 ')) were designed to include an EcoRI restriction site at the 5' end. Combinations of these primers allow for cloning each desired ORF into pET28b (to produce His-tagged recombinant protein) or pET30a (to produce His-tagged or native recombinant protein). The pET28b vector provides a sequence encoding an additional 20 amino terminal amino acids (including methionine within the NdeI restriction site), including a stretch of the six histidine residues that make up the His-tag.

Genomic DNA prepared from Helicobacter pylori strain J99 (ATCC 55679) was used as a template DNA source for PCR amplification reactions (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Des. , 1994). To amplify DNA sequences containing specific Helicobacter pylori ORFs, genomic DNA (50 nanograms) was purchased with 200 nanograms and 50 microliters of forward and reverse synthetic oligonucleotides specific for the desired OFR (GibcoBRL Life Technologies, Gaithersburg). , MD, USA) was introduced into a reaction tube containing PCR SuperMix 45 microliters. PCR SuperMix was supplied at a concentration of 1.1 ×, 22 mM Tris-HCl (pH8.4), 55 mM KCl, 1.65 mM MgCl ₂ , 220 micromoles of dATP, dCTP, dGTP and dTTP, 22 units of recombinant Taq polymerase, respectively. / ml and stabilizer. DNA amplification products for each ORF were obtained using a Perkin Elmer Cetus / Gene Amp PCR System thermal cycler using the following thermal cycling conditions.

Vac32, Vac9 and Vac22 sequences;

Denaturation at 94 ℃ for 30 seconds,

35 cycles of 15 seconds at 94 ° C., 15 seconds at 55 ° C. and 1.5 minutes at 72 ° C.

The reaction was terminated at 72 ° C. for 8 minutes.

Vac10 and Vac41 sequences;

Denaturation at 94 ° C. for 30 seconds.

35 cycles of 15 seconds at 94 ° C., 15 seconds at 55 ° C. and 2.5 minutes at 72 ° C.

The reaction was terminated at 72 ° C. for 8 minutes.

Vac36 and Vac37 sequences;

Denaturation at 94 ° C. for 30 seconds.

2 cycles of 15 seconds at 94 ° C., 15 seconds at 30 ° C. and 1.5 minutes at 72 ° C.

23 cycles of 15 seconds at 94 ° C., 15 seconds at 55 ° C. and 1.5 minutes at 72 ° C.

The reaction was terminated at 72 ° C. for 6 minutes.

After termination of the thermal cycling reaction, each sample of amplified DNA was electrophoresed on 1.0% agarose gel. The DNA was exposed to ethidium bromide and then visualized by irradiation with long wavelength UV and cut into gel pieces. DNA was purified using Wizard PCR Preps kit (Promega Corp., Madison, WI, USA) and digested with BamHI and EcoRI (Current Protocols in Molecular Biology, John wiley and Sons, Inc., F. Ausubel et al. , eds., 1994). The digested PCR amplicons were then electrophoresed again and purified as above.

Ligation of Helicobacter Philoyl DNA Sequence into Cloning Vectors

POK12 vector was prepared for cloning by digestion with BamHI and EcoRI for Vac9, 10, 22, 31 and 32, and pSU21 vector was prepared for cloning by digestion with BamHI and EcoRI for Vac41 ( Current Protocols in Molecular Biology, John wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). Vectors were electrophoresed on 1.0% agarose gel and DNA was purified using Wizard PCR Preps kit (Promega Corp., Madison, Wis., USA). After ligation of the digested and purified vectors with the digested, amplified, and purified Helicobacter pylori ORF, the ligation reaction product was used to determine the E. E. coli JM109 soluble cells were transformed (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). Incubate in LB broth (containing 25 μg / ml kanamycin sulfate for pOK12 based plasmid or 25 μg / ml chloramphenicol for pSU21 based plasmid) for each bacterial colony and in Magic Minipreps system (Promega Corp., Madison, WI, USA) was used to prepare plasmid DNA and to screen colonies containing appropriate recombinant plasmids and then analyzed by restriction enzyme digestion (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al. , eds., 1994).

Cloning of Helicobacter Philoyl DNA Sequence into pET28b and pET30a Prokaryotic Expression Vectors

PET28b and pET30a expression vectors were prepared for cloning by digestion with NdeI and EcoRI (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). Helicobacter pylori DNA sequences were removed from pOK12 (Vac9, 10, 23, 31 and 32) or pSU21 (Vac41) plasmid backbones by digestion with NdeI and EcoRI (Current Protocols in Molecular Biology, John Wiley and Sons, Inc.). , F. Ausubel et al., Eds., 1994). pET28b, pET30a and Helicobacter Philoyl DNA sequences were electrophoresed on 1.0% agarose gel and DNA was purified using Wizard PCR Preps kit (Promega Corp., Madison, Wis., USA). After ligation of the digested and purified expression vector with the digested and purified Helicobacter pylori DNA sequence, the ligation reaction product was used to determine the E. coli. E. coli JM109 soluble cells were transformed (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). Plasmid DNA was prepared as described above for each bacterial colony and then screened for colonies containing the appropriate recombinant plasmid by analysis by restriction enzyme digestion profiles and DNA sequencing (Current Protocols in Molecular Biology, John Wiley and Sons). , Inc., F. Ausubel et al., Eds., 1994). These recombinant plasmids were then used to transform certain E. coli expressing strains.

Transformation of Water-soluble Bacteria Using Recombinant Expression Plasmids

According to standard methods, water soluble bacterial strains BL21 (DE3), BL21 (DE3) pLysS, HMS174 (DE3) and HMS174 (DE3) pLysS were prepared and transformed with recombinant pET28b expression plasmids carrying the cloned Helicobacter Philo sequence ( Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). These expression host strains contain chromosomal copies of the genes for T7 RNA polymerase. These hosts are lambda derivatives containing the genes for the lacI gene, the lcaUV5 promoter and the T7 RNA polymerase as the lysogen of bacteriophage DE3. T7 RNA polymerase expression is induced by the addition of isopropyl-β-D-thiogalactoside (IPTG), and T7 RNA polymerase then contains a target plasmid containing the T7 promoter sequence and the gene of interest, for example pET28b. Warriors

E. of the recombinant Helicobacter pylori sequence. Expression in E. coli

Transformants were recovered from LB agar plates containing 25 μg / ml kanamycin sulfate (to maintain pET28b based recombinant plasmids), inoculated in LB broth containing 25 μg / ml kanamycin sulfate at 600 nm. Was grown to an optical density of 0.5 to 1.0 OD units, at which point 1 mM IPTG was added to the medium for 1-3 hours to induce gene expression of the Helicobacter pylori recombinant DNA construct. After gene expression using IPTG, bacteria were pelleted by centrifugation, resuspended in SDS-PAGE solubilization buffer and applied to SDS-PAGE (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel). et al., eds., 1994). Proteins were visualized by staining with Coomassie Brilliant Blue or detected by Western immunoblotting using specific anti-Histag monoclonal antibodies (Clontech, Palo Alto, CA, USA) according to standard methods (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). Host strains were selected that provide high levels of recombinant protein production for use in large scale induction to purify recombinant proteins. All of the following proteins are recombinantly expressed and strains provide the highest levels of expression: BL21 (DE3) (vac31, vac26, vac37), BL21 (DE3) pLysS (vac9, 32), HMS174 (DE3) ( vac 10, 11).

Purification of Recombinant Proteins and Generation of Specific Antisera

Large cultures were inoculated and grown as above, followed by induction for 3 hours with 1 mM IPTG. After induction, the bacteria were pelleted by centrifugation in a Sorvall centrifuge at 3,500 × g for 15 minutes at 4 ° C. All expressed recombinant proteins were in insoluble inclusion body fractions. Inclusion bodies were purified according to standard methods (Antibodies, Cold Spring Harbor Laboratory Press, E. Harlow and D. Lane, eds., 1988). Recombinant protein produced by vac32 was solubilized in 8M urea and partially purified by nickel chromatography (REF). Denatured recombinant protein was purified by electrophoresis on an SDS-PAGE gel, visualized with Coomassie Brilliant Blue, and then the protein was excised from the gel and the gel fragments homogenized. This material was used to generate specific polyclonal antibodies in mice or rabbits according to standard methods (Antibodies, Cold Spring Harbor Laboratory Press, E. Harlow and D. Lane, eds., 1988).

Immunological Properties of Recombinant Proteins

In all cases where antibody production was attempted, high titers of antiserum were produced, which demonstrated the immunogenicity of the recombinant protein. In addition, this specific antiserum was used to analyze whether the protein encoded by the cloned gene is expressed in Helicobacter pili. Western immunoblot analysis using standard methods (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994) showed that Helicobacter Philoly strain J99 reacted with vac10, vac32, and vac36 antiserum. Proved that the protein of the expected molecular weight. Specific antisera was also used to measure the degree of antigenic preservation between many regions of the world and a large number of Helicobacter pylori isolates obtained in all types of clinical symptoms including gastritis, duodenal ulcers, gastric ulcers and mumps. All strains have been found to produce proteins that specifically react with their respective antisera.

In addition, Helicobacter pilori cells from strains J99, 17874, AH244 and SS1 were fractionated into different cell compartments (Doig and Trust 1994 Infect. Immun. 62: 4526-4533: O'Toole et al. 1995 J. Bacteriol. 177: 6049-6057). Specific antisera was used to probe by Western immunoblot to identify the fraction where the protein is located. In all cases, the immunoreactive protein was present in the outer membrane as expected by sequence properties and motif search herein.

Demonstration of protein efficacy as a vaccine

Purification of vac36 for efficacy studies

All following steps were performed at 4 ° C. Cell pellets were dissolved in 10 mM EDTA, 1 mM phenylmethylsulfonyl fluoride (PMSF) and 0.1% β-mercaptoethanol per gram of cells (50 mM sodium phosphate, pH 8.0, 0.5 M NaCl, 5 mM imidazole). Resuspend in 5 volumes and rupture by multiple passages through a small volume microfluidizer (Model M-110S, Microfluidics International Corporation, Newton, Mass.). The resulting homogenate was treated with 0.2% sodium deoxycholate, stirred for 20 minutes and then centrifuged (10,000 g x 30 minutes). The pellet was washed twice with lysis buffer containing 10 mM EDTA, 1% Triton X-100, 1 mM PMSF and 0.1% β-mercaptoethanol, followed by 1M urea, 1 mM PMSF and 0.1% β-mercaptoethanol. Wash with containing lysis buffer. The resulting white pellets consisted mainly of inclusion bodies and were free of uncleaved cells and membranous material.

Inclusion bodies were dissolved in 20 mM 6M guanidine-HCl in lysis buffer with 1 mM PMSF and 0.1% β-mercaptoethanol and incubated for 1 hour. Undissolved material was removed by centrifugation (100,000 gx 30 minutes). The clear supernatant was filtered through a 0.8 μm Supor filter (Gelman Sciences, FRG) and then pre-equilibrated in 10 ml Ni ²⁺ -NTA in 6M guanidine-HCl in lysis buffer containing 1 mM PMSF and 0.1% β-mercaptoethanol. Direct loading onto agarose column (Hochuli et al. 1987). The column was washed with 20 ml (2 bed volumes) of lysis buffer containing 6 M luminanidine-HCl, 1 mM PMSF and 0.1% β-mercaptoethanol, followed by 0.5% Brij 35, 1 mM PMSF, 0.1% β Guanidine-HCl was slowly removed using a 100 ml linear gradient (6 M to 0 M guanidine-HCl) of lysis buffer containing mercaptoethanol. The column was then developed using a 25 ml linear gradient to increase (from 5 to 500 mM) imidazole in lysis buffer containing 0.5% Brij 35, 1 mM PMSF and 0.1% β-mercaptoethanol. Recombinant protein eluted as a centrally located peak at 100 mM imidazole.

Fractions containing the recombinant protein were collected and concentrated to about 8 ml by centrifugal filtration (Centriprep-10, Amicon, MA) and buffer A (50 mM sodium phosphate, pH8.0, 500 mM NaCl, 0.1 mM EGTA, 1 mM). Buffer directly at 30 ml / h after loading directly onto a 350-ml column (2.2 × 91 cm) of Sephacryl S-100 HR gel filtration medium equilibrated in PMSF, 0.1% β-mercaptoethanol, 0.5% Brij 35) It was developed in A. Fractions containing recombinant protein were confirmed by absorbance at 280 nm and analyzed by SDS-PAGE. Fractions were combined and concentrated to 1.5-2 mg / ml and dialyzed overnight against 10 mM potassium phosphate pH 7.5, 150 mM NaCl, 0.1 mM EGTA and 0.5% Brij 35. The concentration of protein in the dialysate was quantified and then aliquoted before freezing at -20 ° C.

Mouse Model of Helicobacter Phillori Infection

A mouse model of Helicobacter pylori infection was produced by infecting C57BL / 6 mice with Helicobacter pylori Sydney strain SS1, and used to evaluate the efficacy of recombinant Helicobacter pilori vac36. This mouse applied Helicobacter Philoly strain is cagA + vacA +, shows colony formation levels in the same C57BL / 6 mice as observed in humans, forms attachments, colonies for more than 8 months, chronic active gastritis And mucosal atrophy (Lee et al., Gastroenterology, 112: 1386-1397, 1997). Dose response studies showed 100% infection rate of allogeneic C57BL / 6 and Balb / C mice after 8 weeks of challenge with a single inoculation of 10 ⁶ organisms.

Assessment of Stomach Infection of Helicobacter Philoly

The presence of Helicobacter pylori organisms in gastric tissue was determined by culture and quantitative urease analysis of gastric tissue. In quantitative urease analysis, longitudinal fragments of the gastrointestinal tract representing approximately one quarter of the entire gastric antral region were placed in 1 ml of urea broth. The extent of color change and pH increase resulting from urea hydrolysis after 4 hours was quantified by spectrophotometric measurement of A ₅₅₀ (Fox et al., Immunol. 88: 400-406, 1996). Analytical sensitivity is less than 10 ³ Helicobacter pylori organisms. Positive (Helicobacter pilori infection) Gastric tissue was defined as a sample that exhibited two standard deviations above the mean A ₅₅₀ value derived from a group of un challenged, uninfected, age-matched control mice.

Evaluation of Local Immune Responses to Immune Treatment in Gastric Tissues

Longitudinal fragments of gastric tissue from the esophagus to duodenal junctions are impregnated in OCT-containing compounds, frozen in liquid nitrogen, and identified for monoclonal antibodies or IgA containing (IgACC) plasma cells that recognize CD4 ⁺ or CD ⁺ 8T cells Cold fragments were immunostained with antisera against mouse IgA (Pappo et al., Infect. Immun 63: 1246-1252, 1995). The degree of local gastric immune response was quantitatively expressed as the number of CD4 ⁺ , CD ⁺ 8T or IgACC cells per mm ² of irradiated gastric area.

Protective Activity of Purified Recombinant Helicobacter Philoly vac36 Antigen

The ability of the purified recombinant vac36 antigen derived from Helicobacter pilori to interfere with the establishment of Helicobacter pilori infection was investigated in mice. Groups of female C57BL / 6 mice 6-8 weeks old (n = 10) were immunized by four oral administrations at weekly intervals as follows: 1) 100 μg recombinant vac36 antigen and cholera toxin (CT) adjuvant 10 Μg, 2) 1 mg of Helicobacter pylori lysate antigen and 10 μg CT, and 3) 10 μg bicarbonate buffer 0.2 M and CT adjuvant. Two weeks later mice were challenged for 3 consecutive days by oral administration of 10 ⁸ Helicobacter Philoly organisms. The experiment was terminated after 2 weeks of challenge and the Helicobacter pylori infection level was assessed by bacterial colony counts and quantitative urease assay.

Oral immunization with the vac36 antigen prevented the establishment of a Helicobacter pilori infection upon challenge with live Helicobacter pilori organisms. Mice immunized with purified recombinant vac36 antigen showed significantly lower levels of colony formation of Helicobacter phyllori as assessed by gastric urease activity and bacterial count analysis (Table 6). In addition, oral immunization with vac36 antigen also produced a locally protective gastric immune response. More CD4 ⁺ T cells and IgACC were supplemented in the gastric tissue of vac36-immunized mice compared to non-immunized Helicobacter pylori infected mice (Table 7).

Recombinant vac36 antigen protects mice from challenge with Helicobacter Philophyll. Vaccine treatment group Urease activity ^a p ^b Helicobacter Philly Bourden ^c p ^b vac36 0.199 ± 0.080 0.0022 55,800 ± 12,599 0.0125 Helicobacter pylori melt 0.057 ± 0.007 0.0022 2,360 ± 955 0.0002 Buffer 1.655 ± 0.420 - 131,000 ± 18,391 - a: Urease activity is expressed as mean A ± SEM of double gastric foremen samples from group (n = 10) b: by Wilcoxon Rank Sum Test compared to mice immunized with CT adjuvant alone c: Gastric tissue levels of Helicobacter pylori were assessed by bacterial counts and expressed as mean colony forming units ± SEM.

vac36 immunized mice generate a local gastric immune response upon challenge with Helicobacter Philo. Vaccine Treatment Group CD4 ⁺ CD8 ⁺ IgACC vac36 Stomach ^a Stomach inside Jeonjeon government Stomach Stomach Jeonjeon government Stomach Stomach Jeonjeon government 33 ± 9 ^a 54 ± 8 ^* 31 ± 8 3 ± 2 0 1 ± 1 24 ± 12 79 ± 16 67 ± 13 Helicobacter pylori melt 31 ± 13 36 ± 19 24 ± 8 4 ± 2 2 ± 1 2 ± 1 31 ± 9 73 ± 13 ^* 79 ± 15 Buffer 12 ± 2 27 ± 8 18 ± 4 1 ± 1 0 0 4 ± 2 30 ± 13 46 ± 14 a: Average number of cells / mm ^{2 in} the gastric region ± SEM *: p <0.05 by Wilcoxon Rank Sum Test when compared to non-immunized Helicobacter pylori infected mice

V. Sequence Change Analysis of Genes in Helicobacter Philosophy Strains

Four genes from several strains were cloned and sequenced to compare DNA and derived amino acid sequences. This information was used to determine sequence changes between the Helicobacter pilori strain, J99, and other Helicobacter pilori strains isolated from human patients.

Preparation of Chromosome DNA

Cultures of Helicobacter pylori strains (shown in Table 10) were subjected to an OD of 0.2 in BLBB (1% tryptone, 1% peptamine 0.1% glucose, 0.2% yeast extract, 0.5% sodium chloride, 5% fetal bovine serum). Proliferation was reached up to ₆₀₀ . Cells were centrifuged at 3500xg for 15 minutes in volatile RC-3B at 4 ° C and the pellet was resuspended in 0.95 ml of 10 mM Tris-HCl, 0.1 mM EDTA (TE). SDS at 1% at the final concentration, and RNAse A + T1 at 0.5 mg / ml and 5 units / ml, respectively, were added at a final concentration of lysozyme at 1 mg / ml and incubated at 37 ° C. for 1 hour. Proteinase K was then added at a final concentration of 0.4 mg / ml and the samples were incubated at 55 ° C. or higher for over 1 hour. NaCl was added to the sample to a concentration of 0.65 M, mixed carefully, and incubated at 65 ° C. for 20 minutes by addition of 0.15 ml of 10% CTAB in 0.7 M NaCl (final concentration 1% CTAB / 70 mM NaCl). . At this time, the sample was extracted with chloroform: isoamyl alcohol, extracted with phenol and extracted again with chloroform: isoamyl alcohol. DNA was precipitated with EtOH (1.5 fold volume) or isopropanol (0.6 fold volume) at −70 ° C. for 10 minutes, washed with 70% EtOH and resuspended in TE.

PCR amplification and cloning

Genomic DNA prepared from 12 Helicobacter pylori strains was used as a template DNA source for PCR amplification reactions (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). . To amplify the DNA sequence containing Helicobacter Philoly ORF, genomic DNA (10 nanograms) was added to 2 mM MgCl _{2, a} 1 mM synthetic oligonucleotide primer that is complementary and flanking for the defined Helicobacter Philly ORF ( Forward or reverse primer, see Table 7), 0.2 mM each deoxynucleotide triphosphate; dATP, dGTP, dCTP, dTTP and 0.5 units of thermostable DNA polymerase (Amplitaq, Roche Molecular Systems, Inc. Branchburg, NJ, USA) were introduced into a reaction vial containing a final volume of 20 microliters.

The following thermal cycling conditions were used to obtain amplified DNA products for each ORF with a Perkin Elma Setus / Zenamp PCR System 9600 thermal cycler:

Protein 7116626 and Protein 346:

Denaturation at 94 ℃ for 2 minutes,

2 cycles of 15 seconds at 94 ° C., 15 seconds at 30 ° C. and 1.5 minutes at 72 ° C.

23 cycles of 15 seconds at 94 ° C., 15 seconds at 55 ° C. and 1.5 minutes at 72 ° C.

The reaction was terminated at 72 ° C. for 6 minutes.

Protein 26054702 for AH5, 5155, 7958, AH24 and J99 strains:

Denaturation at 94 ℃ for 2 minutes,

2 cycles of 15 seconds at 94 ° C., 15 seconds at 30 ° C. and 15 minutes at 72 ° C.

25 cycles of 15 seconds at 94 ° C, 15 seconds at 55 ° C and 1.5 minutes at 72 ° C

The reaction was terminated at 72 ° C. for 6 minutes.

Protein 26054702 and protein 294796813 for strains AH4, AH15, AH61, 5294, 5640, AH18 and Hp244:

Denaturation at 94 ℃ for 2 minutes,

2 cycles of 15 seconds at 94 ° C., 15 seconds at 30 ° C. and 1.5 minutes at 72 ° C.

25 cycles of 15 seconds at 94 ° C, 15 seconds at 55 ° C and 1.5 minutes at 72 ° C

The reaction was terminated at 72 ° C. for 8 minutes.

After completion of the thermal cycling reaction, each pair of samples was combined and used to clone directly into the pCR cloning vector as described below.

Cloning of Helicobacter Philoyl DNA Sequence into pCR TA Cloning Vector

All amplified inserts were cloned into pCR 2.1 by the method described in the original TA cloning kit (Invitrogen, San Diego, Calif.). Subsequently E. coli described below using the product of the ligation reaction. E. coli TOP10F '(INVaF' for Helicobacter Philo sequence 350) was transformed.

Transformation of Water-soluble Bacteria by Recombinant Plasmids

Water soluble bacteria, ie. E. coli strain TOP10F 'or E. coli. E. coli strain INVaF 'was transformed according to standard methods with recombinant pCR expression plasmid containing cloned Helicobacter Philoly sequence (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds. , 1994). Briefly, 2 ml of 0.5 mM BME was added to each 50 ml of appropriate bacterial vial. Subsequently, 2 ml of the ligation reaction was mixed with appropriate cells and incubated for 30 minutes on the ice bed. This cell and ligation mixture is subjected to "heat shock" at 42 ° C. for 30 seconds, and then placed on ice for an additional 2 minutes, and then the sample is shaken at 37 ° C. for 1 hour while SOC medium (0.5% yeast extract, 2.0% tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl ₂ , 10 mM MgSO ₄ and 20 mM glucose) in 45 ml. Samples were then plated and spread overnight over LB agar plates containing 25 μg / ml kanamycin acid sulfate or 100 μg / ml ampicsilane. The transformed colonies of TOP10F 'or INVaF' were then analyzed to evaluate the cloned insert as described below.

Identification of Recombinant PCR Polismids Containing Helicobacter Philo Sequences

Each TOP10F 'or INVaF' clone transformed with recombinant pCR-Helicobacter pilori ORF was cloned using the same forward and reverse primers used in the original PCR amplification cloning reaction and specific for each Helicobacter pilori sequence The sieve was analyzed by CPR amplification. Successful amplification demonstrated the incorporation of the Helicobacter pilori sequence in the cloning vector (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994).

Each clone of the recombinant pCR vector containing the appropriately cloned Helicobacter pylori ORF was taken and analyzed for sequence. Sequencing was performed in standard protocols (Perkin Elmer) using vector specific primers (eg, PCRII or pCR2.1, Invtrogen, San Diego, Calif.) And sequencing primers specific for ORF as described in Table 9 below. According to the AB1 sequencer.

result

To determine the PCR error rate in this experiment, each of the five clones of SEQ ID NO: 649, prepared from five separate PCR reaction mixtures from the Helicobacter pylori J99 strain, was added to the total length of 897 nucleotides for the total 4485 base accumulation of the DNA sequence. Sequencing was performed. The DNA sequences for the five clones were compared with the DNA sequences of SEQ ID NO: 649 previously obtained by other methods, ie random shotgun cloning and sequencing. The PCR error rate for the experiments described herein was determined to be two bases out of 4485 bases, corresponding to an evaluation error rate of 0.04% or less.

DNA sequence analysis was performed on four different open reading frames identified and amplified as genes by the PCR method from twelve different strains of the Helicobacter pylori bacterium. The derived amino acid sequences of the four open reading frames selected for this study showed statistically significant BLAST homology to certain proteins present in different bacterial species. These ORFs are f. Protein 26054702 homologous to the val A & B gene encoding ABC transporter in F. novicida; H. Protein 7116626 homologous to lipoprotein e (P4) present in the outer membrane of influenza; this. Protein 29479681 homologous to fecA, the outer membrane receptor in iron (citrate) transfer in E. coli. Protein 346 was identified with an unknown open reading frame because it showed low homology with sequences in published databases.

To assess the degree of ORF conservation or variation between various Helicobacter pylori strains, changes in DNA sequence and derived protein sequence were compared with the DNA and derived protein sequences found in J99 strain of Helicobacter pylori (see Table 10 below). . The results are presented in% identity for J99 strain of Helicobacter Philo sequence sequenced by Lambdon Shotgun Cloning. To control any changes in the J99 sequence, each of the four open reading frames was cloned and resequencing from the J99 bacterial strain and the sequence information collected from the insert cloned by the Landon Shotgun sequencing of the J99 strain. Compared with the information. The data indicated that there was a range of differences in DNA sequence ranging from 0.12% difference (protein 346, J99 strain) to about 7% change (protein 26054702, AH5 strain). The derived protein sequence showed no difference (protein 346, AH18 and AH24 strains) or many amino acid changes up to 7.66% (protein 26054702, strain AH5).

VI. Knockout Experimental Protocol for Determining Essential Helicobacter Philosophy Gene as an Efficacy Therapeutic Target

The therapeutic target was selected from genes whose protein products seem to play an important role in essential cellular pathways such as cellular envelope synthesis, DNA synthesis, transcription, translation, regulation and colony formation / virulence.

To identify the essential genes, the protocol for deletion of a portion of the Helicobacter Philoyl gene / ORF and insertional mutation of the kanamycin-resistant cassette was modified from a previously published method (Labigne-Roussel et al., 1988, J. Bacteriology 170, pp. 1704-1708; Cover et al., 1994, J. Biological Chemistry 269, pp. 10566-10573; Reyrat et al., 1995, Proc. Natl. Acad. Sci. 92, 8768-8772). This result is the gene "knockout".

Identification and Cloning of Helicobacter Philoly Gene Sequence

The sequence of the gene or ORF (open reading frame) selected as the knockout target was identified from the Helicobacter Philo genome sequence and used in primer design to specifically amplify the gene / ORF. All synthetic oligonucleotide primers were designed with the help of the OLIGO program (National Biosciences, Inc., Plymouth, MN 55447, USA) and can be purchased from Gibco / BRL Life Technologies (Gaithersburg, MD, USA). If the ORF is less than 800 to 1000 base pairs, flanking primers outside the open reading frame are selected.

Genomic DNA prepared from Helicobacter pylori HpJ99 strain (ATCC 55679) was used as a template DNA source for amplification of ORF by PCR (polymerase chain reaction) (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). See Example I for the preparation of genomic DNA from Helicobacter pylori. PCR amplification was performed using 10 nanograms of genomic HpJ99 DNA, 10 mM Tris pH 8.3, 50 mM KCl, 2 mM MgCl ₂ , 2 mM synthetic oligonucleotide primers (forward = F1 and reverse = R1), 0.2 mM each deoxynucleotide triphosphate. (dATP, dGTP, dCTP, dTTP) and 1.25 units of thermostable DNA polymerase (Amplitaq, Roche Molecular Systems, Inc. Branchburg, NJ, USA) were performed by introducing into a reaction vial containing 40 mL of final volume. PCR is performed using a Perkin Elmer Cetus / GeneAmp PCR System 9600 thermal cycler.

After termination of the thermal cycling reaction, each sample of amplified DNA was visualized on 2% TAE agarose gel stained with ethidium bromide (Current Protocols in Molecular Biology, John wiley and Sons, Inc., F. Ausubel et al. , eds., 1994) was determined whether a single product of predicted size resulted from this reaction. The amplified DNA was then washed and purified using the Qiaquick Spin PCR purification kit (Qiagen Gaithersburg, MD, USA).

PCR products were cloned into pT7Blue T-vector (Catalog # 69820-1, Novagen, Inc., Madison, WI, USA) using a TA cloning strategy (Current Protocols in Molecular Biology, John wiley and Sons, Inc., F.). Ausubel et al., Eds., 1994). Ligation of the PCR product into this vector was carried out using a 6-fold molar excess of the PCR product with 10 ng of the pT7Vlue-T vector (Novargen), 1 ml of T4 DNA ligase buffer (New England Biolabs, Beverly, MA, USA), and T4 DNA. 200 units of ligase (New England Biolabs) were performed by mixing to 10 ml final reactant volume. Ligation was carried out at 16 ° C. for 16 hours.

The ligation product was subjected to XL-1 Blue or DH5-α e. E. coli cells (Clentech Lab., Inc. Palo Alto, CA, USA) were electroporated (Current Protocols in Molecular Biology, John wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). Briefly, 1 ml of the ligation reactant is mixed with 40 μl of cells appropriate for electrolysis and subjected to high voltage pulses (25 microfarads, 2.5 kV, 200 ohms), after which the sample is 0.45 milliliters of SOC medium (0.5% yeast extract). , 2.0% tryptone, 10 Mm NaCl, 2.5 mM KCl, 10 mM MgCl ₂ , 10 mM MgSO ₄ and 20 mM glucose) and incubated at 37 ° C. for 1 hour. The sample was then subjected to LB containing 100 μg / ml, 0.3% X-gal, and 100 μg / ml IPTG (10 g / l bacto tryptone, 5 g / l bacto yeast extract, 10 g / l sodium chloride) The plate was plated. This plate was incubated overnight at 37 ° C. Ampicillin-resistant colonies with white color were selected, grown in liquid LB containing 100 μg / ml of ampicillin and isolated using the Qiagen miniprep protocol (Qiagen, Gaithersburg, MD, USA).

To confirm that the correct Helicobacter Philoyl DNA insert was cloned, pT7Blue plasmid DNA was used as a template for PCR amplification of the cloned insert using the same forward and reverse primers used for initial amplification of the J99 Helicobacter Philoly sequence. Recognition of the primers and PCR products of the correct size visualized on 2% TAE, ethidium bromide-stained agarose gel confirm the correct insert was cloned. Two to six of the above validated clones were obtained from each knockout target and frozen for storage at −70 ° C. To minimize errors due to PCR, plasmid DNA from these confirmed clones was pooled and used for subsequent cloning steps.

The sequence of the gene / ORF is used again to design a second pair of primers flanked by or distant from the Helicobacter Philoyl DNA (up to 250 base pairs) within the ORF. A pool of cyclic plasmid DNA of clones isolated previously is used as template for this time PCR. Because the primer amplification orientations of these deletion primer pairs are separated from each other, the ORF portion between the primers is not included in the resulting PCR product. The PCR product is a linear fragment of Helicobacter Philoyl DNA at each end and a DNA with a pT7Blue vector backbone between them, which essentially results in the deletion of a portion of the ORF. Visualization of PCR products on agarose gels stained with 1% TAE, ethidium bromide confirms that only a single product of the correct size was amplified.

Kanamycin resistance cassette (Labigne-Roussel et al., 1988, J. Bacteriology 170, 1704-1708) was ligated to this PCR product by the TA cloning method used previously (Current Protocols in Molecular Biology, John Wiley and Sons, Inc.). , F. Ausubel et al., Eds., 1994). A kanamycin cassette containing a campylobacter kanamycin resistance gene is obtained by performing EcoRI cleavage of the recombinant plasmid pCTB8: kan (Cover et al., 1994, J. Biological Chemistry 269, pages 10566-10573). Appropriate fragments (1.4 kb) were isolated on 1% TAE gels and isolated using QIAquick gel extraction kits (Qiagen, Gaithersburg, MD, USA). 4 μg of DNA fragment, 0.5 mM of dATP, dGTP, dCTP, dTTP, 2 μl of Klenow buffer (New England Biolabs) and 5 units of Klenow DNA Polymerase I (Klenow) fragment (New England Biolabs) Terminal fragments of this fragment were mixed using a Klenow filling protocol involving inactivation of this enzyme by mixing with 20 μl reaction, incubating at 30 ° C. for 15 minutes and heating at 75 ° C. for 10 minutes. This blunt ended kanamycin cassette was then purified through Qiagen columns (Qiagen, Gaithersburg, MD, USA) to remove nucleotides. The “T” overhang was then followed by 5 μg kanamycin cassette blunt-ended in 100 μl reaction, 10 mM Tris pH 8.3, 20 mM KCl, 2 mM MgCl ₂ , DNA polymerase 5 units (Amplitaq, Roche Moleculat Systems, Inc., Branchburg, NJ, USA), 20 μl of 5 mM dTTP were mixed and incubated at 37 ° C. for 2 hours. This "Kan-T 'cassette is purified using a QIAquick column (Qiagen, Gathersburg, MD, USA) PCR products of deletion primers (F2 and R2) are placed in Kan-T cassette, deletion primer PCR products 10-25 ng 50-75 ng of Kan-T cassette DNA, 1 μl of 10 × T4 DNA ligase reaction mixture, 0.5 μl of T4 DNA ligase (New England Biolabs, Beverly, MA, USA) were mixed in 10 μl reaction and 16 h at 16 ° C. Ligation by incubation for a while.

This ligation product was converted to XL-1 Blue or DH5-α by electroporation as described previously. E. coli cells were transformed. After recovery in SOC, cells were plated on LB plates containing 100 mg / ml ampicillin and grown overnight at 37 ° C. This plate was then replicate plated on plates containing 25 μg / ml kanamycin and allowed to grow overnight. The resulting colonies have both the ampicillin resistance gene and the newly introduced kanamycin resistance gene present in the pT7Blue vector. Colonies are taken in LB containing 25 μg / ml of kanamycin and plasmid DNA is isolated from cultured cells using the Qiagen Miniprep protocol (Qiagen, Gaithersburg, MD, USA).

Several tests by PCR amplification are performed on these plasmids to confirm that kanamycin has been inserted into the Helicobacter pilori gene / ORF and determine the insertion orientation of the kanamycin resistance gene against the Helicobacter pilori gene / ORF. To confirm that the kanamycin cassette is inserted into the Helicobacter pilori sequence, this plasmid DNA is used as a template for PCR amplification using the primer set originally used for cloning the Helicobacter pilori gene / ORF. The exact PCR product size is the size of the deleted gene / ORF, but is increased by adding a 1.4 kb kanamycin cassette. In order to avoid potential polar effects on the expression of kanamycin resistant Helicobacter phyllori genes, the orientation of the kanamycin resistance gene to knockout genes / ORF was determined and both orientations were sometimes used for Helicobacter phyllori transformation (see below). . To determine the insertion orientation of the kanamycin resistance gene, primers are designed from the ends of the kanamycin resistance gene ("Kan-1" 5'-ATCTTACCTATCACCTCAAAT-3 '(SEQ ID NO: 255), and "Kan-2" 5'-AGACAGCAACATCTTTGTGAA) -3 '(SEQ ID NO: 256)). By using each cloning primer with each Kan primer (four primer combinations), the orientation of the kanamycin cassette relative to the Helicobacter Philo sequence is determined. Positive clones in the "A" orientation (the same direction of transcription exists for both the Helicobacter pilori gene and the kanamycin resistance gene), or in the "B" orientation (the transcription direction for the Helicobacter pilori gene is the same as that of the kanamycin resistance gene). Reverse). Clones that share the same orientation (A or B) were pooled for subsequent experiments and transformed independently into Helicobacter phyllori.

Transformation of Helicobacter Philoly Cells with Plasmid DNA

Two Helicobacter pylori strains were used for transformation: ATCC 55679 (a clinical isolate that provided the DNA from which the Helicobacter pylori sequence database was obtained), and AH224 (passed over the mouse and capable of forming colonies to it). Isolate). Transformed cells are grown in Schiff-blend agar plates or Brucella broth juice at 37 ° C., 10% CO ₂ , 100% humidity. The cells are grown exponentially and judged by microscopic examination whether the cells are "healthy" (actively moving cells) and not contaminated. When grown on plates, cells are harvested by stripping cells from the plates in a sterile loop, suspended in 1 ml of Brucella broth, lowered (1 min, maximum speed of Eppendorf microfuse), and reproduced in 200 μl of Brucella broth. It was cloudy. When grown in Brucella broth juice, cells were centrifuged (15 min at 3000 rpm in a Beckman TJ6 centrifuse) and the cell pellet was resuspended in 200 μl of Brucella broth. An aliquot of the cell was taken and the optical density at 600 nm was measured to calculate the cell concentration. Aliquots of suspended cells (1-5 OD ₆₀₀ units / 25 μl) are plated on preheated Sheep-Blood Agar plates, which are further incubated for 4 hours at 37 ° C., 6% CO ₂ , 100% humidity. I was. After this incubation, 10 μl of plasmid DNA (100 μg / μl) is dotted on these cells. Positive control (plasmid DNA with ribonuclease H gene destroyed by kanamycin resistance gene) and negative control (without plasmid DNA) are performed in parallel. The plate is returned during 37 hours of incubation at 6% CO ₂ for an additional 4 hours of incubation. The cells are then plated onto the plate using a cotton swab soaked in Brucella broth and grown for 20 hours at 37 ° C., 6% CO ₂ . Cells are then transferred to Schiff-blood agar plates containing 25 μg / ml kanamycin and grown for 3-5 days at 37 ° C., 6% CO ₂ , 100% humidity. When colonies appear, they are repopulated as patches on fresh Schiff-Blood agar plates containing 25 μg / ml of kanamycin.

Three sets of PCR tests are performed to confirm that colonies of transformants resulted from homologous recombination at the appropriate chromosomal location. The template for PCR (DNA from colony) is obtained by the following rapid boiling DNA production method. A partial sample of colonies (taken into the toothpick with a toothpick) is introduced into 100 μl of 1% Triton X-100, 20 mM Tris, pH 8.5 and boiled for 6 minutes. An equal volume of phenol: chloroform (1: 1) was added and vortexed. The mixture is centrifuged for 5 minutes and the supernatant is used as a DNA template for PCR with the following primers to confirm homologous recombination at the appropriate chromosomal location.

Test 1. PCR using the cloning gene originally used for gene / ORF amplification. A positive result for homologous recombination at the correct chromosomal location is expected to be the size of the deletion gene / ORF but should indicate a single PCR product increased by the addition of 1.4 kb kanamycin cassette. Accurate gene / ORF size PCR products are evidence that the gene has not been knocked out and the transformant is not the result of homologous recombination at the correct chromosomal location.

Test 2. Primers Kan-1 or Kan-2 (kanamycin resistance depending on F3 (primer designed from gene / ORF upstream sequence and not present in plasmid), and whether the plasmid DNA used has an "A" or "B" orientation PCR using primers designed from both ends of the gene. Homologous recombination at the correct chromosomal location will produce a single PCR product of expected size (ie, from the location of F3 to the insertion site of the kanamycin resistance gene). The absence of an incorrectly sized PCR product or PCR product (s) is to demonstrate that the plasmids did not coalesce in the correct position and the gene was not knocked out.

Test 3. R3 (primer designed from gene / ORF downstream and not present in plasmid), and primers Kan-1 or Kan-2 depending on whether the plasmid DNA used had an "A" or "B" orientation PCR. Homologous recombination at the correct chromosomal location will produce a single PCR product of expected size (ie, from the insertion site of the kanamycin resistance gene to the downstream position of R3). In addition, the absence or inaccurate size of the PCR product is to demonstrate that the plasmid did not coalesce in the correct position and the gene was not knocked out.

A transformant that shows positive results for all three tests means that the gene is not essential for survival in vitro.

A negative result in any of the three tests means that the gene was not destroyed and is essential for in vitro survival.

If a positive control in the disrupted ribonuclease H plasmid DNA produced a transformant while no colonies were produced from two independent transformants, before plasmid DNA was plated for colony formation Further analysis is by PCR on DNA from the population of transformants. This will demonstrate that homologous recombination can be performed at the correct location by entering plasmid cells. Briefly, plasmid DNA is incubated according to the transformation protocol described above. Immediately after incubation of this plasmid DNA, DNA is extracted from Helicobacter pylori cells and used as template for Test 2 and Test 3 above. Positive results in Test 2 and Test 3 will demonstrate that the plasmid DNA could enter the cell and perform homologous recombination at the correct chromosomal location. If Test 2 and Test 3 are positive, failing to obtain a viable transformant means that this gene is an essential gene and cells in which this gene is destroyed cannot colonize.

VII. High Throughput Drug Screening Assay

Cloning, Expression and Protein Purification

Cloning, transformation, expression and purification of Helicobacter Philoly target genes and their protein products, such as Helicobacter Philly enzyme, used for high throughput drug screening assays are performed substantially as described in Examples II and III above. The development and application of screening assays for specific Helicobacter Philoly gene product, peptidyl-propyl cis-trans isomerase are described below as embodiments.

Enzyme analysis

This analysis is substantially described in Fischer, G., et al. (1984) Biomed. Biochim. Acta 43: 1101-1111). This assay measures the degree of cis-trans isomerization of Ala-Pro binding on test peptide N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (Sigma # S-7388, Lot # 84H5805). This assay is associated with α-chymotrypsin, which occurs only when the protease ability to cleave the test peptide is in the trans state with Ala-Pro binding. Conversion of test peptides to trans isomers in this assay is analyzed at 390 nm on a Beckman model DU-650 spectrometer. This data is collected every second, with an average scan time of 0.5 seconds. The final volume is 400 μl using 35 mM Hepes, 10 μM α-chymotrypsin (type 1-5 from bovine pancreas, Sigma # C-7762, lot 23H7020) and 10 nM PPIase at pH 8.0. To initiate the reaction, 10 μl of substrate (2 mM N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide in DMSO) is added to 390 μl of reaction mixture at room temperature.

Enzymatic Analysis of Bacterial Crude Extracts

50 ml of Helicobacter Philoly (J99 strain) cultures in Brucella broth were harvested in medium aqueous phase (OD ₆₀₀ nm-1) and the following protease inhibitors: 1 mM PMSF, and each of aprotinin, lupeptin, pepstatin, TLCK, Resuspend in lysis buffer with 10 μg / ml of TPCK and soy trypsin inhibitor. This suspension is circulated three times in freeze-thaw (15 minutes at -70 ° C, then 30 minutes at room temperature) and then sonicated (3 times 20 seconds burst). The lysates are centrifuged (12,000 g × 30 min) and the supernatants are analyzed for enzyme activity as described above.

Many Helicobacter pylori enzymes. It can be expressed in large quantities in active form in E. coli. The high yield of such purified proteins enables the design of various high throughput drug screening assays.

VIII. Truncated gene expression and protein production

Identification, Cloning and Expression of Recombinant Helicobacter Philo Sequence

To facilitate cloning, expression and purification of membrane proteins from Helicobacter pylori, E. coli. The pET gene expression system (Novagen) was selected for cloning and expression of recombinant proteins in E. coli. In addition, for proteins having a signal sequence at the amino terminus, a DNA sequence encoding a peptide tag (His-tag) was fused to the 5 'end of the target Helicobacter pylori DNA sequence to facilitate purification of the recombinant protein product. In some cases, DNA sequences were cloned in-frame with glutathione-S-transferase protein to produce glutathione-S-transferase (GST) -fusion proteins. The vector used in this case was the pGEX series from Pharmacia LKB (Uppsala, Sweden).

PCR amplification and cloning of DNA sequences containing ORFs for membrane and secreted proteins from J99 strain of Helicobacter pylori

Sequences selected for cloning (from the list of DNA sequences of the present invention) from the J99 strain of Helicobacter pylori were prepared for amplification cloning by polymerase chain reaction (PCR). Synthetic oligonucleotide primers (Table 11) were designed and purchased for the desired ORF specific for the expected mature 5 'end of the desired ORF and downstream of the expected translation stop codon (3') or at a specific location within the coding region (Table 11). GibcoBRL Life Technologies, Gaithersburg, MD, USA). All forward primers (specific for the 5 'end of the region of the objective OFR) were designed to include either BamIII restriction sites or NdeI restriction sites. These primers in the NdeI restriction site sequence initiate protein translation at methionine residues (encoded within the NdeI restriction site sequence, resulting in His untagged recombinant protein), or are followed by the remaining coding sequence of native Helicobacter pili DNA. It was designed to fuse in frame (to generate His tagged recombinant protein) with a DNA sequence encoding His tag. Primers with BamHI restriction sites were produced to fuse with the Helicobacter phyllori specific sequence in frame with the C terminus of the glutathione-S-transferase gene in the pGEX vector (Pharmacia LKB, Uppsala, Sweden). All reverse oligonucleotide primers were designed to contain an EcoRI restriction site at the 5 'end. Several reverse oligonucleotide primers were selected that caused truncation of the polypeptide to remove specific portions of the C terminus, in which case the translation termination codon was located after the 5 'term EcoRI restriction site. Combinations of these primers may be used to convert the target ORF (or a portion of the target ORF) into pET28b (to produce His-tagged recombinant protein), pET30a (to produce His-tagged or native recombinant protein) or pGEX-4T or pGEX-5X It can be cloned in a series (to produce GST fusion protein). The pET28b vector provides a sequence encoding an additional 20 amino terminal amino acids (including methionine within the NdeI restriction site), including a stretch of the six histidine residues that make up the His-tag, and the pGEX vector represents a Helicobacter philolyte protein at 26,000 Da. Glutathione-S-transferase protein is fused.

Genomic DNA prepared from Helicobacter pylori strain J99 (ATCC 55679) was used as a template DNA source for PCR amplification reactions (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Des. , 1994). To amplify DNA sequences containing specific Helicobacter pylori ORFs, genomic DNA (50 nanograms) was purchased with 200 nanograms and 50 microliters of forward and reverse synthetic oligonucleotides specific for the desired OFR (GibcoBRL Life Technologies, Gaithersburg). , MD, USA) was introduced into a reaction tube containing PCR SuperMix 45 microliters. PCR SuperMix was supplied at a concentration of 1.1 ×, 22 mM Tris-HCl (pH8.4), 55 mM KCl, 1.65 mM MgCl ₂ , 220 micromoles of dATP, dCTP, dGTP and dTTP, 22 units of recombinant Taq polymerase, respectively. / ml and stabilizer. The DNA amplification product for each ORF was obtained by a Perkin Elmer Cetus / Gene Amp PCR System thermal cycler using the following thermal cycling conditions.

Oligonucleotide primer Gene and location order BamHI after Vac38-signal sequence CGGGATCCGAAGGTGATGGTGTTTATATAGG (SEQ ID NO: 271) NdeI after Vac38-signal sequence CGCATATGGAAGGTGATGGTGTTTATATAGGG (SEQ ID NO: 272) Vac38-EcoRI / Stop codon (third removal of the C terminus of the protein) GCGAATTCTCACTCTTTCCAATAGTTTGCTGCAGAGC (SEQ ID NO: 273) Vac38-EcoRI / Stop codon (removes 11 amino acids in C terminus) CCGGAATTCTTAATCCCGTTTCAAATGGTAATAAAGG (SEQ ID NO: 274) Vac38-EcoRI Downstream of Natural Stop Codons GCGAATTCCCTTTTATTTAAAAAGTGTAGTTATACC (SEQ ID NO: 275)

Vac38 sequence (full length or truncated);

Denaturation at 94 ℃ for 30 seconds,

35 cycles of 15 seconds at 94 ° C., 15 seconds at 55 ° C. and 1.5 minutes at 72 ° C.

The reaction was terminated at 72 ° C. for 8 minutes.

After termination of the thermal cycling reaction, each amplified DNA sample was electrophoresed on 1.0% agarose gel. The DNA was exposed to ethidium bromide and then visualized by irradiation with long wavelength UV and cut into gel pieces. DNA was purified using Wizard PCR Preps kit (Promega Corp., Madison, WI, USA) and digested with BamHI and EcoRI (Current Protocols in Molecular Biology, John wiley and Sons, Inc., F. Ausubel et al. , eds., 1994). The digested PCR amplicons were then electrophoresed again and purified as above.

Ligation of Helicobacter Philoyl DNA Sequence into Cloning Vectors

Prepare pOK12 vectors (J. Vieira and J. Messing, Gene 100: 189-194, 1991) for cloning by digestion with BamHI and EcoRI or NdeI and EcoRI for Vac41, and BamHI and EcoRI for Vac41 PSU21 vectors were prepared for cloning by digestion using (Current Protocols in Molecular Biology, John wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). Vectors were electrophoresed on 1.0% agarose gel and DNA was purified using Wizard PCR Preps kit (Promega Corp., Madison, Wis., USA). After ligation of the digested and purified vectors with the digested, amplified, and purified Helicobacter pylori ORF, the ligation reaction product was used to determine the E. E. coli JM109 soluble cells were transformed (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). Incubate overnight in LB broth (including 25 μg / ml kanamycin sulfate) for each bacterial colony and prepare plasmid DNA using Magic Minipreps system (Promega Corp., Madison, Wis., USA) to contain the appropriate recombinant plasmid. Colonies were screened and analyzed by restriction enzyme digestion (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994).

Cloning of Helicobacter Philoyl DNA Sequence into pET28b, pET30a, and pGEX4T-3 Prokaryotic Expression Vectors

PET28b and pET30a expression vectors were prepared for cloning by digestion with NdeI and EcoRI, and pGEX4T-3 vectors were prepared for cloning by digestion with BamHI and EcoRI (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). Helicobacter pylori DNA sequence was removed from the pOK12 plasmid backbone by digestion with NdeI and EcoRI or BamHI and EcoRI (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994 ). pET28b, pET30a, pGEX4T-3 and Helicobacter Philoyl DNA sequences were all electrophoresed on 1.0% agarose gel and DNA was purified using Wizard PCR Preps kit (Promega Corp., Madison, Wis., USA). After ligation of the digested and purified expression vector with the digested and purified Helicobacter pylori DNA sequence, the ligation reaction product was used to determine the E. coli. E. coli JM109 soluble cells were transformed (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). Plasmid DNA was prepared as described above for each bacterial colony and then screened for colonies containing the appropriate recombinant plasmid by analysis by restriction enzyme digestion profiles and DNA sequencing (Current Protocols in Molecular Biology, John Wiley and Sons). , Inc., F. Ausubel et al., Eds., 1994). These recombinant plasmids were then used to determine specific E. coli. E. coli expressing strains were transformed.

Transformation of Water-soluble Bacteria Using Recombinant Expression Plasmids

According to standard methods, water soluble bacterial strains BL21 (DE3), BL21 (DE3) pLysS, HMS174 (DE3) and HMS174 (DE3) pLysS were prepared and transformed with recombinant pET28b expression plasmids carrying the cloned Helicobacter Philo sequence ( Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). These expression host strains contain chromosomal copies of the genes for T7 RNA polymerase. These hosts are lambda derivatives containing the genes for the lacI gene, the lcaUV5 promoter and the T7 RNA polymerase as the lysogen of bacteriophage DE3. T7 RNA polymerase expression is induced by the addition of isopropyl-β-D-thiogalactoside (IPTG), and T7 RNA polymerase then contains a target plasmid containing the T7 promoter sequence and the gene of interest, for example pET28b. Warriors

Water soluble bacterial strains JM109 and DH5α were prepared and transformed using recombinant pGEX4T-3 expression plasmid containing cloned Helicobacter Philo sequence (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al. , eds., 1994).

E. of the recombinant Helicobacter pylori sequence. Expression in E. coli

Transformants were recovered from LB agar plates containing 25 μg / ml kanamycin sulfate (to maintain pET28b based recombinant plasmid) or 100 μg / ml ampicillin (to maintain pGEX4T-3 based recombinant plasmid). Inoculated in LB broth containing 25 μg / ml kanamycin sulfate or 100 μg / ml ampicillin until the optical density at 600 nm is between 0.5 and 1.0 OD units, at which point 1 mM IPTG is added to the medium. 1 to 3 hours were added to induce gene expression of the Helicobacter pylori recombinant DNA construct. After gene expression using IPTG, bacteria were pelleted by centrifugation, resuspended in SDS-PAGE solubilization buffer and applied to SDS-PAGE (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel). et al., eds., 1994). Proteins are visualized by staining with Coomassie Brilliant Blue or Western immunoblob using specific anti-His tagged monoclonal antibodies (Clontech, Palo Alto, CA, USA) or anti-GST tagged antibodies (Pharmacia LKB) according to standard methods Detection by Current Tests in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994. Host strains were produced that produce the highest levels of recombinant protein for use in large scale induction to purify the recombinant protein. The strains used were HMS174 (DE3) (pET28b based construct) and DH5α (pGEX4T-3 based construct).

Removal of the C-terminal region appeared to improve expression levels in both systems, but this increase was even more pronounced in the GST-fusion system. All recombinant proteins produced had a predicted molecular weight based on the DNA sequence and, if necessary, the size of the fusion tag. The truncated portion of the Helicobacter pylori protein contains some extremely hydrophobic stretches, and their removal may be the cause of increased expression.

Equivalent

Those skilled in the art will be able to know or infer many equivalent examples and methods of the embodiments and methods described herein using only routine experimentation. Such equivalents are also included within the scope of the following claims.

SEQUENCE LISTING

1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: Astra Aktiebolag

(B) STREET: S-151 85

(C) CITY: Sodertalje

(D) STATE:

(E) COUNTRY: Sweden

(F) POSTAL CODE (ZIP)

(ii) TITLE OF OF: NUCLEIC ACID AND AMINO ACID SEQUENCES

RELATING TO HELICOBACTER PYLORI AND

VACCINE COMPOSITIONS THEREOF

(iii) NUMBER OF SEQUENCES: 275

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: CD / ROM ISO9660

(B) COMPUTER:

(C) OPERATING SYSTEM:

(D) SOFTWARE:

(v) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER

(B) FILING DATE:

(vi) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 08 / 759,625

(B) FILING DATE: 05-DEC-1996

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 08 / 823,745

(B) FILING DATE: 25-MAR-1997

(viii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 08 / 891,928

(B) FILING DATE: 14-JULY-1997

(ix) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: LAHIVE & COCKFIELD

(B) STREET: 28 State Street

(C) CITY: Boston

(D) STATE: Massachusetts

(E) COUNTRY: USA

(F) ZIP: 02109-1875

(x) ATTORNEY / AGENT INFORMATION:

(A) NAME: Mandragouras, Amy E.

(B) REGISTRATION NUMBER: 36,207

(C) REFERENCE / DOCKET NUMBER: GTN-011CP2PC

(xi) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (617)227-7400

(B) TELEFAX: (617)227-5941

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 687 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 687

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

ATGAGATTTA AGGGTTCAAG AGTGGAAGCG TTTTTAGGAG CGTTAGAATT TCAAGAGAAT 60

GAATATGAAG AGTTTAAAGA GCTTTATGAG AGCTTAAAAA CCAAGCAAAA GCCCCACACT 120

TTGTTCATTT CTTGCGTGGA TTCACGAGTC GTGCCTAATT TAATCACAGG CACCCAACCG 180

GGCGAATTGT ATGTGATCCG CAACATGGGC AATGTGATCC CCCCTAAAAC AAGCTATAAA 240

GAATCCCTTT CTACCATTGC GAGCGTTGAA TACGCTATCG CGCATGTGGG CGTTCAAAAC 300

TTAATCATTT GCGGGCATAG CGATTGTGGG GCTTGCGGGA GCATTCATTT AATCCATGAT 360

GAAACCACCA AAGCTAAAAC CCCTTACATT GCAAACTGGA TACAATTTTT AGAGCCTATT 420

AAAGAAGAAT TAAAAAACCA CCCGCAATTC AGCAACCATT TCGCCAAGCG TTCATGGCTT 480

ACAGAGCGTT TGAATGCGCG CTTGCAACTC AACAACCTCT TAAGCTATGA TTTCATTCAA 540

GAAAGAGTAA TAAATAACGA ATTAAAAATT TTTGGTTGGC ACTATATCAT AGAAACAGGC 600

AGGATTTATA ATTATAATTT TGAAAGCCAT TTTTTTGAGC CGATTGAAGA AACCATTAAA 660

CAAAGGATAA GTCATGAAAA CTTCTAA 687

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 666 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 666

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

GTGGAAGCGT TTTTAGGAGC GTTAGAATTT CAAGAGAATG AATATGAAGA GTTTAAAGAG 60

CTTTATGAGA GCTTAAAAAC CAAGCAAAAG CCCCACACTT TGTTCATTTC TTGCGTGGAT 120

TCACGAGTCG TGCCTAATTT AATCACAGGC ACCCAACCGG GCGAATTGTA TGTGATCCGC 180

AACATGGGCA ATGTGATCCC CCCTAAAACA AGCTATAAAG AATCCCTTTC TACCATTGCG 240

AGCGTTGAAT ACGCTATCGC GCATGTGGGC GTTCAAAACT TAATCATTTG CGGGCATAGC 300

GATTGTGGGG CTTGCGGGAG CATTCATTTA ATCCATGATG AAACCACCAA AGCTAAAACC 360

CCTTACATTG CAAACTGGAT ACAATTTTTA GAGCCTATTA AAGAAGAATT AAAAAACCAC 420

CCGCAATTCA GCAACCATTT CGCCAAGCGT TCATGGCTTA CAGAGCGTTT GAATGCGCGC 480

TTGCAACTCA ACAACCTCTT AAGCTATGAT TTCATTCAAG AAAGAGTAAT AAATAACGAA 540

TTAAAAATTT TTGGTTGGCA CTATATCATA GAAACAGGCA GGATTTATAA TTATAATTTT 600

GAAAGCCATT TTTTTGAGCC GATTGAAGAA ACCATTAAAC AAAGGATAAG TCATGAAAAC 660

TTCTAA 666

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1008 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 1008

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

ATGTTAGTTA CTCGTTTTAA AAAAGCCTTC ATTTCTTATT CTTTAGGCGT GCTTGTTGTT 60

TCATTATTAT TGAATGTGTG CAACGCTTCA GCACAAGAAG TCAAAGTCAA GGATTATTTT 120

GGGGAGCAAA CCATAAAGCT TCCTGTTTCC AAAATAGCCT ATATAGGGAG TTATGTAGAA 180

GTGCCTGCCA TGCTTAATGT TTGGGATAGG GTTGTAGGCG TTTCTGATTA TGCCTTTAAG 240

GATGACATTG TCAAAGCCAC TCTCAAAGGC GAGGATCTTA AACGAGTCAA ACACATGAGC 300

ACCGATCATA CAGCCGCGTT GAATGTGGAA TTATTAAAAA AGCTTAGCCC TGATCTTGTG 360

GTAACCTTTG TGGGTAACCC TAAAGCGGTA GAGCATGCGA AAAAATTTGG GATTTCATTC 420

CTTTCTTTCC AAGAGACAAC GATTGCAGAG GCCATGCAAG CTATGCAAGC TCAAGCCACG 480

GTCTTAGAAA TTGACGCTTC CAAAAAATTC GCCAAAATGC AAGAAACTTT GGACTTTATT 540

GCTGAGCGTT TGAAGGGCGT TAAAAAGAAA AAGGGGGTGG AGCTTTTCCA TAAAGCCAAT 600

AAAATCAGCG GCCATCAAGC CATTAGCTCA GACATTTTAG AAAAAGGGGG TATAGATAAT 660

TTTGGCTTGA AATACGTTAA GTTTGGACGC GCTGACATTA GTGTGGAAAA AATCGTTAAA 720

GAAAACCCTG AAATCATTTT CATTTGGTGG GTAAGCCCAC TCACTCCTGA AGACGTGTTG 780

AACAACCCTA AATTTTCCAC TATCAAAGCC ATTAAAAATA AGCAAGTCTA TAAGCTCCCC 840

ACGATGGATA TTGGCGGTCC TAGAGCCCCA CTCATTAGTC TTTTTATCGC TTTAAAAGCC 900

CACCCTGAAG CCTTTAAAGG CGTGGATATT AATGCGATAG TCAAAGATTA TTATAAAGTG 960

GTCTTTGATT TGAATGATGC GGAAATTGAG CCATTCTTAT GGCACTGA 1008

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 825 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 825

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

ATGTTAGTTA CTCGTTTTAA AAAAGCCTTC ATTTCTTATT CTTTAGGCGT GCTTGTTGTT 60

TCATTATTAT TGAATGTGTG CAACGCTTCA GCACAAGAAG TCAAAGTCAA GGATTATTTT 120

GGGGAGCAAA CCATAAAGCT TCCTGTTTCC AAAATAGCCT ATATAGGGAG TTATGTAGAA 180

GTGCCTGCCA TGCTTAATGT TTGGGATAGG GTTGTAGGCG TTTCTGATTA TGCCTTTAAG 240

GATGACATTG TCAAAGCCAC TCTCAAAGGC GAGGATCTTA AACGAGTCAA ACACATGAGC 300

ACCGATCATA CAGCCGCGTT GAATGTGGAA TTATTAAAAA AGCTTAGCCC TGATCTTGTG 360

GTAACCTTTG TGGGTAACCC TAAAGCGGTA GAGCATGCGA AAAAATTTGG GATTTCATTC 420

CTTTCTTTCC AAGAGACAAC GATTGCAGAG GCCATGCAAG CTATGCAAGC TCAAGCCACG 480

GTCTTAGAAA TTGACGCTTC CAAAAAATTC GCCAAAATGC AAGAAACTTT GGACTTTATT 540

GCTGATCGTT TGAAGGGCGT TAAAAAGAAA AAGGGGGTGG AGCTTTTCCA TAAAGCCAAT 600

AAAATCAGCG GCCATCAAGC CATTAACTCA GACATTTTAC AACAAGGGGG TATTGATAAT 660

TTTGGCTTGA AATACGTCAA GTTTGGACGC GCTGACATTA GTGTGGAAAA AATCGTTAAA 720

GAAAACCCTG AAATCATTTT CATTAGGTGG GTAACCCCAC TCACTCCTGA TTACGTGTTG 780

AACAACCCAA AATTTTCTAC TATCAATGCC ATTAAAAACA TATAA 825

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1287 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 1287

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

ATGAAGAAAA AATTTCTGTC ATTAACCTTA GGTTCGCTTT TAGTTTCCGC TTTAAGCGCT 60

GAAGACAACG GCTTTTTTGT GAGCGCCGGC TATCAAATCG GTGAATCCGC TCAAATGGTG 120

AAAAACACCA AAGGCATTCA AGATCTTTCA GACAGCTATG AAAGATTGAA CAACCTTTTA 180

ACGAATTATA GCGTCCTAAA CGCTCTCATC AGGCAGTCCG CCGACCCCAA CGCCATCAAT 240

AACGCAAGGG GCAATTTGAA CGCGAGCGCG AAGAATTTGA TCAATGATAA AAAGAATTCC 300

CCGGCGTATC AAGCCGTGCT TTTAGCCTTG AATGCGGCAG CGGGGTTGTG GCAAGTCATG 360

AGCTATGCGA TCAGCCCTTG TGGTCCCGGT AAAGACACAA GCAAAAATGG GGGCGTTCAA 420

ACTTTCCACA ACACGCCTTC AAATCAATGG GGAGGCACTA CCATTACTTG TGGCACTACT 480

GGTTATGAAC CAGGACCATA CAGCATTTTA TCCACTGAAA ATTACGCGAA AATCAATAAA 540

GCTTATCAAA TCATCCAAAA GGCTTTTGGG AGCAGCGGAA AAGATATTCC TGCCTTAAGC 600

GACACCAACA CAGAACTCAA ATTCACAATC AATAAAAATA ATGGAAACAC GAATACGAAT 660

AATAATGGAG AAGAAATTGT TACAAAAAAT AACGCTCAAG TTCTTTTAGA ACAGGCTAGC 720

ACCATTATAA CTACCCTTAA TAGCGCATGC CCATGGATCA ACAATGGTGG TGCAGGTGGT 780

GCGAGTAGTG GTAGTTTATG GGAAGGAATA TATTTGAAAG GCGATGGGAG CGCTTGCGGG 840

ATTTTTAAAA ATGAAATCAG CGCGATTCAA GACATGATCA AAAACGCTGC AATAGCCGTA 900

GAGCAATCCA AGATCGTTGC TGCAAACGCG CAAAACCAGC GCAACCTAGA CACCGGGAAG 960

ACATTCAACC CCTATAAAGA CGCCAACTTC GCCCAAAGCA TGTTCGCTAA CGCCAAAGCG 1020

CAAGCGGAGA TTTTAAACCG CGCCCAAGCA GTGGTGAAAG ACTTTGAAAG AATCCCTGCA 1080

GAGTTCGTAA AAGACTCTTT AGGGGTGTGC CATGAAGTGC AAAACGGCCA TCTCCGTGGC 1140

ACGCCATCCG GCACGGTAAC TGATAACACT TGGGGAGCCG GTTGCGCGTA TGTGGGAGAG 1200

ACCGTAACGA ATCTAAAAGA CAGCATCGCT CATTTTGGCG ACCAAGCCGA GCGAATCCAT 1260

AACGCGCGCA ACCTCGCTAC ACTTTAG 1287

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 537 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 537

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

ATGAACCCCT TATTGCAAGA TTATGCGCGC ATCCTTTTAG AATGGAATCA AACGCACAAC 60

TTGAGCGGCG CGAGAAATTT AAGCGAATTA GAACCCCAGA TCACAGACGC TCTAAAGCCC 120

TTAGAATTTG TCAAAGATTT TAAAAGCTGC TTGGATATTG GGAGCGGGGC GGGACTTCCT 180

GCTATCCCTT TAGCCCTTGA AAAACCTGAA GCGCAATTCA TTCTTTTAGA GCCAAGGGTA 240

AAAAGAGCGG CTTTTTTAAA CTACCTTAAA AGCGTTTTGC CTTTAAACAA CATTGAAATC 300

ATTAAAAAGC GTTTAGAAGA TTATCAAAAT CTTTTACAAG TGGATTTAAT CACTTCTAGA 360

GCGGTCGCTA GCTCTTCTTT TTTGATAGAA AAAAGCCAAC GCTTCCTAAA AGATAAGGGG 420

TATTTTTTAT TCTATAAAGG CGAGCAGTTA AAGAATGAAA TCGCTTATAA AACCACTGAA 480

TGCTTTATGC ATCAAAAGCG CGTTTATTTT TACAAATCAA AGGAAAGTTT ATGTTAA 537

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 723 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 723

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

TTGGGTCTTA AAAAACGAGC TATTTTATGG TCTTTAATGG GATTTTGTGC AGGATTGAGC 60

GCGCTTGATT ATGACACCCT AGACCCAAAA TATTACAAAT ATATCAAGTA TTATAAGGCT 120

TATGAAGATA AAGAAGTTGA AGAATTGATC AGAGACTTGA AAAGGGCGAA CGCTAAAAGC 180

GGGCTTATTT TAGGGATCAA TACCGGTTTT TTTTATAACC ATGAAATCAT GGTCAAAACC 240

AATAGCTCCA GTATCACCGG GAATATTTTA AATTATTTGT TCGCCTATGG CTTGCGTTTT 300

GGCTATCAAA CTTTCAGGCC GTCGTTTTTT GCGCGCTTGG TTAAGCCCAA TATCATTGGC 360

AGGCGCATCT ATATTCAATA TTATGGAGGA GCTCCTAAGA AAGCGGGCTT TGGGAGCGTG 420

GGGTTTCAAT CGGTCATGTT GAATGGGGAT TTTTTATTAG ACTTTCCTTT GCCCTTTGTG 480

GGGAAATACC TTTATATGGG GGGGTATATG GGTTTAGGCT TGGGGGTTGT GGCGCATGGG 540

GTGAATTATA CGGCGGAATG GGGGATGTCT TTTAACGCAG GATTGGCTCT AACGGTATTA 600

GAAAAAAACC GCATTGAATT TGAATTTAAA ATTTTGAATA ATTTCCCTTT TTTGCAATCT 660

AATTCTTCAA AAGAGACTTG GTGGGGAGCT ATAGCAAGCA TTGGGTATCA ATATGTGTTC 720

TAA 723

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 942 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 942

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

TTGAAACTCA AATACTGGTT AGTTTATCTG GCGTTCATTA TAGGACTTCA AGCGACAGAT 60

TATGACAATT TAGAAGAAGA AAACCAACAA TTAGACGAAA AAATAAACAA TTTAAAGCGA 120

CAGCTCACCG AAAAAGGGGT TTCACCCAAA GAGATGGATA AGGATAAGTT TGAAGAAGAA 180

TATTTAGAGC GAACTTACCC AAAGATTTCT TCAAAGAAAA GAAAAAAATT GCTCAAATCT 240

TTTTCCATAG CCGATGATAA GAGTGGGGTG TTTTTAGGGG GCGGGTATGC TTATGGGGAA 300

CTTAACTTGT CTTATCAAGG GGAGATGTTA GACAGGTATG GCGCAAATGC CCCTAGCGCG 360

TTTAAAAACA ATATCAATAT TAACGCTCCT GTTTCTATGA TTAGCGTTAA ATTTGGGTAT 420

CAAAAATACT TCGTGCCTTA TTTTGGGACA CGATTTTATG GGGATTTGTT GCTTGGGGGA 480

GGGGCGTTAA AAGAGAACGC GCTCAAGCAG CCTGTAGGCT CGTTTTTTTA TGTTTTAGGG 540

GCTATGAATA CCGATTTATT GTTTGACATG CCTTTAGATT TTAAGACTAA AAAGCATTTT 600

TTAGGCGTTT ATGCGGGTTT TGGGATAGGG CTTATGCTTT ATCAAGACAA GCCTAATCAA 660

AACGGGAGGA ATTTGATAGT AGGGGGTTAT TCAAGCCCTA ATTTTTTATG GAAATCTTTG 720

ATTGAAGTGG ATTACACTTT TAATGTGGGC GTGAGTTTAA CGCTTTATAG GAAACACCGC 780

TTAGAGATTG GCACAAAATT ACCGATTAGC TATTTGAGGA TGGGAGTAGA AGAGGGAGCG 840

ATTTATCACA ATAAAGAAAA TGATGAACGA TTGTTGATTT CGGCTAACAA CCAGTTCAAA 900

CGATCCAGTT TTTTATTAGT GAATTATGCG TTCATTTTTT GA 942

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1182 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 1182

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

ATGACTTCAG CTTCAAGCCA TTCTTTTAAA GAACAAGATT TTCATATTCC TATCGCTTTC 60

GCTTTTGATA AGAATTATCT CATTCCTGCG GGCGCATGCA TTTATTCCTT GCTAGAAAGC 120

ATCGCTAAAG CCAATAAAAA AATCCGTTAC ACCTTACACG CTTTAGTGGT AGGCTTGAAT 180

GAAGAAGATA AAACAAAACT TAACCAAATC ACAGAGCCTT TTAAAGAATT TGCTGTTTTA 240

GAAGTAAAAG ATATTGAACC TTTTTTAGAC ACTATCCCTA ACCCTTTTGA TGAGGATTTC 300

ACCAAGCGTT TTTCTAAAAT GGTGTTAGTG AAGTATTTTC TAGCGGATTT ATTCCCCAAA 360

TATTCTAAAA TGGTGTGGAG CGATGTGGAT GTTATCTTTT GTAATGAATT TAGCGCTGAT 420

TTCTTAAACA TTAAAGAAGA TGATGAGAAT TATTTTTATG GGGTTTATGA CAAAATATAC 480

CCGTATGAAG GCTTTTTTTA TTGCAACTTA ACTTACCAGC GAAAAAATCA ATTTTGTAAA 540

AAAATATTAG AAATCATACG CGCACAAAAA ATAGATAAAG AACCGCAATT GACAGAATTT 600

TGTCGTTCAA AGATCGCGCC ATTAAAAATA GAGTATTGTA TTTTCCCACA CTATTATAGC 660

CTTTCTGAAG AGCATTTAAA GGGCGTGGCC AATGCAATTT ATCATAACAC CATTAAACAA 720

GCCCTAAGAG AACCTATCGT TATACAATAT GACTCTCATC CTTATTTTCA AATCAAGCCT 780

TGGACATATC CTTTTGGTTT GAAAGCGGAT TTATGGCTGA ACGCTTTGGC TAAAACCCCA 840

TTTATGAGCG ATTGGTCTTA TTTGATCACA GGGGGTGGGG GGATAGGTGG AGAAAAATGG 900

CATTACTACC ATGGCATTGC CGCTTATCAT TACTACTTTC CTTTATGGAA AGCAGAAGAA 960

CAGATTGCCC ATGACGCTCT TAAGACATTT TTAAAACATT ATTTTTTGCA CATTCATGAG 1020

ATTCCCCAAA ACGCAAGGCG AAGACTATTC AAATACTGCA TTTCAATACC GCTTAAGAGC 1080

TTTATTAGTA AAACCCTTAA ATTTCTAAAA CTCCATGCAT TGGTGAAAAA AATCCTAATC 1140

CAACTCAAGC TCTTAAAAAA GAACCAGAGC CAAAACTTTT AA 1182

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1308 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 1308

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

TTGATTTTCT TAAAAAAATC TCTTTGCGCG TTGTTAATTT CAGGTTTTTT CATACCACCC 60

TTAATGAAAG CGGCTAGTTT TGTCTATGAC TTGAAGTTTA TGAGCTTTAA TTTCAATCTG 120

GCTTCCCCTC CAAATAACCC CTATTGGAAT AGCCTAACCA AAATGCAAGG TCGTCTCATG 180

CCTCAAATTG GCGTCCAATT AGACAAAAGA CAGGCCTTGA TGTTTGGGGC GTGGTTCATT 240

CAAAATTTGC ACACGCATTA TAGCTATTTC CCTTATTCGT GGGGGGTTAC CATGTATTAC 300

CAATACATAG GGAAAAATTT GAGATTTTTT TTAGGCATTG TGCCACGAAG CTATCAAATA 360

GGGCATTACC CTTTAAGCGC TTTTAAAAAA CTTTTCTGGT TTATAGACCC TACTTTTAGG 420

GGAGGAGCGT TCCAATTCAA ACCGGCTTAT GATCCCAATC GTTGGTGGAA TGGGTGGTTT 480

GAGGGCGTTG TGGATTGGTA TGGGGGGCGT AATTGGAACA ACCAGCCCAA AAAGAAAAAT 540

TACGATTTTG ATCAATTCTT GTATTTTGTT TCTTCAGAAT TTCAGTTTCT TAAAGGGTAT 600

TTAGGTTTGG GGGGACAGCT TGTCATTTTT CATAACGCCA ACTCTCATAG TATGGGGGAT 660

AACTACCCTT ATGGCGGGAA TTCCTACTTA AAACCAGGCG ATGCAACCCC ACAATGGCCT 720

AATGGCTACC CTTATTTCAG CCAAAAAGAT AACCCACAAG GCGGAGAAAT AGGGAAATAC 780

TCTAACCCTA CCATTTTAGA CAGGGTTTAT TACCATGCTT ATTTAAAAGC AGATTTTAAA 840

AATCTCATGC CTTATATGGA CAATATTTTC ATGACCTTTG GCACGCAGTC GTCTCAAACC 900

CATTATTGCG TGCGTTATGC TAGCGAGTGT AAAAACGCCC GATTTTATAA CAGCTTTGGG 960

GGGGAATTTT ACGCTCAAGC GCAATACAAA GGCTTTGGGA TCTTTAACAG ATACTATTTT 1020

TCCAACAAAC CCCAAATGCA TTTTTATGCC ACTTATGGCC AATCCCTTTA TACCGGATTG 1080

CCATGGTATA GAGCCCCTAA TTTTGACATG ATAGGGCTTT ATTATCTTTA TAAAAACAAA 1140

TGGTTAAGCG TGCGAGCGGA TGCGTTTTTT AGCTTTGTGG GTGGGGGCGA TGGGTACCAT 1200

TTGTATGGCA AGGGGGGTAA GTGGTTTGTG ATGTATCAGC AATTTTTAAC CCTAACCATA 1260

GACACAAGAG AGTTGATTGA TTTTGTCAAA TCTAAAATCC CTAAATAA 1308

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 663 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 663

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

ATGAATAAAA CAACAATTAA AATATTAATG GGCATGGCGT TATTATCATC GCTTCAAGCC 60

GCAGAGGCAG AGCTTGATGA AAAATCAAAA AAACCTAAAT TTGCGGATAG GAATACGTTT 120

TATTTAGGGG TTGGGTATCA GCTTAGCGCG ATCAACACGT CTTTTAGCAC CAGTTCTATA 180

GATAAATCGT ATTTCATGAC CGGCAATGGT TTTGGCGTGG TGTTGGGGGG GAAATTTGTG 240

GCTAAAACGC AAGCTGTAGA GCATGTGGGT TTTCGTTACG GGTTGTTTTA TGATCAGACC 300

TTTTCTTCTC ACAAATCCTA TATTTCTACC TATGGTTTAG AATTTAGCGG TTTGTGGGAC 360

GCTTTCAATT CGCCAAAGAT GTTTTTGGGG TTGGAGTTTG GCTTAGGCAT CGCTGGGGCG 420

ACTTACATGC CAGGAGGGGC CATGCATGGG ATTATCGCTC AATATTTAGG CAAAGAAAAT 480

TCGCTTTTCC AATTGCTTGT GAAAGTGGGT TTTCGTTTTG GCTTTTTCCA CAATGAAATC 540

ACCTTTGGGT TGAAATTCCC TGTCATTCCT AACAAAAAAA CGGAAATCGT TGATGGCTTG 600

AGCGCGACCA CTTTATGGCA ACGCTTGCCG GTAGCCTATT TCAATTATAT CTATAATTTT 660

TAG 663

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 351 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 351

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

TTGAATCTCC ATTTTATGAA AGGATTTGTT ATGAGTGGAT TAAGAACATT TAGTTGTGTA 60

GTGGTTTTAT GCGGTGCAAT GGTTAATGTA GCTGTAGCTG GTCCTAAAAT AGAGGCAAGG 120

GGTGAATTAG GCAAATTTGT AGGGGGAGCT GTTGGAAATT TTGTTGGTGA TAAAATGGGC 180

GGATTTGTTG GTGGTGCAAT AGGAGGATAT ATTGGGTCTG AAGTAGGCGA TAGGGTAGAA 240

GATTATATCC GTGGCGTTGA TAGAGAGCCA CAAAACAAAG AACCACAAAC CCCAAGAGAA 300

CCTATCCGTG ATTTTTATGA TTACGGCTAT AGTTTTGGGC ATGCTTGGTG A 351

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1311 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 1311

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

ATGTCAAGGG ATTTTAAATT TGATTCTAAC TATTTAAATG TCAATACCAA TCCTAAATTA 60

GGCCCCGTTT ATACCAATCA AAATTATCCA GGATTTTTTA TCTTTGATCA TTTAAGGCGT 120

TATGTGATGA ACGCTTTTGA GCCTAATTTG AACTTAGTTG TCAATACCAA TAAAGTTAAG 180

CAAACTTTTA ATGTGGGCAT GCGTTTTATG ACAATGGATA TGTTCATTAG ATCCGATCAA 240

AGCACATGCG AAAAAACAGA TATTATCAAT GGGGTGTGCC ACATGCCTCC TTATGTCCTT 300

TCTAAAACGC CTAACAATAA TCAAGAAATG TTTAATAACT ATACAGCGGT ATGGTTGAGC 360

GATAAAATAG AGTTTTTTGA TTCTAAATTG GTGATAACTC CAGGGCTTAG ATACACTTTT 420

TTGAACTATA ACAACAAAGA GCCAGAAAAG CATGATTTTT CCGTATGGAC CAGTAAAAAA 480

CAGCGTCAAA ACGAATGGAG TCCTGCCCTT AATATTGGCT ATAAACCTAT GGAAAATTGG 540

ATATGGTATG CGAACTACCG CCGCAGTTTT ATCCCCCCAC AACACACAAT GGTAGGCATT 600

ACTAGGACTA ATTACAACCA AATTTTTAAT GAAATTGAAG TGGGGCAGCG CTATAGTTAT 660

AAAAATCTAT TGAGTTTTAA CACCAATTAT TTTGTGATTT TTGCCAAGCG TTACTATGCG 720

GGAGGCTATA GCCCACAGCC TGTGGATGCC AGAAGTCAAG GGGTGGAATT GGAATTGTAT 780

TACGCGCCGA TTAGGGGTTT GCAATTCCAT GTGGCTTACA CTTATATTGA TGCGCGCATC 840

ACTTCTAACG CTGATGATAT TGCTTATTAT TTTACAGGCA TTGTCAATAA ACCCTTTGAC 900

ATTAAAGGGA AGCGCTTGCC CTATGTGAGT CCTAACCAAT TCATATTTGA CATGATGTAT 960

ACTTACAAGC ACACGACTTT TGGTATCAGC AGCTATTTTT ATAGCCGCGC TTATAGTTCC 1020

ATGCTCAATC AAGCCAAAGA TCAAACCGTA TGCCTGCCCT TAAACCCAGA ATACACAGGG 1080

GGGTTAAAGT ATGGTTGTAA TTCAGTGGGG TTATTGCCCT TGTATTTTGT GTTGAATGTC 1140

CAAGTAAGCT CAATCTTATG GCAAAGCGGT AGGCATAAAA TCACAGGGAG TTTGCAAATC 1200

AATAACCTTT TTAACATGAA GTATTATTTT AGGGGGATTG GCACAAGCCC TACAGGGAGA 1260

GAACCCGCGC CAGGGAGATC CATTACAGCG TATTTGAATT ATGAGTTTTA A 1311

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2304 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 2304

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

ATGAAAAGAA TTTTAGTTTC TTTGGCTGTT TTGAGTCATA GCGCGCATGC TGTCAAAACT 60

CATAATTTGG AAAGGGTGGA AGCTTCAGGG GTGGCTAACG ATAAAGAAGC GCCTTTAAGC 120

TGGAGGAGCA AGGAAGTTAG AAATTATATG GGTTCTCGCA CGGTGATTTC TAACAAGCAA 180

CTCACTAAAA GCGCCAATCA AAGCATTGAA GAAGCTTTGC AAAATGTGCC AGGCGTGCAT 240

ATTAGAAACT CTACCGGTAT TGGAGCTGTG CCTAGCATTT CCATTAGGGG GTTTGGTGCT 300

GGAGGCCCAG GGCATTCTAA TACGGGAATG ATTCTAGTCA ATGGGATTCC TATTTATGTC 360

GCGCCCTATG TTGAAATTGG CACGGTTATT TTTCCTGTAA CCTTTCAGTC TGTGGATAGA 420

ATCAGCGTAA CTAAGGGTGG GGAGAGCGTG CGTTATGGCC CTAACGCTTT TGGCGGTGTG 480

ATCAACATCA TCACCAAAGG CATTCCTACC AATTGGGAAA GTCAGGTGAG CGAGAGGACC 540

ACTTTTTGGG GCAAGTCTGA AAACGGGGGC TTTTTCAATC AAAATTCTAA AAACATTGAT 600

AAAAGCTTAG TTAATAACAT GCTTTTTAAC ACCTATTTAA GAACGGGGGG TATGATGAAT 660

AAGCATTTTG GAATCCAAGC TCAAGTCAAT TGGCTCAAAG GGCAAGGGTT TAGATACAAC 720

AGCCCTACGG ATATTCAAAA TTACATGTTA GATTCATTGT ATCAAATCAA TGATAGCAAT 780

AAAATCACCG CTTTTTTTCA ATATTATAGT TATTTCTTGA CAGACCCTGG ATCTTTAGGC 840

ATAGCCGCTT ACAATCAAAA TCGTTTTCAA AACAACCGCC CCAATAACGA TAAAAGCGGG 900

AGAGCGAAGC GATGGGGAGC TGTGTATCAA AACTTTTTTG GGGACACGGA TAGGGTAGGG 960

GGGGATTTCA CTTTTAGCTA CTATGGGCAT GACATGTCAA GGGATTTTAA ATTTGATTCT 1020

AACTATTTAA ATGTCAATAC CAATCCTAAA TTAGGCCCCG TTTATACCAA TCAAAATTAT 1080

CCAGGATTTT TTATCTTTGA TCATTTAAGG CGTTATGTGA TGAACGCTTT TGAGCCTAAT 1140

TTGAACTTAG TTGTCAATAC CAATAAAGTT AAGCAAACTT TTAATGTGGG CATGCGTTTT 1200

ATGACAATGG ATATGTTCAT TAGATCCGAT CAAAGCACAT GCGAAAAAAC AGATATTATC 1260

AATGGGGTGT GCCACATGCC TCCTTATGTC CTTTCTAAAA CGCCTAACAA TAATCAAGAA 1320

ATGTTTAATA ACTATACAGC GGTATGGTTG AGCGATAAAA TAGAGTTTTT TGATTCTAAA 1380

TTGGTGATAA CTCCAGGGCT TAGATACACT TTTTTGAACT ATAACAACAA AGAGCCAGAA 1440

AAGCATGATT TTTCCGTATG GACCAGTAAA AAACAGCGTC AAAACGAATG GAGTCCTGCC 1500

CTTAATATTG GCTATAAACC TATGGAAAAT TGGATATGGT ATGCGAACTA CCGCCGCAGT 1560

TTTATCCCCC CACAACACAC AATGGTAGGC ATTACTAGGA CTAATTACAA CCAAATTTTT 1620

AATGAAATTG AAGTGGGGCA GCGCTATAGT TATAAAAATC TATTGAGTTT TAACACCAAT 1680

TATTTTGTGA TTTTTGCCAA GCGTTACTAT GCGGGAGGCT ATAGCCCACA GCCTGTGGAT 1740

GCCAGAAGTC AAGGGGTGGA ATTGGAATTG TATTACGCGC CGATTAGGGG TTTGCAATTC 1800

CATGTGGCTT ACACTTATAT TGATGCGCGC ATCACTTCTA ACGCTGATGA TATTGCTTAT 1860

TATTTTACAG GCATTGTCAA TAAACCCTTT GACATTAAAG GGAAGCGCTT GCCCTATGTG 1920

AGTCCTAACC AATTCATATT TGACATGATG TATACTTACA AGCACACGAC TTTTGGTATC 1980

AGCAGCTATT TTTATAGCCG CGCTTATAGT TCCATGCTCA ATCAAGCCAA AGATCAAACC 2040

GTATGCCTGC CCTTAAACCC AGAATACACA GGGGGGTTAA AGTATGGTTG TAATTCAGTG 2100

GGGTTATTGC CCTTGTATTT TGTGTTGAAT GTCCAAGTAA GCTCAATCTT ATGGCAAAGC 2160

GGTAGGCATA AAATCACAGG GAGTTTGCAA ATCAATAACC TTTTTAACAT GAAGTATTAT 2220

TTTAGGGGGA TTGGCACAAG CCCTACAGGG AGAGAACCCG CGCCAGGGAG ATCCATTACA 2280

GCGTATTTGA ATTATGAGTT TTAA 2304

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 348 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 348

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

TTGCACCCTC TATGCGCACA CGGCCAATGT GGAAGCGAAG CGATTGCGTG TTTAGAAGCC 60

ATTAGCGTGG GGATTGTGCC TGTTATCGCT AATAGCCCTT TAAGCGCGAC CAGGCAATTC 120

GCGCTAGATG AACGATCGTT ATTTGAGCCT AATAACGCTA AAGATTTGAG CGCTAAAATA 180

GACTGGTGGT TAGAAAACAA ACTTGAAAGA GAAAGAATGC AAAACGAATA CGCTAAAAGC 240

GCTTTAAACT ACACTTTAGA AAATTCAGTC ATTCAAATTG AAAAAGTTTA TGAAGAAGCG 300

ATCAAAGATT TTAAAAACAA CCCCAACCTC TTTAAAACCT TATCGTAA 348

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1170 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 1170

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

ATGGTTATTG TTTTAGTCGT GGATAGCTTT AAAGACACCA GTAATGGCAC TTCTATGACA 60

GCGTTTCGTT TTTTTGAAGC GCTGAAAAAA AGAGGGCATG CGATGAGAGT GGTCGCCCCT 120

CATGTGGATA ATTTAGGGAG TGAAGAAGAG GGGTATTACA ACCTTAAAGA GCGCTATATC 180

CCCCTAGTTA CAGAAATTTC ACACAAGCAA CACATTCTTT TTGCCAAACC GGATGAAAAA 240

ATTCTACGAA AGGCTTTTAA GGGAGCGGAT ATGATCCATA CTTACTTGCC TTTTTTGCTA 300

GAAAAAACAG CCGTAAAAAT CGCGCGAGAA ATGCGAGTGC CTTATATTGG CTCTTTCCAT 360

TTACAGCCAG AGCATATTTC TTATAACATG AAATTGGGGC AATTTTCTTG GCTAAATACC 420

ATGCTTTTTT CATGGTTTAA ATCTTCGCAT TACCGCTATA TCCACCATAT CCATTGCCCA 480

TCAAAATTCA TTGTAGAAGA ATTGGAAAAA TACAACTATG GAGGAAAAAA ATACGCTATC 540

TCTAACGGCT TTGATCCCAT GTTTAAGTTT GAGCACCCGC AAAAAAGCCT TTTTGACACC 600

ACGCCCTTTA AAATCGCTAT GGTAGGGCGC TATTCTAATG AAAAAAATCA AAGCGTTCTC 660

ATTAAAGCGG TTGCTTTAAG CCGATACAAA CAAGACATTG TATTATTACT CAAAGGCAAG 720

GGGCCTGATG AGAAAAAAAT CAAACTTCTA GCCCAAAAAC TAGGCGTAAA AACGGAGTTT 780

GGGTTTGTCA ATTCCCATGA ATTGTTAGAG ATTTTAAAAA CTTGCACCCT CTATGCGCAC 840

ACGGCCAATG TGGAAAGCGA AGCGATTGCG TGTTTAGAAG CCATTAGCGT GGGGATTGTG 900

CCTGTTATCG CTAATAGCCC TTTAAGCGCG ACCAGGCAAT TCGCGCTAGA TGAACGATCG 960

TTATTTGAGC CTAATAACGC TAAAGATTTG AGCGCTAAAA TAGACTGGTG GTTAGAAAAC 1020

AAACTTGAAA GAGAAAGAAT GCAAAACGAA TACGCTAAAA GCGCTTTAAA CTACACTTTA 1080

GAAAATTCAG TCATTCAAAT TGAAAAAGTT TATGAAGAAG CGATCAAAGA TTTTAAAAAC 1140

AACCCCAACC TCTTTAAAAC CTTATCGTAA 1170

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 939 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 939

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

TTGGCTTCTT ACGGGTTTTT TTTAGGAGCG TTGTTTATTT TAGCGAGCGG GATCGTGTGC 60

TTACAGACTG CCGGTAATCC CTTTGTAACC TTGCTTTCTA AAGGTAAAGA AGCCAGAAAC 120

TTGGTTTTAG TCCAGGCGTT CAATTCGCTT GGCACGACTT TAGGGCCTAT TTTTGGGAGC 180

TTGTTGATTT TTAGCGCGAC CAAAACGAGC GATAATTTAA GCCTGATAGA CAAGTTAGCG 240

GACGCTAAAA GCGTTCAAAT GCCTTATTTG GGTTTAGCGG TGTTTTCGCT TCTTTTAGCG 300

CTTGTGATGT ATCTTTTAAA ATTGCCTGAT GTGGAAAAAG AAATGCCCAA AGAAACGACG 360

CAAAAAAGCC TGTTTTCGCA CAAACACTTT GTTTTTGGGG CTTTAGGGAT CTTTTTCTAT 420

GTGGGGGGAG AAGTGGCGAT TGGATCATTC TTGGTGCTAA GCTTTGAAAA GCTTTTGAAT 480

TTAGACGCTC AATCAAGCGC GCATTACTTG GTGTATTATT GGGGCGGCGC GATGGTAGGG 540

CGTTTCTTAG GCAGCGCTTT GATGAATAAA ATCGCTCCTA ATAAATACCT GGCTTTCAAC 600

GCCTTAAGCT CTATCATTCT TATCGCTTTG GCTATTCTTA TTGGAGGCAA GATCGCTTTA 660

TTCGCTCTGA CTTTTGTGGG CTTTTTCAAC TCTATCATGT TCCCTACAAT CTTTTCTTTG 720

GCTACGCTCA ATTTAGGGCA TCTCACTTCT AAGGCTTCTG GAGTGATTAG CATGGCGATT 780

GTGGGAGGGG CGTTAATCCC CCCCATTCAA GGCGTGGTTA CAGACATGCT CACAGCAACC 840

GAATCGAATC TGCTCTACGC TTATAGCGTG CCGTTGTTGT GCTATTTTTA TATCCTCTTC 900

TTTGCACTTA AGGGGTATAA ACAAGAAGAA AACTCCTAA 939

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1224 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 1224

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

ATGCAAAAAA CTTCTAACAC TTTAGCGCTG GGGAGTTTGA CGGCGCTATT CTTTCTAATG 60

GGTTTTATCA CGGTTTTAAA CGACATTTTG ATCCCGCATT TAAAGCCCAT TTTTGACTTG 120

ACCTATTTTG AAGCTTCGCT CATTCAATTT TGCTTTTTTG GGGCGTATTT CATCATGGGG 180

GGAGTCTTTG GGAACGTGAT CAGTAAAATC GGCTACCCTT TTGGCGTGGT GCTTGGTTTT 240

GTGATCACAG CGAGCGGGTG CGCGTTGTTT TATCCGGCGG CGCATTTTGG CTCTTACGGG 300

TTTTTTTTAG GAGCGTTGTT TATTTTAGCG AGCGGGATCG TGTGCTTACA GACTGCCGGT 360

AATCCCTTTG TAACCTTGCT TTCTAAAGGT AAAGAAGCCA GAAACTTGGT TTTAGTCCAG 420

GCGTTCAATT CGCTTGGCAC GACTTTAGGG CCTATTTTTG GGAGCTTGTT GATTTTTAGC 480

GCGACCAAAA CGAGCGATAA TTTAAGCCTG ATAGACAAGT TAGCGGACGC TAAAAGCGTT 540

CAAATGCCTT ATTTGGGTTT AGCGGTGTTT TCGCTTCTTT TAGCGCTTGT GATGTATCTT 600

TTAAAATTGC CTGATGTGGA AAAAGAAATG CCCAAAGAAA CGACGCAAAA AAGCCTGTTT 660

TCGCACAAAC ACTTTGTTTT TGGGGCTTTA GGGATCTTTT TCTATGTGGG GGGAGAAGTG 720

GCGATTGGAT CATTCTTGGT GCTAAGCTTT GAAAAGCTTT TGAATTTAGA CGCTCAATCA 780

AGCGCGCATT ACTTGGTGTA TTATTGGGGC GGCGCGATGG TAGGGCGTTT CTTAGGCAGC 840

GCTTTGATGA ATAAAATCGC TCCTAATAAA TACCTGGCTT TCAACGCCTT AAGCTCTATC 900

ATTCTTATCG CTTTGGCTAT TCTTATTGGA GGCAAGATCG CTTTATTCGC TCTGACTTTT 960

GTGGGCTTTT TCAACTCTAT CATGTTCCCT ACAATCTTTT CTTTGGCTAC GCTCAATTTA 1020

GGGCATCTCA CTTCTAAGGC TTCTGGAGTG ATTAGCATGG CGATTGTGGG AGGGGCGTTA 1080

ATCCCCCCCA TTCAAGGCGT GGTTACAGAC ATGCTCACAG CAACCGAATC GAATCTGCTC 1140

TACGCTTATA GCGTGCCGTT GTTGTGCTAT TTTTATATCC TCTTCTTTGC ACTTAAGGGG 1200

TATAAACAAG AAGAAAACTC CTAA 1224

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 378 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 378

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

ATGAATAAAA TCGCTCCTAA TAAATACCTG GCTTTCGGCG CCTTAAGCTC TATCATTCTT 60

ATCGCTTTGG CTATTCTTAT TGGAGGCAAG ATCGCTTTAT TCGCTCTGAC TTTTGTGGGC 120

TTTTTCAACT CTATCATGTT CCCTACAATC TTTTCTTTGG CTACGCTCAA TTTAGGCATC 180

TCACTTCTAA TGGCTTCTGG AGTGATTAGC ATGGCGATTG TGGGAGGGGC GTTAATCCCC 240

CCCATTCAAG GCGTGGTTAC AGACATGCTC ACAGCAACCG AATCGAATCT GCTCTACGCT 300

TATAGCGTGC CGTTGTTGTG CTATTTTTAT ATCCTCTTCT TTGCACTTAA GGGGTATAAA 360

CAAGAAGAAA ACTCCTAA 378

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 993 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 993

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

TTGAAAAAAA TATTACCGGC TTTGTTAATG GGGTTTGTGG GATTGAATGC TAGTGATCGT 60

TTGTTAGAAA TCATGCGCCT TTATCAAAAA CAAGGCTTGG AAGTGGTGGG TCAAAAATTG 120

GATTCTTATT TAGCGGATAA GTCTTTTTGG GCAGAAGAGC TTCAAAACAA GGACACGGAT 180

TTTGGCTATT ATCAAAACAA GCAGTTTTTA TTTGTGGCGG ATAAATCCAA GCCCAGTTTG 240

GAGTTTTATG AAATAGAAAA TAACATGCTT AAAAAAATCA ACAGCTCTAA AGCCCTTGTA 300

GGCTCTAAAA AGGGCGATAA AACTTTAGAG GGCGATTTGG CCACGCCTAT TGGAGTGTAT 360

CGTATCACGC AGAAATTAGA GCGTTTGGAT CAATATTATG GCGTTTTGGC TTTTGTAACG 420

AATTACCCTA ATTTGTATGA CACTTTGAAA AAACGCACCG GGCATGGCAT TTGGGTGCAT 480

GGAATGCCTT TAAATGGCGA TAGGAATGAA TTGAACACTA AGGGTTGCAT TGCGATTGAA 540

AACCCTATTC TAAGCTCTTA TGACAAAGTG TTAAAAGGCG AAAAAGCGTT CCTTATCACT 600

TATGAAGACA AGTTTTCCCC TAGCACTAAA GAAGAATTGA GCATGATTTT AAGCTCCCTT 660

TTCCAATGGA AAGAAGCTTG GGCTAGGGGC GATTTTGAAC GCTACATGCG TTTTTATAAC 720

CCCAATTTCA CTCGCTATGA CGGCATGAGT TTTAACGCTT TTAAAGAGTA TAAAAAAAGG 780

GTGTTTGCAA AAAATGAAAA AAAGAATATC GCTTTTTCCT CTATCAATGT GATCCCTTAC 840

CCCAACTCTC AAAACAAACG CTTGTTTTAT GTGGTATTTG ACCAAGATTA CAAAGCCTAC 900

CAGCAAAACA AGCTCTCTTA TAGCTCCAAT TCTCAAAAAG AACTCTATGT AGAGATTGAA 960

AACAATCAAG CGTCTATTAT AATGGAAAAA TAA 993

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 510 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 510

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

TTGTTTGAGA AATGGATTGG TCTGACCTTA CTCCTTAGTT CCTTAGGCTA TCCATGCCAA 60

AAGGTAAGTA TTAGTTTCAA GCAATACGAA AATCTTATCC ATATCCATCA AAAAGGTTGC 120

AACAATGAAG TGGTGTGCAG AACGCTCATC TCTATCGCTT TACTAGAAAG CTCTCTAGGG 180

TTGAACAACA AGCGAGAAAA ATCCCTTAAA GACACTTCTT ACTCCATGTT CCATATCACC 240

TTAAACACCG CTAAAAAGTT CTACCCTACC TATTCTAAAA CGCTCCTCAA AACCAAATTG 300

TTAAATGATG TGGGTTTTGC GATCCAATTA GCCAAACAAA TTTTAAAAGA AAATTTTGAT 360

TATTACCACC AAAAACACCC CAACAAAAGC GTGTATCAAT TAGTACAAAT GGCCATAGGC 420

GCTTACAATG GGGGAATGAA ACACAACCCT AATGGCGCTT ACATGAAGAA GTTTCGTTGC 480

ATTTATTCTC AAGTGCGATA CAACGAATAA 510

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 648 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 648

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

ATGAAAAAAC CCTACAGAAA GATTTCTGAT TATGCGATCG TGGGTGGTTT GAGCGCGTTA 60

GTGATGGTAA GCATTGTGGG GTGTAAGAGC AATGCCGATG ACAAACCAAA AGAGCAAAGC 120

TCTTTAAGTC AAAGCGTTCA AAAAGGCGCG TTTGTGATTT TAGAAGAGCA AAAGGATAAA 180

TCTTACAAGG TTGTTGAAGA ATACCCCAGC TCAAGAACCC ACATTGTAGT GCGCGATTTG 240

CAAGGCAATG AACGCGTGTT GAGCAATGAA GAGATTCAAA AGCTCATCAA AGAAGAAGAA 300

GCCAAAATTG ATAACGGCAC GAGCAAGCTT GTCCAGCCTA ATAATGGAGG GAGTAATGAA 360

GGATCAGGCT TTGGCTTGGG AAGCGCGATT TTAGGGAGCG CGGCGGGGGC GATTTTAGGG 420

AGTTATATTG GCAATAAGCT TTTTAATAAC CCTAATTATC AGCAAAACGC CCAACGGACC 480

TACAAATCCC CACAAGCTTA CCAACGCTCT CAAAATTCTT TTTCTAAAAG CGCACCCAGC 540

GCTTCAAGCA TGGGCACAGC GAGTAAGGGA CAGAGCGGGT TTTTTGGCTC TAGTAGGCCT 600

ACTAGTTCGC CTGCAATAAG CTCTGGGACA AGGGGCTTTA ACGCATAA 648

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 762 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 762

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

TTGAAAACTC TATTTAGTGT TTATCTCTTT TTGTCGTTGA ATCCACTCTT TTTAGAAGCT 60

AAAGAAATCA CTTGGTCTCA ATTCTTGGAA AATTTTAAAA ACAAGAATGA AGACGACAAA 120

CCTAAACCCC TAACCATTGA CAAAAACAAT GAAAAACAGC AAATCCTAGA CAAAAACCAG 180

CAAATCTTAA AAAGGGCTTT AGAAAAAAGC CTTAAATTTT TCTTTATTTT TGGATACAAC 240

TATTCGCAAG CCGCTTATTC AACCACTAAT CAAAACTTGA CTCTTACGGC GAATAGCATA 300

GGGTTTAACA CCGCTACAGG CTTGGAGCAT TTTTTAAGAA ACCACCCTAA AGTCGGTTTT 360

AGAATCTTTA GCGTCTATAA CTATTTCCAT TCCGTTTCGC TCTCCCAGCC TCAAATCCTA 420

ATGGTGCAAA ATTACGGAGG CGCGTTAGAT TTTTCTTGGA TTTTTGTGGA TAAAAAAACC 480

TATCGCTTTA GGAGTTATTT AGGAATCGCT TTAGAGCAAG GGGTGTTGTT AGTGGATACG 540

ATTAAAACCG GCTCTTTCAC AACCATCATC CCAAGAACCA AGAAAACCTT TTTTCAAGCC 600

CCTTTGCGTT TTGGTTTTAT CGTGGATTTT ATCGGCTATT TGTCTTTGCA ATTAGGGATT 660

GAAATGCCCT TAGTGAGGAA TGTTTTTTAC ACCTACAATA ACCATCAAGA AAGATTCAAA 720

CCACGATTTA ACGCTAATCT TTCTTTAATC GTTTCGTTTT AG 762

(2) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1011 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 1011

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

TTGTTTTTCA AATTTATTTT ATGTTTATCA TTAGGAATAT TTGCATGGGC AAAAGAGGTC 60

ATTCCCACCC CTTCAACCCC ATTAACGCCC TCTAAACGCT ATTCTATCAA TTTGATGACT 120

GAAAATGATG GTTATATCAA TCCTTACATT GATGAGTATT ACACGGCAGG CAATCAAATA 180

GGCTTTTCTA CTAAAGAGTT TGATTTTTCT AAAAATAAAG CGATGAAATG GTCTTCGTAT 240

TTAGGGTTTT TCAATAAAAG CCCTAGGGTT ACTCGTTTTG GCATTTCTCT CGCCCAAGAC 300

ATGTATACCC CCTCACTTGC AAACAGAAAA CTGGTGCATT TGCATGACAA CCACCCTTAT 360

GGGGGGTATT TGAGGGTGAA TTTGAACGTG TATAACCGCC ATCAAACTTT CATGGAGTTA 420

TTCACGATTT CTTTAGGCAC GACAGGGCAA GATTCTTTGG CCGCTCAAAC GCAGCGTCTC 480

ATTCATAAAT GGGGTCATGA TCCCCAATTT TATGGCTGGA ACACGCAGCT CAAAAACGAA 540

TTTATCTTTG AACTGCACTA CCAATTGCTT AAAAAAGTCC CCCTTTTAAA GACTCGTTTT 600

TTTTCTATGG AGTTGATGCC TGGGTTTAAT GTGGAACTGG GTAATGCGAG GGATTATTTC 660

CAACTCGGCT CGCTCTTTAG GGCTGGGTAT AACTTGGACG CTGATTATGG GGTCAATAAG 720

GTCAATACCG CTTTTGATGG GGGCATGCCT TATAGCGATA AGTTTTCCAT CTATTTTTTT 780

GCAGGGGCTT TTGGGCGCTT CCAACCCCTT AACATCTTCA TTCAAGGCAA TAGCCCTGAA 840

ACTAGGGGCA TTGCCAATTT GGAATACTTT GTTTATGCCA GTGAAATAGG AGCGGCTATG 900

ATGTGGCGTA GCCTCAGGGT GGCTTTTACA ATCACTGATA TTAGTAAAAC CTTTCAGTCC 960

CAGCCTAAGC ACCATCAGAT CGGCACCTTA GAATTGAATT TCGCCTTTTG A 1011

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 327 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 327

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

ATGAAACCAA TCTTTAGCCT CTTTTTCCTC CTTATTGTTT TAAAAGCGCA CCCCATAAAC 60

CCCTTATTAG AGCCGTTATA TTTCCCCAGT TACACGCAAT TTTTAGATTT AGAACCTCAT 120

TTTGTCATTA AAAAAAAGCG CGCTTACAGG CCTTTTCAAT GGGGGAACAC TATTATTATC 180

AAACGCCATG ATTTAGAAGA GCGCCAGAGC AACCAACCAA GCGATATTTT CCGCCAGAAC 240

GCTGAAATCA ATGTGTCTTC TCAAACTTTT TTAAGAGGAA TCAGCAGCGC TTCTTCACGC 300

ATAGTGATCG ATTCGGTCGC TCAGTAA 327

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 588 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 588

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

ATGAGCAATA ACCCCTTTAA AAAAGTGGGC ATGATCAGCT CTCAAAACAA TAACGGCGCT 60

TTGAACGGGC TTGGCGTGCA AGTGGGTTAT AAACAATTCT TTGGCGAAAG CAAAAGATGG 120

GGGTTAAGGT ATTATGGTTT CTTTGATTAC AACCACGGCT ATATCAAATC CAGCTTTTTT 180

AATTCTTCTT CTGATATATG GACTTATGGC GGTGGGAGCG ATTTGTTAGT GAATTTTATC 240

AACGATAGCA TCACAAGAAA GAACAACAAG CTTTCTGTGG GTCTTTTTGG TGGTATCCAA 300

CTAGCAGGGA CTACATGGCT TAATTCTCAA TACATGAATT TAACAGCGTT CAATAACCCT 360

TACAGCGCGA AAGTCAATGC TTCCAATTTC CAATTTTTGT TCAATCTCGG CTTGAGGACG 420

AATCTCGCTA CAGCTAAGAA AAAAGACAGC GAACGTTCCG CGCAACATGG CGTTGAACTG 480

GGCATTAAAA TCCCTACCAT TAACACCAAT TATTATTCTT TTCTAGGCAC TAAGCTAGAA 540

TACAGAAGGC TTTATAGCGT GTATCTCAAT TATGTGTTTG CTTATTAA 588

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 684 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 684

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

GTGCGTTTTG GTAAAATTGA TTATTTGAAC ATGCTCCCTT TTGATGTGTT TATCAAATCC 60

TACCCCACCC CTTGTTATTT CAAACAATTC TTACGGCTTA AAAAAACCTA CCCCTCCAAA 120

CTCAATGAGA GTTTTTTATT CAGGCGCATT GATGCGGGGT TTATTTCTTC TATCGCTGGC 180

TATCCATTCG CTCTTTGTTC TTATTCTCTA GGCATTGTCG CTTATAAGGA AGTTTTAAGC 240

GTGTTGGTTG TAAATAGAGA AAACGCTTTT GACAAAGAAA GCGCTTCTTC AAACGCCCTC 300

TCTAAAGTGT TAGGGTTAAA AGGCGAGGTC TTAATCGGCA ATAAAGCGCT GCAATTTTAT 360

TATTCCAACC CTAAAAAAGA TTTTATAGAT TTAGCCGCTC TGTGGTATGA AAAAAAACGC 420

TTGCCGTTTG TTTTTGGGCG TCTGTGCTAT TATCAAAACA AGGATTTTTA CAAACGCTTG 480

TCTTTAGCCT TCAAACATCA AAAAACAAAA ATCCCTCACT ACATCCTTAA AGAAGCCGCT 540

TTGAAAACCA ACTTGAAACG CCAAGATATT CTAAACTACT TGCAAAAAAT TTACTACACT 600

TTAGGCAAAA AGGAACAATC AGGCCTTAAA GCGTTCTATC GTGAATTGTT GTTCAAACGC 660

ATCCAAAAAC CCAAGCGGTT TTAG 684

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 918 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 918

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

ATGGGTAGAA TTGAATCAAA AAAGCGTTTG AAAGCACTCA TTTTTTTAGC GAGTTTGGGG 60

GTGTTGTGGG GCAATGCGGC TGAAAAAACG CCTTTTTTTA AAACTAAAAA CCACATTTAT 120

TTGGGTTTTA GGCTAGGCAC AGGGGCTACT ACGCGCACAA GCATGTGGCA ACAAGCCTAT 180

AAAGACAACC CCACTTGCCC TAGCAGCGTG TGTTATGGCG AGAAATTAGA AGCCCATTAT 240

AAGGGGGGTA AAAACTTATC TTATACCGGG CAAATAGGCG ATGAAATAGC TTTTGATAAA 300

TACCATATTT TAGGCTTAAG GGTGTGGGGG GATGTAGAAT ACGCTAAGGC TCAATTAGGT 360

CAAAAAGTGG GGGGTAACAC CCTTTTATCC CAAGCGAATT ATAACCCAAG CGCGATTAAA 420

ACCTACGATC CTACTTCAAA CGCTCAAGGC TCTTTAGTTT TGCAAAAAAC CCCAAGCCCC 480

CAAGATTTCC TTTTCAATAA CGGGCATTTC ATGGCGTTTG GTTTGAACGT GAACATGTTT 540

GTCAATCTCC CTATAGACAC CCTTTTAAAA CTCGCTTTAA AAACGGAAAA AATGCTGTTT 600

TTTAAAATAG GCGTGTTTGG TGGGGGTGGG GTGGAATACG CAATCTTGTG GAGTCCTCAA 660

TATAAAAATC AAAATACCCA TCAAGACGAT AAATTTTTTG CCGCAGGTGG GGGGTTTTTT 720

GTGAATTTTG GAGGCTCTTT GTATATAGGC AAGCGCAACC GCTTCAATGT GGGGCTAAAA 780

ATCCCTTATT ATAGCTTGAG CGCGCAAAGT TGGAAAAATT TTGGCTCTAG CAATGTGTGG 840

CAGCAACAAA CGATCCGACA AAACTTCAGC GTTTTTAGGA ATAAAGAAGT TTTTGTCAGC 900

TACGCGTTCT TGTTTTAG 918

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 777 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 777

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

ATGTTTTTAA GATCATACCC AAAGCTTAGA TACGCTTTAT GTTTACCCCT ACTCACTGAG 60

ACTTGCTATA GCGAGGAGCG CACTTTAAAT AAGGTTACCA CCCAAGCTAA AAGGATTTTC 120

ACTTACAATA ATGAGTTTAA GGTTACTTCT AAAGAATTGG ATCAACGCCA AAGCAATGAA 180

GTCAAAGACC TGTTTAGGAC TAACCCTGAT GTGAATGTGG GCGGAGGGAG CGTGATGGGG 240

CAGAAAATCT ACGTGAGAGG CATTGAAGAC AGGCTTTTAA GGGTTACGGT GGATGGGGCT 300

GCGCAAAATG GCAACATCTA CCACCACCAA GGCAACACCG TGATTGACCC TGGCATGCTC 360

AAAAGCGTGG AAGTTACTAA AGGCGCGGCG AATGCGAGCG CGGGGCCAGG AGCGATCGCG 420

GGAGTGATTA AAATGGAGAC TAAAGGAGCG GCTGATTTTA TCCCTAGGGG GAAAAATTAT 480

GCAGCGAGTG GGGCGGTGAG TTTTTATACC AATTTTGGGG ACAGAGAGAC TTTTAGATCG 540

GCCTATCAAA GCGCGCATTT TGATATTATC GCTTACTACA CGCACCAAAA TATTTTCTAT 600

TATAGGAGCG GCGCCACAGT GATGAAAAAC CTTTTCAAAC CCACACAAGC CGATAAAGAG 660

CCAGGAACTC CCAGCGAGCA AAACAACGCT TTGATTAAAA TGAATGGCTA TTTGAGCGAC 720

AGAGACACGC TCACTTTCAG CTGGAACATG ACACGAGATA ACGCCACACG CCTTTAA 777

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 579 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 579

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

ATGTTTTTAA GATCATACCC AAAGCTTAGA TACGCTTTAT GTTTACCCCT ACTCACTGAG 60

ACTTGCTATA GCGAGGAGCG CACTTTAAAT AAGGTTACCA CCCAAGCTAA AAGGATTTTC 120

ACTTACAATA ATGAGTTTAA GGTTACTTCT AAAGAATTGG ATCAACGCCA AAGCAATGAA 180

GTCAAAGACC TGTTTAGGAC TAACCCTGAT GTGAATGTGG GCGGAGGGAG CGTGATGGGG 240

CAGAAAATCT ACGTGAGAGG CATTGAAGAC AGGCTTTTAA GGGTTACGGT GGATGGGGCT 300

GCGCAAAATG GCAACATTTA CCACCACCAA GGCAACACCG TGATTGACCC TGGCATGCTC 360

AAAAGCGTGG AAGTTACTAA AGGCGCGGCG AATGCGAGCG CGGGGCCAGG AGCGATCGCG 420

GGAGTGATTA AAATGGAGAC TAAAGGAGCG GCTGATTTTA TCCCTAGGGG GAAAAATTAT 480

GCAGCGAGTG GGGCGGTGAG TTTTTATACC AATTTTGGGG ACAGAGAGAC TTTTAGATCG 540

GCCTATCAAA GCGCGCATTT TGATATTATC GCTTACTAG 579

(2) INFORMATION FOR SEQ ID NO: 31:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 381 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 381

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

GTGCCCTTGA GTTTGGGAGG CAACCTCTTA AACCCTAACA ACAGTAGCGT GCTGAATTTA 60

AAAAACAGCC AGCTTGTTTT TAGCGATCAA GGGAGCTTGA ATATCGCTAA CATTGATTTA 120

CTAAGCGATC TGAATGGTAA TAAAAATCGT GTGTATAACA TCATTCAAGC GGACATGAAT 180

GGTAATTGGT ATGAGCGTAT CAACTTCTTT GGCATGCGCA TTAATGATGG GATTTATGAC 240

GCTAAAAACC AAACTTATAG TTTCACTAAC CCTCTCAATA ACGCCGTAAA ATTCACCGAG 300

AGCTTTTTCA TACACCGCCT GTGCGGTTCG CTCTCTCAAA TACAAAAAAA AAAAAACACA 360

ATAGTCTCAC CTCGGCTCTG A 381

(2) INFORMATION FOR SEQ ID NO: 32:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1698 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 1698

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

GTGTATTCTT ATAGCGATGA CGCACAAGGC GTGTTTTATC TCACGAGCAG CGTGAAAGGC 60

TATTACAACC CCAACCAATC CTATCAAGCC AGCGGCAGCA ATAACACCAC GAAAAATAAC 120

AATCTAACCT CTGAATCTTC TGTCATTTCG CAAACCTATA ACGCGCAAGG CAACCCTATC 180

AGCGCGTTAC ACGTCTATAA CAAGGGCTAT AATTTCAGTA ATATCAAAGC GTTAGGGCAA 240

ATGGCGCTCA AACTCTACCC TGAAATCAAA AAGATATTAG GGAATGATTT TTCGCTTTCA 300

AGTTTGAGCA ATTTAAAAGG CGATGCGCTA AACCAGCTTA CCAAGCTCAT CACGCCTAGC 360

GATTGGAAAA ACATTAACGA GTTGATTGAT AACGCAAACA ATTCGGTCGT GCAAAATTTC 420

AATAACGGCA CTTTGATTAT AGGAGCGACT AAAATAGGGC AAACAGACAC CAATAGTGCG 480

GTGGTTTTTG GGGGCTTGGG CTATCAAAAG CCTTGCGATT ACACTGATAT TGTGTGCCAA 540

AAATTTAGAG GCACTTATTT GGGGCAGCTT TTGGAGTCCA ACTCCGCTGA TTTGGGCTAT 600

ATTGACACGA CTTTTAACGC TAAAGAAATT TATCTTACCG GCACTTTAGG GAGCGGGAAC 660

GCATGGGGGA CTGGGGGGAG TGCGAGCGTA ACTTTTAACA GCCAAACTTC GCTCATTCTC 720

AACCAAGCGA ATATCGTAAG CTCGCAAACC GATGGGATTT TTAGCATGCT GGGTCAAGAG 780

GGCATCAATA AGGTTTTCAA TCAAGCCGGG CTCGCTAATA TTTTGGGCGA AGTGGCAATG 840

CAATCCATTA ACAAAGCCGG GGGATTAGGG AATTTGATAG TAAATACGCT AGGGAGTGAT 900

AGCGTGATTG GGGGGTATTT AACGCCTGAG CAAAAAAATC AAACCCTAAG CCAGCTTTTG 960

GGGCAGAATA ATTTTGATAA CCTCATGAAC GATAGCGGTT TGAACACGGC GATTAAGGAT 1020

TTGATCAGAC AAAAATTAGG CTTTTGGACC GGGCTAGTGG GGGGATTAGC CGGACTGGGG 1080

GGCATTGATT TGCAAAACCC TGAAAAGCTT ATAGGCAGCA TGTCCATCAA TGATTTATTG 1140

AGTAAAAAGG GGTTGTTCAA TCAGATCACC GGCTTTATTT CCGCTAACGA TATAGGGCAA 1200

GTCATAAGCG TGATGCTGCA AGATATTGTC AAGCCGAGCG ACGCTTTAAA AAACGATGTA 1260

GCCGCTTTGG GCAAGCAAAT GATTGGCGAA TTTTTAGGCC AAGACACGCT CAATTCTTTA 1320

GAAAGCTTGC TGCAAAACCA GCAGATTAAA AGCGTTTTAG ACAAAGTCTT AGCGGCTAAA 1380

GGATTAGGGT CTATTTATGA ACAAGGTTTG GGGGATTTGA TCCCTAATCT TGGTAAAAAG 1440

GGGATTTTCG CTCCCTATGG CTTGAGTCAA GTGTGGCAAA AAGGGGATTT TAGTTTCAAC 1500

GCGCAAGGCA ATGTTTTTGT GCAAAATTCC ACTTTCTCTA ACGCTAATGG AGGCACGCTC 1560

AGTTTTAACG CAGGAAATTC GCTCATTTTT GCCGGAAACA ACCACATCGC TTTCACTAAC 1620

CATTCTGGAA CGCTCAATTT GTTGTCTAAT CAAGTTTCTA ACATTAACGT CACCATGCTT 1680

AACGCAGCAA CGGCCTAA 1698

(2) INFORMATION FOR SEQ ID NO: 33:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 519 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 519

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

GTGTTTGGAT TGAGTTTGGC GGATATGATT TTAGAGCGTT TTAAAGATTT TATGAGAGAA 60

TACCCTGAGC CTTACAAGTT TTTACAGGTT TTTTACGCGC AAGAAAAAGA ACGCTTCTTA 120

AATCATAAAA TGAACGATTA TATCAAGCAA AATAAGAGCA AGGAAGAGGC TAGTATTTTG 180

GCCAGACAAG GCTTTGTCAG CGTAATTGGA AGAGCGTTAG AAAAAATCAT AGAACTTTTA 240

TTAAAAGATT TTTGTATTAA AAACAATGTA AAAATGACGA ACGATAAAAC CTTAAGGGCT 300

AAGCGCATTA ATGGCGAATT AGATAAGGTC AAACGGGCTT TATTGGTGCA TTTTGGAGGA 360

TATAGCGTTT TACCCGATAT TATTCTTTAT CAAACCAACA AAGATAATAT CAAAATCCTA 420

GCGATTTTAT CGGTAAAAAA TTCGTTTAGA GAGCGTTTCA CAAAAGACGC CTTATTGGAA 480

ATTAAAACTT TTGCAATCGC CTGTAACTTC TCACATTAA 519

(2) INFORMATION FOR SEQ ID NO: 34:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 996 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 996

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

ATGAAAAGAT TTGTTTTATT CTTGTTATTC ATATGTGTTT GCGTTTGCGT TCAAGCTTAC 60

GCTGAGCAAG ATTACTTTTT TAGGGATTTT AAATCTATAG ATTTGCCCCA AAAACTCCAC 120

CTTGATAAAA AGCTCTCCCA AACAATACAG CCATGCGCGC AACTTAACGC ATCAAAACAC 180

TACACTGCTA CTGGGGTTAG AGAGCCTGAT GCCTGCACCA AGAGTTTTAA AAAATCCGCT 240

ATGGTTTCCT ATGATTTAGC GCTAGGCTAT TTAGTGAGCC AAAACAAACC ATACGGCTTA 300

AAAGCTATAG AGATTTTAAA CGCTTGGGCT AATGAGCTTC AAAGCGTGGA TACTTATCAA 360

AGCGAGGACA ATATCAATTT TTACATGCCT TATATGAACA TGGCTTATTG GTTTGTCAAA 420

AAAGAATTTC CTAGCCCAGA ATATGAAGAT TTCATTAGGC GGATGCGTCA GTATTCTCAA 480

TCAGCTCTTA ACACTAACCA TGGGGCGTGG GGGATTCTCT TTGATGTGAG CTCTGCACTA 540

GCGCTAGATG ATCATGCCCT TTTGCAAAGT AGCGCTAATC GGTGGCAGGA GTGGGTGTTT 600

AAAGCCATAG ATGAGAACGG GGTTATTGCT AGCGCGATCA CTAGGAGCGA TACGAGCGAT 660

TATCATGGCG GCCCTACAAA GGGCATTAAG GGGATAGCTT ATACCAATTT TGCGCTTCTT 720

GCGATAACTA TATCAGGCGA ATTGCTTTTT GAGAACGGGT ATGATTTGTG GGGTAGTGGA 780

GCCGGGCAAA GGCTCTCTGT GGCGTATAAC AAAGCCGCAA CATGGATTCT AAACCCTGAA 840

ACTTTCCCCT ATTTTCAGCC TAACCTCATT GGGGTGCATA ACAACGCCTA TTTCATTATT 900

TTAGCCAAAC ATTATTCTAG CCCTAGCGCG GATGAGCTTT TAGAGCAAGG CGATTTGCAT 960

GAAGATGGCT TCAGGCTGAA ACTCCGATCG CCATGA 996

(2) INFORMATION FOR SEQ ID NO: 35:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 384 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 384

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

ATGCGTCAGT ATTCTCAATC AGCTCTTAAC ACTAACCATG GGGCGTGGGG GATTCTCTTT 60

GATGTGAGCT CTGCACTAGC GCTAGATGAT CATGCCCTTT TGCAAAGTAG CGCTAATCGG 120

TGGCAGGAGT GGGTGTTTAA AGCCATAGAT GAGAACGGGG TTATTGCTAG CGCGATCACT 180

AGGAGCGATA CGAGCGATTA TCATGGCGGC CCTACAAAGG GCATTAAGGG GATAGCTTAT 240

ACCAATTTTG CGCTTCTTGC GATAACTATA TCAGGCGAAT TGCTTTTTGA GAACGGGTAT 300

GATTTGTGGG GTAGTGGAGC CGGGCAAAGG CTCTCTGTGG CGTATAACAA AGCCGCAACA 360

TGGATTCTAA ACCCTGAAAC TTTC 384

(2) INFORMATION FOR SEQ ID NO: 36:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 738 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 738

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

TTGAGAACCT TGTTAAAAAT GTTGGTTGGT GTGAGCTTAC TAACACACGC TTTAATGGCT 60

ACAGAAGAAA GCGCTGCCCC TTCTTGGACA AAAAATTTGT ATATGGGATT CAATTACCAA 120

ACAGGTTCTA TCAATTTAAT GACTAATATT CATGAAGTTA GAGAAGTTAC TAGCTATCAA 180

ACCGGTTACA CCAATGTAAT GACTAGCATT AATAGCGTTA AAAAACTCAC TAACATGGGT 240

TCTAATGGGA TTGGCTTAGT CATGGGCTAT AACCACTTTT TCCATCCGGA TAAAGTCTTG 300

GGTTTGCGCT ATTTTGCTTT TTTAGATTGG CAAGGCTATG GCATGAGATA CCCTAAAGGC 360

TATTATGGGG GCAATAACAT GATCACTTAT GGCGTGGGCG TGGATGCGAT ATGGAATTTC 420

TTCCAAGGGA GTTTTTATCA AGATGATATT GGCGTGGATA TTGGCGTTTT TGGGGGGATT 480

GCGATTGCTG GGAATAGCTG GTATATTGGC AATAAAGGGC AGGAATTATT AGGCATCACC 540

AATAGTAGTG CGGTTGATAA CACCTCTTTT CAATTCCTCT TTAACTTTGG TTTCAAAGCT 600

TTATTTGTAG ATGAACATGA ATTTGAAATT GGGTTTAAAT TCCCCACTCT TAACAACAAA 660

TACTACACCA CCGACGCGCT CAAGGTTCAA ATGCGTAGGG TCTTTGCCTT TTATGTGGGG 720

TATAATTACC ACTTCTAA 738

(2) INFORMATION FOR SEQ ID NO: 37:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 873 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 873

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

ATGTTTGAAG AAATTACCCT AGCGCATAAG GACTTGTTTT CAAGGTTTTT ACAAACTCAA 60

AAAATCGTTT TATCGGATGT GAGTTTTACC AATTGCTTTT TATGGCAGCA CGCAAGGCTC 120

ATTCAAGTGG CTGTGATTAG GGATTGTTTG GTGATTCAAA CCACTTATGA AAACCAAAAA 180

CCCTTTTATT TCTATCCTAT CGGTAAGAGG CCGCATGAAT GCGTGAAAGA GCTTTTGGAA 240

TTAGAAAAAA ATTTAAGATT CCACTCCCTG ACTTTAGAGC AAAAAGACGA TTTGAAAGAC 300

AATTTTGTAG GGGTGTTTGA TTTCACTTAC AACCGAGACA GGAGCGATTA TGTTTATTCT 360

ATTGAAGAAC TAATCGCGCT CAAAGGGAAA AAATACCATA AGAAAAAAAA CCACTTAAAC 420

CAGTTTTTAA CCAATCATGC GAATTTTGTT TATGAAAAAA TTTCTCCTCA AAACAGAAAG 480

GAAGTTTTAG AAGCCTCTAA AGCGTGGTTT TTAGAAAGCC AGACCGATGA TATAGGGTTA 540

ATCAACGAAA ATAAGGGCAT TCAAAGCGTT TTAGAAAATT ATGAAAGCTT GGATTTAAAG 600

GGGGGGCTTA TTAGGGTTAA TGGGGAAATA GTCTCGTTTA GTTTTGGGGA AGTTTTAAAC 660

GAAGAGAGCG CGCTCATCCA CATTGAAAAA GCCCGCACAG ATATTGCAGG CGCGTATCAA 720

ATCATCAACC AACAATTGCT TTTGAATGAA TTTAGCCATT TAACTTACGC TAACAGAGAA 780

GAAGATCTAG GATTAGAGGG CTTAAGAAGG TCTAAAATGA GCTATAACCC GGTGTTTTTG 840

ATAGACAAAT ACGAAGCGGT TGCTAGAAAT TAA 873

(2) INFORMATION FOR SEQ ID NO: 38:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 333 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 333

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

ATGATGTTCA TTGTAGCGGT TTTGATGCTG GCGTTTTTGA TCTTTGTCCA TGAGTTAGGG 60

CATTTCATTA TCGCTAGGAT TTGTGGGGTG AAAGTGGAAG TGTTTAGCAT TGGTTTTGGT 120

AAAAAACTCT GGTTTTTCAA GCTTTTTGGC ACGCAATTCG CTCTGTCTTT GATCCCGCTT 180

GGGGGCTATG TGAAATTAAA GGGCATGGAT AAAGAAGAAA ATGAAGAAAA TAAAATTAAT 240

CAAGCGAATG ATAGCTACGC CAAAAAAGCC CTTTCCAAAA GCTATGGATA TTGTTTGGTG 300

GGGCGTTTTT TAATTTTCTT TTTGCGGTTT TAG 333

(2) INFORMATION FOR SEQ ID NO: 39:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1056 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 1056

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

ATGATGTTCA TTGTAGCGGT TTTGATGCTG GCGTTTTTGA TCTTTGTCCA TGAGTTAGGG 60

CATTTCATTA TCGCTAGGAT TTGTGGGGTG AAAGTGGAAG TGTTTAGCAT TGGTTTTGGT 120

AAAAAACTCT GGTTTTTCAA GCTTTTTGGC ACGCAATTCG CTCTGTCTTT GATCCCGCTT 180

GGGGGCTATG TGAAATTAAA GGGCATGGAT AAAGAAGAAA ATGAAGAAAA TAAAATTAAT 240

CAAGCGAATG ATAGCTACGC GCAAAAAAGC CCTTTCCAAA AGCTATGGAT ATTGTTTGGT 300

GGGGCGTTTT TTAATTTTCT TTTTGCGGTT TTAGTGTATT TTTTTCTGGC ATTGAGCGGG 360

GAAAAAGTCT TACTGCCCGT CATTGGCGGT TTAGAAAAAA ACGCGCTAGA AGCCGGGCTG 420

TTAAAGGGGG ATAGAATCCT TTCTATCAAC CATCAAAAAA TAGCGAGTTT TAGAGAGATT 480

AGAGAGATAG TGGCGCGTTC TCAAGGCGAG TTAATTTTAG AAATAGAGCG AAACAATCAG 540

ATTTTAGAAA AACGACTGAC CCCCAAAATC GTGGCGGTGA TAAGCGAGTC TAATGATCCT 600

AATGAAATCA TCAAGTATAA AATAATAGGC ATTAAACCGG ACATGCAAAA AATGGGCGTT 660

GTCTCTTATT CCGTGTTTCA AGCGTTTGAA AAGGCTTTGA GTCGGTTTAA AGAGGGCGTT 720

GTTTTGATTG TGGATTCTTT AAGGCGTTTG ATTATGGGGA GCGCTTCAGT TAAAGAATTG 780

AGTGGGGTAA TAGGCATTGT GGGGGCGTTA AGCCATGCCA ATAGCGTGAG CATGCTTTTG 840

TTGTTTGGGG CGTTTTTATC TATCAATCTA GGGATTTTAA ATTTATTACC CATTCCAGCC 900

TTAGATGGGG CGCAAATGCT AGGGGTCGTT TTTAAAAATA TTTTTCATAT CGCTTTGCCA 960

ACGCCCATAC AAAATGCGTT GTGGCTAGTG GGGGTGGGGT TTTTGGTTTT TGTCATGTTT 1020

TTAGGGCTTT TTAATGACAT TACTCGTTTG CTATAA 1056

(2) INFORMATION FOR SEQ ID NO: 40:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 303 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 303

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

ATGCAAAAGA ATTTGGATAG TCTTTTAGAA AATTTAAGGG CTGAAATTGA TGCGTTGGAT 60

AATGAATTGA GCGATCTTTT AGACAAACGC TTAGGAATCG CTTTAAAAAT CGCTCTCATC 120

AAACAAGAAA GCCCCCAAGA AAACCCCATT TATTGCCCTA AAAGAGAGCA AGAGATTTTA 180

AAACGACTCA GCCAAAGGGG TTTCAAGCAT TTGAATGGAG AAATCCTTGC AAGTTTTTAT 240

GCAGAGGTTT TTAAGATTTC TAGAAATTTT CAAGAAAACG CCCTAAAAGA GTTAAAAAAA 300

TAA 303

(2) INFORMATION FOR SEQ ID NO: 41:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 525 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 525

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

GTGAAAATGC GTTTTTTTAG TGGTTTTGGG TTTGTTAATG AAAGCGTTTT GTTTGAAGAG 60

TGGCTTTTAA AAGGGGCTTA TGATGTGTCA GGCTTTTCTA TGGGGGCGAT TAAGGCGATA 120

GAATACGCCT ATAATGAAGT CTTGCAACAA CGGCGCATCC ATTCCTTATT GTTGTTTTCG 180

CCTTGCATGC TAGCGCATAA GAGTTTGGCG TTCAAACGCT TGCAACTTTT CTTGTTTCAA 240

AAAGATCCGC AAAGCTACAT GGATAACTTT TATAAGGAAG TGGGATTGGA CGCTCAATTG 300

GAGCGTTTTA AAAAAGAGGG TTCTTTAGAA GAATTGGAAT TTTTATTGGA TTACAAGTAT 360

AGTGATTCTA TAATTAGATT TTTATTGGAA AAGGGCGTGA AGATTGAAGT GTTTATCGGT 420

TTAAAAGATA GAATCACTGA CATTCAAGCC CTTTTAGAAT TTTTTATGCC CTTAGTTCAA 480

GTGTGGCAGT TTAAGGATTG TAACCATTTG TTGCAAAAAT CTTAA 525

(2) INFORMATION FOR SEQ ID NO: 42:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1416 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 1416

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

ATGAAAAATA CCAATACAAA AGAGATAAAG AATACAAGGA TGAAAAAAGG TTATAGTCAA 60

TACCACACGC TCAAAAAAGG GCTTTTAAAA ACCGCTCTGC TTTTTAGCCT TCCTTTAAGC 120

GTGGCGTTAG CTGAAGACGA TGGCTTTTAT ATGGGAGTGG GCTATCAAAT CGGCGGCGCG 180

CAACAAAACA TCAACAACAA AGGCAGCACC CTAAGGAATA ATGTCATTGA TGATTTCCGC 240

CAAGTGGGCG TGGGTATGGC AGGGGGTAAT GGGCTTTTAG CTTTAGCGAC AAACACGACC 300

ATGGACGCTC TTTTAGGGAT AGGCAACCAA ATTGTCAATA CTAATACAAC TGTTGGCAAC 360

AACAACGCAG AGTTAACCCA GTTTAAAAAA ATACTCCCCC AAATTGAACA ACGCTTTGAG 420

ACGAATAAAA ACGCTTATAG CGTTCAAGCC TTGCAAGTGT ATTTGAGTAA TGTGCTTTAT 480

AACTTGGTTA ATAATAGTAA TAATGGTAGC AATAATGGAG TCGTTCCTGA ATATGTAGGG 540

ATTATAAAAG TTCTCTATGG TTCTCAAAAT GAATTCAGTC TCTTAGCCAC GGAGAGTGTG 600

GCGCTTTTAA ACGCGCTCAC GAGAGTGAAT CTGGATAGTA ATTCGGTGTT TTTAAAAGGG 660

CTATTAGCCC AAATGCAGCT TTTTAATGAC ACTTCTTCAG CAAAGCTAGG TCAGATCGCA 720

GAAAACTTGA AGAACGGTGG TGCAGGGGCC ATGCTTCAAA AGGATGTGAA AACCATCTCG 780

GATCGAATCG CTACTTACCA AGAGAATCTA AAACAGCTAG GAGGGATGTT AAAGAATTAC 840

GATGAGCCAT ACCTACCCCA ATTTGGGCCA GGCACAAGCT CTCAGCATGG GGTTATTAAT 900

GGCTTTGGCA TTCAAGTGGG CTATAAGCAA TTTTTTGGGA GCAAGAAGAA TATAGGCTTA 960

CGATATTACG CTTTCTTTGA TTATGGCTTT ACGCAATTGG GCAGTCTTAA CAGTGCTGTT 1020

AAAGCGAACA TCTTTACTTA TGGTGCTGGC ACGGACTTTT TATGGAATAT CTTTAGAAGG 1080

GTTTTTAGCG ATCAGTCCTT GAATGTGGGG GTGTTTGGGG GCATTCAAAT AGCGGGTAAC 1140

ACTTGGGATA GCTCTTTAAG AGGTCAAATT GAAAACTCGT TTAAAGAATA CCCCACTCCC 1200

ACGAATTTCC AATTTTTGTT TAATTTGGGC TTAAGGGCTC ATTTTGCCAG CACCATGCAC 1260

CGCCGGTTTT TGAGCGCGTC TCAAAGCATT CAGCATGGTA TGGAATTTGG CGTGAAAATC 1320

CCAGCTATCA ATCAAAGGTA TTTGAAAGCG AATGGGGCTG ATGTGGATTA CAGGCGTTTG 1380

TATGCGTTCT ATATCAATTA CACGATAGGT TTTTAA 1416

(2) INFORMATION FOR SEQ ID NO: 43:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 390 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 390

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

ATGAAAAGCA TCAGAAGAGG CGATGGGCTG AATGTTGTCC CTTTCATTGA TATTATGCTC 60

GTCTTACTAG CGATTGTGTT GAGTATTTCT ACTTTTATCG CGCAAGGTAA GATTAAAGTC 120

AGTCTCCCTA ACGCTAAAAA TGCGGAAAAA TCCCAGCCAA ACGATCAAAA AGTGGTGGTC 180

ATCTCTGTGG ATGAGCATGA CAATATTTTC GTAGATGACA AACCGACGAA TTTAGAAGCT 240

TTGAGCGCTG TAGTCAAGCA AACAGACCCT AAAACCCTTA TAGATTTAAA AAGCGACAAG 300

AGCTCTCGTT TTGAAACTTT TATCAGCATT ATGGATATTT TAAAAGAGCA TAATCATGAA 360

AATTTCTCCA TCTCCACGCA AGCTCAGTAA 390

(2) INFORMATION FOR SEQ ID NO: 44:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 225 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 225

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

ATGCTCGTCT TACTAGCGAT TGTGTTGAGT ATTTCTACTT TTATCGCGCA AGGTAAGATT 60

AAAGTCAGTC TCCCTAACGC TAAAAATGCG GAAAAATCCC GACCAAACGA TCAAAAAGTG 120

GTGGTCATCT CTGTGGATGA GCATGACAAT ATTTTCGTAG ATGACAAACC GACGAATTTA 180

GAAGCTTTGA GCGCTGTAGT CAAGCAAACA GACCCTAAAA CCCTT 225

(2) INFORMATION FOR SEQ ID NO: 45:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 672 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 672

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

ATGTTTTCAC TTTCTTATGT TTCCAAGAAA TTTTTAAGCG TGTTGCTATT GATTTCGCTG 60

TTTTTAAGCG CTTGCAAATC CAACAATAAA GACAAATTGG ATGAAAATCT TTTAAGCTCC 120

GGCACTCAAA GCTCCAAAGA ATTAAACGAC AAGCGAGACA ATATAGACAA AAAGAGCTAC 180

GCTGGTTTAG AAGATGTTTT TTTAGACAAC AAGTCCATTA GCCCTAATGA TAAATACATG 240

CTTTTAGTTT TTGGCCGTAA TGGTTGCTCC TATTGTGAAA GGCTTAAAAA AGATCTCAAA 300

AATGTCAAAG AATTGCGCAA CTATATTAAA GAGCATTTTA GTGCTTACTA TGTCAATATC 360

AGCTATTCTA AAGAGCATAA TTTTAAAGTC GGCGATAAGG ATAAAAATGA TGAAAAAGAA 420

ATCAAAATGT CCACAGAAGA ATTAGCGCAA ATTTATGCCG TCCAATCCAC CCCTACGATT 480

GTTTTATCCG ATAAAACCGG CAAAACCATC TATGAATTGC CGGGCTATAT GCCTTCTGTG 540

CAATTTTTAG CCGTGTTAGA ATTTATCGGC GATGGGAAGT ATCAAGACAC GAAAAACGAT 600

GAGGATCTCA CTAAAAAATT AAAGGCTTAC ATCAAGTATA AAACCAACCT TTCTAAGAGC 660

AAGTCCAGCT AG 672

(2) INFORMATION FOR SEQ ID NO: 46:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 351 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 351

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

TTGATGAAAT CTAAAATCAC TCATTTTATC GTTATCTCTT TTGTTTTAAG CGTGTTGAGC 60

GCCTGCAAAG ATGAGCCTAA AAAATCGTCC CAATCGCACC AAAACAACAC TAAAACCACT 120

CAAAACAATC AAATCAATCA ACCTAATAAG GATATAAAAA AGATTGAGCA TGAAGAAGAA 180

GATGAAAAAG TCACCAAAGA AGTGAATGAT CTGATCAATA ACGAAAATAA AATTGATGAA 240

ATCAATAATG AAGAAAACGC TGATCCTTCG CAAAAAAGAA CGAACAATGT TTTGCAACGA 300

GCCACTAACC ACCAAGACAA TCTCAGTTCC CCACTCAACA GGAAGTATTA A 351

(2) INFORMATION FOR SEQ ID NO: 47:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 240 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 240

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

ATGTTTGAAA AAATACGCAA GATTTTAGCG GATATTGAAG ATTCGCAAAA TGAAATTGAA 60

ATGCTTTTAA AATTAGCGAA TTTGAGTTTG GGGGATTTTA TTGAGATTAA AAGAGGGAGC 120

ATGGACATGC CAAAGGGCGT GAATGAAGCG TTTTTTACGC AATTAAGCGA AGAAGTGGAG 180

CGCCTAAAGG AGCTTATCAA CGCTTTGAAT AAAATCAAAA AAGGGTTATT GGTGTTTTAA 240

(2) INFORMATION FOR SEQ ID NO: 48:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 156 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 156

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

ATGTCTATGT TCATTTCTAA TCTGGCTTTC ACGAGCGAAC ATAAGGACGC TATGGAAGTG 60

GCAAAAATTG CGATTTTACT CGGATCTTTG ATTTCTGGGA TCATAGGGGC TTTATATTTA 120

TTCGCACTAG ATAAAAGAGC GGCTTTAAAG AAATAG 156

(2) INFORMATION FOR SEQ ID NO: 49:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1350 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 1350

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

ATGGGTTTGA AAATAAAAAT TTTAAGGTTG TCTATGAATC TCAAAAAAAC AGAAAACGCG 60

CTCAGTTTGA CGCTTAAAAA CTTCATTAAA AGCGAGTCTT TTGGAGGGAT TTTCCTCTTT 120

TTGAACGCCG TTTTAGCGAT GGTGGTGGCT AATTCGTTTT TAAAAGAAAG TTATTTTGCG 180

CTATGGCACA CCCCTTTTGG GTTTCAAGTA GGGGATTTTT TTATCGGCTT TAGTTTGCAC 240

AACTGGATTG ATGATGTCTT AATGGCGTTA TTCTTTTTAA TGATAGGCTT AGAGATCAAG 300

CGAGAATTGT TGTTTGGGGA ATTATCCAGT TTTAAAAAAG CTTCTTTCCC TGTGATCGCA 360

GCCATAGGGG GCATGATAGC TCCAGGATTG ATTTATTTTT TTCTTAACGC CAACACGCCC 420

TCTCAGCATG GTTTTGGGAT CCCTATGGCA ACGGATATTG CGTTCGCTTT AGGCGTGATC 480

ATGCTTTTAG GCAAGAGGGT GCCAACCGCC TTAAAGGTTT TTTTAATCAC TCTAGCGGTG 540

GCTGATGACT TAGGGGCTAT TGTGGTGATC GCGCTCTTTT ATACCACGAA TTTAAAATTC 600

GCATGGCTTT TAGGGGCTTT AGGGGTGGTT CTTGTTTTAG CCATATTGAA CCGCCTGAAT 660

ATCCGATCGC TCATCCCTTA CTTGCTTTTA GGGGTGTTGC TTTGGTTTTG CGTGCATCAA 720

AGCGGTATCC ATGCGACGAT CGCTGCGGTG GTTCTAGCTT TTATGATACC GGTGAAAATC 780

CCTAAAGATT CTAAAAATGT AGAGCTTTTG GAATTAGGCA AACGATACGC AGAGACGAGT 840

TCAGGAGTGC TTTTAACCAA AGAGCAGCAA GAAATCTTGC ATTCTATTGA AGAAAAAGCG 900

AGTGCTTTAC AAAGCCCCTT AGAAAGATTG GAGCATTTTC TAGCCCCCAT CAGCGGGTAT 960

TTCATCATGC CCTTATTCGC GTTTGCAAAC GCTGGGGTGA GCGTTGATTC TAGCATCAAT 1020

TTAGAAGTGG ATAAGGTGCT TTTAGGGGTT ATTTTAGGGC TTTGTTTGGG CAAGCCTTTA 1080

GGGATTTTCT TAATCACTTT CATAAGCGAA AAGCTTAAAA TCACTGCGCG CCCTAAAGGC 1140

ATCGGCTGGT GGCATATTTT AGGGGCTGGG CTTTTAGCAG GGATTGGCTT TACCATGTCT 1200

ATGTTCATTT CTAATCTGGC TTTCACGAGC GAACATAAGG ACGCTATGGA AGTGGCAAAA 1260

ATTGCGATTT TACTCGGATC TTTGATTTCT GGGATCATAG GGGCTTTATA TTTATTCGCA 1320

CTAGATAAAA GAGCGGCTTT AAAGAAATAG 1350

(2) INFORMATION FOR SEQ ID NO: 50:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2448 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 2448

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:

ATGAATGACA AGCGTTTTAG AAAATATTGT AGTTTTTCTA TTTTTTTGTC CTTATTAGGA 60

ACGTTTGAAT TAGAGGCTAA AGAAGAAGAA AAAGAAGAAA AAAAGACAGA AAGGAACAAA 120

GATAAAGAAA AGAACGCCCA ACACACTTTG GGTAAAGTTA CCACTCAAGC GGCTAAAATC 180

TTTAATTACA ACAACCAGAC AACCATTTCA AGTAAAGAAT TAGAAAGAAG GCAAGCCAAC 240

CAAATCAGCG ACATGTTTAG AAGAAACCCC AATATCAATG TGGGCGGTGG TGCGGTGATA 300

GCGCAAAAAA TTTACGTGCG CGGTATTGAA GACAGATTGG CTAGGGTTAC GGTGGATGGC 360

GTGGCGCAAA TGGGCGCAAG CTATGGGCAT CAAGGCAATA CAATCATTGA CCCTGGAATG 420

CTCAAAAGCG TGGTGGTTAC CAAGGGGGCG GCTCAAGCGA GCGCGGGGCC TATGGCTTTA 480

ATTGGCGCGA TCAAAATGGA GACTAGGAGC GCGAGCGATT TTATCCCTAA AGGCAAAGAC 540

TACGCCATAA GTGGGGCTGC CACTTTTTTA ACCAACTTTG GGGATAGGGA AACCATTATG 600

GGCGCTTATC GTAACCATCA TTTTGATGCG CTTTTGTATT ACACGCACCA AAATATTTTT 660

TATTATCGTG ATGGGGATAA CGCGATGAAA AATCTTTTTG ACCCTAAAGC GGATAATAAA 720

GTTACAGCAA GCCCTAGCGA ACAAAACAAT GTGATGGCTA AGATCAATGG TTATTTGAGC 780

GAAAGGGATA CCTTAACGCT CAGTTATAAC ATGACTAGAG ATAACGCCAA TCGCCCTTTA 840

AGAGCGAATT TTACCGGCAC TTTTTTACCC TATTCTTGTG GTGATTTCAA CGCTTTCCCT 900

AACGAGAAAA ACCCTAGCGA TTGTTTGTTT GAAAATGACG CCAGTTTGTT TAAAACTTAT 960

AGCGTCAATT TAGTGCATAA CGTGAGCTTG AATTATGAAA GGGAAGGGGG GAGTCGCTTT 1020

GGCGATCCTA AATTAAAAAT CAATGGCTAC ACGAGCATTA GGAATGTCCA AATTGATCCG 1080

CTTTTCAGAC CTAGCGATAT AGCGACTACC ATTCCTTTCA CCCCAAACCC GCAGCTCTCT 1140

CAAGGCGAAG AAAATCAATG CGTGGCGCAA GGGGGCATTT ATGACGCTCT TAAACAAACT 1200

TGCTCCATCA CTTTTAAAAG CCTTGGAGGG GGTTCTGTTG TCGCTAATAA AAATTTATTC 1260

ATCATCAATT CTGGGTTTAA TGCGAACGTG ATCCACACCA TAGACCACAA GAATGACAAT 1320

CTTTTGGAAT ACGGGTTGAA TTACCAGAAT TTAACCACTT TTGATAAAGC GATCCCTGAT 1380

AGCGAATTAG TCAAGCCCGG CGATGCCCCT GATGCGTGCT TAAGAGTTAC AGGACCTGAT 1440

GATCCTAACA TGAACGGGCG CTGCCAACGG AATGGCGCTA CGGCGAATGT GGTTGGGGTG 1500

TATGCGCAAG CGAATTACAC CTTGCACCCT ATGGTAACTT TAGGGGCAGG GACTCGTTAT 1560

GACGTTTATA CTTTAGTGGA TAAAGACTGG CAATTGCACG TAACTCAAGG GTTTAGCCCT 1620

AGCGCGGCTT TAAACGTCTC GCCTTTAGAA AATTTGAATT TCAGGCTTTC TTACGCGTAT 1680

GTAACTAGAG GCCCTATGCC TGGAGGTTTG GTGTGGATGC GTCAAGACAA TTTGCGCTAT 1740

AACCGCAATT TAAAGCCAGA AATTGGGCAA AATGCGGAAT TTAACACCGA ATACAGCAGT 1800

CAGTATTTTG ATTTCAGAGC CGCCGGTTTT GTCCAATTGA TTTCTAATTA CATCAATCAA 1860

TTTTCTTCAA CGCTTTTTGT CACCAACTTG CCCGCACAAG ATATTATTTA TGTGCCTGGC 1920

TATGAAGTTT CAGGGACGGC TAAATACAAG GGTTTTTCTT TAGGCTTGAG CGTGGCGCGA 1980

TCATGGCCTT CTTTAAAAGG GCGTTTGATC GCTGACGTGT ATGAATTGGC GGCTACGACA 2040

GGCAATGTGT TTATTTTAAC GGCAAGCTAT ACAATCCCAC GCACCGGCCT TAGCATCACT 2100

TGGCTTTCAC GCTTTGTTAC TAATTTGAGT TATTGCTCTT ATAGCCCTTA TCGTAACGGC 2160

CCTACGGATA TTGACAGAAG GCCTAGTAAT TGCCCTAAAA CGCCCGGGAT TTTTCATGTG 2220

CATAAACCCG GCTATGGGGT GAGCAGTTTC TTTATCACTT ACAAGCCTAC TTATAAGAAA 2280

CTCAAAGGGT TGAGCCTGAA CGCGGTGTTT AATAATGTTT TTAACCAACA ATATATTGAT 2340

CAAGCAAGCC CGGTGATGAG CCCTGATGAA CCCAATCAAG ACAAATACGC AAGGGGCATG 2400

GCAGAGCCTG GCTTTAACGC TAGGTTTGAA ATTTCTTATA AGTTTTAA 2448

(2) INFORMATION FOR SEQ ID NO: 51:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2445 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 2445

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:

ATGACAAGCG TTTTAGAAAA ATATTGTAGT TTTTCTATTT TTTTGTCCTT ATTAGGAACG 60

TTTGAATTAG AGGCTAAAGA AGAAGAAAAA GAAGAAAAAA AGACAGAAAG GAACAAAGAT 120

AAAGAAAAGA ACGCCCAACA CACTTTGGGT AAAGTTACCA CTCAAGCGGC TAAAATCTTT 180

AATTACAACA ACCAGACAAC CATTTCAAGT AAAGAATTAG AAAGAAGGCA AGCCAACCAA 240

ATCAGCGACA TGTTTAGAAG AAACCCCAAT ATCAATGTGG GCGGTGGTGC GGTGATAGCG 300

CAAAAAATTT ACGTGCGCGG TATTGAAGAC AGATTGGCTA GGGTTACGGT GGATGGCGTG 360

GCGCAAATGG GCGCAAGCTA TGGGCATCAA GGCAATACAA TCATTGACCC TGGAATGCTC 420

AAAAGCGTGG TGGTTACCAA GGGGGCGGCT CAAGCGAGCG CGGGGCCTAT GGCTTTAATT 480

GGCGCGATCA AAATGGAGAC TAGGAGCGCG AGCGATTTTA TCCCTAAAGG CAAAGACTAC 540

GCCATAAGTG GGGCTGCCAC TTTTTTAACC AACTTTGGGG ATAGGGAAAC CATTATGGGC 600

GCTTATCGTA ACCATCATTT TGATGCGCTT TTGTATTACA CGCACCAAAA TATTTTTTAT 660

TATCGTGATG GGGATAACGC GATGAAAAAT CTTTTTGACC CTAAAGCGGA TAATAAAGTT 720

ACAGCAAGCC CTAGCGAACA AAACAATGTG ATGGCTAAGA TCAATGGTTA TTTGAGCGAA 780

AGGGATACCT TAACGCTCAG TTATAACATG ACTAGAGATA ACGCCAATCG CCCTTTAAGA 840

GCGAATTTTA CCGGCACTTT TTTACCCTAT TCTTGTGGTG ATTTCAACGC TTTCCCTAAC 900

GAGAAAAACC CTAGCGATTG TTTGTTTGAA AATGACGCCA GTTTGTTTAA AACTTATAGC 960

GTCAATTTAG TGCATAACGT GAGCTTGAAT TATGAAAGGG AAGGGGGGAG TCGCTTTGGC 1020

GATCCTAAAT TAAAAATCAA TGGCTACACG AGCATTAGGA ATGTCCAAAT TGATCCGCTT 1080

TTCAGACCTA GCGATATAGC GACTACCATT CCTTTCACCC CAAACCCGCA GCTCTCTCAA 1140

GGCGAAGAAA ATCAATGCGT GGCGCAAGGG GGCATTTATG ACGCTCTTAA ACAAACTTGC 1200

TCCATCACTT TTAAAAGCCT TGGAGGGGGT TCTGTTGTCG CTAATAAAAA TTTATTCATC 1260

ATCAATTCTG GGTTTAATGC GAACGTGATC CACACCATAG ACCACAAGAA TGACAATCTT 1320

TTGGAATACG GGTTGAATTA CCAGAATTTA ACCACTTTTG ATAAAGCGAT CCCTGATAGC 1380

GAATTAGTCA AGCCCGGCGA TGCCCCTGAT GCGTGCTTAA GAGTTACAGG ACCTGATGAT 1440

CCTAACATGA ACGGGCGCTG CCAACGGAAT GGCGCTACGG CGAATGTGGT TGGGGTGTAT 1500

GCGCAAGCGA ATTACACCTT GCACCCTATG GTAACTTTAG GGGCAGGGAC TCGTTATGAC 1560

GTTTATACTT TAGTGGATAA AGACTGGCAA TTGCACGTAA CTCAAGGGTT TAGCCCTAGC 1620

GCGGCTTTAA ACGTCTCGCC TTTAGAAAAT TTGAATTTCA GGCTTTCTTA CGCGTATGTA 1680

ACTAGAGGCC CTATGCCTGG AGGTTTGGTG TGGATGCGTC AAGACAATTT GCGCTATAAC 1740

CGCAATTTAA AGCCAGAAAT TGGGCAAAAT GCGGAATTTA ACACCGAATA CAGCAGTCAG 1800

TATTTTGATT TCAGAGCCGC CGGTTTTGTC CAATTGATTT CTAATTACAT CAATCAATTT 1860

TCTTCAACGC TTTTTGTCAC CAACTTGCCC GCACAAGATA TTATTTATGT GCCTGGCTAT 1920

GAAGTTTCAG GGACGGCTAA ATACAAGGGT TTTTCTTTAG GCTTGAGCGT GGCGCGATCA 1980

TGGCCTTCTT TAAAAGGGCG TTTGATCGCT GACGTGTATG AATTGGCGGC TACGACAGGC 2040

AATGTGTTTA TTTTAACGGC AAGCTATACA ATCCCACGCA CCGGCCTTAG CATCACTTGG 2100

CTTTCACGCT TTGTTACTAA TTTGAGTTAT TGCTCTTATA GCCCTTATCG TAACGGCCCT 2160

ACGGATATTG ACAGAAGGCC TAGTAATTGC CCTAAAACGC CCGGGATTTT TCATGTGCAT 2220

AAACCCGGCT ATGGGGTGAG CAGTTTCTTT ATCACTTACA AGCCTACTTA TAAGAAACTC 2280

AAAGGGTTGA GCCTGAACGC GGTGTTTAAT AATGTTTTTA ACCAACAATA TATTGATCAA 2340

GCAAGCCCGG TGATGAGCCC TGATGAACCC AATCAAGACA AATACGCAAG GGGCATGGCA 2400

GAGCCTGGCT TTAACGCTAG GTTTGAAATT TCTTATAAGT TTTAA 2445

(2) INFORMATION FOR SEQ ID NO: 52:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1584 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 1584

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:

ATGAAACAAA ATTTAAAGCC ATTCAAAATG ATTAAGGAAA ATTTAATGAC ACAATCTCAA 60

AAAGTAAGAT TCTTAGCCCC TTTGAGCCTA GCGTTAAGCT TGAGCTTCAA TCCAGTGGGC 120

GCTGAAGAAG ATGGGGGCTT TATGACCTTT GGGTATGAAT TAGGTCAGGT GGTCCAGCAA 180

GTGAAAAACC CGGGTAAAAT CAAAGCCGAA GAATTAGCGG GCCTGTTAAA CTCTACCACG 240

ACAAACAACA CCAATATCAA TATTGCAGGC ACAGGAGGGA ATGTCGCCGG GACTTTGGGC 300

AACCTTTTTA TGAACCAATT GGGCAATTTG ATTGATTTGT ATCCTACTTT GAAAACTAAT 360

AATCTTCACC AATGCGGTAG CACTAATAGC GGTAATGGCG CTACTGCTGC CGCTGCTACT 420

AACAATAGCC CTTGTTTCCA AGGTAACCTG GCTCTTTATA ACGAAATGGT TGACTCTATC 480

AAAACTTTGA GTCAAAACAT CAGCAAGAAC ATCTTTCAAG GCGACAACAA CACCACGAGC 540

GCTAATCTCT CCAACCAGCT CAGTGAGTTG AACACCGCTA GCGTTTATTT GACTTACATG 600

AACTCGTTCT TAAACGCCAA CAACCAAGCG GGTGGGATTT TTCAAAACAA CACCAATCAA 660

GCTTACGAGA ATGGTGTTAC CGCTCAACAA ATCGCTTATG TCCTAAAGCA AGCTTCAATC 720

ACTATGGGGC CAAGCGGTGA TAGTGGGGCT GCGGGAGCGT TTTTAGACGC CGCTTTAGCC 780

CAACATGTTT TCAACTCGGC TAACGCTGGG AACGATTTGA GCGCTAAGGA ATTCACTAGC 840

TTGGTGCAAA ACATCGTCAA TAATTCTCAA AACGCTTTAA CGCTAGCCAA CAACGCTAAC 900

ATCAGCAATT CAACAGGCTA TCAAGTGAGC TATGGTGGGA ATATTGATCA AGCGCGCTCT 960

ACCCAACTGT TAAACAACAC CACAAACACT TTGGCTAAAG TTACCGCTCT AAACAACGAG 1020

CTTAAAGCTA ACCCATGGCT TGGGAATTTC GCTGCTGGTA ACAGCTCTCA AGTGAATGCG 1080

TTTAACGGGT TTATCACTAA AATCGGTTAT AAGCAATTCT TCGGGGAAAA CAAGAATGTG 1140

GGCTTACGCT ACTACGGGTT CTTCAGCTAT AACGGCGCGG GCGTGGGTAA TGGCCCCACT 1200

TACAATCAAG TCAATCTGCT CACTTATGGG GTGGGGACTG ATGTGCTTTA CAATGTGTTT 1260

AGCCGCTCTT TTGGCAGTAG GAGTCTTAAT GCGGGCTTCT TTGGGGGGAT CCAACTCGCA 1320

GGGGACACTT ACATCAGCAC GCTAAGAAAC AGCCCTCAGC TTGCGAGCAG ACCTACAGCG 1380

ACAAAATTCC AATTCTTGTT TGATGTGGGC TTACGCATGA ACTTTGGTAT CTTGAAAAAA 1440

GACCTAAAAA GCCATAACCA GCATTCTATA GAAATCGGTG TGCAAATCCC TACGATTTAC 1500

AACACTTACT ATAAAGCTGG TGGCGCTGAA GTGAAATACT TCCGCCCTTA TAGCGTGTAT 1560

TGGGTCTATG GCTACGCCTT CTAA 1584

(2) INFORMATION FOR SEQ ID NO: 53:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1380 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 1380

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:

GTGGTGTTAT TAACAATGAC AAAACGACTT TTTAAAGGGT TGTTAGCGAT TTCTCTTGCG 60

GTGAGTTTGC ATGGTGGTGA AGTTAAGGAA AAAAAGCCGG TCAAGCCGGT CAAAGAAGAT 120

CCGCAAGAAT TAGCGGCTAA AAGGGTGGAA GCGTTCAGTC GTTTCTCTAA TGTGGTTACA 180

GAAATTGAAA AAAAGTATGT GGATAAGATC AGTATTTCTG AGATCATGAC TAAAGCGATT 240

GAAGGCTTAC TCTCTAATTT GGACGCGCAT TCAGCGTATT TGAATGAAAA GAAGTTTAAG 300

GAATTTCAGG CCCAAACCGA GGGCGAATTT GGGGGGCTTG GGATCACGGT GGGCATGCGC 360

GATGGCGTTT TGACCGTTAT TGCACCTTTA GAGGGCACTC CAGCTTACAA GGCTGGGGTT 420

AAATCAGGCG ATAGCATTTT AAAAATCAAT AACGAAAGCA CGCTGAGCAT GAGCATTGAT 480

GATGCGGTTA ATCTCATGCG CGGCAAGCCA AAAACCTCTA TTCAGATCAC TGTTGTTAGG 540

AAAAATGAGC CAAAACCCTT GGTATTTAAT ATCGTTAGGG ATATTATCAA GATCCCCTCT 600

GTCTATGTGA AAAAGATTAA AGACACACCT TATTTGTACG TGAGAGTCAA TTCTTTTGAT 660

AAAAATGTTA CCAAATCGGT TTTAGACGGC TTGAAGGCTA ACCCTAACAT TAAGGGCGTT 720

GTGTTGGATT TGAGGGGGAA TCCTGGAGGG CTATTAAACC AGGCGGTAGG CTTGTCTAAC 780

CTTTTCATTA AAGAGGGGGT TTTAGTCTCT CAAAGAGGCA AAAATAAGGA GGAAAACTTA 840

GAATACAAGG CTAATGGCAG AGCCCCTTAT ACCAATTTAC CTGTTGTGGT GTTAGTCAAT 900

GGCGGTTCAG CGAGCGCGAG CGAGATCGTC GCAGGGGCAC TGCAAGATCA CAAGCGAGCC 960

ATCATTATCG GTGAAAAAAC CTTTGGTAAG GGAAGCGTGC AAGTGTTGCT CCCTGTCAAT 1020

AAAGACGAAG CCATTAAAAT CACGACCGCG CGCTATTATT TGCCGAGCGG GCGCACCATT 1080

CAAGCTAAGG GGATCACGCC TGATATTGTG ATTTATCCGG GTAAAGTGCC AGAAAATGAA 1140

AATAAATTCA GTTTGAAAGA AGCGGATTTA AAACACCATT TAGAGCAAGA GCTTAAAAAA 1200

CTTGATGATA AAACCCCTAT TTCCAAAGAG GCGGATAAAG ACAAGAAAAG CGAAGAGGAA 1260

AAAGAGGTTA CTCCTAAAAT GATCAATGAT GATATTCAGC TAAAAACCGC TATTGACAGC 1320

TTGAAAACCT GGTCTATCGT AGATGAGAAA ATGGATGAAA AAGTGCCTAA GAAGAAATAA 1380

(2) INFORMATION FOR SEQ ID NO: 54:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 315 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 315

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:

TTGCTTTTGC ACCCCTTGCA TGCTCATGCA CAAGTGCTTG GCTTCACAAA CCACGATCAC 60

GCCCCTTGGC TCTATGATTT CATCAAAAGT TTCTGCAATT TGAGTGGTCA GCCTTTCTTG 120

GATTTGCAGG CGTTTGCTAT AAATTTCAAT GAGTTTAGCG ATCGCGCTAA TGCCTACAAT 180

CTTTTCCTTA GGGATATATC CCACGCTAAT ATTCCCAAAA AAAGGGAGCA AATGGTGCTC 240

GCAAGTGGAG TAAAATTCAA TGTTTTGAGC CACTATCATT TCATCGCAAA CGCCTTGAAA 300

ATACGCGCTT TTTAA 315

(2) INFORMATION FOR SEQ ID NO: 55:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 498 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 498

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55:

ATGATTGAAC TAATCTTACA CAATAAGTCC ATACAAATTG ATGAAACATT GCTGAATGTA 60

AAAGAGCATT TAGAAAAGTT TTATTCAAAC AAAGAACAAG AGACAATCGC AAAAACCTTA 120

GAGAGCCAAA CAGAGCTTAC TTGCAGTTAT TTATTGGATA AAGATTTTTC ATTGCTAGAA 180

AAGCATTTAG AAAATAGCTT AGGGCATTTT ACTTTTGAGA GTGAGTTTGC CCTACTAAAA 240

GACAAAGAGC CTTTGAATTT AGCTCAAATC AAACAAATCG GTGTTTTAAA GGTTATTACC 300

TATGAAATGA CACAAGCCTT AAAAAATCAA ATCATTCATT TAACGCAAAT TGTCAATGAA 360

GAAAATTTAG AGTTTGATGA AGAACTTGTT ATTTATCACT TAAATTTTAA GCTCAATCAA 420

AATACTTACA AAGTGTTAGC GAAATTTTGC GTATTAAAAA AGAAAGGAAC ATTGCATGAA 480

AAATTTAAGG CATTTTAG 498

(2) INFORMATION FOR SEQ ID NO: 56:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 642 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 642

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56:

ATGGATACCG AAACACAAGA AAAGTTTTTA GCGTATTTGT TTGAAAAAGC TTTACAAAAA 60

AATCTACAAG CTTATTGGAT AACAACAACT GAAACTAAGA ATGAATTAAC AAGAGAAGAG 120

TTTTCAAATT TAATAAGAAA AACAATGATT GAACTAATCT TACACAATAA GTCCATACAA 180

ATTGATGAAA CATTGCTGAA TGTAAAAGAG CATTTAGAAA AGTTTTATTC AAACAAAGAA 240

CAAGAGACAA TCGCAAAAAC CTTAGAGAGC CAAACAGAGC TTACTTGCAG TTATTTATTG 300

GATAAAGATT TTTCATTGCT AGAAAAGCAT TTAGAAAATA GCTTAGGGCA TTTTACTTTT 360

GAGAGTGAGT TTGCCCTACT AAAAGACAAA GAGCCTTTGA ATTTAGCTCA AATCAAACAA 420

ATCGGTGTTT TAAAGGTTAT TACCTATGAA ATGACACAAG CCTTAAAAAA TCAAATCATT 480

CATTTAACGC AAATTGTCAA TGAAGAAAAT TTAGAGTTTG ATGAAGAACT TGTTATTTAT 540

CACTTAAATT TTAAGCTCAA TCAAAATACT TACAAAGTGT TAGCGAAATT TTGCGTATTA 600

AAAAAGAAAG GAACATTGCA TGAAAAATTT AAGGCATTTT AG 642

(2) INFORMATION FOR SEQ ID NO: 57:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 762 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 762

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57:

ATGGCGATCT CTATTAAAAG CCCAAAAGAA ATCAAAGCCC TAAGAAAAGC CGGGGAATTA 60

ACCGCTCAAG CGTTAGCCCT TTTAGAGCGA GAAGTAAGGC CTGGGGTTTC ACTTTTAGAG 120

CTGGATAAAA TGGCTGAAGA TTTTATCAAA TCCTCGCATG CTAGGCCTGC TTTTAAGGGG 180

CTCTATGGTT TCCCTAACTC TGTGTGCATG TCCTTAAATG AGGTGGTTAT TCATGGTATT 240

CCTACGGATT ATGTTTTACA AGAAGGGGAT ATTATAGGCT TGGATTTGGG GGTGGAGGTG 300

GATGGCTATT ATGGCGATTC AGCCCTCACG CTTCCCATAG GCGCGATAAG CCCGCAAGAT 360

GAAAAATTGC TCGCTTGCTC TAAAGAGAGC TTGATGCATG CCATTAGCTC AATTAGAGTG 420

GGCATGCATT TTAAAGAGTT GAGTCAGATT TTAGAGGGCG CTATTACAGA AAGGGGCTTT 480

GTGCCTTTGA AGGGATTTTG CGGGCATGGC ATTGGTAAAA AGCCCCATGA AGAGCCAGAA 540

ATCCCCAACT ACCTAGAAAA AGGCGTCAAA GCTAATAGCG GCCCTAAAAT CAAAGAGGGC 600

ATGGTGTTTT GTTTAGAGCC TATGGTGTGT CAAAAACAAG GCGAGCCTAA AATACTAGCG 660

GATAAGTGGA GCGTGGTTTC AGTGGATGGA CTTAACACAA GCCACCATGA GCATACTATC 720

GCCATAGTTG GCAATAAAGC AGTGATTCTT ACGGAGCGTT AA 762

(2) INFORMATION FOR SEQ ID NO: 58:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 744 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 744

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:

AAGCCCAAAA GAAATCAAAG CCCTAAGAAA AGCCGGGAAT TAACCGCTCA AGCGTTAGCC 60

CTTTTAGAGC GAGAAGTAAG GCCTGGGGTT TCACTTTTAG AGCTGGATAA AATGGCTGAA 120

GATTTTATCA AATCCTCGCA TGCTAGGCCT GCTTTTAAGG GGCTCTATGG TTTCCCTAAC 180

TCTGTGTGCA TGTCCTTAAA TGAGGTGGTT ATTCATGGTA TTCCTACGGA TTATGTTTTA 240

CAAGAAGGGG ATATTATAGG CTTGGATTTG GGGGTGGAGG TGGATGGCTA TTATGGCGAT 300

TCAGCCCTCA CGCTTCCCAT AGGCGCGATA AGCCCGCAAG ATGAAAAATT GCTCGCTTGC 360

TCTAAAGAGA GCTTGATGCA TGCCATTAGC TCAATTAGAG TGGGCATGCA TTTTAAAGAG 420

TTGAGTCAGA TTTTAGAGGG CGCTATTACA GAAAGGGGCT TTGTGCCTTT GAAGGGATTT 480

TGCGGGCATG GCATTGGTAA AAAGCCCCAT GAAGAGCCAG AAATCCCCAA CTACCTAGAA 540

AAAGGCGTCA AAGCTAATAG CGGCCCTAAA ATCAAAGAGG GCATGGTGTT TTGTTTAGAG 600

CCTATGGTGT GTCAAAAACA AGGCGAGCCT AAAATACTAG CGGATAAGTG GAGCGTGGTT 660

TCAGTGGATG GACTTAACAC AAGCCACCAT GAGCATACTA TCGCCATAGT TGGCAATAAA 720

GCAGTGATTC TTACGGAGCG TTAA 744

(2) INFORMATION FOR SEQ ID NO: 59:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1023 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 1023

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59:

ATGTATCGTA AAGATTTGGA TAATTACTTA AAACAGCGCC TCCCTAAAGC GGTGTTTTTG 60

TATGGGGAGT TTGATTTTTT CATCCATTAT TATATTCAAA CGATTAGCGC GCTTTTTAAA 120

GGCAATAACC CTGACACAGA AACTTCGCTT TTTTATGCGA GCGATTATGA AAAAAGCCAG 180

ATTGCGACCC TTTTAGAGCA GGATTCTTTA TTTGGAGGGA GCAGTTTAGT TATTTTAAAA 240

CTGGATTTTG CATTGCATAA GAAATTTAAG GAAAATGATA TCAATCCTTT TTTAAAAGCT 300

TTAGAGCGGC CTAGCCATAA TAGGCTTATC ATAGGGCTTT ATAATGCTAA AAGCGACACC 360

ACAAAATACA AATACACTAG CGAAATTATC GTTAAATTTT TCCAAAAAAG CCCCTTGAAA 420

GATGAAGCCA TTTGCGTGCG CTTTTTTACC CCTAAAGCGT GGGAGAGTTT GAAATTCTTG 480

CAAGAAAGGG CTAATTTTTT GCATTTAGAC ATCAGCGGCC ATCTTTTAAA CGCTCTTTTT 540

GAAATTAATA ACGAAGATTT AAGCGTTTCG TTTAACGATT TAGACAAGCT AGCGGTTTTA 600

AACGCGCCCA TCACTTTAGA AGACATTCAA GAATTAAGCT CCAATGCGGG GGATATGGAT 660

TTGCAAAAGC TCATTTTAGG GCTTTTTTTG AAAAAAAGCG TCCTTGATAT TTATGATTAT 720

TTGTTAAAAG AGGGCAAAAA GGATGCGGAT ATTTTAAGGG GGTTAGAGCG CTATTTTTAC 780

CAGCTTTTTT TATTTTTCGC CCACATTAAA ACGACCGGTT TAATGGACGC TAAAGAGGTC 840

TTAGGCTACG CTCCTCCTAA AGAGATTGTA GAAAATTACG CTAAAAACGC CCTGCGTTTG 900

AAAGAAGCCG GCTATAAGAG GGTTTTTGAA ATTTTTAGGT TATGGCACCT TCAAAGCATG 960

CAAGGGCAAA AGGAATTGGG CTTTTTGTAT TTGACCCCCA TTCAAAAAAT CATTAACCCT 1020

TGA 1023

(2) INFORMATION FOR SEQ ID NO: 60:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 603 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 603

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60:

GTGTTTATGA CAAGCGCTCT GTTAGGCTTA CAAATTGTTT TAGCGGTATT GATTGTGGTG 60

GTGGTTTTGT TGCAAAAAAG TTCTAGCATC GGCTTAGGGG CTTATAGCGG AAGCAACGAT 120

TCTTTATTTG GCGCTAAAGG GCCCGCAAGC TTTATGGCGA AATTGACCAT GTTTTTAGGT 180

TTATTGTTTG TCATCAACAC CATCGCTTTG GGCTATTTTT ACAACAAAGA ATACGGCAAG 240

AGCGTTTTAG ATGAAACTAA AACCAATAAA GAGCTTTCGC CCTTAGTCCC TGCCACCGGC 300

ACGCTCAACC CTACGCTTAA TCCCACATTA AACCCAACGC TCAACCCTTT AGAGCAAGCC 360

CCCACTAATC CTTTAATGCC TACACAAACG CCTAAAGAGC TTCCTAAAGA GCCAGCCAAA 420

ACGCCTTTTG TTGAAAGCCC CAAACAGAAT GAAAAGAATG AAAAGAATGA TGCCAAAGAA 480

AATGGTATAA AGGGTGTTGA AAAAAACAAA GAGAACGCCA AAACGCCCCC AACCACCCAC 540

CAAAAGCCTA AAACGCATGC GACAACCAAC GCCCATACCA ACCAAAAAAA GGATGAAAAA 600

TAA 603

(2) INFORMATION FOR SEQ ID NO: 61:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 480 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 480

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61:

ATGCGTTCTC CAAATTTAGA AAAAGAAGAA ACTGAAATCA TAGAAACGCT TCTTGTGCGT 60

GAAAAAATGC GTTTATGCCC CTTGTATTGG CGCATCTTAG CGTTTTTAAT CGATAGTTTA 120

TTGGTGGCGT TTTTATTGAG CGATCTTTTA AGGGCATGCG CTTTTTTACA TTCTTTATAT 180

TGGCTGACTA ACCCCATTTA TTACAGCGCG TTTGTTGTGA TGGGTTTTAT CATCTTGTAT 240

GGCGTTTATG AAATCTTTTT TGTGTGTTTG TGCAAGATGA GTTTGGCTAA ACTGGTTTTT 300

AGGATTAAGA TCATTGATAT TTATTTAGCG GATTGCCCCA GTAGGGCTAT TTTATTGAAG 360

CGTTTAGGGT TAAAAATCGT GGTTTTTCTA TGCCCCTTTT TATGGTTTGT GGTGTTTAAA 420

AACCCCTATC ATAGGGCATG GCATGAAGAA AAAAGCAAAA GTCTTTTGGT GTTGTTTTAA 480

(2) INFORMATION FOR SEQ ID NO: 62:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 705 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 705

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62:

TTGAATACGG ACTTTAGCCA TATCACCGAT ATTGAGGGCA TGCGTTTTGT TAATGAAGAA 60

GACGCTTTAA ACAAATTGAT TAATGAAATC CACACGCGCC ACATTGATTT AAAAGATTCC 120

ATCATGCTCG CTTTGAGTTT TAACGCCTTG TATTTAGCTA ACGCTTTAGC GCAAAAATTT 180

GGGGCGACTT ATGATATACT TTTTTTAGAA CCTATCTTAG CCCCTTTAAA CTCAAAGTGT 240

GAAATCGCTT TAGTGAGTGA AAGCATGGAT ATAGTGATGA ATGAAAGTTT AATCAATTCC 300

TTTGACATCG CTTTAGACTA TGTTTATGGG GAAGCCAAGC GGGCTTATGA AGAAGACATT 360

CTGTCTCACA TCTATCAGTA TCGCAAAGGC AATGCGATCA AAAGCCTAAA AGATAAAAAT 420

ATTTTTATCG TAGATAGGGG GATTGAGACC GGGTTTAGAG CAGGGTTAGG CGTGCAAACT 480

TGTTTGAAAA AAGAATGCCA AGACATTTAT ATTTTAACCC CCATTCTCGC GCAAAATGTC 540

GCTCAAGGCT TAGAAAGCTT GTGCGATGGG GTGATTAGCG TGTATCGCCC TGAATGTTTT 600

GTCTCTGTGG AACACCATTA TAAAGAACTC AAGCGATTAA GCAATGAAGA AATTGAAAAA 660

TACTTGGGCG CTAACAACGC GCCCAATCTC AAAAAGGAAC ATTAA 705

(2) INFORMATION FOR SEQ ID NO: 63:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 864 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 864

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63:

TTGAAACAAA GCGAAATGGC CATGGAATTT AATGATCCTA GGATGCGTTT TTTTATTGGC 60

GATGTCAGGG ATTTAGAACG CTTGAATTAC GCTTTAGAGG GCGTGGATAT TTGTATCCAT 120

GCGGCCGCGC TCAAGCATGT GCCTATCGCT GAATACAACC CCCTAGAATG CATTAAAACT 180

AACATCATGG GAGCGAGCAA TGTGATTAAC GCATGCTTAA AAAATGAAAT CAGCCAGGTT 240

ATTGCCCTAA GCACCGATAA AGCCGCTAAC CCCATTAACC TCTACGGCGC AACCAAATTG 300

TGCAGCGACA AGCTCTTTGT GAGCGCGAAC AACTTTAAAG GCCCTTCTCA AACGCAATTT 360

GGCGTGGTGC GTTATGGTAA TGTGGTGGGG AGTCGTGGGA GCGTGGTGCC GTTTTTTAAA 420

AAATTAGTCC AAAACAAAGC GAGTGAAATC CCCATTACCG ATATTCGCAT GACACGATTT 480

TGGATCACCT TAGATGAGGG GGTTTCTTTT GTGCTTAAAA GCTTGAAAAG AATGCATGGG 540

GGGGAAATTT TTGTGCCTAA AATCCCCAGC ATGAAAATGA TTGATCTCGC CAAAGCCCTA 600

GCCCCCAATA TCCCTACTAA AATCATAGGG ATTCGCCCGG GCGAAAAACT CCATGAAGTG 660

ATGATCCCTA AAGATGAAAG CCATTTAGCC CTAGAATTTG AAGACTTTTT TATTATTCAG 720

CCCACTATAA GCTTCCAAAC GCCTAAAGAT TACACGCTCA CCAAACTCCA TGAAAAAGGC 780

CAAAAAGTCG CCCCTGATTT TGAATACAGC AGCCATACTA ATAACCAATG GCTAGAGCCT 840

GATGATTTGT TAAAATTATT ATGA 864

(2) INFORMATION FOR SEQ ID NO: 64:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 606 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 606

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64:

ATGCGTTTGC ACACTGCCTT TTTTGGTATT AATTCGTTGC TTGTCGCCAC TCTTTTGATA 60

AGCGGTTGCA GTCTCTTTAA AAAGCGTAAC ACTAACGCTC AGCTAATCCC CCCTTCAGCT 120

AACGGGTTGC AAGCCCCCAT TTATCCCCCA ACCAATTTCA CCCCCAGAAA GAGCATTCAG 180

CCTCTCCCAA GCCCTCGCCT TGAGAATAAC GATCAGCCCA TCATTAGCTC TAATCCCACT 240

AACGCTATCC CTAACACCCC CATTCTCACG CCCAATAATG TCATTGAGTT GAATGCGGTG 300

GGCATGGGTG TGGCTCCAGA ATCCACCATT TCGCCCTCTC AAGCTCTAGC TTTAGCTAAG 360

CGAGCGGCTA TTGTTGATGG CTACCGCCAG TTGGGTGAAA AAATGTATGG CATCAGAGTG 420

AACGCTCAAG ACACCGTCAA AGACATGGTT TTACAAAATT CCGTGATTAA AACGAGAGTG 480

AATGCCCTCA TTCGTAACGC TGAAATCACT GAGACTATCT ATAAAGACGG CTTGTGCCAG 540

GTAAGCATGG AGCTTAAATT AGACGGCAGG ATTTGGTATC GTATTTTGAG CGGATCGAGA 600

GGATAA 606

(2) INFORMATION FOR SEQ ID NO: 65:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1068 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 1068

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65:

ATGAGTTATA CTATTAATAA ACGCTTTTCT GTGGGTGTGG GTTTAAGGGG GCTTTATGCG 60

ACCGGGAGCT TTAATAACAC CGTTTATGTG CCTTTAGAGG GCGCTTCAGT TTTGAGCGCG 120

GAGCAAATCT TAAACTTACC CAACAATGTT TTTGCCGATC AAGTGCCAAG TAACATGATG 180

ACTTTATTAG GCAATATTGG CTACCAACCA GCGCTTAATT GCCAAAAAGC CGGTGGGGAC 240

ATGAGTGATC AGAGCTGTCA AGAGTTTTAC AACGGCTTGA AAAAAATCAT GGGTTATAGC 300

GGTTTAATCA AAGCGAGCGC GAATCTTTAT GGCACGACTC AAGTCGTGCA AAAATCTAAC 360

GGACAAGGCG TATCGGGGGG GTATAGAGTG GGTTCGAGTT TGCGTGTGTT TGATCATGGC 420

ATGTTTTCTG TGGTGTATAA TTCTTCAGTT ACCTTTAACA TGAAAGGCGG TTTGGTGGCT 480

ATCACAGAGC TTGGCCCTTC TTTAGGGAGC GTTTTGACTA AAGGCAGCTT GAATATCAAT 540

GTTTCACTCC CCCAAACTTT AAGCTTAGCC TACGCCCACC AATTTTTTAA AGATCGCCTA 600

AGGGTTGAAG GGGTGTTTGA GCGCACTTTT TGGAGTCAAG GGAATAAATT TTTAGTCACC 660

CCTGATTTTG CGAACGCCAC TTACAAGGGC TTGAGCGGGA CGGTGGCTTC CTTGGACTCT 720

GAAACGCTTA AAAAAATGGT AGGCCTAGCG AATTTTAAAA GCGTGATGAA CATGGGGGCT 780

GGCTGGAGGG ACACCAACAC CTTTAGATTA GGGGTAACTT ACATGGGTAA AAGCTTGCGT 840

TTAATGGGCG CTATTGATTA TGATCAAGCC CCAAGCCCCC AAGACGCGAT AGGCATTCCG 900

GACTCTAATG GCTATACCGT GGCTTTTGGG ACTAAATACA ATTTTAGGGG CTTTGATTTG 960

GGCGTAGCGG GGAGTTTCAC TTTTAAGAGC AACCGCTCCA GTTTGTATCA ATCCCCAACT 1020

ATTGGGCAAT TGAGAATCTT TAGCGCCTCT TTAGGCTATC GCTGGTAA 1068

(2) INFORMATION FOR SEQ ID NO: 66:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1764 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 1764

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66:

ATGAAAAACT TTTCCCCACT CTATTGTCTT AAAAAGCTCA AAAAACGCCA TTTAATCGCT 60

CTGAGTCTGC CCTTGCTTTC TTATGCGAAT GGCTTTAAAA TCCAAGAGCA AAGCTTGAAT 120

GGCACGGCTT TAGGCTCGGC GTATGTCGCT GGGGCTAGGG GTGCTGACGC TTCTTTTTAC 180

AACCCGGCTA ACATGGGCTT TACTAACGAT TGGGGCGAAA ACAGAAGCGA ATTTGAAATG 240

ACCACCACCG TGATCAATAT CCCGGCCTTT AGCTTTAAAG TCCCTACGAC CAATCAAGGC 300

TTATATTCGG TAACAAGTTT AGAAATTGAT AAAAGCCAAC AAAATATTTT AGGCATCATC 360

AACACTATAG GGTTAGGCAA TATCCTTAAA GCGCTTGGCA ATACGGCCGC TACCAATGGC 420

TTATCACAAG CTATCAATCG TGTTCAAGGG CTTATGAACT TAACCAATCA AAAAGTCGTA 480

ACCCTCGCTT CAAAACCTGA CACTCAAATC GTGAATGGCT GGACAGGCAC GACTAATTTT 540

GTTTTACCTA AATTCTTTTA TAAAACGCGC ACGCATAACG GCTTCACTTT TGGGGGGAGT 600

TTTACCGCTC CTAGTGGGTT GGGTATGAAA TGGAATGGTA AGGGGGGGGA ATTTTTGCAT 660

GACGTGTTTA TCATGATGGT AGAGCTTGCC CCTAGCATGA GTTATACTAT TAATAAACGC 720

TTTTCTGTGG GTGTGGGTTT AAGGGGGCTT TATGCGACCG GGAGCTTTAA TAACACCGTT 780

TATGTGCCTT TAGAGGGCGC TTCAGTTTTG AGCGCGGAGC AAATCTTAAA CTTACCCAAC 840

AATGTTTTTG CCGATCAAGT GCCAAGTAAC ATGATGACTT TATTAGGCAA TATTGGCTAC 900

CAACCAGCGC TTAATTGCCA AAAAGCCGGT GGGGACATGA GTGATCAGAG CTGTCAAGAG 960

TTTTACAACG GCTTGAAAAA AATCATGGGT TATAGCGGTT TAATCAAAGC GAGCGCGAAT 1020

CTTTATGGCA CGACTCAAGT CGTGCAAAAA TCTAACGGAC AAGGCGTATC GGGGGGGTAT 1080

AGAGTGGGTT CGAGTTTGCG TGTGTTTGAT CATGGCATGT TTTCTGTGGT GTATAATTCT 1140

TCAGTTACCT TTAACATGAA AGGCGGTTTG GTGGCTATCA CAGAGCTTGG CCCTTCTTTA 1200

GGGAGCGTTT TGACTAAAGG CAGCTTGAAT ATCAATGTTT CACTCCCCCA AACTTTAAGC 1260

TTAGCCTACG CCCACCAATT TTTTAAAGAT CGCCTAAGGG TTGAAGGGGT GTTTGAGCGC 1320

ACTTTTTGGA GTCAAGGGAA TAAATTTTTA GTCACCCCTG ATTTTGCGAA CGCCACTTAC 1380

AAGGGCTTGA GCGGGACGGT GGCTTCCTTG GACTCTGAAA CGCTTAAAAA AATGGTAGGC 1440

CTAGCGAATT TTAAAAGCGT GATGAACATG GGGGCTGGCT GGAGGGACAC CAACACCTTT 1500

AGATTAGGGG TAACTTACAT GGGTAAAAGC TTGCGTTTAA TGGGCGCTAT TGATTATGAT 1560

CAAGCCCCAA GCCCCCAAGA CGCGATAGGC ATTCCGGACT CTAATGGCTA TACCGTGGCT 1620

TTTGGGACTA AATACAATTT TAGGGGCTTT GATTTGGGCG TAGCGGGGAG TTTCACTTTT 1680

AAGAGCAACC GCTCCAGTTT GTATCAATCC CCAACTATTG GGCAATTGAG AATCTTTAGC 1740

GCCTCTTTAG GCTATCGCTG GTAA 1764

(2) INFORMATION FOR SEQ ID NO: 67:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 618 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 618

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67:

TTGATTTTTA GATTTTTCTT AATCTTAAGC CTTTTAAAAG GGGTTTTACT GGCCAAAAAG 60

GATTGGAATT TTTTCAAACC TTTAGAGCCT ACTAAAAAAT ATTTTGGCTC TTTTAAAATC 120

GGCTATCTTT ACCAACATGC AGAAACGACT AAAAGATTCC CCATCCGCCC TAAAAACCGC 180

CCGCCTATTT TAATGGATAA AATTTACCAT GACGCTTCTT TGGGTTTTGA CGCAGGGTAT 240

GTTTTGAAAA AGAAAGCTTT ATTGGGGGGG TATTTGGATG CAGGAATGGG CGATTCGTAT 300

TTCATGAGCG CTGGGCTAGT CGCTGGGGTG AGGCTTTTTA AGGGGTGGGT TATCCCTAAA 360

ATCGCCTTAG GCTATCAGCT TCAAATTTTA GGGGCTAAGA TTGATAAGTA TCAATTCAAT 420

ATCCAATCAG CGGTGGGGAG TGTGGGCTTG TTTTTCAATG CGGCTAAAAA TTTTGGCTTG 480

AGTATAGAAG CAAGGGGCGG TATCCCTTTT TATTTCATTC AGAGCAGGTT TTCTAAGGCT 540

TTCGGCACGC CACGATTGAA TATCTATTCT GTTGGTATCA CATTCACTTT TTATGACTTT 600

ACGAGATTTT TAGGGTAA 618

(2) INFORMATION FOR SEQ ID NO: 68:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 762 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 762

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68:

TTGTGGCATG CTGCCTTTAG CGTTGGCGAG TGGGGATGGA ACGGCGATGA AATCCCCTAT 60

AGGGATTGCG ATGAGTGGGG GCTTGATGAT TTCTATGGTG TTAAGCCTAC TGATTGTGCC 120

GGTGTTTTAT CGTTTGCTCG CTCCCATAGA CGACAAAATC AAGCGGTTTT ATCAAAACCA 180

AAAAGCTTTA GAATGAAAAA AATTGCTTTC ATTTTGGCTT TATGGGTGGG CTTGTTAGGG 240

GCGTTTGAGC CTAAAAAAAG TCATATTTAT TTTGGGGCTA TGGTGGGTTT AGCCCCTGTT 300

AAAATAACCC CAAAACCGGC TAGTGATTCT TCTTATACGG CTTTTTTATG GGGGGCTAAA 360

GGGGGGTATC AATTCGCTTT TTTTAAAGCT CTAGCGTTAA GGGGTGAATT TTCCTACCTT 420

ATGGCGATCA AACCCACCGC ACTGCACACG ATTAACACTT CTTTATTGAG TTTAAATATG 480

GATGTGTTGA GCGATTTTTA CACTTATAAA AAATACAGCT TTGGGGTGTA TGGGGGGCTT 540

GGGATAGGGT ATTTTTATCA AAGCAACCAT TTAGGCATGA AAAATAGTTC GTTTATGGGT 600

TATAACGGCT TGTTTAATGT GGGGCTTGGC AGCACGATCG ATCGCCACCA CCGCGTAGAG 660

CTTGGGGCTA AGATCCCTTT TTCAAAGACT AGAAATTCTT TTAAAAATTC TTATTTTTTA 720

GAGAGCGTTT TTATCCATGC GGCTTATAGT TATATGTTTT AA 762

(2) INFORMATION FOR SEQ ID NO: 69:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1239 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 1239

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69:

ATGGAATCAG TAAAAACAGT AAAAACAAAT AAAGTTGGCA AAAACACAGA GACAGCTAAC 60

ACAGAGGCAA GTAAAGAGAC TCATTTTAAA CAAGCGAGTG CCATTACAAA TACGCTCCGA 120

TCAATTGGTG GGATTTTTAC AAAAATTGCA AAGAAAGTTA GAGAACTTGT GAAAAAACAT 180

CCCAAGAAAA GCAGTGTGGC ATTAGTAGTA TTGACCCATA TTGCGTGCAA GAGGGCAAAA 240

GAATTGGACG ATAAAGTCCA AGATAAATCC AAACAAGCTG AAAAAGAAAA TCAAATCAAT 300

TGGTGGAAAT ATTCAGGATT AACAATAGCG GCAAGTTTAT TATTAGCCGC TTGTAGCACT 360

GGTGATATTG ATAAACAAAT AGAACTAGAA CAAGAAAAAA AGGAAGCAAA TAAGAGTGGG 420

ATAAAGTTAG AACAAGAAAG ACAGAAAACA GAACAAGAAA GACAGAAGAC AAATAAGAGT 480

GAGATAGAGT TAGAACAAGA AAGACAAAAA ACAAACAAGA GTGGGATAGA ACTCGCTAAT 540

AGTCAAATAA AAGCAGAACA AGAAAGACAA AAGACAGAAC AAGAAAAACA AAAAGCAAAT 600

AAGAGTGAGA TAGAGTTAGA ACAGCAAAAA CAAAAGACAA TTAATACACA AAGAGATTTG 660

ATTAAAGAAC AGAAAGATTT CATTAAAGAA ACAGAACAAA ATTGCCAAGA AAAACATGGC 720

CAATTGTTTA TTAAAAAAGC AAGAATTAAG ACCGGTATTA CTACTGGTAT TGCCATAGAA 780

ATAGAAGCTG AATGCAAAAC CCCTAAACCT GCAAAAACCA ATCAAACCCC TATCCAGCCA 840

AAACACCTCC CAAACTCTAA ACAACCCCGC TCTCAAAGAG GATCAAAAGC GCAAGAGCTT 900

ATCGCTTATT TGCAAAAAGA GCTAGAATCT CTGCCCTATT CGCAAAAAGC TATCGCTAAA 960

CAAGTGGATT TTTATAAACC AAGTTCTATC GCTTATTTAG AACTAGACCC TAGAGATTTT 1020

AAGGTTACAG AAGAATGGCA AAAAGAAAAT TTAAAAATAC GCTCTAAAGC TCAAGCTAAA 1080

ATGCTTGAAA TGAGAAACCC ACAAGCCCAC CTTCCAACCT CTCAAAGCCT TTTGTTCGTT 1140

CAAAAAATAT TTGCTGATAT TAATAAAGAA ATAGAAGCAG TTGCTAATAC TGAAAAGAAA 1200

ACAGAAAAAG CGGGTTATGG TTATAGTAAA AGGATGTAG 1239

(2) INFORMATION FOR SEQ ID NO: 70:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 450 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 450

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70:

TTGAATTGGG AGCATTTGAT GAAAAAATTA GCGTTTTCTT TATTATTTAC AGGGACTTTT 60

TTGGGGCTTT TTTTGAATGC GAGTGATTTT AAGAGCATGG ATAACAAGCA ACTATTAGAG 120

CAAGCAGGGA AAGTCGCTCC TAGCGAAGTT CCAGAGTTTC GCACAGAAGT CAATAAACGA 180

TTAGAAGCGA TGAAAGAAGA AGAGCGTCAA AAATATAAAG CGGATTTTAA GAAAGCGATG 240

GATAAGAATT TGGCTTCTTT AAGCCAAGAA GATCGCAACA AGCGTAAAAA AGAAATCCTT 300

GAAGTCATTG CTAACAAAAA GAAAACAATG ACCATGAAAG AGTATCGTGA AGAGGGGTTG 360

GATTTGCATG ATTGCGCATG CGAAGGCCCT TTTCATGATC ATGAAAAAAA GGGGCAAAAA 420

GGGAAAAAAC CAAGCCATCA TAAGCATTAG 450

(2) INFORMATION FOR SEQ ID NO: 71:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 615 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 615

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71:

ATGCAAGCAG TGATTTTAGC GAATGGGGAG TTTCCTAAAT CTAAAAAATG CTTAGACATT 60

TTACAAAACG CTCCCTTTTT AATCGCATGC GATGGGGCTG TTATATCATT GCATGCGCTT 120

CAATTCAAAC CCAGCGTTGT TATAGGCGAT TTGGATAGCA TTGATTCGCA TTTGAAAGCC 180

TTGTATAACC CTATACGCGT GAGCGAACAA GACAGCAACG ATTTGTCCAA AGCCTTTTTT 240

TATGCTTTGA ATAGGGGTTG TGATGATTTT ATTTTTTTAG GGTTGAATGG CAAGCGAGAA 300

GACCACGCTT TAGCGAACAC TTTTTTATTG TTGGAGTATT TTAAATTTTG CAAAAAAATC 360

CAATCCGTAA GCGATTATGG CCTTTTTAGG GTGTTAGAAA CCCCTTTTAC TTTGCCCAGT 420

TTTAAGGGGG AGCAAATCTC GCTTTTTAGC TTGGATCTTA AAGCCCGATT CACTTCTAAA 480

AACCTCAAAT ACCCCTTAAA AGACTTGCGT CTAAAAACGC TCTTTTCCGG CTCGCTCAAT 540

GAAGCCACTA ATCATTGTTT TAGCCTTAGC TCTGAACCTA AATCGGTGGT GCTAGTGTAT 600

CAAAAATTCT CATGA 615

(2) INFORMATION FOR SEQ ID NO: 72:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 843 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 843

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72:

GTGTTTGACT CATTGGGCGG ATTTTTGGGG TATAAAACTT TTAAGCCGAT AGTGGATAAG 60

GTTAAAAATA TAAACGCTTG GATAAAAAAT TACGATAATA AAAAAGCTCA AGAGATTATG 120

GGTTTTATAG AAAATCCTAC GCCTGATTTC CAAAATAATA AGTTTTTGTG TGTTTTAAAC 180

CGACAAGGAA CAAGGCACAA CAATTATCTT GGTTTAACCT CTACAAACCT TCTAATCGGC 240

GCGATCTATT TCTCCATCCG CCATTGCATC AAAGCCACAT GGCAAAACGA TAGGGATCAA 300

TTCTACGCCC CTTATGATGA CGCTTTCCAA GACGACAGCG AGTTTAAAAA CAATTGTTTG 360

GCGTTCATGC TTTTTCACAC CCAAAACCGC ATCACTGCCA CTCAAGGGAC TAACCATTTT 420

ATCCCCTTTA GCGAAGATGA AGTTGATTCT AAAGAAAGGT ATTTGAGCCA TGCTTTATTA 480

GACTTTTTAA AAGGCGAAAT CAAAGAACCT AAAAAGAGCG ATAGCCTCTT TTTAAACGCC 540

AAAAAAGAAA ACAAGCCCCT AAAATTCAGC TCGAGCGCTT CAAAGGTGTT TGACGCTGGC 600

AGAGAGATTT ATCGCTATTA CCACACACAA GATTTCATCC ACACCCCCTA TAACGCTAAC 660

GCAAGCCTTT ATGACATCAA AGAATTTTTT CAAGGCCGTA ACAAGCAAGG CAGATTAAAC 720

TCACCCACCA AAGCCAAAGA TGAATATTAC AAACAGCTTT ACGCTAACTT GCAATACGCC 780

CTAAAAGATC TCGCCAAAGA AATACAGCCT AAAGTCTATG AATACGGATT TTTAAGGGAG 840

TAG 843

(2) INFORMATION FOR SEQ ID NO: 73:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 930 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 930

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73:

TGTGACAGGG CAATTCCCCA TTGGCTTTTT AGTCTGGGAT ACCGCTACCC CCCCCCCTTA 60

AAACCAACCA ACGCGTTCAA TTTAGAAGTG TTTGACTCAT TGGGCGGATT TTTGGGGTAT 120

AAAACTTTTA AGCCGATAGT GGATAAGGTT AAAAATATAA ACGCTTGGAT AAAAAATTAC 180

GATAATAAAA AAGCTCAAGA GATTATGGGT TTTATAGAAA ATCCTACGCC TGATTTCCAA 240

AATAATAAGT TTTTGTGTGT TTTAAACCGA CAAGGAACAA GGCACAACAA TTATCTTGGT 300

TTAACCTCTA CAAACCTTCT AATCGGCGCG ATCTATTTCT CCATCCGCCA TTGCATCAAA 360

GCCACATGGC AAAACGATAG GGATCAATTC TACGCCCCTT ATGATGACGC TTTCCAAGAC 420

GACAGCGAGT TTAAAAACAA TTGTTTGGCG TTCATGCTTT TTCACACCCA AAACCGCATC 480

ACTGCCACTC AAGGGACTAA CCATTTTATC CCCTTTAGCG AAGATGAAGT TGATTCTAAA 540

GAAAGGTATT TGAGCCATGC TTTATTAGAC TTTTTAAAAG GCGAAATCAA AGAACCTAAA 600

AAGAGCGATA GCCTCTTTTT AAACGCCAAA AAAGAAAACA AGCCCCTAAA ATTCAGCTCG 660

AGCGCTTCAA AGGTGTTTGA CGCTGGCAGA GAGATTTATC GCTATTACCA CACACAAGAT 720

TTCATCCACA CCCCCTATAA CGCTAACGCA AGCCTTTATG ACATCAAAGA ATTTTTTCAA 780

GGCCGTAACA AGCAAGGCAG ATTAAACTCA CCCACCAAAG CCAAAGATGA ATATTACAAA 840

CAGCTTTACG CTAACTTGCA ATACGCCCTA AAAGATCTCG CCAAAGAAAT ACAGCCTAAA 900

GTCTATGAAT ACGGATTTTT AAGGGAGTAG 930

(2) INFORMATION FOR SEQ ID NO: 74:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 564 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 564

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74:

TTGGAAACTT ATATCATTGA TGCAGATAAT ATAGATGGGG ATTTATTTTT CTATAATCTT 60

ACTAGAAACA GCAATGATTT TTCCATGTTG CCCGTTTTTG AACTCGATCG CATTGCCCAA 120

AAAATTAGAA ATATTCTTAA AAAACATGGC AGTAGAAAAG ACATTATTTT AAAACACAAT 180

GAAATTAAAG AAGCCTTTTT TAGCCCGTTC AAACCGCAGC TAAAAACCGT TCAAGTGTTC 240

CTCTCGCACT CGCATGCGGA TAAAAATAAG GCTTTAGGGG TTAAGGACTA TTTGGAAAGC 300

AAAACAAAAC GCAAAGTGTT TATCGATTCG CTTTTTTGGG ATTATAAAGA CGATGTTTTA 360

AACAAATTGG CAAAACACGA TGATATAAGC AAGATTGAAG ACGCTTTCAC GCTCATTCTC 420

AGAAAATCTT TACAAGATAT GATTGAAAAA TGCCCTTATT TTGTGTTTTT ACAAAGCAAG 480

AACAGCGTTT CTAATCAAGG GCTATCACGC ATCACTTATT CCGCATGGAT TTATGAAGAA 540

TTAAAAATCG CTTCATTCTA TTAG 564

(2) INFORMATION FOR SEQ ID NO: 75:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 597 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 597

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75:

TTGGAAACTT ATATCATTGA TGCAGATAAT ATAGATGGGG ATTTATTTTT CTATAATCTT 60

ACTAGAAACA GCAATGATTT TTCCATGTTG CCCGTTTTTG AACTCGATCG CATTGCCCAA 120

AAAATTAGAA ATATTCTTAA AAAACATGGC AGTAGAAAAG ACATTATTTT AAAACACAAT 180

GAAATTAAAG AAGCCTTTTT TAGCCCGTTC AAACCGCAGC TAAAAACCGT TCAAGTGTTC 240

CTCTCGCACT CGCATGCGGA TAAAAATAAG GCTTTAGGGG TTAAGGACTA TTTGGAAAGC 300

AAAACAAAAC GCAAAGTGTT TATCGATTCG CTTTTTTGGG ATTATAAAGA CGATGTTTTA 360

AACAAATTGG CAAAACACGA TGATATAAGC AAGATTGAAG ACGCTTTCAC GCTCATTCTC 420

AGAAAATCTT TACAAGATAT GATTGAAAAA TGCCCTTATT TTGTGTTTTT ACAAAGCAAG 480

AACAGCGTTT CTAATCAAGG GCTATCACGC ATCACTTATT CCGCATGGAT TTATGAAGAA 540

TTAAAAATCG CTTCATTTCT ATTAGCGCTA TTAACGAGAG TCGCCCAATT CCAATGA 597

(2) INFORMATION FOR SEQ ID NO: 76:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 570 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 570

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76:

ATGATGACTA AGAACGCTTA TGCGTTTGTC GTGATTGAAA AAAGTATTAT GGTGTTTAAA 60

TGCGCCAAAG ACAAGGGGCT AATCCCTATC ACTGAAGGCT TTGTGCCGTT AAAAGAGGGC 120

TTTTTGAGAA GTTTTAAAGA GCGTTGCAAT CTGGATTTTT TAGAAAATTT AGACCTTTTG 180

TTTTTGTATG ACTACCAATT TCCAAGCGAG GTTTTTTCAT TGTGTAAGGA TTTGAAAAAT 240

TCCATTTGGG ACAGAAAGCT TGTGGTAGTG CTAGTGGAGG CTTTGGAGGG TTTTAAGGGT 300

TTGAATTTGT CTCTTAAGAT AGAAGATAGG CATTCTAATA GCTTGGGTAA TGGCGTTCAA 360

AAATTGCTCA CCAACGCTGA TTTGGGGAGC AACCACAAAC CAATCGTAAT AGACAGCATG 420

AAAACATACC ACCAAAGCCA GCAAGAAAAA TACAAAAGAG AAAGAGGCGA AACGCTAGAG 480

GTTCGCCCCA CAACACCCCC TAGCTATGGG GGTGGGAGCA TTAGAATCAG CGGCGATAAA 540

AAGCCTGATT CCAATGAAGA AAATTTTTAA 570

(2) INFORMATION FOR SEQ ID NO: 77:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1773 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 1773

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 77:

ATGAAAGCGA TAAAAATACT TCTTATAATG ACACTCAGTT TAAACGCTAT CAGCGTGAAT 60

AGGGCGTTGT TTGATTTAAA AGATTCGCAA TTAAAAGGGG AATTAACGCC AAAAATAGTG 120

GATTTTGGGG GTTATAAAAG CAACACCACA GAGTGGGGAG CTACGGCTTT AAACTATATC 180

AATGCGGCTA ATGGCGATGC GAAAAAATTC AGCGCGTTAG TGGAAAAAAT GCGTTTTAAC 240

TCTGGTATCT TGGGGAATTT TAGAGCGCAT GCACATTTGA GGCAAGCCCT AAAATTGCAA 300

AAGAATTTGA AATATTGCCT TAAAATCATC GCTAGGGATT CTTTTTATAG TTACCGCACC 360

GGTATTTATA TCCCCTTAGG CATTTCTTTA AAAGATCAAA AAACGGCTCA AAAAATGCTC 420

GCTGATTTGA GCGTGGTAGG GGCGTATCTT AAAAAGCAAC AGGAGAATGA AAAGGCTCAA 480

AGCCCTTATT ACAGGAGCAA CAACTATTAC AACTCCTACT ATAGCCCTTA TTATGGCATG 540

TATGGCATGT ATGGAATGGG CATGTATGGA ATGTATGGCA TGGGCATGTA TGATTTTTAT 600

GACTTTTATG ATGGCATGTA TGGGTTCTAC CCTAACATGT TTTTCATGAT GCAAGTTCAA 660

GACTACTTGA TGTTAGAAAA TTACATGTAT GCACTCGATC AAGAAGAGAT TTTAGACCAT 720

GACGCTTCCA TCAACCAACT TGATACGCCT ACTGATGATG ACAGAGACGA TAAAGACGAT 780

AAATCTTCGC AACCAGCGAA TCTCATGAGC TTTTATCGTG ATCCCAAATT CAGCAAAGAC 840

ATTCAAACCA ACCGCTTGAA TAGCGCCTTA GTCAATTTAG ACAACAGCCA CATGCTCAAA 900

GACAATTCGC TCTTCCACAC TAAAGCCATG CCCACTAAAA GCGTGGATGC GATCACTTCT 960

CAAGCTAAAG AGCTTAACCA TTTGGTGGGG CAAATCAAAG AGATGAAGCA AGACGGGGCG 1020

AGTCCTAATA AGATTGATTC AGTGGTCAAT AAAGCTATGG AGGTTAGGGA CAAATTAGAC 1080

AACAACCTCA ACCAACTAGA CAATGACTTA AAAGATCAAA AAGGGCTTTC AAGCGAGCAG 1140

CAAGCCCAAG TGGATAAAGC CTTAGACAGC GTGCAACAAT TAAGCCATAG CAGCGATGTG 1200

GTAGGGAATT ATTTAGACGG GAGTTTGAAA ATTGATGGCG ATGACAGAGA CGATTTGAAT 1260

GATGCGATCA ATAACCCTAT GCAACAACCT GCGCAACAAA CGCCTATTAA CAACATGGAC 1320

AACACCCATG CAAATGACAG CAAAGATCAA GGGGGTAACG CGCTCATAAA CCCTAACAAC 1380

GCCACCAACG ATGATCACAA CGATGATCAC ATGGACACTA ACACCACTGA CACTAGCAAC 1440

GCAAACGACA CCCCCACTGA TGATAAAGAT GCTAGCGGCA ACAATACCGG CGATATGAAT 1500

AACACCGACA CCGGCAATAC GGACACTGGC AACACCGACA CCGGTAACAC TGATGATATG 1560

AGCAACATGA ACAACGGCAA CGATGATACG GGTAACACTA ACGACGACAT GGGTAATAGC 1620

AACGACATGG GCGATGACAT GAATAACGCG AACGACATGA ACGACGACAT GGGTAACAGC 1680

AACGATGACA TGGGCGATAT GGGGGACATG AACGATGACA TGGGTGGCGA TATGGGAGAC 1740

ATGGGGGATA TGGGTGGCGA TATGGGGAAT TGA 1773

(2) INFORMATION FOR SEQ ID NO: 78:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 588 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 588

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78:

TTGAATTTAC GATTGGCTGG AGCAAGCGTT TTAACGGCTT GTGTCTTTTC GGGGTGTTTT 60

TTTTTAAAAA TGTTTGACAA AAAACTTTCT AGCAACGATT GGCATATCCA AAAAGTAGAA 120

ATGAACCATC AAGTGTATGA CATTGAAACC ATGCTCGCTG ATAGCGCTTT TAGAGAGCAT 180

GAAGAAGAGC AAGACTCCTC TTTAAATACC GCTTTGCCTG AAGATAAAAC AGCGATTGAA 240

GCCAAAGAGC AAGAGCAAAA AGAAAAAAGG AAACACTGGT ATGAGCTTTT TAAAAAGAAG 300

CCAAAGCCCA AAAGCTCTAT GGGAGAGTTT GTGTTTGATC AAAAAGAAAA TCGTATTTAT 360

GGGAAAGGCT ATTGCAACCG GTATTTTGCT AGCTACACAT GGCAGGGCGA TAGGCACATC 420

GCAATTGAAG ATAGCGGGAT TTCAAGAAAA GTGTGTAGAG ATGAGCATTT GATGGCGTTT 480

GAATTGGAAT TTATGGAGAA TTTTAAGGGT AATTTTGCGG TAACTAAGGG CAAGGACACG 540

CTCATTTTAG ACAACCAAAA AATGAAAATT TATTTGAAAA CGCCATGA 588

(2) INFORMATION FOR SEQ ID NO: 79:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2235 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 2235

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 79:

ATGTTAAAAC TCGCCAGTAA AACGATTTGT TTGTCCCTAA TCAGCTCATT CACGGCTGTA 60

GAAGCCTTTC AAAAACACCA AAAAGACGGC TTTTTCATAG AAGCCGGCTT TGAAACCGGG 120

CTATTACAAG GCACACAAAC CCAAGAACAA ACCATAGCCA CCACTCAAGA AAAACCCAAA 180

CCCAAACCCA AACCAAAACC CATTACCCCT CAAAGCACCT ATGGGAAATA CTACATCTCC 240

CAAAGCACCA TTTTAAAGAA TGCGACTGAG TTGTTTGCAG AGGATAATAT CACCAACTTA 300

ACCTTTTACT CTCAAAACCC TGTGTATGTA ACCGCTTATA ACCAAGAAAG CGCTGAAGAA 360

GCTGGCTATG GTAATAACAG CTTGATTATG ATACAAAACT TCTTGCCTTA TAACTTGAAC 420

AACATTGAGC TGAGTTACAC GGACGATCAA GGCAATGTGG TCAGTTTGGG CGTGATAGAG 480

ACTATCCCTA AACAATCTCA AATCATTCTG CCCGCAAGCT TGTTTAACGA CCCACAGCTT 540

AACGCCGATG GCTTCCAACA ACTCCAAACC AACACCACAC GATTTTCTGA TGCCAGCACG 600

CAGAATCTGT TTAACAAGCT CAGCAAGGTT ACAACCAATC TTCAAATGAC TTATATCAAT 660

TACAACCAAT TTTCTAGCGG TAACGGCAGT GGCTCTAAAC CCCCATGCCC CCCATACGAA 720

AACCAAGCAA ATTGTGTGGC TAAAGTGCCG CCTTTCACCT CTCAAGACGC TAAAAATTTG 780

ACCAATTTAA TGCTGAACAT GATGGCGGTG TTTGATTCTA AATCTTGGGA AGACGCCGTC 840

TTAAACGCTC CTTTCCAATT CAGCGACAAC AACCTGTCAG CGCCATGTTA TTCTGATTAC 900

CTTACATGCG TGAATCCTTA CAACGATGGG CTTGTTGATC CTAAATTGAT CGCCAAAAAT 960

AAAGGAGATG AATACAATAT AGAAAACGGG CAAACAGGCT CAGTGATATT AACGCCGCAA 1020

GATGTTATCT ATAGCTATAG AGTCGCTAAT AATATTTATG TGAATCTCTT GCCCACAAGA 1080

GGAGGGGATT TAGGGTTAGG GTCTCAATAT GGTGGCCCGA ATGGCCCAGG CGATGATGGC 1140

ACCAATTTTG GCGCTTTAGG GATATTGTCC CCTTTCTTAG ACCCTGAAAT ATTGTTTGGC 1200

AAAGAATTGA ATAAAGTCGC CATCATGCAA TTAAGAGACA TCATCCATGA ATACGGCCAT 1260

ACTTTAGGCT ATACGCATAA CGGGAACATG ACTTATCAAA GAGTGCGCAT GTGCGAAGAA 1320

AACAATGGGC CAGAAGAGCG CTGTCAGGGC GGAAGGATAG AGCAAGTGGA TGGGAAAGAA 1380

GTGCAAGTGT TTGACAACGG GCATGAAGTG CGAGACACCG ATGGCTCTAC CTATGATGTG 1440

TGTTCTCGTT TTAAAGATAA GCCCTATACA GCGGGCAGCT ATCCTAATTC CATCTATACC 1500

GATTGCTCTC AAGTCCCCGC TGGGCTTATA GGCGTTACCA GCGCTGTTTG GCAACAACTC 1560

ATTGATCAAA ACGCCCTACC GGTGGATTTT ACTAATTTGA GCAGCCAAAC CAACTATTTG 1620

AACGCCAGCT TGAACACGCA AGACTTTGCG ACCACCATGC TTAGCGCGAT CAGTCAAAGC 1680

CTTTCATCTT CTAAATCTAG CGCCACTACT TATCGCACTT CAAAAACCTC ACGGCCCTTT 1740

GGAGCCCCCC TATTAGGCGT TAATCTTAAA ATGGGCTATC AAAAATATTT TAATGATTAT 1800

CTAGGGTTGT CTTCTTATGG CATTATCAAA TACAACTACG CTCAAGCCAA CAACGAAAAA 1860

ATCCAGCAAT TAAGCTATGG CGTGGGAATG GATGTGCTGT TTGATTTCAT CACCAATTAC 1920

ACTAACGAAA AGAACCCCAA AAGCAATCTA ACCAAGAAAG TTTTCACTTC CTCTCTTGGG 1980

GTGTTTGGGG GGTTAAGGGG CTTATACAAC AGCTATTATT TGTTGAACCA ATACAAAGGG 2040

AGCGGTAATT TAAATGTGAC CGGTGGGTTG AATTACCGCT ACAAGCATTC CAAATATTCT 2100

ATAGGCATTA GCGTTCCTTT GGTCCAGTTG AAATCTAGGA TCGTTTCTAG CGATGGTGCT 2160

TATACCAATT CTATCACCCT CAATGAAGGG GGCAGTCATT TTAAAGTGTT TTTTAATTAC 2220

GGGTGGATTT TCTAA 2235

(2) INFORMATION FOR SEQ ID NO: 80:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1590 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 1590

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80:

ATGACTTATA TCAATTACAA CCAATTTTCT AGCGGTAACG GCAGTGGCTC TAAACCCCCA 60

TGCCCCCCAT ACGAAAACCA AGCAAATTGT GTGGCTAAAG TGCCGCCTTT CACCTCTCAA 120

GACGCTAAAA ATTTGACCAA TTTAATGCTG AACATGATGG CGGTGTTTGA TTCTAAATCT 180

TGGGAAGACG CCGTCTTAAA CGCTCCTTTC CAATTCAGCG ACAACAACCT GTCAGCGCCA 240

TGTTATTCTG ATTACCTTAC ATGCGTGAAT CCTTACAACG ATGGGCTTGT TGATCCTAAA 300

TTGATCGCCA AAAATAAAGG AGATGAATAC AATATAGAAA ACGGGCAAAC AGGCTCAGTG 360

ATATTAACGC CGCAAGATGT TATCTATAGC TATAGAGTCG CTAATAATAT TTATGTGAAT 420

CTCTTGCCCA CAAGAGGAGG GGATTTAGGG TTAGGGTCTC AATATGGTGG CCCGAATGGC 480

CCAGGCGATG ATGGCACCAA TTTTGGCGCT TTAGGGATAT TGTCCCCTTT CTTAGACCCT 540

GAAATATTGT TTGGCAAAGA ATTGAATAAA GTCGCCATCA TGCAATTAAG AGACATCATC 600

CATGAATACG GCCATACTTT AGGCTATACG CATAACGGGA ACATGACTTA TCAAAGAGTG 660

CGCATGTGCG AAGAAAACAA TGGGCCAGAA GAGCGCTGTC AGGGCGGAAG GATAGAGCAA 720

GTGGATGGGA AAGAAGTGCA AGTGTTTGAC AACGGGCATG AAGTGCGAGA CACCGATGGC 780

TCTACCTATG ATGTGTGTTC TCGTTTTAAA GATAAGCCCT ATACAGCGGG CAGCTATCCT 840

AATTCCATCT ATACCGATTG CTCTCAAGTC CCCGCTGGGC TTATAGGCGT TACCAGCGCT 900

GTTTGGCAAC AACTCATTGA TCAAAACGCC CTACCGGTGG ATTTTACTAA TTTGAGCAGC 960

CAAACCAACT ATTTGAACGC CAGCTTGAAC ACGCAAGACT TTGCGACCAC CATGCTTAGC 1020

GCGATCAGTC AAAGCCTTTC ATCTTCTAAA TCTAGCGCCA CTACTTATCG CACTTCAAAA 1080

ACCTCACGGC CCTTTGGAGC CCCCCTATTA GGCGTTAATC TTAAAATGGG CTATCAAAAA 1140

TATTTTAATG ATTATCTAGG GTTGTCTTCT TATGGCATTA TCAAATACAA CTACGCTCAA 1200

GCCAACAACG AAAAAATCCA GCAATTAAGC TATGGCGTGG GAATGGATGT GCTGTTTGAT 1260

TTCATCACCA ATTACACTAA CGAAAAGAAC CCCAAAAGCA ATCTAACCAA GAAAGTTTTC 1320

ACTTCCTCTC TTGGGGTGTT TGGGGGGTTA AGGGGCTTAT ACAACAGCTA TTATTTGTTG 1380

AACCAATACA AAGGGAGCGG TAATTTAAAT GTGACCGGTG GGTTGAATTA CCGCTACAAG 1440

CATTCCAAAT ATTCTATAGG CATTAGCGTT CCTTTGGTCC AGTTGAAATC TAGGATCGTT 1500

TCTAGCGATG GTGCTTATAC CAATTCTATC ACCCTCAATG AAGGGGGCAG TCATTTTAAA 1560

GTGTTTTTTA ATTACGGGTG GATTTTCTAA 1590

(2) INFORMATION FOR SEQ ID NO: 81:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 564 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 564

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81:

TTGGGTTGCG TATCAATGAC TCTAGGTATT GATGAAGCGG GGAGGGGGTG TTTGGCCGGT 60

TCGCTTTTTG TGGCGGGGGT GGTGTGTAAT GAAAAAATAG CCTTAGAATT TCTAAAAATG 120

GGTCTTAAGG ATAGCAAGAA GCTCAGCCCC AAAAAGCGCT TTTTCTTAGA AGATAAAATC 180

AAAACGCATG GTGAGGTGGG GTTTTTCGTG GTTAAAAAAA GCGCGAATGA AATTGATCAT 240

TTGGGCTTAG GGGCGTGTTT GAAACTCGCT ATTGAAGAAA TTGTAGAAAA TGGTTGCTCT 300

TTAGCCAATG AAATAAAAAT AGATGGCAAC ACGGCGTTTG GCTTGAACAA ACGCTACCCC 360

AACATACAAA CCATCATCAA GGGCGATGAA ACAATCGCTC AAATCGCTAT GGCGTCTGTT 420

TTGGCGAAAG CTTCTAAGGA TAGGGAAATG TTAGAACTGC ACGCTTTGTT TAAGGAATAC 480

GGCTGGGATA AGAATTGCGG GTATGGGACT AAACAACATA TAGAAGCGAT CAATAAGCTA 540

GGGGCTACGC TTTCATCGGC ATAG 564

(2) INFORMATION FOR SEQ ID NO: 82:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 615 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 615

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82:

ATGACTCTAG GTATTGATGA AGCGGGGAGG GGGTGTTTGG CCGGTTCGCT TTTTGTGGCG 60

GGGGTGGTGT GTAATGAAAA AATAGCCTTA GAATTTCTAA AAATGGGTCT TAAGGATAGC 120

AAGAAGCTCA GCCCCAAAAA GCGCTTTTTC TTAGAAGATA AAATCAAAAC GCATGGTGAG 180

GTGGGGTTTT TCGTGGTTAA AAAAAGCGCG AATGAAATTG ATCATTTGGG CTTAGGGGCG 240

TGTTTGAAAC TCGCTATTGA AGAAATTGTA GAAAATGGTT GCTCTTTAGC CAATGAAATA 300

AAAATAGATG GCAACACGGC GTTTGGCTTG AACAAACGCT ACCCCAACAT ACAAACCATC 360

ATCAAGGGCG ATGAAACAAT CGCTCAAATC GCTATGGCGT CTGTTTTGGC GAAAGCTTCT 420

AAGGATAGGG AAATGTTAGA ACTGCACGCT TTGTTTAAGG AATACGGCTG GGATAAGAAT 480

TGCGGGTATG GGACTAAACA ACATATAGAA GCGATCAATA AGCTAGGGGC TACGCCTTTT 540

CATCGGCATA GCTTCACGCT TAAAAACCGC ATCTTAAATC CCAAACTCTT AGAGGTGGAA 600

CAACGCCTTG TTTAA 615

(2) INFORMATION FOR SEQ ID NO: 83:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 579 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 579

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 83:

ATGAATGCAT TGAAAAAATT AAGTTTTTGC GCCTTGTTAT CCCTAGGCCT CTTCGCTCAA 60

ACAGTGCATG CTCAGCATTT AAAGGACACG ATTAACTATC CTGATTGGCT TAAAATCAAT 120

CTTTTTGATA AAAAGAACCC GCCCAATCAA TATGTCGGAT CGGCTTCAAT TTCTGGTAAA 180

AGGAACGATT TTTATTCCAA TTACATCCCC TATGATGACA AATTGCCCCC TGAAAAGAAC 240

GCTGAAGAAA TCGCTCTTTT AAGGGCCAGA ATGAACGCTT ACAGCACTTT AGAAAGCGCT 300

TTACTCACTA AAATGTGCAA TCGCATTGTT AAAGCGCTTC AAGTTAAAAA TAATGTTATC 360

AGCCATTTAT TCGGGTTTGT TGATTTTTTA ACGTCTAAAT CCATTTTGGC TAAAAGGTTC 420

GTGGATACCA CCAACCATCG TGTGTATGTC ATGGTGCAAT TCCCTTTCAT TCAGCCTGAA 480

GACTTAATCG CTTACTTTAA AGCCAAACGC ATCGACCTTT CTTTAGCGAG CGCTACCAAT 540

CTCAGCGCCA TTTTAAACAA GGCGTTGTTC CACCTCTAA 579

(2) INFORMATION FOR SEQ ID NO: 84:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 261 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 261

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 84:

ATGAATGCAT TGAAAAAATT AAGTTTTTGC GCCTTGTTAT CCCTAGGCCT CTTCGCTCAA 60

ACAGTGCATG CTCAGCATTT AAAGGACACG ATTAACTATC CTGATTGGCT TAAAATCAAT 120

CTTTTTGATA AAAAGAACCC GCCCAATCAA TATGTCGGAT CGGCTTCAAT TTCTGGTAAA 180

AGGAACGATT TTTATTCCAA TTACATCCCC TATGATGACA AATTGCCCCC TGAAAGAACG 240

CTGAAGAAAT CGCTCTTTTA A 261

(2) INFORMATION FOR SEQ ID NO: 85:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 228 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 228

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 85:

TTGAAAATTT TAACCCTTTT TTTGATAGGT TTAAACGCAT TGTTCGCCCT AGATTTGAAC 60

GCGCTTAAAA CAGAAATCAA AGAAACCTAT CTCAAAGAAT ACAAAGACTT AAAATTGGAA 120

ATTGAAACAA TTAATTTAGA AATCCCAGAG CGTTTTTCTC ACGCTTCCAT TTTAAGCTAT 180

GAATTGAACG CTTCTAACAA GCTTAAAAAA GATGGGTCGT GTTTTTAA 228

(2) INFORMATION FOR SEQ ID NO: 86:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 636 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 636

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 86:

ATGTTTTCAA TAATTCTGGG GGGGGGGGGG GGTAATACCC CATGCGGCTT GACATGGCAA 60

CACTTCAAAT TAGGGGATTT GTTTGAAATT GAAAAAACCT TAAGCTTTAA TAAAGACGCT 120

TTAACGCAAG GACAAGATTA CGATTATATT ACAAGAACTT CGCAAAATCA AGGCGTTTTG 180

CAAACTACAG GATTTGTCAA TGCAGAAAAT TTAAACCCAC CATTTACTTG GAGTTTAGGG 240

CTTTTGCAAA TGGATTTTTT CTATCGTAAA AAGTCATGGT ATGCGGGACA ATTCATGCGA 300

AAAATCACAC CAAAAACTGA AATTAAAAAT AAAATTAATT CACGCATAGC CCACTATTTC 360

ACAACGCTTT TAAACGCCTT AAAACGCCCT TTATTGAGTG TATTAGTTAG GGATATTGAT 420

AAAACTTTTA GGGAGCAAAA AATCCAACTA CCCCTAAAAC CCACCGCTAA AACTCAAAGC 480

CTTGATGGTA TTGATTTTGA TTTCATGCAC ACCCTAATCA ACGCCCTGAT GAAGCAAACC 540

ATTCAAGGCG TGGTTCAATA CTGCGACGCT AAAATACAGG CTACAAAAGA AGTTATCAGC 600

CAAGAAACGC CTATTCAAAA AGACTCGTTA TTTTGA 636

(2) INFORMATION FOR SEQ ID NO: 87:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1221 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 1221

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 87:

GTGATTGGCC CCCTTAGCAG CCAACTCAAC GCTATTAAGT GGGGCGAGTT CAAATTAGGG 60

GATTTGTTTG AAGCGAGTAA CGGCGATTTT GACATTCAAA AACGCCACAT CAATCATAAG 120

GGCGAATTTG TCATCACCGC AGGGCTTAGC AATAATGGCG TTTTAGGGCA AAGCGATATA 180

AAAGCAAAAG TTTTTGAAAG CCATACCATT ACTATTGACA TGTTTGGTTG CGCGTTTTAT 240

CGCAGTTTTG CTTATAAAAT GGTAACACAT GCTAGGGTAT TTTCTCTCAA ACCTAAATTT 300

GAAATCAACC ATAAAATCGG CTTGTTTTTA TCCACGCTAT TTTTTGGTTA CCATAAAAAA 360

TTCGGCTATG AAAACATGTG TTCATGGGCA AAAATTAAAA ACGATAAAGT CATTCTACCC 420

CTAAAACCCA CCGCTAACAC TCAAACCCTT GAGGGTATTG ATTTTGATTT CATGGAAAAA 480

TTCATAGCCG AACTTGAGCA GTGTCGGCTC GCCGAACTTC AGGCTTATTT AAAAGCTACA 540

GGGCTAGAAA ACACCACCCT TTCTAACGAT GAAGAAAATG CCCTTAATGT TTTCAATAAT 600

TCTGGGGGGG GGGGGGGTAA TACCCCATGC GGCTTGACAT GGCAACACTT CAAATTAGGG 660

GATTTGTTTG AAATTGAAAA AACCTTAAGC TTTAATAAAG ACGCTTTAAC GCAAGGACAA 720

GATTACGATT ATATTACAAG AACTTCGCAA AATCAAGGCG TTTTGCAAAC TACAGGATTT 780

GTCAATGCAG AAAATTTAAA CCCACCATTT ACTTGGAGTT TAGGGCTTTT GCAAATGGAT 840

TTTTTCTATC GTAAAAAGTC ATGGTATGCG GGACAATTCA TGCGAAAAAT CACACCAAAA 900

ACTGAAATTA AAAATAAAAT TAATTCACGC ATAGCCCACT ATTTCACAAC GCTTTTAAAC 960

GCCTTAAAAC GCCCTTTATT GAGTGTATTA GTTAGGGATA TTGATAAAAC TTTTAGGGAG 1020

CAAAAAATCC AACTACCCCT AAAACCCACC GCTAAAACTC AAAGCCTTGA TGGTATTGAT 1080

TTTGATTTCA TGCACACCCT AATCAACGCC CTGATGAAGC AAACCATTCA AGGCGTGGTT 1140

CAATACTGCG ACGCTAAAAT ACAGGCTACA AAAGAAGTTA TCAGCCAAGA AACGCCTATT 1200

CAAAAAGACT CGTTATTTTG A 1221

(2) INFORMATION FOR SEQ ID NO: 88:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 828 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 828

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 88:

ATGAGTAAGA GTTTATACCA AACTTTAAAC GTGAGCGAAA ACGCCAGCCA AGATGAAATC 60

AAAAAATCCT ACCGCCGTTT AGCCAGGCAA TACCACCCGG ATTTGAATAA AACCAAAGAA 120

GCCGAAGAGA AATTCAAAGA AATCAACGCC GCTTATGAAA TTTTGAGCGA TGAAGAAAAA 180

CGCCGCCAAT ACGATCAATT TGGCGACAAC ATGTTTGGCG GGCAGAATTT CAGCGATTTT 240

GCCAGAAGCC GTGGTCCTAG TGAAGATTTA GATGATATTT TAAGCTCTAT TTTTGGGAAA 300

GGAGGCTTTT CGCAAAGATT TTCTCAAAAT TCGCAAGGCT TTTCTGGCTT TAATTTTTCC 360

AATTTCGCCC CTGAAAATTT AGATGTAACC GCTATTTTAA ATGTCTCTGT TTTAGACACC 420

CTTTTAGGCA ATAAAAAACA AGTGAGCGTC AATAATGAGA CTTTTAGCCT TAAAATCCCT 480

ATCGGCGTGG AAGAGGGCGA AAAGATTAGG GTTCGCAACA AAGGGAAAAT GGGGCGAACG 540

GGTAGGGGCG ATTTGCTCTT ACAGATCCAT ATTGAAGAAG ATGAAATGTA TAGGCGCGAA 600

AAAGACGATA TTATCCAAAT CTTTGATTTA CCCTTAAAAA CGGCTCTTTT TGGAGGGAAA 660

ATTGAAATCG CTACTTGGCA TAAAACCTTA ACCCTAACCA TTCCCCCTAA CACCAAAGCC 720

ATGCAAAAAT TCCGCATCAA AGACAAAGGG ATCAAAAGCA GAAAAACTTC GCATGTGGGG 780

GATTGTATTG CAAGCTCGTT TGATCTGCTA AAATTGAAAC GCTTCTAA 828

(2) INFORMATION FOR SEQ ID NO: 89:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 837 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 837

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 89:

ATGAGTAAGA GTTTATACCA AACTTTAAAC GTGAGCGAAA ACGCCAGCCA AGATGAAATC 60

AAAAAATCCT ACCGCCGTTT AGCCAGGCAA TACCACCCGG ATTTGAATAA AACCAAAGAA 120

GCCGAAGAGA AATTCAAAGA AATCAACGCC GCTTATGAAA TTTTGAGCGA TGAAGAAAAA 180

CGCCGCCAAT ACGATCAATT TGGCGACAAC ATGTTTGGCG GGCAGAATTT CAGCGATTTT 240

GCCAGAAGCC GTGGTCCTAG TGAAGATTTA GATGATATTT TAAGCTCTAT TTTTGGGAAA 300

GGAGGCTTTT CGCAAAGATT TTCTCAAAAT TCGCAAGGCT TTTCTGGCTT TAATTTTTCC 360

AATTTCGCCC CTGAAAATTT AGATGTAACC GCTATTTTAA ATGTCTCTGT TTTAGACACC 420

CTTTTAGGCA ATAAAAAACA AGTGAGCGTC AATAATGAGA CTTTTAGCCT TAAAATCCCT 480

ATCGGCGTGG AAGAGGGCGA AAAGATTAGG GTTCGCAACA AAGGGAAAAT GGGGCGAACG 540

GGTAGGGGCG ATTTGCTCTT ACAGATCCAT ATTGAAGAAG ATGAAATGTA TAGGCGCGAA 600

AAAGACGATA TTATCCAAAT CTTTGATTTA CCCTTAAAAA CGGCTCTTTT TGGAGGGAAA 660

ATTGAAATCG CTACTTGGCA TAAAACCTTA ACCCTAACCA TTCCCCCTAA CACCAAAGCC 720

ATGCAAAAAT TCCGCATCAA AGACAAAGGG ATCAAAAGCA GAAAAACTTC GCATGTGGGG 780

GATTGTATTG CAAGCTCGTT TGATCTGCCT AAAATTGAAA CGCTTCTAAT GAGTTGA 837

(2) INFORMATION FOR SEQ ID NO: 90:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 699 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 699

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 90:

GTGGTTCAAA AATTTAATTT TTATAAGACA GGTGGCATGC GTTTAAAACA TTTTAAGACA 60

TTCCTTTTTA TCACAATGGC GGTGATTGTG ATAGGCACTG GTTGTGCGAA TAAAAAGAAA 120

AAAAAAGATG AATACAACAA ACCGGCGATC TTTTGGTATC AAGGGATTTT GAGAGAAATT 180

CTTTTTGCTA ATTTAGAAAC AGCGGACAAT TACTATTCTT CCTTACAGAG CGAACACATC 240

AATTCCCCCC TTGTCCCAGA AGCTATGCTA GCTTTAGGGC AAGCGCACAT GAAAAAGAAA 300

GAGTATGTTT TAGCGTCTTT TTACTTTGAT GAATACATCA AGCGCTTTGG GACGAAGGAC 360

AATGTGGATT ATTTGACCTT TTTGAAACTG CAATCGCATT ATTACGCTTT CAAAAACCAT 420

TCTAAAGACC AGGAATTTAT CTCTAATTCT ATTGTGAGTT TAGGCGAATT TATAGAAAAA 480

TACCCTAACA GCCGTTACCG CCCCTATGTA GAATACATGC AAATCAAATT CATTTTAGGG 540

CAAAATGAGC TCAATCGCGC GATCGCGAAT GTCTATAAAA AACGCCACAA GCCCGAGGGC 600

GTGAAACGCT ATTTAGAAAG GATAGATGAG ACTTTAGAAA AAGAGACTAA ACCCAAACCA 660

TCGCACATGC CTTGGTATGT GTTAATTTTT GATTGGTAG 699

(2) INFORMATION FOR SEQ ID NO: 91:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 345 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 345

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 91:

ATGCGTTTTT TGAATAACAA ACATAGAGAA AAGGGCTTAA AGGCTGAAGA AGAAGCTTGC 60

GGGTTTTTAA AAACGCTGGG TTTTGAAATG ATAGAGAGGA ACTTTTTTTC ACAATTTGGT 120

GAAATTGATA TTATCGCTTT GAAAAAAGGG GTTTTGCATT TCATTGAAGT CAAAAGCGGG 180

GAAAATTTTG ATCCCATTTA TGCGATCACG CCGAGCAAAT TAAAAAAGAT GATTAAAACG 240

ATCCGCTGTT ATTTGTCTCA AAAAGATCCC AATAGCGATT TTTGCATTGA CGCTCTTATT 300

GTGAAAAATG GTAAATTTGA GCTTTTAGAA AATATCACTT TTTAG 345

(2) INFORMATION FOR SEQ ID NO: 92:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 306 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 306

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 92:

ATGGGCAGCA TTGGGGCTAT GACTAAAGGG AGCTCTGATA GGTATTTTCA AGAGGGCGTG 60

GCGAGTGAAA AATTAGTCCC AGAAGGCATT GAGGGGCGTG TGCCTTATCG TGGTAAGGTT 120

TCGGATATGA TTTTCCAATT AGTAGGGGGC GTGCGTTCTT CTATGGGGTA TCAGGGGGCG 180

AAGAATATTT TGGAATTGTA TCAAAACGCT GAATTTGTAG AAATCACTAG CGCGGGGTTA 240

AAAAAAAGCC ATGTGCATGG CGTGGATATT ACTAAAGAAG CCCCTAATAT TATGGGTGAA 300

TTTTAA 306

(2) INFORMATION FOR SEQ ID NO: 93:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1446 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 1446

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 93:

ATGAGAATTT TACAAAGGGC TTTGACTTTT GAAGACGTGT TGATGGTGCC TAGAAAATCC 60

AGCGTTTTAC CTAAAGATGT GAGCTTAAAG TCTCGCCTAA CCAAAAACAT TGGTTTGAAT 120

ATCCCTTTTA TTAGTGCGGC TATGGATACG GTTACAGAGC ATAAAACCGC TATCGCTATG 180

GCGCGCCTTG GGGGTATTGG CATCGTGCAT AAAAACATGG ATATTCAAAC GCAAGTCAAA 240

GAAATCACTA AAGTTAAAAA AAGCGAGAGC GGGGTGATTA ATGATCCTAT TTTTATCCAT 300

GCGCACAGGA CGCTAGCGGA CGCTAAAGTC ATAACGGATA ATTATAAGAT TTCAGGCGTG 360

CCTGTGGTAG ATGATAAGGG GTTGTTGATT GGGATTTTAA CCAACAGAGA CGTGCGTTTT 420

GAAACCGATT TGAGTAAAAA AGTGGGCGAT GTGATGACTA AAATGCCTTT AGTTACCGCT 480

CATGTGGGCA TTAGCTTAGA TGAAGCGAGC GATTTGATGC ACAAGCATAA GATTGAAAAA 540

TTGCCCATTG TGGATAAAGA TAATGTTTTA AAAGGCTTGA TCACGATCAA AGACATTCAA 600

AAACGCATTG AATACCCTGA GGCCAATAAA GATGATTTTG GGAGGTTGAG AGTGGGGGCG 660

GCTATTGGAG TGGGGCAGTT GGATAGGGCT GAAATGTTAG TTAAAGCGGG GGTGGATGCG 720

TTGGTGTTAG ACAGCGCGCA TGGGCATTCA GCCAATATTT TACACACTTT AGAAGAGATT 780

AAAAAAAGCT TGGTAGTGGA TGTGATTGTG GGGAATGTGG TTACTAAAGA AGCCACAAGC 840

GATTTGATTA GCGCGGGAGC GGACGCTGTT AAAGTGGGTA TTGGGCCAGG AAGCATTTGC 900

ACCACTAGGA TTGTGGCCGG GGTGGGAATG CCCCAAGTGA GCGCAATTGA TAATTGCGTG 960

GAAGTGGCGT CTAAATTTGA TATTCCTGTG ATTGCCGATG GAGGGATCCG CTATTCAGGC 1020

GATGTGGCTA AGGCTCTAGC TTTAGGAGCA TCAAGCGTGA TGATAGGCTC TTTACTCGCT 1080

GGCACAGAAG AATCTCCAGG GGATTTTATG ATTTACCAAG GGAGGCAATA TAAAAGCTAT 1140

AGGGGCATGG GCAGCATTGG GGCTATGACT AAAGGGAGCT CTGATAGGTA TTTTCAAGAG 1200

GGCGTGGCGA GTGAAAAATT AGTCCCAGAA GGCATTGAGG GGCGTGTGCC TTATCGTGGT 1260

AAGGTTTCGG ATATGATTTT CCAATTAGTA GGGGGCGTGC GTTCTTCTAT GGGGTATCAG 1320

GGGGCGAAGA ATATTTTGGA ATTGTATCAA AACGCTGAAT TTGTAGAAAT CACTAGCGCG 1380

GGGTTAAAAG AAAGCCATGT GCATGGCGTG GATATTACTA AAGAAGCCCC TAATTATTAT 1440

GGGTGA 1446

(2) INFORMATION FOR SEQ ID NO: 94:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 615 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 615

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 94:

ATGCAAGGGT TTCTTTTACA AACACAAAGC ATAAGAGATG AAGATTTGAT CGTGCACGTT 60

TTAACCAAAA ACCAGCTCAA AACCCTCTAT CGTTTCTATG GCAAACGCCA CAGCGTGCTG 120

AATGTGGGTC GTAAAATTGA TTTTGAAGAA GAAAACGATG ATAAATTTTT ACCCAAGTTA 180

AGGAATATTT TGCATTTAGG CTATATTTGG GAAAGAGAAA TGGAGCGCTT GTTTTTTTGG 240

CAACGCTTTT GCGCTCTTTT GTTCAAGCAT TTAGAGGGCG TGCATTCTTT AGATAGCATC 300

TATTTTGACA CTTTAGATGA TGGGGCTAGC AAACTCTCCA AACAGCACCC CTTAAGAGTG 360

ATTTTAGAAA TGTATGCAGT CCTTTTGAAT TTTGAAGGGC GCTTGCAAAG TTACAATTCT 420

TGTTTTTTAT GCGATGCAAA ATTAGAGCGT TCTGTCGCTT TAGCGCAAGG GTTTATTTTA 480

GCGCACCCCT CTTGCTTGAA AGCTAAAAGC TTGGATTTAG AAAAAATCCA AGCTTTTTTC 540

CGCACTCAAA GCACGATTGA TCTAGAAACA GAAGAAGTGG AAGAATTATG GCGCACGCTG 600

AATTTAGGGT TTTGA 615

(2) INFORMATION FOR SEQ ID NO: 95:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 249 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 249

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 95:

ATGGGCGTCG GACGGGTCGG CAATATGGCA CTGTTGGCGT GTGCAGGTCC GATGGGCATC 60

GGCGCTATTG CTATCGCCAT TAACGGCGGC AGACAACGGT CGCGGATGTT GGTGGTCGAT 120

ATAGACGACA AACGTCTGGA GCAGGTACAG AAGATGCTGC CGGGGAATTG GCGGCCAGTA 180

ACGGCATTGA GCTGGTGTCT GTGCATACCA AAGCGAGGAG CGATCCGTGC CAGATGCTGC 240

GAGCGCTGA 249

(2) INFORMATION FOR SEQ ID NO: 96:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 204 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 204

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 96:

TTGTCCGGTA CAGCCGTGAG TTGCCGGTGC ACATGCCGCA TACAGTTGGT ATTGGTGCGC 60

ACCAGCATCC CGGTTGTTAT CGGGTGCTCA TGCCCATTCC TTTCCAGTAT TGGGTTCACA 120

ACGGGAACCC ACCAATCACC CGTTAAACGC TGCGGGGTTA ACGCCGGAAA AACACCGTCA 180

AAAAAACATT TGCATTTAAA CTAA 204

(2) INFORMATION FOR SEQ ID NO: 97:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 345 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 345

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 97:

GTGTGGCTGG CGGCGCTGGG CTTCCTGATC ACCGCGGTGG GGCTGCCGGT GATCACCGTG 60

ATCGCCCTGG CCAAGGTCGG CGGTTCGTCG ACGCCCTCAG CCATCCGATC GGCAGGTATG 120

CCGGCGGCCT GCTGGCGGCG GTCTGCTACC TGGCGGTCGG CCCGCTGTTC GCCATTCCGC 180

GCACCGCCAC GGTGTCCTTC GAAGGTCAGC GTGGTGCCGC TGCTCGGCGA AGAAGCGGCA 240

CGGCGCTGTT CGTCTACAGC CTGGCGTACT TCCTCCTCGC CCTGGCCATC TCCCTCTACC 300

CCGGTCGCCT GCTGGACACC GTCGGACGCT TCCTCGCCCC GCTGA 345

(2) INFORMATION FOR SEQ ID NO: 98:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 228 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 228

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 98:

Met Arg Phe Lys Gly Ser Arg Val Glu Ala Phe Leu Gly Ala Leu Glu

1 5 10 15

Phe Gln Glu Asn Glu Tyr Glu Glu Phe Lys Glu Leu Tyr Glu Ser Leu

20 25 30

Lys Thr Lys Gln Lys Pro His Thr Leu Phe Ile Ser Cys Val Asp Ser

35 40 45

Arg Val Val Pro Asn Leu Ile Thr Gly Thr Gln Pro Gly Glu Leu Tyr

50 55 60

Val Ile Arg Asn Met Gly Asn Val Ile Pro Pro Lys Thr Ser Tyr Lys

65 70 75 80

Glu Ser Leu Ser Thr Ile Ala Ser Val Glu Tyr Ala Ile Ala His Val

85 90 95

Gly Val Gln Asn Leu Ile Ile Cys Gly His Ser Asp Cys Gly Ala Cys

100 105 110

Gly Ser Ile His Leu Ile His Asp Glu Thr Thr Lys Ala Lys Thr Pro

115 120 125

Tyr Ile Ala Asn Trp Ile Gln Phe Leu Glu Pro Ile Lys Glu Glu Leu

130 135 140

Lys Asn His Pro Gln Phe Ser Asn His Phe Ala Lys Arg Ser Trp Leu

145 150 155 160

Thr Glu Arg Leu Asn Ala Arg Leu Gln Leu Asn Asn Leu Leu Ser Tyr

165 170 175

Asp Phe Ile Gln Glu Arg Val Ile Asn Asn Glu Leu Lys Ile Phe Gly

180 185 190

Trp His Tyr Ile Ile Glu Thr Gly Arg Ile Tyr Asn Tyr Asn Phe Glu

195 200 205

Ser His Phe Phe Glu Pro Ile Glu Glu Thr Ile Lys Gln Arg Ile Ser

210 215 220

His Glu Asn Phe

225

(2) INFORMATION FOR SEQ ID NO: 99:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 221 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 221

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 99:

Val Glu Ala Phe Leu Gly Ala Leu Glu Phe Gln Glu Asn Glu Tyr Glu

1 5 10 15

Glu Phe Lys Glu Leu Tyr Glu Ser Leu Lys Thr Lys Gln Lys Pro His

20 25 30

Thr Leu Phe Ile Ser Cys Val Asp Ser Arg Val Val Pro Asn Leu Ile

35 40 45

Thr Gly Thr Gln Pro Gly Glu Leu Tyr Val Ile Arg Asn Met Gly Asn

50 55 60

Val Ile Pro Pro Lys Thr Ser Tyr Lys Glu Ser Leu Ser Thr Ile Ala

65 70 75 80

Ser Val Glu Tyr Ala Ile Ala His Val Gly Val Gln Asn Leu Ile Ile

85 90 95

Cys Gly His Ser Asp Cys Gly Ala Cys Gly Ser Ile His Leu Ile His

100 105 110

Asp Glu Thr Thr Lys Ala Lys Thr Pro Tyr Ile Ala Asn Trp Ile Gln

115 120 125

Phe Leu Glu Pro Ile Lys Glu Glu Leu Lys Asn His Pro Gln Phe Ser

130 135 140

Asn His Phe Ala Lys Arg Ser Trp Leu Thr Glu Arg Leu Asn Ala Arg

145 150 155 160

Leu Gln Leu Asn Asn Leu Leu Ser Tyr Asp Phe Ile Gln Glu Arg Val

165 170 175

Ile Asn Asn Glu Leu Lys Ile Phe Gly Trp His Tyr Ile Ile Glu Thr

180 185 190

Gly Arg Ile Tyr Asn Tyr Asn Phe Glu Ser His Phe Phe Glu Pro Ile

195 200 205

Glu Glu Thr Ile Lys Gln Arg Ile Ser His Glu Asn Phe

210 215 220

(2) INFORMATION FOR SEQ ID NO: 100:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 335 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 335

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 100:

Met Leu Val Thr Arg Phe Lys Lys Ala Phe Ile Ser Tyr Ser Leu Gly

1 5 10 15

Val Leu Val Val Ser Leu Leu Leu Asn Val Cys Asn Ala Ser Ala Gln

20 25 30

Glu Val Lys Val Lys Asp Tyr Phe Gly Glu Gln Thr Ile Lys Leu Pro

35 40 45

Val Ser Lys Ile Ala Tyr Ile Gly Ser Tyr Val Glu Val Pro Ala Met

50 55 60

Leu Asn Val Trp Asp Arg Val Val Gly Val Ser Asp Tyr Ala Phe Lys

65 70 75 80

Asp Asp Ile Val Lys Ala Thr Leu Lys Gly Glu Asp Leu Lys Arg Val

85 90 95

Lys His Met Ser Thr Asp His Thr Ala Ala Leu Asn Val Glu Leu Leu

100 105 110

Lys Lys Leu Ser Pro Asp Leu Val Val Thr Phe Val Gly Asn Pro Lys

115 120 125

Ala Val Glu His Ala Lys Lys Phe Gly Ile Ser Phe Leu Ser Phe Gln

130 135 140

Glu Thr Thr Ile Ala Glu Ala Met Gln Ala Met Gln Ala Gln Ala Thr

145 150 155 160

Val Leu Glu Ile Asp Ala Ser Lys Lys Phe Ala Lys Met Gln Glu Thr

165 170 175

Leu Asp Phe Ile Ala Glu Arg Leu Lys Gly Val Lys Lys Lys Lys Gly

180 185 190

Val Glu Leu Phe His Lys Ala Asn Lys Ile Ser Gly His Gln Ala Ile

195 200 205

Ser Ser Asp Ile Leu Glu Lys Gly Gly Ile Asp Asn Phe Gly Leu Lys

210 215 220

Tyr Val Lys Phe Gly Arg Ala Asp Ile Ser Val Glu Lys Ile Val Lys

225 230 235 240

Glu Asn Pro Glu Ile Ile Phe Ile Trp Trp Val Ser Pro Leu Thr Pro

245 250 255

Glu Asp Val Leu Asn Asn Pro Lys Phe Ser Thr Ile Lys Ala Ile Lys

260 265 270

Asn Lys Gln Val Tyr Lys Leu Pro Thr Met Asp Ile Gly Gly Pro Arg

275 280 285

Ala Pro Leu Ile Ser Leu Phe Ile Ala Leu Lys Ala His Pro Glu Ala

290 295 300

Phe Lys Gly Val Asp Ile Asn Ala Ile Val Lys Asp Tyr Tyr Lys Val

305 310 315 320

Val Phe Asp Leu Asn Asp Ala Glu Ile Glu Pro Phe Leu Trp His

325 330 335

(2) INFORMATION FOR SEQ ID NO: 101:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 274 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 274

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 101:

Met Leu Val Thr Arg Phe Lys Lys Ala Phe Ile Ser Tyr Ser Leu Gly

1 5 10 15

Val Leu Val Val Ser Leu Leu Leu Asn Val Cys Asn Ala Ser Ala Gln

20 25 30

Glu Val Lys Val Lys Asp Tyr Phe Gly Glu Gln Thr Ile Lys Leu Pro

35 40 45

Val Ser Lys Ile Ala Tyr Ile Gly Ser Tyr Val Glu Val Pro Ala Met

50 55 60

Leu Asn Val Trp Asp Arg Val Val Gly Val Ser Asp Tyr Ala Phe Lys

65 70 75 80

Asp Asp Ile Val Lys Ala Thr Leu Lys Gly Glu Asp Leu Lys Arg Val

85 90 95

Lys His Met Ser Thr Asp His Thr Ala Ala Leu Asn Val Glu Leu Leu

100 105 110

Lys Lys Leu Ser Pro Asp Leu Val Val Thr Phe Val Gly Asn Pro Lys

115 120 125

Ala Val Glu His Ala Lys Lys Phe Gly Ile Ser Phe Leu Ser Phe Gln

130 135 140

Glu Thr Thr Ile Ala Glu Ala Met Gln Ala Met Gln Ala Gln Ala Thr

145 150 155 160

Val Leu Glu Ile Asp Ala Ser Lys Lys Phe Ala Lys Met Gln Glu Thr

165 170 175

Leu Asp Phe Ile Ala Asp Arg Leu Lys Gly Val Lys Lys Lys Lys Gly

180 185 190

Val Glu Leu Phe His Lys Ala Asn Lys Ile Ser Gly His Gln Ala Ile

195 200 205

Asn Ser Asp Ile Leu Gln Gln Gly Gly Ile Asp Asn Phe Gly Leu Lys

210 215 220

Tyr Val Lys Phe Gly Arg Ala Asp Ile Ser Val Glu Lys Ile Val Lys

225 230 235 240

Glu Asn Pro Glu Ile Ile Phe Ile Arg Trp Val Thr Pro Leu Thr Pro

245 250 255

Asp Tyr Val Leu Asn Asn Pro Lys Phe Ser Thr Ile Asn Ala Ile Lys

260 265 270

Asn yle

(2) INFORMATION FOR SEQ ID NO: 102:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 428 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 428

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 102:

Met Lys Lys Lys Phe Leu Ser Leu Thr Leu Gly Ser Leu Leu Val Ser

1 5 10 15

Ala Leu Ser Ala Glu Asp Asn Gly Phe Phe Val Ser Ala Gly Tyr Gln

20 25 30

Ile Gly Glu Ser Ala Gln Met Val Lys Asn Thr Lys Gly Ile Gln Asp

35 40 45

Leu Ser Asp Ser Tyr Glu Arg Leu Asn Asn Leu Leu Thr Asn Tyr Ser

50 55 60

Val Leu Asn Ala Leu Ile Arg Gln Ser Ala Asp Pro Asn Ala Ile Asn

65 70 75 80

Asn Ala Arg Gly Asn Leu Asn Ala Ser Ala Lys Asn Leu Ile Asn Asp

85 90 95

Lys Lys Asn Ser Pro Ala Tyr Gln Ala Val Leu Leu Ala Leu Asn Ala

100 105 110

Ala Ala Gly Leu Trp Gln Val Met Ser Tyr Ala Ile Ser Pro Cys Gly

115 120 125

Pro Gly Lys Asp Thr Ser Lys Asn Gly Gly Val Gln Thr Phe His Asn

130 135 140

Thr Pro Ser Asn Gln Trp Gly Gly Thr Thr Ile Thr Cys Gly Thr Thr

145 150 155 160

Gly Tyr Glu Pro Gly Pro Tyr Ser Ile Leu Ser Thr Glu Asn Tyr Ala

165 170 175

Lys Ile Asn Lys Ala Tyr Gln Ile Ile Gln Lys Ala Phe Gly Ser Ser

180 185 190

Gly Lys Asp Ile Pro Ala Leu Ser Asp Thr Asn Thr Glu Leu Lys Phe

195 200 205

Thr Ile Asn Lys Asn Asn Gly Asn Thr Asn Thr Asn Asn Asn Gly Glu

210 215 220

Glu Ile Val Thr Lys Asn Asn Ala Gln Val Leu Leu Glu Gln Ala Ser

225 230 235 240

Thr Ile Ile Thr Thr Leu Asn Ser Ala Cys Pro Trp Ile Asn Asn Gly

245 250 255

Gly Ala Gly Gly Ala Ser Ser Gly Ser Leu Trp Glu Gly Ile Tyr Leu

260 265 270

Lys Gly Asp Gly Ser Ala Cys Gly Ile Phe Lys Asn Glu Ile Ser Ala

275 280 285

Ile Gln Asp Met Ile Lys Asn Ala Ala Ile Ala Val Glu Gln Ser Lys

290 295 300

Ile Val Ala Ala Asn Ala Gln Asn Gln Arg Asn Leu Asp Thr Gly Lys

305 310 315 320

Thr Phe Asn Pro Tyr Lys Asp Ala Asn Phe Ala Gln Ser Met Phe Ala

325 330 335

Asn Ala Lys Ala Gln Ala Glu Ile Leu Asn Arg Ala Gln Ala Val Val

340 345 350

Lys Asp Phe Glu Arg Ile Pro Ala Glu Phe Val Lys Asp Ser Leu Gly

355 360 365

Val Cys His Glu Val Gln Asn Gly His Leu Arg Gly Thr Pro Ser Gly

370 375 380

Thr Val Thr Asp Asn Thr Trp Gly Ala Gly Cys Ala Tyr Val Gly Glu

385 390 395 400

Thr Val Thr Asn Leu Lys Asp Ser Ile Ala His Phe Gly Asp Gln Ala

405 410 415

Glu Arg Ile His Asn Ala Arg Asn Leu Ala Thr Leu

420 425

(2) INFORMATION FOR SEQ ID NO: 103:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 178 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 178

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 103:

Met Asn Pro Leu Leu Gln Asp Tyr Ala Arg Ile Leu Leu Glu Trp Asn

1 5 10 15

Gln Thr His Asn Leu Ser Gly Ala Arg Asn Leu Ser Glu Leu Glu Pro

20 25 30

Gln Ile Thr Asp Ala Leu Lys Pro Leu Glu Phe Val Lys Asp Phe Lys

35 40 45

Ser Cys Leu Asp Ile Gly Ser Gly Ala Gly Leu Pro Ala Ile Pro Leu

50 55 60

Ala Leu Glu Lys Pro Glu Ala Gln Phe Ile Leu Leu Glu Pro Arg Val

65 70 75 80

Lys Arg Ala Ala Phe Leu Asn Tyr Leu Lys Ser Val Leu Pro Leu Asn

85 90 95

Asn Ile Glu Ile Ile Lys Lys Arg Leu Glu Asp Tyr Gln Asn Leu Leu

100 105 110

Gln Val Asp Leu Ile Thr Ser Arg Ala Val Ala Ser Ser Ser Phe Leu

115 120 125

Ile Glu Lys Ser Gln Arg Phe Leu Lys Asp Lys Gly Tyr Phe Leu Phe

130 135 140

Tyr Lys Gly Glu Gln Leu Lys Asn Glu Ile Ala Tyr Lys Thr Thr Glu

145 150 155 160

Cys Phe Met His Gln Lys Arg Val Tyr Phe Tyr Lys Ser Lys Glu Ser

165 170 175

Leu cys

(2) INFORMATION FOR SEQ ID NO: 104:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 240 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 240

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 104:

Leu Gly Leu Lys Lys Arg Ala Ile Leu Trp Ser Leu Met Gly Phe Cys

1 5 10 15

Ala Gly Leu Ser Ala Leu Asp Tyr Asp Thr Leu Asp Pro Lys Tyr Tyr

20 25 30

Lys Tyr Ile Lys Tyr Tyr Lys Ala Tyr Glu Asp Lys Glu Val Glu Glu

35 40 45

Leu Ile Arg Asp Leu Lys Arg Ala Asn Ala Lys Ser Gly Leu Ile Leu

50 55 60

Gly Ile Asn Thr Gly Phe Phe Tyr Asn His Glu Ile Met Val Lys Thr

65 70 75 80

Asn Ser Ser Ser Ile Thr Gly Asn Ile Leu Asn Tyr Leu Phe Ala Tyr

85 90 95

Gly Leu Arg Phe Gly Tyr Gln Thr Phe Arg Pro Ser Phe Phe Ala Arg

100 105 110

Leu Val Lys Pro Asn Ile Ile Gly Arg Arg Ile Tyr Ile Gln Tyr Tyr

115 120 125

Gly Gly Ala Pro Lys Lys Ala Gly Phe Gly Ser Val Gly Phe Gln Ser

130 135 140

Val Met Leu Asn Gly Asp Phe Leu Leu Asp Phe Pro Leu Pro Phe Val

145 150 155 160

Gly Lys Tyr Leu Tyr Met Gly Gly Tyr Met Gly Leu Gly Leu Gly Val

165 170 175

Val Ala His Gly Val Asn Tyr Thr Ala Glu Trp Gly Met Ser Phe Asn

180 185 190

Ala Gly Leu Ala Leu Thr Val Leu Glu Lys Asn Arg Ile Glu Phe Glu

195 200 205

Phe Lys Ile Leu Asn Asn Phe Pro Phe Leu Gln Ser Asn Ser Ser Lys

210 215 220

Glu Thr Trp Trp Gly Ala Ile Ala Ser Ile Gly Tyr Gln Tyr Val Phe

225 230 235 240

(2) INFORMATION FOR SEQ ID NO: 105:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 313 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 313

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 105:

Leu Lys Leu Lys Tyr Trp Leu Val Tyr Leu Ala Phe Ile Ile Gly Leu

1 5 10 15

Gln Ala Thr Asp Tyr Asp Asn Leu Glu Glu Glu Asn Gln Gln Leu Asp

20 25 30

Glu Lys Ile Asn Asn Leu Lys Arg Gln Leu Thr Glu Lys Gly Val Ser

35 40 45

Pro Lys Glu Met Asp Lys Asp Lys Phe Glu Glu Glu Tyr Leu Glu Arg

50 55 60

Thr Tyr Pro Lys Ile Ser Ser Lys Lys Arg Lys Lys Leu Leu Lys Ser

65 70 75 80

Phe Ser Ile Ala Asp Asp Lys Ser Gly Val Phe Leu Gly Gly Gly Tyr

85 90 95

Ala Tyr Gly Glu Leu Asn Leu Ser Tyr Gln Gly Glu Met Leu Asp Arg

100 105 110

Tyr Gly Ala Asn Ala Pro Ser Ala Phe Lys Asn Asn Ile Asn Ile Asn

115 120 125

Ala Pro Val Ser Met Ile Ser Val Lys Phe Gly Tyr Gln Lys Tyr Phe

130 135 140

Val Pro Tyr Phe Gly Thr Arg Phe Tyr Gly Asp Leu Leu Leu Gly Gly

145 150 155 160

Gly Ala Leu Lys Glu Asn Ala Leu Lys Gln Pro Val Gly Ser Phe Phe

165 170 175

Tyr Val Leu Gly Ala Met Asn Thr Asp Leu Leu Phe Asp Met Pro Leu

180 185 190

Asp Phe Lys Thr Lys Lys His Phe Leu Gly Val Tyr Ala Gly Phe Gly

195 200 205

Ile Gly Leu Met Leu Tyr Gln Asp Lys Pro Asn Gln Asn Gly Arg Asn

210 215 220

Leu Ile Val Gly Gly Tyr Ser Ser Pro Asn Phe Leu Trp Lys Ser Leu

225 230 235 240

Ile Glu Val Asp Tyr Thr Phe Asn Val Gly Val Ser Leu Thr Leu Tyr

245 250 255

Arg Lys His Arg Leu Glu Ile Gly Thr Lys Leu Pro Ile Ser Tyr Leu

260 265 270

Arg Met Gly Val Glu Glu Gly Ala Ile Tyr His Asn Lys Glu Asn Asp

275 280 285

Glu Arg Leu Leu Ile Ser Ala Asn Asn Gln Phe Lys Arg Ser Ser Phe

290 295 300

Leu Leu Val Asn Tyr Ala Phe Ile Phe

305 310

(2) INFORMATION FOR SEQ ID NO: 106:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 393 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 393

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 106:

Met Thr Ser Ala Ser Ser His Ser Phe Lys Glu Gln Asp Phe His Ile

1 5 10 15

Pro Ile Ala Phe Ala Phe Asp Lys Asn Tyr Leu Ile Pro Ala Gly Ala

20 25 30

Cys Ile Tyr Ser Leu Leu Glu Ser Ile Ala Lys Ala Asn Lys Lys Ile

35 40 45

Arg Tyr Thr Leu His Ala Leu Val Val Gly Leu Asn Glu Glu Asp Lys

50 55 60

Thr Lys Leu Asn Gln Ile Thr Glu Pro Phe Lys Glu Phe Ala Val Leu

65 70 75 80

Glu Val Lys Asp Ile Glu Pro Phe Leu Asp Thr Ile Pro Asn Pro Phe

85 90 95

Asp Glu Asp Phe Thr Lys Arg Phe Ser Lys Met Val Leu Val Lys Tyr

100 105 110

Phe Leu Ala Asp Leu Phe Pro Lys Tyr Ser Lys Met Val Trp Ser Asp

115 120 125

Val Asp Val Ile Phe Cys Asn Glu Phe Ser Ala Asp Phe Leu Asn Ile

130 135 140

Lys Glu Asp Asp Glu Asn Tyr Phe Tyr Gly Val Tyr Asp Lys Ile Tyr

145 150 155 160

Pro Tyr Glu Gly Phe Phe Tyr Cys Asn Leu Thr Tyr Gln Arg Lys Asn

165 170 175

Gln Phe Cys Lys Lys Ile Leu Glu Ile Ile Arg Ala Gln Lys Ile Asp

180 185 190

Lys Glu Pro Gln Leu Thr Glu Phe Cys Arg Ser Lys Ile Ala Pro Leu

195 200 205

Lys Ile Glu Tyr Cys Ile Phe Pro His Tyr Tyr Ser Leu Ser Glu Glu

210 215 220

His Leu Lys Gly Val Ala Asn Ala Ile Tyr His Asn Thr Ile Lys Gln

225 230 235 240

Ala Leu Arg Glu Pro Ile Val Ile Gln Tyr Asp Ser His Pro Tyr Phe

245 250 255

Gln Ile Lys Pro Trp Thr Tyr Pro Phe Gly Leu Lys Ala Asp Leu Trp

260 265 270

Leu Asn Ala Leu Ala Lys Thr Pro Phe Met Ser Asp Trp Ser Tyr Leu

275 280 285

Ile Thr Gly Gly Gly Gly Ile Gly Gly Glu Lys Trp His Tyr Tyr His

290 295 300

Gly Ile Ala Ala Tyr His Tyr Tyr Phe Pro Leu Trp Lys Ala Glu Glu

305 310 315 320

Gln Ile Ala His Asp Ala Leu Lys Thr Phe Leu Lys His Tyr Phe Leu

325 330 335

His Ile His Glu Ile Pro Gln Asn Ala Arg Arg Arg Leu Phe Lys Tyr

340 345 350

Cys Ile Ser Ile Pro Leu Lys Ser Phe Ile Ser Lys Thr Leu Lys Phe

355 360 365

Leu Lys Leu His Ala Leu Val Lys Lys Ile Leu Ile Gln Leu Lys Leu

370 375 380

Leu Lys Lys Asn Gln Ser Gln Asn Phe

385 390

(2) INFORMATION FOR SEQ ID NO: 107:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 435 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 435

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 107:

Leu Ile Phe Leu Lys Lys Ser Leu Cys Ala Leu Leu Ile Ser Gly Phe

1 5 10 15

Phe Ile Pro Pro Leu Met Lys Ala Ala Ser Phe Val Tyr Asp Leu Lys

20 25 30

Phe Met Ser Phe Asn Phe Asn Leu Ala Ser Pro Pro Asn Asn Pro Tyr

35 40 45

Trp Asn Ser Leu Thr Lys Met Gln Gly Arg Leu Met Pro Gln Ile Gly

50 55 60

Val Gln Leu Asp Lys Arg Gln Ala Leu Met Phe Gly Ala Trp Phe Ile

65 70 75 80

Gln Asn Leu His Thr His Tyr Ser Tyr Phe Pro Tyr Ser Trp Gly Val

85 90 95

Thr Met Tyr Tyr Gln Tyr Ile Gly Lys Asn Leu Arg Phe Phe Leu Gly

100 105 110

Ile Val Pro Arg Ser Tyr Gln Ile Gly His Tyr Pro Leu Ser Ala Phe

115 120 125

Lys Lys Leu Phe Trp Phe Ile Asp Pro Thr Phe Arg Gly Gla Ala Phe

130 135 140

Gln Phe Lys Pro Ala Tyr Asp Pro Asn Arg Trp Trp Asn Gly Trp Phe

145 150 155 160

Glu Gly Val Val Asp Trp Tyr Gly Gly Arg Asn Trp Asn Asn Gln Pro

165 170 175

Lys Lys Lys Asn Tyr Asp Phe Asp Gln Phe Leu Tyr Phe Val Ser Ser

180 185 190

Glu Phe Gln Phe Leu Lys Gly Tyr Leu Gly Leu Gly Gly Gln Leu Val

195 200 205

Ile Phe His Asn Ala Asn Ser His Ser Met Gly Asp Asn Tyr Pro Tyr

210 215 220

Gly Gly Asn Ser Tyr Leu Lys Pro Gly Asp Ala Thr Pro Gln Trp Pro

225 230 235 240

Asn Gly Tyr Pro Tyr Phe Ser Gln Lys Asp Asn Pro Gln Gly Gly Glu

245 250 255

Ile Gly Lys Tyr Ser Asn Pro Thr Ile Leu Asp Arg Val Tyr Tyr His

260 265 270

Ala Tyr Leu Lys Ala Asp Phe Lys Asn Leu Met Pro Tyr Met Asp Asn

275 280 285

Ile Phe Met Thr Phe Gly Thr Gln Ser Ser Gln Thr His Tyr Cys Val

290 295 300

Arg Tyr Ala Ser Glu Cys Lys Asn Ala Arg Phe Tyr Asn Ser Phe Gly

305 310 315 320

Gly Glu Phe Tyr Ala Gln Ala Gln Tyr Lys Gly Phe Gly Ile Phe Asn

325 330 335

Arg Tyr Tyr Phe Ser Asn Lys Pro Gln Met His Phe Tyr Ala Thr Tyr

340 345 350

Gly Gln Ser Leu Tyr Thr Gly Leu Pro Trp Tyr Arg Ala Pro Asn Phe

355 360 365

Asp Met Ile Gly Leu Tyr Tyr Leu Tyr Lys Asn Lys Trp Leu Ser Val

370 375 380

Arg Ala Asp Ala Phe Phe Ser Phe Val Gly Gly Gly Asp Gly Tyr His

385 390 395 400

Leu Tyr Gly Lys Gly Gly Lys Trp Phe Val Met Tyr Gln Gln Phe Leu

405 410 415

Thr Leu Thr Ile Asp Thr Arg Glu Leu Ile Asp Phe Val Lys Ser Lys

420 425 430

Ile Pro Lys

435

(2) INFORMATION FOR SEQ ID NO: 108:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 220 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 220

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 108:

Met Asn Lys Thr Thr Ile Lys Ile Leu Met Gly Met Ala Leu Leu Ser

1 5 10 15

Ser Leu Gln Ala Ala Glu Ala Glu Leu Asp Glu Lys Ser Lys Lys Pro

20 25 30

Lys Phe Ala Asp Arg Asn Thr Phe Tyr Leu Gly Val Gly Tyr Gln Leu

35 40 45

Ser Ala Ile Asn Thr Ser Phe Ser Thr Ser Ser Ile Asp Lys Ser Tyr

50 55 60

Phe Met Thr Gly Asn Gly Phe Gly Val Val Leu Gly Gly Lys Phe Val

65 70 75 80

Ala Lys Thr Gln Ala Val Glu His Val Gly Phe Arg Tyr Gly Leu Phe

85 90 95

Tyr Asp Gln Thr Phe Ser Ser His Lys Ser Tyr Ile Ser Thr Tyr Gly

100 105 110

Leu Glu Phe Ser Gly Leu Trp Asp Ala Phe Asn Ser Pro Lys Met Phe

115 120 125

Leu Gly Leu Glu Phe Gly Leu Gly Ile Ala Gly Ala Thr Tyr Met Pro

130 135 140

Gly Gly Ala Met His Gly Ile Ile Ala Gln Tyr Leu Gly Lys Glu Asn

145 150 155 160

Ser Leu Phe Gln Leu Leu Val Lys Val Gly Phe Arg Phe Gly Phe Phe

165 170 175

His Asn Glu Ile Thr Phe Gly Leu Lys Phe Pro Val Ile Pro Asn Lys

180 185 190

Lys Thr Glu Ile Val Asp Gly Leu Ser Ala Thr Thr Leu Trp Gln Arg

195 200 205

Leu Pro Val Ala Tyr Phe Asn Tyr Ile Tyr Asn Phe

210 215 220

(2) INFORMATION FOR SEQ ID NO: 109:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 116 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 116

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 109:

Leu Asn Leu His Phe Met Lys Gly Phe Val Met Ser Gly Leu Arg Thr

1 5 10 15

Phe Ser Cys Val Val Val Leu Cys Gly Ala Met Val Asn Val Ala Val

20 25 30

Ala Gly Pro Lys Ile Glu Ala Arg Gly Glu Leu Gly Lys Phe Val Gly

35 40 45

Gly Ala Val Gly Asn Phe Val Gly Asp Lys Met Gly Gly Phe Val Gly

50 55 60

Gly Ala Ile Gly Gly Tyr Ile Gly Ser Glu Val Gly Asp Arg Val Glu

65 70 75 80

Asp Tyr Ile Arg Gly Val Asp Arg Glu Pro Gln Asn Lys Glu Pro Gln

85 90 95

Thr Pro Arg Glu Pro Ile Arg Asp Phe Tyr Asp Tyr Gly Tyr Ser Phe

100 105 110

Gly His Ala Trp

115

(2) INFORMATION FOR SEQ ID NO: 110:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 436 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 436

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 110:

Met Ser Arg Asp Phe Lys Phe Asp Ser Asn Tyr Leu Asn Val Asn Thr

1 5 10 15

Asn Pro Lys Leu Gly Pro Val Tyr Thr Asn Gln Asn Tyr Pro Gly Phe

20 25 30

Phe Ile Phe Asp His Leu Arg Arg Tyr Val Met Asn Ala Phe Glu Pro

35 40 45

Asn Leu Asn Leu Val Val Asn Thr Asn Lys Val Lys Gln Thr Phe Asn

50 55 60

Val Gly Met Arg Phe Met Thr Met Asp Met Phe Ile Arg Ser Asp Gln

65 70 75 80

Ser Thr Cys Glu Lys Thr Asp Ile Ile Asn Gly Val Cys His Met Pro

85 90 95

Pro Tyr Val Leu Ser Lys Thr Pro Asn Asn Asn Gln Glu Met Phe Asn

100 105 110

Asn Tyr Thr Ala Val Trp Leu Ser Asp Lys Ile Glu Phe Phe Asp Ser

115 120 125

Lys Leu Val Ile Thr Pro Gly Leu Arg Tyr Thr Phe Leu Asn Tyr Asn

130 135 140

Asn Lys Glu Pro Glu Lys His Asp Phe Ser Val Trp Thr Ser Lys Lys

145 150 155 160

Gln Arg Gln Asn Glu Trp Ser Pro Ala Leu Asn Ile Gly Tyr Lys Pro

165 170 175

Met Glu Asn Trp Ile Trp Tyr Ala Asn Tyr Arg Arg Ser Phe Ile Pro

180 185 190

Pro Gln His Thr Met Val Gly Ile Thr Arg Thr Asn Tyr Asn Gln Ile

195 200 205

Phe Asn Glu Ile Glu Val Gly Gln Arg Tyr Ser Tyr Lys Asn Leu Leu

210 215 220

Ser Phe Asn Thr Asn Tyr Phe Val Ile Phe Ala Lys Arg Tyr Tyr Ala

225 230 235 240

Gly Gly Tyr Ser Pro Gln Pro Val Asp Ala Arg Ser Gln Gly Val Glu

245 250 255

Leu Glu Leu Tyr Tyr Ala Pro Ile Arg Gly Leu Gln Phe His Val Ala

260 265 270

Tyr Thr Tyr Ile Asp Ala Arg Ile Thr Ser Asn Ala Asp Asp Ile Ala

275 280 285

Tyr Tyr Phe Thr Gly Ile Val Asn Lys Pro Phe Asp Ile Lys Gly Lys

290 295 300

Arg Leu Pro Tyr Val Ser Pro Asn Gln Phe Ile Phe Asp Met Met Tyr

305 310 315 320

Thr Tyr Lys His Thr Thr Phe Gly Ile Ser Ser Tyr Phe Tyr Ser Arg

325 330 335

Ala Tyr Ser Ser Met Leu Asn Gln Ala Lys Asp Gln Thr Val Cys Leu

340 345 350

Pro Leu Asn Pro Glu Tyr Thr Gly Gly Leu Lys Tyr Gly Cys Asn Ser

355 360 365

Val Gly Leu Leu Pro Leu Tyr Phe Val Leu Asn Val Gln Val Ser Ser

370 375 380

Ile Leu Trp Gln Ser Gly Arg His Lys Ile Thr Gly Ser Leu Gln Ile

385 390 395 400

Asn Asn Leu Phe Asn Met Lys Tyr Tyr Phe Arg Gly Ile Gly Thr Ser

405 410 415

Pro Thr Gly Arg Glu Pro Ala Pro Gly Arg Ser Ile Thr Ala Tyr Leu

420 425 430

Asn Tyr Glu Phe

435

(2) INFORMATION FOR SEQ ID NO: 111:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 767 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 767

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 111:

Met Lys Arg Ile Leu Val Ser Leu Ala Val Leu Ser His Ser Ala His

1 5 10 15

Ala Val Lys Thr His Asn Leu Glu Arg Val Glu Ala Ser Gly Val Ala

20 25 30

Asn Asp Lys Glu Ala Pro Leu Ser Trp Arg Ser Lys Glu Val Arg Asn

35 40 45

Tyr Met Gly Ser Arg Thr Val Ile Ser Asn Lys Gln Leu Thr Lys Ser

50 55 60

Ala Asn Gln Ser Ile Glu Glu Ala Leu Gln Asn Val Pro Gly Val His

65 70 75 80

Ile Arg Asn Ser Thr Gly Ile Gly Ala Val Pro Ser Ile Ser Ile Arg

85 90 95

Gly Phe Gly Ala Gly Gly Pro Gly His Ser Asn Thr Gly Met Ile Leu

100 105 110

Val Asn Gly Ile Pro Ile Tyr Val Ala Pro Tyr Val Glu Ile Gly Thr

115 120 125

Val Ile Phe Pro Val Thr Phe Gln Ser Val Asp Arg Ile Ser Val Thr

130 135 140

Lys Gly Gly Glu Ser Val Arg Tyr Gly Pro Asn Ala Phe Gly Gly Val

145 150 155 160

Ile Asn Ile Ile Thr Lys Gly Ile Pro Thr Asn Trp Glu Ser Gln Val

165 170 175

Ser Glu Arg Thr Thr Phe Trp Gly Lys Ser Glu Asn Gly Gly Phe Phe

180 185 190

Asn Gln Asn Ser Lys Asn Ile Asp Lys Ser Leu Val Asn Asn Met Leu

195 200 205

Phe Asn Thr Tyr Leu Arg Thr Gly Gly Met Met Asn Lys His Phe Gly

210 215 220

Ile Gln Ala Gln Val Asn Trp Leu Lys Gly Gln Gly Phe Arg Tyr Asn

225 230 235 240

Ser Pro Thr Asp Ile Gln Asn Tyr Met Leu Asp Ser Leu Tyr Gln Ile

245 250 255

Asn Asp Ser Asn Lys Ile Thr Ala Phe Phe Gln Tyr Tyr Ser Tyr Phe

260 265 270

Leu Thr Asp Pro Gly Ser Leu Gly Ile Ala Ala Tyr Asn Gln Asn Arg

275 280 285

Phe Gln Asn Asn Arg Pro Asn Asn Asp Lys Ser Gly Arg Ala Lys Arg

290 295 300

Trp Gly Ala Val Tyr Gln Asn Phe Phe Gly Asp Thr Asp Arg Val Gly

305 310 315 320

Gly Asp Phe Thr Phe Ser Tyr Tyr Gly His Asp Met Ser Arg Asp Phe

325 330 335

Lys Phe Asp Ser Asn Tyr Leu Asn Val Asn Thr Asn Pro Lys Leu Gly

340 345 350

Pro Val Tyr Thr Asn Gln Asn Tyr Pro Gly Phe Phe Ile Phe Asp His

355 360 365

Leu Arg Arg Tyr Val Met Asn Ala Phe Glu Pro Asn Leu Asn Leu Val

370 375 380

Val Asn Thr Asn Lys Val Lys Gln Thr Phe Asn Val Gly Met Arg Phe

385 390 395 400

Met Thr Met Asp Met Phe Ile Arg Ser Asp Gln Ser Thr Cys Glu Lys 405 410 415

Thr Asp Ile Ile Asn Gly Val Cys His Met Pro Pro Tyr Val Leu Ser

420 425 430

Lys Thr Pro Asn Asn Asn Gln Glu Met Phe Asn Asn Tyr Thr Ala Val

435 440 445

Trp Leu Ser Asp Lys Ile Glu Phe Phe Asp Ser Lys Leu Val Ile Thr

450 455 460

Pro Gly Leu Arg Tyr Thr Phe Leu Asn Tyr Asn Asn Lys Glu Pro Glu

465 470 475 480

Lys His Asp Phe Ser Val Trp Thr Ser Lys Lys Gln Arg Gln Asn Glu

485 490 495

Trp Ser Pro Ala Leu Asn Ile Gly Tyr Lys Pro Met Glu Asn Trp Ile

500 505 510

Trp Tyr Ala Asn Tyr Arg Arg Ser Phe Ile Pro Pro Gln His Thr Met

515 520 525

Val Gly Ile Thr Arg Thr Asn Tyr Asn Gln Ile Phe Asn Glu Ile Glu

530 535 540

Val Gly Gln Arg Tyr Ser Tyr Lys Asn Leu Leu Ser Phe Asn Thr Asn

545 550 555 560

Tyr Phe Val Ile Phe Ala Lys Arg Tyr Tyr Ala Gly Gly Tyr Ser Pro

565 570 575

Gln Pro Val Asp Ala Arg Ser Gln Gly Val Glu Leu Glu Leu Tyr Tyr

580 585 590

Ala Pro Ile Arg Gly Leu Gln Phe His Val Ala Tyr Thr Tyr Ile Asp

595 600 605

Ala Arg Ile Thr Ser Asn Ala Asp Asp Ile Ala Tyr Tyr Phe Thr Gly

610 615 620

Ile Val Asn Lys Pro Phe Asp Ile Lys Gly Lys Arg Leu Pro Tyr Val

625 630 635 640

Ser Pro Asn Gln Phe Ile Phe Asp Met Met Tyr Thr Tyr Lys His Thr

645 650 655

Thr Phe Gly Ile Ser Ser Tyr Phe Tyr Ser Arg Ala Tyr Ser Ser Met

660 665 670

Leu Asn Gln Ala Lys Asp Gln Thr Val Cys Leu Pro Leu Asn Pro Glu

675 680 685

Tyr Thr Gly Gly Leu Lys Tyr Gly Cys Asn Ser Val Gly Leu Leu Pro

690 695 700

Leu Tyr Phe Val Leu Asn Val Gln Val Ser Ser Ile Leu Trp Gln Ser

705 710 715 720

Gly Arg His Lys Ile Thr Gly Ser Leu Gln Ile Asn Asn Leu Phe Asn

725 730 735

Met Lys Tyr Tyr Phe Arg Gly Ile Gly Thr Ser Pro Thr Gly Arg Glu

740 745 750

Pro Ala Pro Gly Arg Ser Ile Thr Ala Tyr Leu Asn Tyr Glu Phe

755 760 765

(2) INFORMATION FOR SEQ ID NO: 112:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 115 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 115

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 112:

Leu His Pro Leu Cys Ala His Gly Gln Cys Gly Ser Glu Ala Ile Ala

1 5 10 15

Cys Leu Glu Ala Ile Ser Val Gly Ile Val Pro Val Ile Ala Asn Ser

20 25 30

Pro Leu Ser Ala Thr Arg Gln Phe Ala Leu Asp Glu Arg Ser Leu Phe

35 40 45

Glu Pro Asn Asn Ala Lys Asp Leu Ser Ala Lys Ile Asp Trp Trp Leu

50 55 60

Glu Asn Lys Leu Glu Arg Glu Arg Met Gln Asn Glu Tyr Ala Lys Ser

65 70 75 80

Ala Leu Asn Tyr Thr Leu Glu Asn Ser Val Ile Gln Ile Glu Lys Val

85 90 95

Tyr Glu Glu Ala Ile Lys Asp Phe Lys Asn Asn Pro Asn Leu Phe Lys

100 105 110

Thr leu ser

115

(2) INFORMATION FOR SEQ ID NO: 113:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 389 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 389

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 113:

Met Val Ile Val Leu Val Val Asp Ser Phe Lys Asp Thr Ser Asn Gly

1 5 10 15

Thr Ser Met Thr Ala Phe Arg Phe Phe Glu Ala Leu Lys Lys Arg Gly

20 25 30

His Ala Met Arg Val Val Ala Pro His Val Asp Asn Leu Gly Ser Glu

35 40 45

Glu Glu Gly Tyr Tyr Asn Leu Lys Glu Arg Tyr Ile Pro Leu Val Thr

50 55 60

Glu Ile Ser His Lys Gln His Ile Leu Phe Ala Lys Pro Asp Glu Lys

65 70 75 80

Ile Leu Arg Lys Ala Phe Lys Gly Ala Asp Met Ile His Thr Tyr Leu

85 90 95

Pro Phe Leu Leu Glu Lys Thr Ala Val Lys Ile Ala Arg Glu Met Arg

100 105 110

Val Pro Tyr Ile Gly Ser Phe His Leu Gln Pro Glu His Ile Ser Tyr

115 120 125

Asn Met Lys Leu Gly Gln Phe Ser Trp Leu Asn Thr Met Leu Phe Ser

130 135 140

Trp Phe Lys Ser Ser His Tyr Arg Tyr Ile His His Ile His Cys Pro

145 150 155 160

Ser Lys Phe Ile Val Glu Glu Leu Glu Lys Tyr Asn Tyr Gly Gly Lys

165 170 175

Lys Tyr Ala Ile Ser Asn Gly Phe Asp Pro Met Phe Lys Phe Glu His

180 185 190

Pro Gln Lys Ser Leu Phe Asp Thr Thr Pro Phe Lys Ile Ala Met Val

195 200 205

Gly Arg Tyr Ser Asn Glu Lys Asn Gln Ser Val Leu Ile Lys Ala Val

210 215 220

Ala Leu Ser Arg Tyr Lys Gln Asp Ile Val Leu Leu Leu Lys Gly Lys

225 230 235 240

Gly Pro Asp Glu Lys Lys Ile Lys Leu Leu Ala Gln Lys Leu Gly Val

245 250 255

Lys Thr Glu Phe Gly Phe Val Asn Ser His Glu Leu Leu Glu Ile Leu

260 265 270

Lys Thr Cys Thr Leu Tyr Ala His Thr Ala Asn Val Glu Ser Glu Ala

275 280 285

Ile Ala Cys Leu Glu Ala Ile Ser Val Gly Ile Val Pro Val Ile Ala

290 295 300

Asn Ser Pro Leu Ser Ala Thr Arg Gln Phe Ala Leu Asp Glu Arg Ser

305 310 315 320

Leu Phe Glu Pro Asn Asn Ala Lys Asp Leu Ser Ala Lys Ile Asp Trp

325 330 335

Trp Leu Glu Asn Lys Leu Glu Arg Glu Arg Met Gln Asn Glu Tyr Ala

340 345 350

Lys Ser Ala Leu Asn Tyr Thr Leu Glu Asn Ser Val Ile Gln Ile Glu

355 360 365

Lys Val Tyr Glu Glu Ala Ile Lys Asp Phe Lys Asn Asn Pro Asn Leu

370 375 380

Phe Lys Thr Leu Ser

385

(2) INFORMATION FOR SEQ ID NO: 114:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 312 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 312

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 114:

Leu Ala Ser Tyr Gly Phe Phe Leu Gly Ala Leu Phe Ile Leu Ala Ser

1 5 10 15

Gly Ile Val Cys Leu Gln Thr Ala Gly Asn Pro Phe Val Thr Leu Leu

20 25 30

Ser Lys Gly Lys Glu Ala Arg Asn Leu Val Leu Val Gln Ala Phe Asn

35 40 45

Ser Leu Gly Thr Thr Leu Gly Pro Ile Phe Gly Ser Leu Leu Ile Phe

50 55 60

Ser Ala Thr Lys Thr Ser Asp Asn Leu Ser Leu Ile Asp Lys Leu Ala

65 70 75 80

Asp Ala Lys Ser Val Gln Met Pro Tyr Leu Gly Leu Ala Val Phe Ser

85 90 95

Leu Leu Leu Ala Leu Val Met Tyr Leu Leu Lys Leu Pro Asp Val Glu

100 105 110

Lys Glu Met Pro Lys Glu Thr Thr Gln Lys Ser Leu Phe Ser His Lys

115 120 125

His Phe Val Phe Gly Ala Leu Gly Ile Phe Phe Tyr Val Gly Gly Glu

130 135 140

Val Ala Ile Gly Ser Phe Leu Val Leu Ser Phe Glu Lys Leu Leu Asn

145 150 155 160

Leu Asp Ala Gln Ser Ser Ala His Tyr Leu Val Tyr Tyr Trp Gly Gly

165 170 175

Ala Met Val Gly Arg Phe Leu Gly Ser Ala Leu Met Asn Lys Ile Ala

180 185 190

Pro Asn Lys Tyr Leu Ala Phe Asn Ala Leu Ser Ser Ile Ile Leu Ile

195 200 205

Ala Leu Ala Ile Leu Ile Gly Gly Lys Ile Ala Leu Phe Ala Leu Thr

210 215 220

Phe Val Gly Phe Phe Asn Ser Ile Met Phe Pro Thr Ile Phe Ser Leu

225 230 235 240

Ala Thr Leu Asn Leu Gly His Leu Thr Ser Lys Ala Ser Gly Val Ile

245 250 255

Ser Met Ala Ile Val Gly Gly Ala Leu Ile Pro Pro Ile Gln Gly Val

260 265 270

Val Thr Asp Met Leu Thr Ala Thr Glu Ser Asn Leu Leu Tyr Ala Tyr

275 280 285

Ser Val Pro Leu Leu Cys Tyr Phe Tyr Ile Leu Phe Phe Ala Leu Lys

290 295 300

Gly Tyr Lys Gln Glu Glu Asn Ser

305 310

(2) INFORMATION FOR SEQ ID NO: 115:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 407 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 407

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 115:

Met Gln Lys Thr Ser Asn Thr Leu Ala Leu Gly Ser Leu Thr Ala Leu

1 5 10 15

Phe Phe Leu Met Gly Phe Ile Thr Val Leu Asn Asp Ile Leu Ile Pro

20 25 30

His Leu Lys Pro Ile Phe Asp Leu Thr Tyr Phe Glu Ala Ser Leu Ile

35 40 45

Gln Phe Cys Phe Phe Gly Ala Tyr Phe Ile Met Gly Gly Val Phe Gly

50 55 60

Asn Val Ile Ser Lys Ile Gly Tyr Pro Phe Gly Val Val Leu Gly Phe

65 70 75 80

Val Ile Thr Ala Ser Gly Cys Ala Leu Phe Tyr Pro Ala Ala His Phe

85 90 95

Gly Ser Tyr Gly Phe Phe Leu Gly Ala Leu Phe Ile Leu Ala Ser Gly

100 105 110

Ile Val Cys Leu Gln Thr Ala Gly Asn Pro Phe Val Thr Leu Leu Ser

115 120 125

Lys Gly Lys Glu Ala Arg Asn Leu Val Leu Val Gln Ala Phe Asn Ser

130 135 140

Leu Gly Thr Thr Leu Gly Pro Ile Phe Gly Ser Leu Leu Ile Phe Ser

145 150 155 160

Ala Thr Lys Thr Ser Asp Asn Leu Ser Leu Ile Asp Lys Leu Ala Asp

165 170 175

Ala Lys Ser Val Gln Met Pro Tyr Leu Gly Leu Ala Val Phe Ser Leu

180 185 190

Leu Leu Ala Leu Val Met Tyr Leu Leu Lys Leu Pro Asp Val Glu Lys

195 200 205

Glu Met Pro Lys Glu Thr Thr Gln Lys Ser Leu Phe Ser His Lys His

210 215 220

Phe Val Phe Gly Ala Leu Gly Ile Phe Phe Tyr Val Gly Gly Glu Val

225 230 235 240

Ala Ile Gly Ser Phe Leu Val Leu Ser Phe Glu Lys Leu Leu Asn Leu

245 250 255

Asp Ala Gln Ser Ser Ala His Tyr Leu Val Tyr Tyr Trp Gly Gly Ala

260 265 270

Met Val Gly Arg Phe Leu Gly Ser Ala Leu Met Asn Lys Ile Ala Pro

275 280 285

Asn Lys Tyr Leu Ala Phe Asn Ala Leu Ser Ser Ile Leu Ile Ala

290 295 300

Leu Ala Ile Leu Ile Gly Gly Lys Ile Ala Leu Phe Ala Leu Thr Phe

305 310 315 320

Val Gly Phe Phe Asn Ser Ile Met Phe Pro Thr Ile Phe Ser Leu Ala

325 330 335

Thr Leu Asn Leu Gly His Leu Thr Ser Lys Ala Ser Gly Val Ile Ser

340 345 350

Met Ala Ile Val Gly Gly Ala Leu Ile Pro Pro Ile Gln Gly Val Val

355 360 365

Thr Asp Met Leu Thr Ala Thr Glu Ser Asn Leu Leu Tyr Ala Tyr Ser

370 375 380

Val Pro Leu Leu Cys Tyr Phe Tyr Ile Leu Phe Phe Ala Leu Lys Gly

385 390 395 400

Tyr Lys Gln Glu Glu Asn Ser

405

(2) INFORMATION FOR SEQ ID NO: 116:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 125 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 125

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 116:

Met Asn Lys Ile Ala Pro Asn Lys Tyr Leu Ala Phe Gly Ala Leu Ser

1 5 10 15

Ser Ile Ile Leu Ile Ala Leu Ala Ile Leu Ile Gly Gly Lys Ile Ala

20 25 30

Leu Phe Ala Leu Thr Phe Val Gly Phe Phe Asn Ser Ile Met Phe Pro

35 40 45

Thr Ile Phe Ser Leu Ala Thr Leu Asn Leu Gly Ile Ser Leu Leu Met

50 55 60

Ala Ser Gly Val Ile Ser Met Ala Ile Val Gly Gly Ala Leu Ile Pro

65 70 75 80

Pro Ile Gln Gly Val Val Thr Asp Met Leu Thr Ala Thr Glu Ser Asn

85 90 95

Leu Leu Tyr Ala Tyr Ser Val Pro Leu Leu Cys Tyr Phe Tyr Ile Leu

100 105 110

Phe Phe Ala Leu Lys Gly Tyr Lys Gln Glu Glu Asn Ser

115 120 125

(2) INFORMATION FOR SEQ ID NO: 117:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 330 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 330

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 117:

Leu Lys Lys Ile Leu Pro Ala Leu Leu Met Gly Phe Val Gly Leu Asn

1 5 10 15

Ala Ser Asp Arg Leu Leu Glu Ile Met Arg Leu Tyr Gln Lys Gln Gly

20 25 30

Leu Glu Val Val Gly Gln Lys Leu Asp Ser Tyr Leu Ala Asp Lys Ser

35 40 45

Phe Trp Ala Glu Glu Leu Gln Asn Lys Asp Thr Asp Phe Gly Tyr Tyr

50 55 60

Gln Asn Lys Gln Phe Leu Phe Val Ala Asp Lys Ser Lys Pro Ser Leu

65 70 75 80

Glu Phe Tyr Glu Ile Glu Asn Asn Met Leu Lys Lys Ile Asn Ser Ser

85 90 95

Lys Ala Leu Val Gly Ser Lys Lys Gly Asp Lys Thr Leu Glu Gly Asp

100 105 110

Leu Ala Thr Pro Ile Gly Val Tyr Arg Ile Thr Gln Lys Leu Glu Arg

115 120 125

Leu Asp Gln Tyr Tyr Gly Val Leu Ala Phe Val Thr Asn Tyr Pro Asn

130 135 140

Leu Tyr Asp Thr Leu Lys Lys Arg Thr Gly His Gly Ile Trp Val His

145 150 155 160

Gly Met Pro Leu Asn Gly Asp Arg Asn Glu Leu Asn Thr Lys Gly Cys

165 170 175

Ile Ala Ile Glu Asn Pro Ile Leu Ser Ser Tyr Asp Lys Val Leu Lys

180 185 190

Gly Glu Lys Ala Phe Leu Ile Thr Tyr Glu Asp Lys Phe Ser Pro Ser

195 200 205

Thr Lys Glu Glu Leu Ser Met Ile Leu Ser Ser Leu Phe Gln Trp Lys

210 215 220

Glu Ala Trp Ala Arg Gly Asp Phe Glu Arg Tyr Met Arg Phe Tyr Asn

225 230 235 240

Pro Asn Phe Thr Arg Tyr Asp Gly Met Ser Phe Asn Ala Phe Lys Glu

245 250 255

Tyr Lys Lys Arg Val Phe Ala Lys Asn Glu Lys Lys Asn Ile Ala Phe

260 265 270

Ser Ser Ile Asn Val Ile Pro Tyr Pro Asn Ser Gln Asn Lys Arg Leu

275 280 285

Phe Tyr Val Val Phe Asp Gln Asp Tyr Lys Ala Tyr Gln Gln Asn Lys

290 295 300

Leu Ser Tyr Ser Ser Asn Ser Gln Lys Glu Leu Tyr Val Glu Ile Glu

305 310 315 320

Asn Asn Gln Ala Ser Ile Met Glu Lys

325 330

(2) INFORMATION FOR SEQ ID NO: 118:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 169 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 169

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 118:

Leu Phe Glu Lys Trp Ile Gly Leu Thr Leu Leu Leu Ser Ser Leu Gly

1 5 10 15

Tyr Pro Cys Gln Lys Val Ser Ile Ser Phe Lys Gln Tyr Glu Asn Leu

20 25 30

Ile His Ile His Gln Lys Gly Cys Asn Asn Glu Val Val Cys Arg Thr

35 40 45

Leu Ile Ser Ile Ala Leu Leu Glu Ser Ser Leu Gly Leu Asn Asn Lys

50 55 60

Arg Glu Lys Ser Leu Lys Asp Thr Ser Tyr Ser Met Phe His Ile Thr

65 70 75 80

Leu Asn Thr Ala Lys Lys Phe Tyr Pro Thr Tyr Ser Lys Thr Leu Leu

85 90 95

Lys Thr Lys Leu Leu Asn Asp Val Gly Phe Ala Ile Gln Leu Ala Lys

100 105 110

Gln Ile Leu Lys Glu Asn Phe Asp Tyr Tyr His Gln Lys His Pro Asn

115 120 125

Lys Ser Val Tyr Gln Leu Val Gln Met Ala Ile Gly Ala Tyr Asn Gly

130 135 140

Gly Met Lys His Asn Pro Asn Gly Ala Tyr Met Lys Lys Phe Arg Cys

145 150 155 160

Ile Tyr Ser Gln Val Arg Tyr Asn Glu

165

(2) INFORMATION FOR SEQ ID NO: 119:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 215 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 215

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 119:

Met Lys Lys Pro Tyr Arg Lys Ile Ser Asp Tyr Ala Ile Val Gly Gly

1 5 10 15

Leu Ser Ala Leu Val Met Val Ser Ile Val Gly Cys Lys Ser Asn Ala

20 25 30

Asp Asp Lys Pro Lys Glu Gln Ser Ser Leu Ser Gln Ser Val Gln Lys

35 40 45

Gly Ala Phe Val Ile Leu Glu Glu Gln Lys Asp Lys Ser Tyr Lys Val

50 55 60

Val Glu Glu Tyr Pro Ser Ser Arg Thr His Ile Val Val Arg Asp Leu

65 70 75 80

Gln Gly Asn Glu Arg Val Leu Ser Asn Glu Glu Ile Gln Lys Leu Ile

85 90 95

Lys Glu Glu Glu Ala Lys Ile Asp Asn Gly Thr Ser Lys Leu Val Gln

100 105 110

Pro Asn Asn Gly Gly Ser Asn Glu Gly Ser Gly Phe Gly Leu Gly Ser

115 120 125

Ala Ile Leu Gly Ser Ala Ala Gly Ala Ile Leu Gly Ser Tyr Ile Gly

130 135 140

Asn Lys Leu Phe Asn Asn Pro Asn Tyr Gln Gln Asn Ala Gln Arg Thr

145 150 155 160

Tyr Lys Ser Pro Gln Ala Tyr Gln Arg Ser Gln Asn Ser Phe Ser Lys

165 170 175

Ser Ala Pro Ser Ala Ser Ser Met Gly Thr Ala Ser Lys Gly Gln Ser

180 185 190

Gly Phe Phe Gly Ser Ser Arg Pro Thr Ser Ser Pro Ala Ile Ser Ser

195 200 205

Gly Thr Arg Gly Phe Asn Ala

210 215

(2) INFORMATION FOR SEQ ID NO: 120:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 253 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 253

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 120:

Leu Lys Thr Leu Phe Ser Val Tyr Leu Phe Leu Ser Leu Asn Pro Leu

1 5 10 15

Phe Leu Glu Ala Lys Glu Ile Thr Trp Ser Gln Phe Leu Glu Asn Phe

20 25 30

Lys Asn Lys Asn Glu Asp Asp Lys Pro Lys Pro Leu Thr Ile Asp Lys

35 40 45

Asn Asn Glu Lys Gln Gln Ile Leu Asp Lys Asn Gln Gln Ile Leu Lys

50 55 60

Arg Ala Leu Glu Lys Ser Leu Lys Phe Phe Phe Ile Phe Gly Tyr Asn

65 70 75 80

Tyr Ser Gln Ala Ala Tyr Ser Thr Thr Asn Gln Asn Leu Thr Leu Thr

85 90 95

Ala Asn Ser Ile Gly Phe Asn Thr Ala Thr Gly Leu Glu His Phe Leu

100 105 110

Arg Asn His Pro Lys Val Gly Phe Arg Ile Phe Ser Val Tyr Asn Tyr

115 120 125

Phe His Ser Val Ser Leu Ser Gln Pro Gln Ile Leu Met Val Gln Asn

130 135 140

Tyr Gly Gly Ala Leu Asp Phe Ser Trp Ile Phe Val Asp Lys Lys Thr

145 150 155 160

Tyr Arg Phe Arg Ser Tyr Leu Gly Ile Ala Leu Glu Gln Gly Val Leu

165 170 175

Leu Val Asp Thr Ile Lys Thr Gly Ser Phe Thr Thr Ile Ile Pro Arg

180 185 190

Thr Lys Lys Thr Phe Phe Gln Ala Pro Leu Arg Phe Gly Phe Ile Val

195 200 205

Asp Phe Ile Gly Tyr Leu Ser Leu Gln Leu Gly Ile Glu Met Pro Leu

210 215 220

Val Arg Asn Val Phe Tyr Thr Tyr Asn Asn His Gln Glu Arg Phe Lys

225 230 235 240

Pro Arg Phe Asn Ala Asn Leu Ser Leu Ile Val Ser Phe

245 250

(2) INFORMATION FOR SEQ ID NO: 121:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 336 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 336

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 121:

Leu Phe Phe Lys Phe Ile Leu Cys Leu Ser Leu Gly Ile Phe Ala Trp

1 5 10 15

Ala Lys Glu Val Ile Pro Thr Pro Ser Thr Pro Leu Thr Pro Ser Lys

20 25 30

Arg Tyr Ser Ile Asn Leu Met Thr Glu Asn Asp Gly Tyr Ile Asn Pro

35 40 45

Tyr Ile Asp Glu Tyr Tyr Thr Ala Gly Asn Gln Ile Gly Phe Ser Thr

50 55 60

Lys Glu Phe Asp Phe Ser Lys Asn Lys Ala Met Lys Trp Ser Ser Tyr

65 70 75 80

Leu Gly Phe Phe Asn Lys Ser Pro Arg Val Thr Arg Phe Gly Ile Ser

85 90 95

Leu Ala Gln Asp Met Tyr Thr Pro Ser Leu Ala Asn Arg Lys Leu Val

100 105 110

His Leu His Asp Asn His Pro Tyr Gly Gly Tyr Leu Arg Val Asn Leu

115 120 125

Asn Val Tyr Asn Arg His Gln Thr Phe Met Glu Leu Phe Thr Ile Ser

130 135 140

Leu Gly Thr Thr Gly Gln Asp Ser Leu Ala Ala Gln Thr Gln Arg Leu

145 150 155 160

Ile His Lys Trp Gly His Asp Pro Gln Phe Tyr Gly Trp Asn Thr Gln

165 170 175

Leu Lys Asn Glu Phe Ile Phe Glu Leu His Tyr Gln Leu Leu Lys Lys

180 185 190

Val Pro Leu Leu Lys Thr Arg Phe Phe Ser Met Glu Leu Met Pro Gly

195 200 205

Phe Asn Val Glu Leu Gly Asn Ala Arg Asp Tyr Phe Gln Leu Gly Ser

210 215 220

Leu Phe Arg Ala Gly Tyr Asn Leu Asp Ala Asp Tyr Gly Val Asn Lys

225 230 235 240

Val Asn Thr Ala Phe Asp Gly Gly Met Pro Tyr Ser Asp Lys Phe Ser

245 250 255

Ile Tyr Phe Phe Ala Gly Ala Phe Gly Arg Phe Gln Pro Leu Asn Ile

260 265 270

Phe Ile Gln Gly Asn Ser Pro Glu Thr Arg Gly Ile Ala Asn Leu Glu

275 280 285

Tyr Phe Val Tyr Ala Ser Glu Ile Gly Ala Ala Met Met Trp Arg Ser

290 295 300

Leu Arg Val Ala Phe Thr Ile Thr Asp Ile Ser Lys Thr Phe Gln Ser

305 310 315 320

Gln Pro Lys His His Gln Ile Gly Thr Leu Glu Leu Asn Phe Ala Phe

325 330 335

(2) INFORMATION FOR SEQ ID NO: 122:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 108 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 108

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 122:

Met Lys Pro Ile Phe Ser Leu Phe Phe Leu Leu Ile Val Leu Lys Ala

1 5 10 15

His Pro Ile Asn Pro Leu Leu Glu Pro Leu Tyr Phe Pro Ser Tyr Thr

20 25 30

Gln Phe Leu Asp Leu Glu Pro His Phe Val Ile Lys Lys Lys Arg Ala

35 40 45

Tyr Arg Pro Phe Gln Trp Gly Asn Thr Ile Ile Ile Lys Arg His Asp

50 55 60

Leu Glu Glu Arg Gln Ser Asn Gln Pro Ser Asp Ile Phe Arg Gln Asn

65 70 75 80

Ala Glu Ile Asn Val Ser Ser Gln Thr Phe Leu Arg Gly Ile Ser Ser

85 90 95

Ala Ser Ser Arg Ile Val Ile Asp Ser Val Ala Gln

100 105

(2) INFORMATION FOR SEQ ID NO: 123:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 195 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 195

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 123:

Met Ser Asn Asn Pro Phe Lys Lys Val Gly Met Ile Ser Ser Gln Asn

1 5 10 15

Asn Asn Gly Ala Leu Asn Gly Leu Gly Val Gln Val Gly Tyr Lys Gln

20 25 30

Phe Phe Gly Glu Ser Lys Arg Trp Gly Leu Arg Tyr Tyr Gly Phe Phe

35 40 45

Asp Tyr Asn His Gly Tyr Ile Lys Ser Ser Phe Phe Asn Ser Ser Ser

50 55 60

Asp Ile Trp Thr Tyr Gly Gly Gly Ser Asp Leu Leu Val Asn Phe Ile

65 70 75 80

Asn Asp Ser Ile Thr Arg Lys Asn Asn Lys Leu Ser Val Gly Leu Phe

85 90 95

Gly Gly Ile Gln Leu Ala Gly Thr Thr Trp Leu Asn Ser Gln Tyr Met

100 105 110

Asn Leu Thr Ala Phe Asn Asn Pro Tyr Ser Ala Lys Val Asn Ala Ser

115 120 125

Asn Phe Gln Phe Leu Phe Asn Leu Gly Leu Arg Thr Asn Leu Ala Thr

130 135 140

Ala Lys Lys Lys Asp Ser Glu Arg Ser Ala Gln His Gly Val Glu Leu

145 150 155 160

Gly Ile Lys Ile Pro Thr Ile Asn Thr Asn Tyr Tyr Ser Phe Leu Gly

165 170 175

Thr Lys Leu Glu Tyr Arg Arg Leu Tyr Ser Val Tyr Leu Asn Tyr Val

180 185 190

Phe Ala Tyr

195

(2) INFORMATION FOR SEQ ID NO: 124:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 227 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 227

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 124:

Val Arg Phe Gly Lys Ile Asp Tyr Leu Asn Met Leu Pro Phe Asp Val

1 5 10 15

Phe Ile Lys Ser Tyr Pro Thr Pro Cys Tyr Phe Lys Gln Phe Leu Arg

20 25 30

Leu Lys Lys Thr Tyr Pro Ser Lys Leu Asn Glu Ser Phe Leu Phe Arg

35 40 45

Arg Ile Asp Ala Gly Phe Ile Ser Ser Ile Ala Gly Tyr Pro Phe Ala

50 55 60

Leu Cys Ser Tyr Ser Leu Gly Ile Val Ala Tyr Lys Glu Val Leu Ser

65 70 75 80

Val Leu Val Val Asn Arg Glu Asn Ala Phe Asp Lys Glu Ser Ala Ser

85 90 95

Ser Asn Ala Leu Ser Lys Val Leu Gly Leu Lys Gly Glu Val Leu Ile

100 105 110

Gly Asn Lys Ala Leu Gln Phe Tyr Tyr Ser Asn Pro Lys Lys Asp Phe

115 120 125

Ile Asp Leu Ala Ala Leu Trp Tyr Glu Lys Lys Arg Leu Pro Phe Val

130 135 140

Phe Gly Arg Leu Cys Tyr Tyr Gln Asn Lys Asp Phe Tyr Lys Arg Leu

145 150 155 160

Ser Leu Ala Phe Lys His Gln Lys Thr Lys Ile Pro His Tyr Ile Leu

165 170 175

Lys Glu Ala Ala Leu Lys Thr Asn Leu Lys Arg Gln Asp Ile Leu Asn

180 185 190

Tyr Leu Gln Lys Ile Tyr Tyr Thr Leu Gly Lys Lys Glu Gln Ser Gly

195 200 205

Leu Lys Ala Phe Tyr Arg Glu Leu Leu Phe Lys Arg Ile Gln Lys Pro

210 215 220

Lys Arg Phe

225

(2) INFORMATION FOR SEQ ID NO: 125:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 305 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 305

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 125:

Met Gly Arg Ile Glu Ser Lys Lys Arg Leu Lys Ala Leu Ile Phe Leu

1 5 10 15

Ala Ser Leu Gly Val Leu Trp Gly Asn Ala Ala Glu Lys Thr Pro Phe

20 25 30

Phe Lys Thr Lys Asn His Ile Tyr Leu Gly Phe Arg Leu Gly Thr Gly

35 40 45

Ala Thr Thr Arg Thr Ser Met Trp Gln Gln Ala Tyr Lys Asp Asn Pro

50 55 60

Thr Cys Pro Ser Ser Val Cys Tyr Gly Glu Lys Leu Glu Ala His Tyr

65 70 75 80

Lys Gly Gly Lys Asn Leu Ser Tyr Thr Gly Gln Ile Gly Asp Glu Ile

85 90 95

Ala Phe Asp Lys Tyr His Ile Leu Gly Leu Arg Val Trp Gly Asp Val

100 105 110

Glu Tyr Ala Lys Ala Gln Leu Gly Gln Lys Val Gly Gly Asn Thr Leu

115 120 125

Leu Ser Gln Ala Asn Tyr Asn Pro Ser Ala Ile Lys Thr Tyr Asp Pro

130 135 140

Thr Ser Asn Ala Gln Gly Ser Leu Val Leu Gln Lys Thr Pro Ser Pro

145 150 155 160

Gln Asp Phe Leu Phe Asn Asn Gly His Phe Met Ala Phe Gly Leu Asn

165 170 175

Val Asn Met Phe Val Asn Leu Pro Ile Asp Thr Leu Leu Lys Leu Ala

180 185 190

Leu Lys Thr Glu Lys Met Leu Phe Phe Lys Ile Gly Val Phe Gly Gly

195 200 205

Gly Gly Val Glu Tyr Ala Ile Leu Trp Ser Pro Gln Tyr Lys Asn Gln

210 215 220

Asn Thr His Gln Asp Asp Lys Phe Ala Ala Gly Gly Gly Phe Phe

225 230 235 240

Val Asn Phe Gly Gly Ser Leu Tyr Ile Gly Lys Arg Asn Arg Phe Asn

245 250 255

Val Gly Leu Lys Ile Pro Tyr Tyr Ser Leu Ser Ala Gln Ser Trp Lys

260 265 270

Asn Phe Gly Ser Ser Asn Val Trp Gln Gln Gln Thr Ile Arg Gln Asn

275 280 285

Phe Ser Val Phe Arg Asn Lys Glu Val Phe Val Ser Tyr Ala Phe Leu

290 295 300

Phe

305

(2) INFORMATION FOR SEQ ID NO: 126:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 258 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 258

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 126:

Met Phe Leu Arg Ser Tyr Pro Lys Leu Arg Tyr Ala Leu Cys Leu Pro

1 5 10 15

Leu Leu Thr Glu Thr Cys Tyr Ser Glu Glu Arg Thr Leu Asn Lys Val

20 25 30

Thr Thr Gln Ala Lys Arg Ile Phe Thr Tyr Asn Asn Glu Phe Lys Val

35 40 45

Thr Ser Lys Glu Leu Asp Gln Arg Gln Ser Asn Glu Val Lys Asp Leu

50 55 60

Phe Arg Thr Asn Pro Asp Val Asn Val Gly Gly Gly Ser Val Met Gly

65 70 75 80

Gln Lys Ile Tyr Val Arg Gly Ile Glu Asp Arg Leu Leu Arg Val Thr

85 90 95

Val Asp Gly Ala Ala Gln Asn Gly Asn Ile Tyr His His Gln Gly Asn

100 105 110

Thr Val Ile Asp Pro Gly Met Leu Lys Ser Val Glu Val Thr Lys Gly

115 120 125

Ala Ala Asn Ala Ser Ala Gly Pro Gly Ala Ile Ala Gly Val Ile Lys

130 135 140

Met Glu Thr Lys Gly Ala Ala Asp Phe Ile Pro Arg Gly Lys Asn Tyr

145 150 155 160

Ala Ala Ser Gly Ala Val Ser Phe Tyr Thr Asn Phe Gly Asp Arg Glu

165 170 175

Thr Phe Arg Ser Ala Tyr Gln Ser Ala His Phe Asp Ile Ile Ala Tyr

180 185 190

Tyr Thr His Gln Asn Ile Phe Tyr Tyr Arg Ser Gly Ala Thr Val Met

195 200 205

Lys Asn Leu Phe Lys Pro Thr Gln Ala Asp Lys Glu Pro Gly Thr Pro

210 215 220

Ser Glu Gln Asn Asn Ala Leu Ile Lys Met Asn Gly Tyr Leu Ser Asp

225 230 235 240

Arg Asp Thr Leu Thr Phe Ser Trp Asn Met Thr Arg Asp Asn Ala Thr

245 250 255

Arg leu

(2) INFORMATION FOR SEQ ID NO: 127:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 192 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 192

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 127:

Met Phe Leu Arg Ser Tyr Pro Lys Leu Arg Tyr Ala Leu Cys Leu Pro

1 5 10 15

Leu Leu Thr Glu Thr Cys Tyr Ser Glu Glu Arg Thr Leu Asn Lys Val

20 25 30

Thr Thr Gln Ala Lys Arg Ile Phe Thr Tyr Asn Asn Glu Phe Lys Val

35 40 45

Thr Ser Lys Glu Leu Asp Gln Arg Gln Ser Asn Glu Val Lys Asp Leu

50 55 60

Phe Arg Thr Asn Pro Asp Val Asn Val Gly Gly Gly Ser Val Met Gly

65 70 75 80

Gln Lys Ile Tyr Val Arg Gly Ile Glu Asp Arg Leu Leu Arg Val Thr

85 90 95

Val Asp Gly Ala Ala Gln Asn Gly Asn Ile Tyr His His Gln Gly Asn

100 105 110

Thr Val Ile Asp Pro Gly Met Leu Lys Ser Val Glu Val Thr Lys Gly

115 120 125

Ala Ala Asn Ala Ser Ala Gly Pro Gly Ala Ile Ala Gly Val Ile Lys

130 135 140

Met Glu Thr Lys Gly Ala Ala Asp Phe Ile Pro Arg Gly Lys Asn Tyr

145 150 155 160

Ala Ala Ser Gly Ala Val Ser Phe Tyr Thr Asn Phe Gly Asp Arg Glu

165 170 175

Thr Phe Arg Ser Ala Tyr Gln Ser Ala His Phe Asp Ile Ile Ala Tyr

180 185 190

(2) INFORMATION FOR SEQ ID NO: 128:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 126 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 126

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 128:

Val Pro Leu Ser Leu Gly Gly Asn Leu Leu Asn Pro Asn Asn Ser Ser

1 5 10 15

Val Leu Asn Leu Lys Asn Ser Gln Leu Val Phe Ser Asp Gln Gly Ser

20 25 30

Leu Asn Ile Ala Asn Ile Asp Leu Leu Ser Asp Leu Asn Gly Asn Lys

35 40 45

Asn Arg Val Tyr Asn Ile Ile Gln Ala Asp Met Asn Gly Asn Trp Tyr

50 55 60

Glu Arg Ile Asn Phe Phe Gly Met Arg Ile Asn Asp Gly Ile Tyr Asp

65 70 75 80

Ala Lys Asn Gln Thr Tyr Ser Phe Thr Asn Pro Leu Asn Asn Ala Val

85 90 95

Lys Phe Thr Glu Ser Phe Phe Ile His Arg Leu Cys Gly Ser Leu Ser

100 105 110

Gln Ile Gln Lys Lys Lys Asn Thr Ile Val Ser Pro Arg Leu

115 120 125

(2) INFORMATION FOR SEQ ID NO: 129:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 565 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 565

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 129:

Val Tyr Ser Tyr Ser Asp Asp Ala Gln Gly Val Phe Tyr Leu Thr Ser

1 5 10 15

Ser Val Lys Gly Tyr Tyr Asn Pro Asn Gln Ser Tyr Gln Ala Ser Gly

20 25 30

Ser Asn Asn Thr Thr Lys Asn Asn Asn Leu Thr Ser Glu Ser Ser Val

35 40 45

Ile Ser Gln Thr Tyr Asn Ala Gln Gly Asn Pro Ile Ser Ala Leu His

50 55 60

Val Tyr Asn Lys Gly Tyr Asn Phe Ser Asn Ile Lys Ala Leu Gly Gln

65 70 75 80

Met Ala Leu Lys Leu Tyr Pro Glu Ile Lys Lys Ile Leu Gly Asn Asp

85 90 95

Phe Ser Leu Ser Ser Leu Ser Asn Leu Lys Gly Asp Ala Leu Asn Gln

100 105 110

Leu Thr Lys Leu Ile Thr Pro Ser Asp Trp Lys Asn Ile Asn Glu Leu

115 120 125

Ile Asp Asn Ala Asn Asn Ser Val Val Gln Asn Phe Asn Asn Gly Thr

130 135 140

Leu Ile Ile Gly Ala Thr Lys Ile Gly Gln Thr Asp Thr Asn Ser Ala

145 150 155 160

Val Val Phe Gly Gly Leu Gly Tyr Gln Lys Pro Cys Asp Tyr Thr Asp

165 170 175

Ile Val Cys Gln Lys Phe Arg Gly Thr Tyr Leu Gly Gln Leu Leu Glu

180 185 190

Ser Asn Ser Ala Asp Leu Gly Tyr Ile Asp Thr Thr Phe Asn Ala Lys

195 200 205

Glu Ile Tyr Leu Thr Gly Thr Leu Gly Ser Gly Asn Ala Trp Gly Thr

210 215 220

Gly Gly Ser Ala Ser Val Thr Phe Asn Ser Gln Thr Ser Leu Ile Leu

225 230 235 240

Asn Gln Ala Asn Ile Val Ser Ser Gln Thr Asp Gly Ile Phe Ser Met

245 250 255

Leu Gly Gln Glu Gly Ile Asn Lys Val Phe Asn Gln Ala Gly Leu Ala

260 265 270

Asn Ile Leu Gly Glu Val Ala Met Gln Ser Ile Asn Lys Ala Gly Gly

275 280 285

Leu Gly Asn Leu Ile Val Asn Thr Leu Gly Ser Asp Ser Val Ile Gly

290 295 300

Gly Tyr Leu Thr Pro Glu Gln Lys Asn Gln Thr Leu Ser Gln Leu Leu

305 310 315 320

Gly Gln Asn Asn Phe Asp Asn Leu Met Asn Asp Ser Gly Leu Asn Thr

325 330 335

Ala Ile Lys Asp Leu Ile Arg Gln Lys Leu Gly Phe Trp Thr Gly Leu

340 345 350

Val Gly Gly Leu Ala Gly Leu Gly Gly Ile Asp Leu Gln Asn Pro Glu

355 360 365

Lys Leu Ile Gly Ser Met Ser Ile Asn Asp Leu Leu Ser Lys Lys Gly

370 375 380

Leu Phe Asn Gln Ile Thr Gly Phe Ile Ser Ala Asn Asp Ile Gly Gln

385 390 395 400

Val Ile Ser Val Met Leu Gln Asp Ile Val Lys Pro Ser Asp Ala Leu

405 410 415

Lys Asn Asp Val Ala Ala Leu Gly Lys Gln Met Ile Gly Glu Phe Leu

420 425 430

Gly Gln Asp Thr Leu Asn Ser Leu Glu Ser Leu Leu Gln Asn Gln Gln

435 440 445

Ile Lys Ser Val Leu Asp Lys Val Leu Ala Ala Lys Gly Leu Gly Ser

450 455 460

Ile Tyr Glu Gln Gly Leu Gly Asp Leu Ile Pro Asn Leu Gly Lys Lys

465 470 475 480

Gly Ile Phe Ala Pro Tyr Gly Leu Ser Gln Val Trp Gln Lys Gly Asp

485 490 495

Phe Ser Phe Asn Ala Gln Gly Asn Val Phe Val Gln Asn Ser Thr Phe

500 505 510

Ser Asn Ala Asn Gly Gly Thr Leu Ser Phe Asn Ala Gly Asn Ser Leu

515 520 525

Ile Phe Ala Gly Asn Asn His Ile Ala Phe Thr Asn His Ser Gly Thr

530 535 540

Leu Asn Leu Leu Ser Asn Gln Val Ser Asn Ile Asn Val Thr Met Leu

545 550 555 560

Asn Ala Ala Thr Ala

565

(2) INFORMATION FOR SEQ ID NO: 130:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 172 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 172

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 130:

Val Phe Gly Leu Ser Leu Ala Asp Met Ile Leu Glu Arg Phe Lys Asp

1 5 10 15

Phe Met Arg Glu Tyr Pro Glu Pro Tyr Lys Phe Leu Gln Val Phe Tyr

20 25 30

Ala Gln Glu Lys Glu Arg Phe Leu Asn His Lys Met Asn Asp Tyr Ile

35 40 45

Lys Gln Asn Lys Ser Lys Glu Glu Ala Ser Ile Leu Ala Arg Gln Gly

50 55 60

Phe Val Ser Val Ile Gly Arg Ala Leu Glu Lys Ile Ile Glu Leu Leu

65 70 75 80

Leu Lys Asp Phe Cys Ile Lys Asn Asn Val Lys Met Thr Asn Asp Lys

85 90 95

Thr Leu Arg Ala Lys Arg Ile Asn Gly Glu Leu Asp Lys Val Lys Arg

100 105 110

Ala Leu Leu Val His Phe Gly Gly Tyr Ser Val Leu Pro Asp Ile Ile

115 120 125

Leu Tyr Gln Thr Asn Lys Asp Asn Ile Lys Ile Leu Ala Ile Leu Ser

130 135 140

Val Lys Asn Ser Phe Arg Glu Arg Phe Thr Lys Asp Ala Leu Leu Glu

145 150 155 160

Ile Lys Thr Phe Ala Ile Ala Cys Asn Phe Ser His

165 170

(2) INFORMATION FOR SEQ ID NO: 131:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 331 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 331

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 131:

Met Lys Arg Phe Val Leu Phe Leu Leu Phe Ile Cys Val Cys Val Cys

1 5 10 15

Val Gln Ala Tyr Ala Glu Gln Asp Tyr Phe Phe Arg Asp Phe Lys Ser

20 25 30

Ile Asp Leu Pro Gln Lys Leu His Leu Asp Lys Lys Leu Ser Gln Thr

35 40 45

Ile Gln Pro Cys Ala Gln Leu Asn Ala Ser Lys His Tyr Thr Ala Thr

50 55 60

Gly Val Arg Glu Pro Asp Ala Cys Thr Lys Ser Phe Lys Lys Ser Ala

65 70 75 80

Met Val Ser Tyr Asp Leu Ala Leu Gly Tyr Leu Val Ser Gln Asn Lys

85 90 95

Pro Tyr Gly Leu Lys Ala Ile Glu Ile Leu Asn Ala Trp Ala Asn Glu

100 105 110

Leu Gln Ser Val Asp Thr Tyr Gln Ser Glu Asp Asn Ile Asn Phe Tyr

115 120 125

Met Pro Tyr Met Asn Met Ala Tyr Trp Phe Val Lys Lys Glu Phe Pro

130 135 140

Ser Pro Glu Tyr Glu Asp Phe Ile Arg Arg Met Arg Gln Tyr Ser Gln

145 150 155 160

Ser Ala Leu Asn Thr Asn His Gly Ala Trp Gly Ile Leu Phe Asp Val

165 170 175

Ser Ser Ala Leu Ala Leu Asp Asp His Ala Leu Leu Gln Ser Ser Ala

180 185 190

Asn Arg Trp Gln Glu Trp Val Phe Lys Ala Ile Asp Glu Asn Gly Val

195 200 205

Ile Ala Ser Ala Ile Thr Arg Ser Asp Thr Ser Asp Tyr His Gly Gly

210 215 220

Pro Thr Lys Gly Ile Lys Gly Ile Ala Tyr Thr Asn Phe Ala Leu Leu

225 230 235 240

Ala Ile Thr Ile Ser Gly Glu Leu Leu Phe Glu Asn Gly Tyr Asp Leu

245 250 255

Trp Gly Ser Gly Ala Gly Gln Arg Leu Ser Val Ala Tyr Asn Lys Ala

260 265 270

Ala Thr Trp Ile Leu Asn Pro Glu Thr Phe Pro Tyr Phe Gln Pro Asn

275 280 285

Leu Ile Gly Val His Asn Asn Ala Tyr Phe Ile Ile Leu Ala Lys His

290 295 300

Tyr Ser Ser Pro Ser Ala Asp Glu Leu Leu Glu Gln Gly Asp Leu His

305 310 315 320

Glu Asp Gly Phe Arg Leu Lys Leu Arg Ser Pro

325 330

(2) INFORMATION FOR SEQ ID NO: 132:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 128 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 128

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 132:

Met Arg Gln Tyr Ser Gln Ser Ala Leu Asn Thr Asn His Gly Ala Trp

1 5 10 15

Gly Ile Leu Phe Asp Val Ser Ser Ala Leu Ala Leu Asp Asp His Ala

20 25 30

Leu Leu Gln Ser Ser Ala Asn Arg Trp Gln Glu Trp Val Phe Lys Ala

35 40 45

Ile Asp Glu Asn Gly Val Ile Ala Ser Ala Ile Thr Arg Ser Asp Thr

50 55 60

Ser Asp Tyr His Gly Gly Pro Thr Lys Gly Ile Lys Gly Ile Ala Tyr

65 70 75 80

Thr Asn Phe Ala Leu Leu Ala Ile Thr Ile Ser Gly Glu Leu Leu Phe

85 90 95

Glu Asn Gly Tyr Asp Leu Trp Gly Ser Gly Ala Gly Gln Arg Leu Ser

100 105 110

Val Ala Tyr Asn Lys Ala Ala Thr Trp Ile Leu Asn Pro Glu Thr Phe

115 120 125

(2) INFORMATION FOR SEQ ID NO: 133:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 245 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 245

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 133:

Leu Arg Thr Leu Leu Lys Met Leu Val Gly Val Ser Leu Leu Thr His

1 5 10 15

Ala Leu Met Ala Thr Glu Glu Ser Ala Ala Pro Ser Trp Thr Lys Asn

20 25 30

Leu Tyr Met Gly Phe Asn Tyr Gln Thr Gly Ser Ile Asn Leu Met Thr

35 40 45

Asn Ile His Glu Val Arg Glu Val Thr Ser Tyr Gln Thr Gly Tyr Thr

50 55 60

Asn Val Met Thr Ser Ile Asn Ser Val Lys Lys Leu Thr Asn Met Gly

65 70 75 80

Ser Asn Gly Ile Gly Leu Val Met Gly Tyr Asn His Phe Phe His Pro

85 90 95

Asp Lys Val Leu Gly Leu Arg Tyr Phe Ala Phe Leu Asp Trp Gln Gly

100 105 110

Tyr Gly Met Arg Tyr Pro Lys Gly Tyr Tyr Gly Gly Asn Asn Met Ile

115 120 125

Thr Tyr Gly Val Gly Val Asp Ala Ile Trp Asn Phe Phe Gln Gly Ser

130 135 140

Phe Tyr Gln Asp Asp Ile Gly Val Asp Ile Gly Val Phe Gly Gly Ile

145 150 155 160

Ala Ile Ala Gly Asn Ser Trp Tyr Ile Gly Asn Lys Gly Gln Glu Leu

165 170 175

Leu Gly Ile Thr Asn Ser Ser Ala Val Asp Asn Thr Ser Phe Gln Phe

180 185 190

Leu Phe Asn Phe Gly Phe Lys Ala Leu Phe Val Asp Glu His Glu Phe

195 200 205

Glu Ile Gly Phe Lys Phe Pro Thr Leu Asn Asn Lys Tyr Tyr Thr Thr

210 215 220

Asp Ala Leu Lys Val Gln Met Arg Arg Val Phe Ala Phe Tyr Val Gly

225 230 235 240

Tyr Asn Tyr His Phe

245

(2) INFORMATION FOR SEQ ID NO: 134:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 290 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 290

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 134:

Met Phe Glu Glu Ile Thr Leu Ala His Lys Asp Leu Phe Ser Arg Phe

1 5 10 15

Leu Gln Thr Gln Lys Ile Val Leu Ser Asp Val Ser Phe Thr Asn Cys

20 25 30

Phe Leu Trp Gln His Ala Arg Leu Ile Gln Val Ala Val Ile Arg Asp

35 40 45

Cys Leu Val Ile Gln Thr Thr Tyr Glu Asn Gln Lys Pro Phe Tyr Phe

50 55 60

Tyr Pro Ile Gly Lys Arg Pro His Glu Cys Val Lys Glu Leu Leu Glu

65 70 75 80

Leu Glu Lys Asn Leu Arg Phe His Ser Leu Thr Leu Glu Gln Lys Asp

85 90 95

Asp Leu Lys Asp Asn Phe Val Gly Val Phe Asp Phe Thr Tyr Asn Arg

100 105 110

Asp Arg Ser Asp Tyr Val Tyr Ser Ile Glu Glu Leu Ile Ala Leu Lys

115 120 125

Gly Lys Lys Tyr His Lys Lys Lys Asn His Leu Asn Gln Phe Leu Thr

130 135 140

Asn His Ala Asn Phe Val Tyr Glu Lys Ile Ser Pro Gln Asn Arg Lys

145 150 155 160

Glu Val Leu Glu Ala Ser Lys Ala Trp Phe Leu Glu Ser Gln Thr Asp

165 170 175

Asp Ile Gly Leu Ile Asn Glu Asn Lys Gly Ile Gln Ser Val Leu Glu

180 185 190

Asn Tyr Glu Ser Leu Asp Leu Lys Gly Gly Leu Ile Arg Val Asn Gly

195 200 205

Glu Ile Val Ser Phe Ser Phe Gly Glu Val Leu Asn Glu Glu Ser Ala

210 215 220

Leu Ile His Ile Glu Lys Ala Arg Thr Asp Ile Ala Gly Ala Tyr Gln

225 230 235 240

Ile Ile Asn Gln Gln Leu Leu Leu Asn Glu Phe Ser His Leu Thr Tyr

245 250 255

Ala Asn Arg Glu Glu Asp Leu Gly Leu Glu Gly Leu Arg Arg Ser Lys

260 265 270

Met Ser Tyr Asn Pro Val Phe Leu Ile Asp Lys Tyr Glu Ala Val Ala

275 280 285

Arg asn

290

(2) INFORMATION FOR SEQ ID NO: 135:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 110 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 110

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 135:

Met Met Phe Ile Val Ala Val Leu Met Leu Ala Phe Leu Ile Phe Val

1 5 10 15

His Glu Leu Gly His Phe Ile Ile Ala Arg Ile Cys Gly Val Lys Val

20 25 30

Glu Val Phe Ser Ile Gly Phe Gly Lys Lys Leu Trp Phe Phe Lys Leu

35 40 45

Phe Gly Thr Gln Phe Ala Leu Ser Leu Ile Pro Leu Gly Gly Tyr Val

50 55 60

Lys Leu Lys Gly Met Asp Lys Glu Glu Asn Glu Glu Asn Lys Ile Asn

65 70 75 80

Gln Ala Asn Asp Ser Tyr Ala Lys Lys Ala Leu Ser Lys Ser Tyr Gly

85 90 95

Tyr Cys Leu Val Gly Arg Phe Leu Ile Phe Phe Leu Arg Phe

100 105 110

(2) INFORMATION FOR SEQ ID NO: 136:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 351 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 351

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 136:

Met Met Phe Ile Val Ala Val Leu Met Leu Ala Phe Leu Ile Phe Val

1 5 10 15

His Glu Leu Gly His Phe Ile Ile Ala Arg Ile Cys Gly Val Lys Val

20 25 30

Glu Val Phe Ser Ile Gly Phe Gly Lys Lys Leu Trp Phe Phe Lys Leu

35 40 45

Phe Gly Thr Gln Phe Ala Leu Ser Leu Ile Pro Leu Gly Gly Tyr Val

50 55 60

Lys Leu Lys Gly Met Asp Lys Glu Glu Asn Glu Glu Asn Lys Ile Asn

65 70 75 80

Gln Ala Asn Asp Ser Tyr Ala Gln Lys Ser Pro Phe Gln Lys Leu Trp

85 90 95

Ile Leu Phe Gly Gly Ala Phe Phe Asn Phe Leu Phe Ala Val Leu Val

100 105 110

Tyr Phe Phe Leu Ala Leu Ser Gly Glu Lys Val Leu Leu Pro Val Ile

115 120 125

Gly Gly Leu Glu Lys Asn Ala Leu Glu Ala Gly Leu Leu Lys Gly Asp

130 135 140

Arg Ile Leu Ser Ile Asn His Gln Lys Ile Ala Ser Phe Arg Glu Ile

145 150 155 160

Arg Glu Ile Val Ala Arg Ser Gln Gly Glu Leu Ile Leu Glu Ile Glu

165 170 175

Arg Asn Asn Gln Ile Leu Glu Lys Arg Leu Thr Pro Lys Ile Val Ala

180 185 190

Val Ile Ser Glu Ser Asn Asp Pro Asn Glu Ile Ile Lys Tyr Lys Ile

195 200 205

Ile Gly Ile Lys Pro Asp Met Gln Lys Met Gly Val Val Ser Tyr Ser

210 215 220

Val Phe Gln Ala Phe Glu Lys Ala Leu Ser Arg Phe Lys Glu Gly Val

225 230 235 240

Val Leu Ile Val Asp Ser Leu Arg Arg Leu Ile Met Gly Ser Ala Ser

245 250 255

Val Lys Glu Leu Ser Gly Val Ile Gly Ile Val Gly Ala Leu Ser His

260 265 270

Ala Asn Ser Val Ser Met Leu Leu Leu Phe Gly Ala Phe Leu Ser Ile

275 280 285

Asn Leu Gly Ile Leu Asn Leu Leu Pro Ile Pro Ala Leu Asp Gly Ala

290 295 300

Gln Met Leu Gly Val Val Phe Lys Asn Ile Phe His Ile Ala Leu Pro

305 310 315 320

Thr Pro Ile Gln Asn Ala Leu Trp Leu Val Gly Val Gly Phe Leu Val

325 330 335

Phe Val Met Phe Leu Gly Leu Phe Asn Asp Ile Thr Arg Leu Leu

340 345 350

(2) INFORMATION FOR SEQ ID NO: 137:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 100 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 100

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 137:

Met Gln Lys Asn Leu Asp Ser Leu Leu Glu Asn Leu Arg Ala Glu Ile

1 5 10 15

Asp Ala Leu Asp Asn Glu Leu Ser Asp Leu Leu Asp Lys Arg Leu Gly

20 25 30

Ile Ala Leu Lys Ile Ala Leu Ile Lys Gln Glu Ser Pro Gln Glu Asn

35 40 45

Pro Ile Tyr Cys Pro Lys Arg Glu Gln Glu Ile Leu Lys Arg Leu Ser

50 55 60

Gln Arg Gly Phe Lys His Leu Asn Gly Glu Ile Leu Ala Ser Phe Tyr

65 70 75 80

Ala Glu Val Phe Lys Ile Ser Arg Asn Phe Gln Glu Asn Ala Leu Lys

85 90 95

Glu Leu Lys Lys

100

(2) INFORMATION FOR SEQ ID NO: 138:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 174 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 174

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 138:

Val Lys Met Arg Phe Phe Ser Gly Phe Gly Phe Val Asn Glu Ser Val

1 5 10 15

Leu Phe Glu Glu Trp Leu Leu Lys Gly Ala Tyr Asp Val Ser Gly Phe

20 25 30

Ser Met Gly Ala Ile Lys Ala Ile Glu Tyr Ala Tyr Asn Glu Val Leu

35 40 45

Gln Gln Arg Arg Ile His Ser Leu Leu Leu Phe Ser Pro Cys Met Leu

50 55 60

Ala His Lys Ser Leu Ala Phe Lys Arg Leu Gln Leu Phe Leu Phe Gln

65 70 75 80

Lys Asp Pro Gln Ser Tyr Met Asp Asn Phe Tyr Lys Glu Val Gly Leu

85 90 95

Asp Ala Gln Leu Glu Arg Phe Lys Lys Glu Gly Ser Leu Glu Glu Leu

100 105 110

Glu Phe Leu Leu Asp Tyr Lys Tyr Ser Asp Ser Ile Arle Phe Leu

115 120 125

Leu Glu Lys Gly Val Lys Ile Glu Val Phe Ile Gly Leu Lys Asp Arg

130 135 140

Ile Thr Asp Ile Gln Ala Leu Leu Glu Phe Phe Met Pro Leu Val Gln

145 150 155 160

Val Trp Gln Phe Lys Asp Cys Asn His Leu Leu Gln Lys Ser

165 170

(2) INFORMATION FOR SEQ ID NO: 139:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 471 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 471

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 139:

Met Lys Asn Thr Asn Thr Lys Glu Ile Lys Asn Thr Arg Met Lys Lys

1 5 10 15

Gly Tyr Ser Gln Tyr His Thr Leu Lys Lys Gly Leu Leu Lys Thr Ala

20 25 30

Leu Leu Phe Ser Leu Pro Leu Ser Val Ala Leu Ala Glu Asp Asp Gly

35 40 45

Phe Tyr Met Gly Val Gly Tyr Gln Ile Gly Gly Ala Gln Gln Asn Ile

50 55 60

Asn Asn Lys Gly Ser Thr Leu Arg Asn Asn Val Ile Asp Asp Phe Arg

65 70 75 80

Gln Val Gly Val Gly Met Ala Gly Gly Asn Gly Leu Leu Ala Leu Ala

85 90 95

Thr Asn Thr Thr Met Asp Ala Leu Leu Gly Ile Gly Asn Gln Ile Val

100 105 110

Asn Thr Asn Thr Thr Val Gly Asn Asn Asn Ala Glu Leu Thr Gln Phe

115 120 125

Lys Lys Ile Leu Pro Gln Ile Glu Gln Arg Phe Glu Thr Asn Lys Asn

130 135 140

Ala Tyr Ser Val Gln Ala Leu Gln Val Tyr Leu Ser Asn Val Leu Tyr

145 150 155 160

Asn Leu Val Asn Asn Ser Asn Asn Gly Ser Asn Asn Gly Val Val Pro

165 170 175

Glu Tyr Val Gly Ile Ile Lys Val Leu Tyr Gly Ser Gln Asn Glu Phe

180 185 190

Ser Leu Leu Ala Thr Glu Ser Val Ala Leu Leu Asn Ala Leu Thr Arg

195 200 205

Val Asn Leu Asp Ser Asn Ser Val Phe Leu Lys Gly Leu Leu Ala Gln

210 215 220

Met Gln Leu Phe Asn Asp Thr Ser Ser Ala Lys Leu Gly Gln Ile Ala

225 230 235 240

Glu Asn Leu Lys Asn Gly Gly Ala Gly Ala Met Leu Gln Lys Asp Val

245 250 255

Lys Thr Ile Ser Asp Arg Ile Ala Thr Tyr Gln Glu Asn Leu Lys Gln

260 265 270

Leu Gly Gly Met Leu Lys Asn Tyr Asp Glu Pro Tyr Leu Pro Gln Phe

275 280 285

Gly Pro Gly Thr Ser Ser Gln His Gly Val Ile Asn Gly Phe Gly Ile

290 295 300

Gln Val Gly Tyr Lys Gln Phe Phe Gly Ser Lys Lys Asn Ile Gly Leu

305 310 315 320

Arg Tyr Tyr Ala Phe Phe Asp Tyr Gly Phe Thr Gln Leu Gly Ser Leu

325 330 335

Asn Ser Ala Val Lys Ala Asn Ile Phe Thr Tyr Gly Ala Gly Thr Asp

340 345 350

Phe Leu Trp Asn Ile Phe Arg Arg Val Phe Ser Asp Gln Ser Leu Asn

355 360 365

Val Gly Val Phe Gly Gly Ile Gln Ile Ala Gly Asn Thr Trp Asp Ser

370 375 380

Ser Leu Arg Gly Gln Ile Glu Asn Ser Phe Lys Glu Tyr Pro Thr Pro

385 390 395 400

Thr Asn Phe Gln Phe Leu Phe Asn Leu Gly Leu Arg Ala His Phe Ala

405 410 415

Ser Thr Met His Arg Arg Phe Leu Ser Ala Ser Gln Ser Ile Gln His

420 425 430

Gly Met Glu Phe Gly Val Lys Ile Pro Ala Ile Asn Gln Arg Tyr Leu

435 440 445

Lys Ala Asn Gly Ala Asp Val Asp Tyr Arg Arg Leu Tyr Ala Phe Tyr

450 455 460

Ile Asn Tyr Thr Ile Gly Phe

465 470

(2) INFORMATION FOR SEQ ID NO: 140:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 129 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 129

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 140:

Met Lys Ser Ile Arg Arg Gly Asp Gly Leu Asn Val Val Pro Phe Ile

1 5 10 15

Asp Ile Met Leu Val Leu Leu Ala Ile Val Leu Ser Ile Ser Thr Phe

20 25 30

Ile Ala Gln Gly Lys Ile Lys Val Ser Leu Pro Asn Ala Lys Asn Ala

35 40 45

Glu Lys Ser Gln Pro Asn Asp Gln Lys Val Val Val Ile Ser Val Asp

50 55 60

Glu His Asp Asn Ile Phe Val Asp Asp Lys Pro Thr Asn Leu Glu Ala

65 70 75 80

Leu Ser Ala Val Val Lys Gln Thr Asp Pro Lys Thr Leu Ile Asp Leu

85 90 95

Lys Ser Asp Lys Ser Ser Arg Phe Glu Thr Phe Ile Ser Ile Met Asp

100 105 110

Ile Leu Lys Glu His Asn His Glu Asn Phe Ser Ile Ser Thr Gln Ala

115 120 125

Gln

(2) INFORMATION FOR SEQ ID NO: 141:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 75 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 75

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 141:

Met Leu Val Leu Leu Ala Ile Val Leu Ser Ile Ser Thr Phe Ile Ala

1 5 10 15

Gln Gly Lys Ile Lys Val Ser Leu Pro Asn Ala Lys Asn Ala Glu Lys

20 25 30

Ser Arg Pro Asn Asp Gln Lys Val Val Val Ile Ser Val Asp Glu His

35 40 45

Asp Asn Ile Phe Val Asp Asp Lys Pro Thr Asn Leu Glu Ala Leu Ser

50 55 60

Ala Val Val Lys Gln Thr Asp Pro Lys Thr Leu

65 70 75

(2) INFORMATION FOR SEQ ID NO: 142:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 223 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 223

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 142:

Met Phe Ser Leu Ser Tyr Val Ser Lys Lys Phe Leu Ser Val Leu Leu

1 5 10 15

Leu Ile Ser Leu Phe Leu Ser Ala Cys Lys Ser Asn Asn Lys Asp Lys

20 25 30

Leu Asp Glu Asn Leu Leu Ser Ser Gly Thr Gln Ser Ser Lys Glu Leu

35 40 45

Asn Asp Lys Arg Asp Asn Ile Asp Lys Lys Ser Tyr Ala Gly Leu Glu

50 55 60

Asp Val Phe Leu Asp Asn Lys Ser Ile Ser Pro Asn Asp Lys Tyr Met

65 70 75 80

Leu Leu Val Phe Gly Arg Asn Gly Cys Ser Tyr Cys Glu Arg Leu Lys

85 90 95

Lys Asp Leu Lys Asn Val Lys Glu Leu Arg Asn Tyr Ile Lys Glu His

100 105 110

Phe Ser Ala Tyr Tyr Val Asn Ile Ser Tyr Ser Lys Glu His Asn Phe

115 120 125

Lys Val Gly Asp Lys Asp Lys Asn Asp Glu Lys Glu Ile Lys Met Ser

130 135 140

Thr Glu Glu Leu Ala Gln Ile Tyr Ala Val Gln Ser Thr Pro Thr Ile

145 150 155 160

Val Leu Ser Asp Lys Thr Gly Lys Thr Ile Tyr Glu Leu Pro Gly Tyr

165 170 175

Met Pro Ser Val Gln Phe Leu Ala Val Leu Glu Phe Ile Gly Asp Gly

180 185 190

Lys Tyr Gln Asp Thr Lys Asn Asp Glu Asp Leu Thr Lys Lys Leu Lys

195 200 205

Ala Tyr Ile Lys Tyr Lys Thr Asn Leu Ser Lys Ser Lys Ser Ser

210 215 220

(2) INFORMATION FOR SEQ ID NO: 143:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 116 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 116

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 143:

Leu Met Lys Ser Lys Ile Thr His Phe Ile Val Ile Ser Phe Val Leu

1 5 10 15

Ser Val Leu Ser Ala Cys Lys Asp Glu Pro Lys Lys Ser Ser Gln Ser

20 25 30

His Gln Asn Asn Thr Lys Thr Thr Gln Asn Asn Gln Ile Asn Gln Pro

35 40 45

Asn Lys Asp Ile Lys Lys Ile Glu His Glu Glu Glu Asp Glu Lys Val

50 55 60

Thr Lys Glu Val Asn Asp Leu Ile Asn Asn Glu Asn Lys Ile Asp Glu

65 70 75 80

Ile Asn Asn Glu Glu Asn Ala Asp Pro Ser Gln Lys Arg Thr Asn Asn

85 90 95

Val Leu Gln Arg Ala Thr Asn His Gln Asp Asn Leu Ser Ser Pro Leu

100 105 110

Asn Arg Lys Tyr

115

(2) INFORMATION FOR SEQ ID NO: 144:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 79 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 79

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 144:

Met Phe Glu Lys Ile Arg Lys Ile Leu Ala Asp Ile Glu Asp Ser Gln

1 5 10 15

Asn Glu Ile Glu Met Leu Leu Lys Leu Ala Asn Leu Ser Leu Gly Asp

20 25 30

Phe Ile Glu Ile Lys Arg Gly Ser Met Asp Met Pro Lys Gly Val Asn

35 40 45

Glu Ala Phe Phe Thr Gln Leu Ser Glu Glu Val Glu Arg Leu Lys Glu

50 55 60

Leu Ile Asn Ala Leu Asn Lys Ile Lys Lys Gly Leu Leu Val Phe

65 70 75

(2) INFORMATION FOR SEQ ID NO: 145:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 51 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 51

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 145:

Met Ser Met Phe Ile Ser Asn Leu Ala Phe Thr Ser Glu His Lys Asp

1 5 10 15

Ala Met Glu Val Ala Lys Ile Ala Ile Leu Leu Gly Ser Leu Ile Ser

20 25 30

Gly Ile Ile Gly Ala Leu Tyr Leu Phe Ala Leu Asp Lys Arg Ala Ala

35 40 45

Leu Lys Lys

50

(2) INFORMATION FOR SEQ ID NO: 146:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 449 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 449

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 146:

Met Gly Leu Lys Ile Lys Ile Leu Arg Leu Ser Met Asn Leu Lys Lys

1 5 10 15

Thr Glu Asn Ala Leu Ser Leu Thr Leu Lys Asn Phe Ile Lys Ser Glu

20 25 30

Ser Phe Gly Gly Ile Phe Leu Phe Leu Asn Ala Val Leu Ala Met Val

35 40 45

Val Ala Asn Ser Phe Leu Lys Glu Ser Tyr Phe Ala Leu Trp His Thr

50 55 60

Pro Phe Gly Phe Gln Val Gly Asp Phe Phe Ile Gly Phe Ser Leu His

65 70 75 80

Asn Trp Ile Asp Asp Val Leu Met Ala Leu Phe Phe Leu Met Ile Gly

85 90 95

Leu Glu Ile Lys Arg Glu Leu Leu Phe Gly Glu Leu Ser Ser Phe Lys

100 105 110

Lys Ala Ser Phe Pro Val Ile Ala Ala Ile Gly Gly Met Ile Ala Pro

115 120 125

Gly Leu Ile Tyr Phe Phe Leu Asn Ala Asn Thr Pro Ser Gln His Gly

130 135 140

Phe Gly Ile Pro Met Ala Thr Asp Ile Ala Phe Ala Leu Gly Val Ile

145 150 155 160

Met Leu Leu Gly Lys Arg Val Pro Thr Ala Leu Lys Val Phe Leu Ile

165 170 175

Thr Leu Ala Val Ala Asp Asp Leu Gly Ala Ile Val Val Ile Ala Leu

180 185 190

Phe Tyr Thr Thr Asn Leu Lys Phe Ala Trp Leu Leu Gly Ala Leu Gly

195 200 205

Val Val Leu Val Leu Ala Ile Leu Asn Arg Leu Asn Ile Arg Ser Leu

210 215 220

Ile Pro Tyr Leu Leu Leu Gly Val Leu Leu Trp Phe Cys Val His Gln

225 230 235 240

Ser Gly Ile His Ala Thr Ile Ala Ala Val Val Leu Ala Phe Met Ile

245 250 255

Pro Val Lys Ile Pro Lys Asp Ser Lys Asn Val Glu Leu Leu Glu Leu

260 265 270

Gly Lys Arg Tyr Ala Glu Thr Ser Ser Gly Val Leu Leu Thr Lys Glu

275 280 285

Gln Gln Glu Ile Leu His Ser Ile Glu Glu Lys Ala Ser Ala Leu Gln

290 295 300

Ser Pro Leu Glu Arg Leu Glu His Phe Leu Ala Pro Ile Ser Gly Tyr

305 310 315 320

Phe Ile Met Pro Leu Phe Ala Phe Ala Asn Ala Gly Val Ser Val Asp

325 330 335

Ser Ser Ile Asn Leu Glu Val Asp Lys Val Leu Leu Gly Val Ile Leu

340 345 350

Gly Leu Cys Leu Gly Lys Pro Leu Gly Ile Phe Leu Ile Thr Phe Ile

355 360 365

Ser Glu Lys Leu Lys Ile Thr Ala Arg Pro Lys Gly Ile Gly Trp Trp

370 375 380

His Ile Leu Gly Ala Gly Leu Leu Ala Gly Ile Gly Phe Thr Met Ser

385 390 395 400

Met Phe Ile Ser Asn Leu Ala Phe Thr Ser Glu His Lys Asp Ala Met

405 410 415

Glu Val Ala Lys Ile Ala Ile Leu Leu Gly Ser Leu Ile Ser Gly Ile

420 425 430

Ile Gly Ala Leu Tyr Leu Phe Ala Leu Asp Lys Arg Ala Ala Leu Lys

435 440 445

Lys

(2) INFORMATION FOR SEQ ID NO: 147:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 815 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 815

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 147:

Met Asn Asp Lys Arg Phe Arg Lys Tyr Cys Ser Phe Ser Ile Phe Leu

1 5 10 15

Ser Leu Leu Gly Thr Phe Glu Leu Glu Ala Lys Glu Glu Glu Lys Glu

20 25 30

Glu Lys Lys Thr Glu Arg Asn Lys Asp Lys Glu Lys Asn Ala Gln His

35 40 45

Thr Leu Gly Lys Val Thr Thr Gln Ala Ala Lys Ile Phe Asn Tyr Asn

50 55 60

Asn Gln Thr Thr Ile Ser Ser Lys Glu Leu Glu Arg Arg Gln Ala Asn

65 70 75 80

Gln Ile Ser Asp Met Phe Arg Arg Asn Pro Asn Ile Asn Val Gly Gly

85 90 95

Gly Ala Val Ile Ala Gln Lys Ile Tyr Val Arg Gly Ile Glu Asp Arg

100 105 110

Leu Ala Arg Val Thr Val Asp Gly Val Ala Gln Met Gly Ala Ser Tyr

115 120 125

Gly His Gln Gly Asn Thr Ile Ile Asp Pro Gly Met Leu Lys Ser Val

130 135 140

Val Val Thr Lys Gly Ala Ala Gln Ala Ser Ala Gly Pro Met Ala Leu

145 150 155 160

Ile Gly Ala Ile Lys Met Glu Thr Arg Ser Ala Ser Asp Phe Ile Pro

165 170 175

Lys Gly Lys Asp Tyr Ala Ile Ser Gly Ala Ala Thr Phe Leu Thr Asn

180 185 190

Phe Gly Asp Arg Glu Thr Ile Met Gly Ala Tyr Arg Asn His His Phe

195 200 205

Asp Ala Leu Leu Tyr Tyr Thr His Gln Asn Ile Phe Tyr Tyr Arg Asp

210 215 220

Gly Asp Asn Ala Met Lys Asn Leu Phe Asp Pro Lys Ala Asp Asn Lys

225 230 235 240

Val Thr Ala Ser Pro Ser Glu Gln Asn Asn Val Met Ala Lys Ile Asn

245 250 255

Gly Tyr Leu Ser Glu Arg Asp Thr Leu Thr Leu Ser Tyr Asn Met Thr

260 265 270

Arg Asp Asn Ala Asn Arg Pro Leu Arg Ala Asn Phe Thr Gly Thr Phe

275 280 285

Leu Pro Tyr Ser Cys Gly Asp Phe Asn Ala Phe Pro Asn Glu Lys Asn

290 295 300

Pro Ser Asp Cys Leu Phe Glu Asn Asp Ala Ser Leu Phe Lys Thr Tyr

305 310 315 320

Ser Val Asn Leu Val His Asn Val Ser Leu Asn Tyr Glu Arg Glu Gly

325 330 335

Gly Ser Arg Phe Gly Asp Pro Lys Leu Lys Ile Asn Gly Tyr Thr Ser

340 345 350

Ile Arg Asn Val Gln Ile Asp Pro Leu Phe Arg Pro Ser Asp Ile Ala

355 360 365

Thr Thr Ile Pro Phe Thr Pro Asn Pro Gln Leu Ser Gln Gly Glu Glu

370 375 380

Asn Gln Cys Val Ala Gln Gly Gly Ile Tyr Asp Ala Leu Lys Gln Thr

385 390 395 400

Cys Ser Ile Thr Phe Lys Ser Leu Gly Gly Gly Ser Val Val Ala Asn

405 410 415

Lys Asn Leu Phe Ile Ile Asn Ser Gly Phe Asn Ala Asn Val Ile His

420 425 430

Thr Ile Asp His Lys Asn Asp Asn Leu Leu Glu Tyr Gly Leu Asn Tyr

435 440 445

Gln Asn Leu Thr ThrPhe Asp Lys Ala Ile Pro Asp Ser Glu Leu Val

450 455 460

Lys Pro Gly Asp Ala Pro Asp Ala Cys Leu Arg Val Thr Gly Pro Asp

465 470 475 480

Asp Pro Asn Met Asn Gly Arg Cys Gln Arg Asn Gly Ala Thr Ala Asn

485 490 495

Val Val Gly Val Tyr Ala Gln Ala Asn Tyr Thr Leu His Pro Met Val

500 505 510

Thr Leu Gly Ala Gly Thr Arg Tyr Asp Val Tyr Thr Leu Val Asp Lys

515 520 525

Asp Trp Gln Leu His Val Thr Gln Gly Phe Ser Pro Ser Ala Ala Leu

530 535 540

Asn Val Ser Pro Leu Glu Asn Leu Asn Phe Arg Leu Ser Tyr Ala Tyr

545 550 555 560

Val Thr Arg Gly Pro Met Pro Gly Gly Leu Val Trp Met Arg Gln Asp

565 570 575

Asn Leu Arg Tyr Asn Arg Asn Leu Lys Pro Glu Ile Gly Gln Asn Ala

580 585 590

Glu Phe Asn Thr Glu Tyr Ser Ser Gln Tyr Phe Asp Phe Arg Ala Ala

595 600 605

Gly Phe Val Gln Leu Ile Ser Asn Tyr Ile Asn Gln Phe Ser Ser Thr

610 615 620

Leu Phe Val Thr Asn Leu Pro Ala Gln Asp Ile Ile Tyr Val Pro Gly

625 630 635 640

Tyr Glu Val Ser Gly Thr Ala Lys Tyr Lys Gly Phe Ser Leu Gly Leu

645 650 655

Ser Val Ala Arg Ser Trp Pro Ser Leu Lys Gly Arg Leu Ile Ala Asp

660 665 670

Val Tyr Glu Leu Ala Ala Thr Thr Gly Asn Val Phe Ile Leu Thr Ala

675 680 685

Ser Tyr Thr Ile Pro Arg Thr Gly Leu Ser Ile Thr Trp Leu Ser Arg

690 695 700

Phe Val Thr Asn Leu Ser Tyr Cys Ser Tyr Ser Pro Tyr Arg Asn Gly

705 710 715 720

Pro Thr Asp Ile Asp Arg Arg Pro Ser Asn Cys Pro Lys Thr Pro Gly

725 730 735

Ile Phe His Val His Lys Pro Gly Tyr Gly Val Ser Ser Phe Phe Ile

740 745 750

Thr Tyr Lys Pro Thr Tyr Lys Lys Leu Lys Gly Leu Ser Leu Asn Ala

755 760 765

Val Phe Asn Asn Val Phe Asn Gln Gln Tyr Ile Asp Gln Ala Ser Pro

770 775 780

Val Met Ser Pro Asp Glu Pro Asn Gln Asp Lys Tyr Ala Arg Gly Met

785 790 795 800

Ala Glu Pro Gly Phe Asn Ala Arg Phe Glu Ile Ser Tyr Lys Phe

805 810 815

(2) INFORMATION FOR SEQ ID NO: 148:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 814 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 814

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 148:

Met Thr Ser Val Leu Glu Lys Tyr Cys Ser Phe Ser Ile Phe Leu Ser

1 5 10 15

Leu Leu Gly Thr Phe Glu Leu Glu Ala Lys Glu Glu Glu Lys Glu Glu

20 25 30

Lys Lys Thr Glu Arg Asn Lys Asp Lys Glu Lys Asn Ala Gln His Thr

35 40 45

Leu Gly Lys Val Thr Thr Gln Ala Ala Lys Ile Phe Asn Tyr Asn Asn

50 55 60

Gln Thr Thr Ile Ser Ser Lys Glu Leu Glu Arg Arg Gln Ala Asn Gln

65 70 75 80

Ile Ser Asp Met Phe Arg Arg Asn Pro Asn Ile Asn Val Gly Gly Gly

85 90 95

Ala Val Ile Ala Gln Lys Ile Tyr Val Arg Gly Ile Glu Asp Arg Leu

100 105 110

Ala Arg Val Thr Val Asp Gly Val Ala Gln Met Gly Ala Ser Tyr Gly

115 120 125

His Gln Gly Asn Thr Ile Ile Asp Pro Gly Met Leu Lys Ser Val Val

130 135 140

Val Thr Lys Gly Ala Ala Gln Ala Ser Ala Gly Pro Met Ala Leu Ile

145 150 155 160

Gly Ala Ile Lys Met Glu Thr Arg Ser Ala Ser Asp Phe Ile Pro Lys

165 170 175

Gly Lys Asp Tyr Ala Ile Ser Gly Ala Ala Thr Phe Leu Thr Asn Phe

180 185 190

Gly Asp Arg Glu Thr Ile Met Gly Ala Tyr Arg Asn His His Phe Asp

195 200 205

Ala Leu Leu Tyr Tyr Thr His Gln Asn Ile Phe Tyr Tyr Arg Asp Gly

210 215 220

Asp Asn Ala Met Lys Asn Leu Phe Asp Pro Lys Ala Asp Asn Lys Val

225 230 235 240

Thr Ala Ser Pro Ser Glu Gln Asn Asn Val Met Ala Lys Ile Asn Gly

245 250 255

Tyr Leu Ser Glu Arg Asp Thr Leu Thr Leu Ser Tyr Asn Met Thr Arg

260 265 270

Asp Asn Ala Asn Arg Pro Leu Arg Ala Asn Phe Thr Gly Thr Phe Leu

275 280 285

Pro Tyr Ser Cys Gly Asp Phe Asn Ala Phe Pro Asn Glu Lys Asn Pro

290 295 300

Ser Asp Cys Leu Phe Glu Asn Asp Ala Ser Leu Phe Lys Thr Tyr Ser

305 310 315 320

Val Asn Leu Val His Asn Val Ser Leu Asn Tyr Glu Arg Glu Gly Gly

325 330 335

Ser Arg Phe Gly Asp Pro Lys Leu Lys Ile Asn Gly Tyr Thr Ser Ile

340 345 350

Arg Asn Val Gln Ile Asp Pro Leu Phe Arg Pro Ser Asp Ile Ala Thr

355 360 365

Thr Ile Pro Phe Thr Pro Asn Pro Gln Leu Ser Gln Gly Glu Glu Asn

370 375 380

Gln Cys Val Ala Gln Gly Gly Ile Tyr Asp Ala Leu Lys Gln Thr Cys

385 390 395 400

Ser Ile Thr Phe Lys Ser Leu Gly Gly Gly Ser Val Val Ala Asn Lys

405 410 415

Asn Leu Phe Ile Ile Asn Ser Gly Phe Asn Ala Asn Val Ile His Thr

420 425 430

Ile Asp His Lys Asn Asp Asn Leu Leu Glu Tyr Gly Leu Asn Tyr Gln

435 440 445

Asn Leu Thr Thr Phe Asp Lys Ala Ile Pro Asp Ser Glu Leu Val Lys

450 455 460

Pro Gly Asp Ala Pro Asp Ala Cys Leu Arg Val Thr Gly Pro Asp Asp

465 470 475 480

Pro Asn Met Asn Gly Arg Cys Gln Arg Asn Gly Ala Thr Ala Asn Val

485 490 495

Val Gly Val Tyr Ala Gln Ala Asn Tyr Thr Leu His Pro Met Val Thr

500 505 510

Leu Gly Ala Gly Thr Arg Tyr Asp Val Tyr Thr Leu Val Asp Lys Asp

515 520 525

Trp Gln Leu His Val Thr Gln Gly Phe Ser Pro Ser Ala Ala Leu Asn

530 535 540

Val Ser Pro Leu Glu Asn Leu Asn Phe Arg Leu Ser Tyr Ala Tyr Val

545 550 555 560

Thr Arg Gly Pro Met Pro Gly Gly Leu Val Trp Met Arg Gln Asp Asn

565 570 575

Leu Arg Tyr Asn Arg Asn Leu Lys Pro Glu Ile Gly Gln Asn Ala Glu

580 585 590

Phe Asn Thr Glu Tyr Ser Ser Gln Tyr Phe Asp Phe Arg Ala Ala Gly

595 600 605

Phe Val Gln Leu Ile Ser Asn Tyr Ile Asn Gln Phe Ser Ser Thr Leu

610 615 620

Phe Val Thr Asn Leu Pro Ala Gln Asp Ile Ile Tyr Val Pro Gly Tyr

625 630 635 640

Glu Val Ser Gly Thr Ala Lys Tyr Lys Gly Phe Ser Leu Gly Leu Ser

645 650 655

Val Ala Arg Ser Trp Pro Ser Leu Lys Gly Arg Leu Ile Ala Asp Val

660 665 670

Tyr Glu Leu Ala Ala Thr Thr Gly Asn Val Phe Ile Leu Thr Ala Ser

675 680 685

Tyr Thr Ile Pro Arg Thr Gly Leu Ser Ile Thr Trp Leu Ser Arg Phe

690 695 700

Val Thr Asn Leu Ser Tyr Cys Ser Tyr Ser Pro Tyr Arg Asn Gly Pro

705 710 715 720

Thr Asp Ile Asp Arg Arg Pro Ser Asn Cys Pro Lys Thr Pro Gly Ile

725 730 735

Phe His Val His Lys Pro Gly Tyr Gly Val Ser Ser Phe Phe Ile Thr

740 745 750

Tyr Lys Pro Thr Tyr Lys Lys Leu Lys Gly Leu Ser Leu Asn Ala Val

755 760 765

Phe Asn Asn Val Phe Asn Gln Gln Tyr Ile Asp Gln Ala Ser Pro Val

770 775 780

Met Ser Pro Asp Glu Pro Asn Gln Asp Lys Tyr Ala Arg Gly Met Ala

785 790 795 800

Glu Pro Gly Phe Asn Ala Arg Phe Glu Ile Ser Tyr Lys Phe

805 810

(2) INFORMATION FOR SEQ ID NO: 149:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 527 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 527

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 149:

Met Lys Gln Asn Leu Lys Pro Phe Lys Met Ile Lys Glu Asn Leu Met

1 5 10 15

Thr Gln Ser Gln Lys Val Arg Phe Leu Ala Pro Leu Ser Leu Ala Leu

20 25 30

Ser Leu Ser Phe Asn Pro Val Gly Ala Glu Glu Asp Gly Gly Phe Met

35 40 45

Thr Phe Gly Tyr Glu Leu Gly Gln Val Val Gln Gln Val Lys Asn Pro

50 55 60

Gly Lys Ile Lys Ala Glu Glu Leu Ala Gly Leu Leu Asn Ser Thr Thr

65 70 75 80

Thr Asn Asn Thr Asn Ile Asn Ile Ala Gly Thr Gly Gly Asn Val Ala

85 90 95

Gly Thr Leu Gly Asn Leu Phe Met Asn Gln Leu Gly Asn Leu Ile Asp

100 105 110

Leu Tyr Pro Thr Leu Lys Thr Asn Asn Leu His Gln Cys Gly Ser Thr

115 120 125

Asn Ser Gly Asn Gly Ala Thr Ala Ala Ala Ala Thr Asn Asn Ser Pro

130 135 140

Cys Phe Gln Gly Asn Leu Ala Leu Tyr Asn Glu Met Val Asp Ser Ile

145 150 155 160

Lys Thr Leu Ser Gln Asn Ile Ser Lys Asn Ile Phe Gln Gly Asp Asn

165 170 175

Asn Thr Thr Ser Ala Asn Leu Ser Asn Gln Leu Ser Glu Leu Asn Thr

180 185 190

Ala Ser Val Tyr Leu Thr Tyr Met Asn Ser Phe Leu Asn Ala Asn Asn

195 200 205

Gln Ala Gly Gly Ile Phe Gln Asn Asn Thr Asn Gln Ala Tyr Glu Asn

210 215 220

Gly Val Thr Ala Gln Gln Ile Ala Tyr Val Leu Lys Gln Ala Ser Ile

225 230 235 240

Thr Met Gly Pro Ser Gly Asp Ser Gly Ala Ala Gly Ala Phe Leu Asp

245 250 255

Ala Ala Leu Ala Gln His Val Phe Asn Ser Ala Asn Ala Gly Asn Asp

260 265 270

Leu Ser Ala Lys Glu Phe Thr Ser Leu Val Gln Asn Ile Val Asn Asn

275 280 285

Ser Gln Asn Ala Leu Thr Leu Ala Asn Asn Ala Asn Ile Ser Asn Ser

290 295 300

Thr Gly Tyr Gln Val Ser Tyr Gly Gly Asn Ile Asp Gln Ala Arg Ser

305 310 315 320

Thr Gln Leu Leu Asn Asn Thr Thr Asn Thr Leu Ala Lys Val Thr Ala

325 330 335

Leu Asn Asn Glu Leu Lys Ala Asn Pro Trp Leu Gly Asn Phe Ala Ala

340 345 350

Gly Asn Ser Ser Gln Val Asn Ala Phe Asn Gly Phe Ile Thr Lys Ile

355 360 365

Gly Tyr Lys Gln Phe Phe Gly Glu Asn Lys Asn Val Gly Leu Arg Tyr

370 375 380

Tyr Gly Phe Phe Ser Tyr Asn Gly Ala Gly Val Gly Asn Gly Pro Thr

385 390 395 400

Tyr Asn Gln Val Asn Leu Leu Thr Tyr Gly Val Gly Thr Asp Val Leu

405 410 415

Tyr Asn Val Phe Ser Arg Ser Phe Gly Ser Arg Ser Leu Asn Ala Gly

420 425 430

Phe Phe Gly Gly Ile Gln Leu Ala Gly Asp Thr Tyr Ile Ser Thr Leu

435 440 445

Arg Asn Ser Pro Gln Leu Ala Ser Arg Pro Thr Ala Thr Lys Phe Gln

450 455 460

Phe Leu Phe Asp Val Gly Leu Arg Met Asn Phe Gly Ile Leu Lys Lys

465 470 475 480

Asp Leu Lys Ser His Asn Gln His Ser Ile Glu Ile Gly Val Gln Ile

485 490 495

Pro Thr Ile Tyr Asn Thr Tyr Tyr Lys Ala Gly Gly Ala Glu Val Lys

500 505 510

Tyr Phe Arg Pro Tyr Ser Val Tyr Trp Val Tyr Gly Tyr Ala Phe

515 520 525

(2) INFORMATION FOR SEQ ID NO: 150:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 459 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 459

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 150:

Val Val Leu Leu Thr Met Thr Lys Arg Leu Phe Lys Gly Leu Leu Ala

1 5 10 15

Ile Ser Leu Ala Val Ser Leu His Gly Gly Glu Val Lys Glu Lys Lys

20 25 30

Pro Val Lys Pro Val Lys Glu Asp Pro Gln Glu Leu Ala Ala Lys Arg

35 40 45

Val Glu Ala Phe Ser Arg Phe Ser Asn Val Val Thr Glu Ile Glu Lys

50 55 60

Lys Tyr Val Asp Lys Ile Ser Ile Ser Glu Ile Met Thr Lys Ala Ile

65 70 75 80

Glu Gly Leu Leu Ser Asn Leu Asp Ala His Ser Ala Tyr Leu Asn Glu

85 90 95

Lys Lys Phe Lys Glu Phe Gln Ala Gln Thr Glu Gly Glu Phe Gly Gly

100 105 110

Leu Gly Ile Thr Val Gly Met Arg Asp Gly Val Leu Thr Val Ile Ala

115 120 125

Pro Leu Glu Gly Thr Pro Ala Tyr Lys Ala Gly Val Lys Ser Gly Asp

130 135 140

Ser Ile Leu Lys Ile Asn Asn Glu Ser Thr Leu Ser Met Ser Ile Asp

145 150 155 160

Asp Ala Val Asn Leu Met Arg Gly Lys Pro Lys Thr Ser Ile Gln Ile

165 170 175

Thr Val Val Arg Lys Asn Glu Pro Lys Pro Leu Val Phe Asn Ile Val

180 185 190

Arg Asp Ile Ile Lys Ile Pro Ser Val Tyr Val Lys Lys Ile Lys Asp

195 200 205

Thr Pro Tyr Leu Tyr Val Arg Val Asn Ser Phe Asp Lys Asn Val Thr

210 215 220

Lys Ser Val Leu Asp Gly Leu Lys Ala Asn Pro Asn Ile Lys Gly Val

225 230 235 240

Val Leu Asp Leu Arg Gly Asn Pro Gly Gly Leu Leu Asn Gln Ala Val

245 250 255

Gly Leu Ser Asn Leu Phe Ile Lys Glu Gly Val Leu Val Ser Gln Arg

260 265 270

Gly Lys Asn Lys Glu Glu Asn Leu Glu Tyr Lys Ala Asn Gly Arg Ala

275 280 285

Pro Tyr Thr Asn Leu Pro Val Val Val Leu Val Asn Gly Gly Ser Ala

290 295 300

Ser Ala Ser Glu Ile Val Ala Gly Ala Leu Gln Asp His Lys Arg Ala

305 310 315 320

Ile Ile Ile Gly Glu Lys Thr Phe Gly Lys Gly Ser Val Gln Val Leu

325 330 335

Leu Pro Val Asn Lys Asp Glu Ala Ile Lys Ile Thr Thr Ala Arg Tyr

340 345 350

Tyr Leu Pro Ser Gly Arg Thr Ile Gln Ala Lys Gly Ile Thr Pro Asp

355 360 365

Ile Val Ile Tyr Pro Gly Lys Val Pro Glu Asn Glu Asn Lys Phe Ser

370 375 380

Leu Lys Glu Ala Asp Leu Lys His His Leu Glu Gln Glu Leu Lys Lys

385 390 395 400

Leu Asp Asp Lys Thr Pro Ile Ser Lys Glu Ala Asp Lys Asp Lys Lys

405 410 415

Ser Glu Glu Glu Lys Glu Val Thr Pro Lys Met Ile Asn Asp Asp Ile

420 425 430

Gln Leu Lys Thr Ala Ile Asp Ser Leu Lys Thr Trp Ser Ile Val Asp

435 440 445

Glu Lys Met Asp Glu Lys Val Pro Lys Lys Lys

450 455

(2) INFORMATION FOR SEQ ID NO: 151:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 104 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 104

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 151:

Leu Leu Leu His Pro Leu His Ala His Ala Gln Val Leu Gly Phe Thr

1 5 10 15

Asn His Asp His Ala Pro Trp Leu Tyr Asp Phe Ile Lys Ser Phe Cys

20 25 30

Asn Leu Ser Gly Gln Pro Phe Leu Asp Leu Gln Ala Phe Ala Ile Asn

35 40 45

Phe Asn Glu Phe Ser Asp Arg Ala Asn Ala Tyr Asn Leu Phe Leu Arg

50 55 60

Asp Ile Ser His Ala Asn Ile Pro Lys Lys Arg Glu Gln Met Val Leu

65 70 75 80

Ala Ser Gly Val Lys Phe Asn Val Leu Ser His Tyr His Phe Ile Ala

85 90 95

Asn Ala Leu Lys Ile Arg Ala Phe

100

(2) INFORMATION FOR SEQ ID NO: 152:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 165 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 165

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 152:

Met Ile Glu Leu Ile Leu His Asn Lys Ser Ile Gln Ile Asp Glu Thr

1 5 10 15

Leu Leu Asn Val Lys Glu His Leu Glu Lys Phe Tyr Ser Asn Lys Glu

20 25 30

Gln Glu Thr Ile Ala Lys Thr Leu Glu Ser Gln Thr Glu Leu Thr Cys

35 40 45

Ser Tyr Leu Leu Asp Lys Asp Phe Ser Leu Leu Glu Lys His Leu Glu

50 55 60

Asn Ser Leu Gly His Phe Thr Phe Glu Ser Glu Phe Ala Leu Leu Lys

65 70 75 80

Asp Lys Glu Pro Leu Asn Leu Ala Gln Ile Lys Gln Ile Gly Val Leu

85 90 95

Lys Val Ile Thr Tyr Glu Met Thr Gln Ala Leu Lys Asn Gln Ile Ile

100 105 110

His Leu Thr Gln Ile Val Asn Glu Glu Asn Leu Glu Phe Asp Glu Glu

115 120 125

Leu Val Ile Tyr His Leu Asn Phe Lys Leu Asn Gln Asn Thr Tyr Lys

130 135 140

Val Leu Ala Lys Phe Cys Val Leu Lys Lys Lys Gly Thr Leu His Glu

145 150 155 160

Lys Phe Lys Ala Phe

165

(2) INFORMATION FOR SEQ ID NO: 153:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 213 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 213

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 153:

Met Asp Thr Glu Thr Gln Glu Lys Phe Leu Ala Tyr Leu Phe Glu Lys

1 5 10 15

Ala Leu Gln Lys Asn Leu Gln Ala Tyr Trp Ile Thr Thr Thr Glu Thr

20 25 30

Lys Asn Glu Leu Thr Arg Glu Glu Phe Ser Asn Leu Ile Arg Lys Thr

35 40 45

Met Ile Glu Leu Ile Leu His Asn Lys Ser Ile Gln Ile Asp Glu Thr

50 55 60

Leu Leu Asn Val Lys Glu His Leu Glu Lys Phe Tyr Ser Asn Lys Glu

65 70 75 80

Gln Glu Thr Ile Ala Lys Thr Leu Glu Ser Gln Thr Glu Leu Thr Cys

85 90 95

Ser Tyr Leu Leu Asp Lys Asp Phe Ser Leu Leu Glu Lys His Leu Glu

100 105 110

Asn Ser Leu Gly His Phe Thr Phe Glu Ser Glu Phe Ala Leu Leu Lys

115 120 125

Asp Lys Glu Pro Leu Asn Leu Ala Gln Ile Lys Gln Ile Gly Val Leu

130 135 140

Lys Val Ile Thr Tyr Glu Met Thr Gln Ala Leu Lys Asn Gln Ile Ile

145 150 155 160

His Leu Thr Gln Ile Val Asn Glu Glu Asn Leu Glu Phe Asp Glu Glu

165 170 175

Leu Val Ile Tyr His Leu Asn Phe Lys Leu Asn Gln Asn Thr Tyr Lys

180 185 190

Val Leu Ala Lys Phe Cys Val Leu Lys Lys Lys Gly Thr Leu His Glu

195 200 205

Lys Phe Lys Ala Phe

210

(2) INFORMATION FOR SEQ ID NO: 154:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 253 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 253

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 154:

Met Ala Ile Ser Ile Lys Ser Pro Lys Glu Ile Lys Ala Leu Arg Lys

1 5 10 15

Ala Gly Glu Leu Thr Ala Gln Ala Leu Ala Leu Leu Glu Arg Glu Val

20 25 30

Arg Pro Gly Val Ser Leu Leu Glu Leu Asp Lys Met Ala Glu Asp Phe

35 40 45

Ile Lys Ser Ser His Ala Arg Pro Ala Phe Lys Gly Leu Tyr Gly Phe

50 55 60

Pro Asn Ser Val Cys Met Ser Leu Asn Glu Val Val Ile His Gly Ile

65 70 75 80

Pro Thr Asp Tyr Val Leu Gln Glu Gly Asp Ile Ile Gly Leu Asp Leu

85 90 95

Gly Val Glu Val Asp Gly Tyr Tyr Gly Asp Ser Ala Leu Thr Leu Pro

100 105 110

Ile Gly Ala Ile Ser Pro Gln Asp Glu Lys Leu Leu Ala Cys Ser Lys

115 120 125

Glu Ser Leu Met His Ala Ile Ser Ser Ile Arg Val Gly Met His Phe

130 135 140

Lys Glu Leu Ser Gln Ile Leu Glu Gly Ala Ile Thr Glu Arg Gly Phe

145 150 155 160

Val Pro Leu Lys Gly Phe Cys Gly His Gly Ile Gly Lys Lys Pro His

165 170 175

Glu Glu Pro Glu Ile Pro Asn Tyr Leu Glu Lys Gly Val Lys Ala Asn

180 185 190

Ser Gly Pro Lys Ile Lys Glu Gly Met Val Phe Cys Leu Glu Pro Met

195 200 205

Val Cys Gln Lys Gln Gly Glu Pro Lys Ile Leu Ala Asp Lys Trp Ser

210 215 220

Val Val Ser Val Asp Gly Leu Asn Thr Ser His His Glu His Thr Ile

225 230 235 240

Ala Ile Val Gly Asn Lys Ala Val Ile Leu Thr Glu Arg

245 250

(2) INFORMATION FOR SEQ ID NO: 155:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 247 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 247

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 155:

Lys Pro Lys Arg Asn Gln Ser Pro Lys Lys Ser Arg Glu Leu Thr Ala

1 5 10 15

Gln Ala Leu Ala Leu Leu Glu Arg Glu Val Arg Pro Gly Val Ser Leu

20 25 30

Leu Glu Leu Asp Lys Met Ala Glu Asp Phe Ile Lys Ser Ser His Ala

35 40 45

Arg Pro Ala Phe Lys Gly Leu Tyr Gly Phe Pro Asn Ser Val Cys Met

50 55 60

Ser Leu Asn Glu Val Val Ile His Gly Ile Pro Thr Asp Tyr Val Leu

65 70 75 80

Gln Glu Gly Asp Ile Ile Gly Leu Asp Leu Gly Val Glu Val Asp Gly

85 90 95

Tyr Tyr Gly Asp Ser Ala Leu Thr Leu Pro Ile Gly Ala Ile Ser Pro

100 105 110

Gln Asp Glu Lys Leu Leu Ala Cys Ser Lys Glu Ser Leu Met His Ala

115 120 125

Ile Ser Ser Ile Arg Val Gly Met His Phe Lys Glu Leu Ser Gln Ile

130 135 140

Leu Glu Gly Ala Ile Thr Glu Arg Gly Phe Val Pro Leu Lys Gly Phe

145 150 155 160

Cys Gly His Gly Ile Gly Lys Lys Pro His Glu Glu Pro Glu Ile Pro

165 170 175

Asn Tyr Leu Glu Lys Gly Val Lys Ala Asn Ser Gly Pro Lys Ile Lys

180 185 190

Glu Gly Met Val Phe Cys Leu Glu Pro Met Val Cys Gln Lys Gln Gly

195 200 205

Glu Pro Lys Ile Leu Ala Asp Lys Trp Ser Val Val Ser Val Asp Gly

210 215 220

Leu Asn Thr Ser His His Glu His Thr Ile Ala Ile Val Gly Asn Lys

225 230 235 240

Ala Val Ile Leu Thr Glu Arg

245

(2) INFORMATION FOR SEQ ID NO: 156:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 340 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 340

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 156:

Met Tyr Arg Lys Asp Leu AspAsn Tyr Leu Lys Gln Arg Leu Pro Lys

1 5 10 15

Ala Val Phe Leu Tyr Gly Glu Phe Asp Phe Phe Ile His Tyr Tyr Ile

20 25 30

Gln Thr Ile Ser Ala Leu Phe Lys Gly Asn Asn Pro Asp Thr Glu Thr

35 40 45

Ser Leu Phe Tyr Ala Ser Asp Tyr Glu Lys Ser Gln Ile Ala Thr Leu

50 55 60

Leu Glu Gln Asp Ser Leu Phe Gly Gly Ser Ser Leu Val Ile Leu Lys

65 70 75 80

Leu Asp Phe Ala Leu His Lys Lys Phe Lys Glu Asn Asp Ile Asn Pro

85 90 95

Phe Leu Lys Ala Leu Glu Arg Pro Ser His Asn Arg Leu Ile Gly

100 105 110

Leu Tyr Asn Ala Lys Ser Asp Thr Thr Lys Tyr Lys Tyr Thr Ser Glu

115 120 125

Ile Ile Val Lys Phe Phe Gln Lys Ser Pro Leu Lys Asp Glu Ala Ile

130 135 140

Cys Val Arg Phe Phe Thr Pro Lys Ala Trp Glu Ser Leu Lys Phe Leu

145 150 155 160

Gln Glu Arg Ala Asn Phe Leu His Leu Asp Ile Ser Gly His Leu Leu

165 170 175

Asn Ala Leu Phe Glu Ile Asn Asn Glu Asp Leu Ser Val Ser Phe Asn

180 185 190

Asp Leu Asp Lys Leu Ala Val Leu Asn Ala Pro Ile Thr Leu Glu Asp

195 200 205

Ile Gln Glu Leu Ser Ser Asn Ala Gly Asp Met Asp Leu Gln Lys Leu

210 215 220

Ile Leu Gly Leu Phe Leu Lys Lys Ser Val Leu Asp Ile Tyr Asp Tyr

225 230 235 240

Leu Leu Lys Glu Gly Lys Lys Asp Ala Asp Ile Leu Arg Gly Leu Glu

245 250 255

Arg Tyr Phe Tyr Gln Leu Phe Leu Phe Phe Ala His Ile Lys Thr Thr

260 265 270

Gly Leu Met Asp Ala Lys Glu Val Leu Gly Tyr Ala Pro Pro Lys Glu

275 280 285

Ile Val Glu Asn Tyr Ala Lys Asn Ala Leu Arg Leu Lys Glu Ala Gly

290 295 300

Tyr Lys Arg Val Phe Glu Ile Phe Arg Leu Trp His Leu Gln Ser Met

305 310 315 320

Gln Gly Gln Lys Glu Leu Gly Phe Leu Tyr Leu Thr Pro Ile Gln Lys

325 330 335

Ile Ile Asn Pro

340

(2) INFORMATION FOR SEQ ID NO: 157:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 200 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 200

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 157:

Val Phe Met Thr Ser Ala Leu Leu Gly Leu Gln Ile Val Leu Ala Val

1 5 10 15

Leu Ile Val Val Val Val Leu Leu Gln Lys Ser Ser Ser Ile Gly Leu

20 25 30

Gly Ala Tyr Ser Gly Ser Asn Asp Ser Leu Phe Gly Ala Lys Gly Pro

35 40 45

Ala Ser Phe Met Ala Lys Leu Thr Met Phe Leu Gly Leu Leu Phe Val

50 55 60

Ile Asn Thr Ile Ala Leu Gly Tyr Phe Tyr Asn Lys Glu Tyr Gly Lys

65 70 75 80

Ser Val Leu Asp Glu Thr Lys Thr Asn Lys Glu Leu Ser Pro Leu Val

85 90 95

Pro Ala Thr Gly Thr Leu Asn Pro Thr Leu Asn Pro Thr Leu Asn Pro

100 105 110

Thr Leu Asn Pro Leu Glu Gln Ala Pro Thr Asn Pro Leu Met Pro Thr

115 120 125

Gln Thr Pro Lys Glu Leu Pro Lys Glu Pro Ala Lys Thr Pro Phe Val

130 135 140

Glu Ser Pro Lys Gln Asn Glu Lys Asn Glu Lys Asn Asp Ala Lys Glu

145 150 155 160

Asn Gly Ile Lys Gly Val Glu Lys Asn Lys Glu Asn Ala Lys Thr Pro

165 170 175

Pro Thr Thr His Gln Lys Pro Lys Thr His Ala Thr Thr Asn Ala His

180 185 190

Thr Asn Gln Lys Lys Asp Glu Lys

195 200

(2) INFORMATION FOR SEQ ID NO: 158:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 159 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 159

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 158:

Met Arg Ser Pro Asn Leu Glu Lys Glu Glu Thr Glu Ile Ilu Glu Thr

1 5 10 15

Leu Leu Val Arg Glu Lys Met Arg Leu Cys Pro Leu Tyr Trp Arg Ile

20 25 30

Leu Ala Phe Leu Ile Asp Ser Leu Leu Val Ala Phe Leu Leu Ser Asp

35 40 45

Leu Leu Arg Ala Cys Ala Phe Leu His Ser Leu Tyr Trp Leu Thr Asn

50 55 60

Pro Ile Tyr Tyr Ser Ala Phe Val Val Met Gly Phe Ile Ile Leu Tyr

65 70 75 80

Gly Val Tyr Glu Ile Phe Phe Val Cys Leu Cys Lys Met Ser Leu Ala

85 90 95

Lys Leu Val Phe Arg Ile Lys Ile Ile Asp Ile Tyr Leu Ala Asp Cys

100 105 110

Pro Ser Arg Ala Ile Leu Leu Lys Arg Leu Gly Leu Lys Ile Val Val

115 120 125

Phe Leu Cys Pro Phe Leu Trp Phe Val Val Phe Lys Asn Pro Tyr His

130 135 140

Arg Ala Trp His Glu Glu Lys Ser Lys Ser Leu Leu Val Leu Phe

145 150 155

(2) INFORMATION FOR SEQ ID NO: 159:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 234 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 234

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 159:

Leu Asn Thr Asp Phe Ser His Ile Thr Asp Ile Glu Gly Met Arg Phe

1 5 10 15

Val Asn Glu Glu Asp Ala Leu Asn Lys Leu Ile Asn Glu Ile His Thr

20 25 30

Arg His Ile Asp Leu Lys Asp Ser Ile Met Leu Ala Leu Ser Phe Asn

35 40 45

Ala Leu Tyr Leu Ala Asn Ala Leu Ala Gln Lys Phe Gly Ala Thr Tyr

50 55 60

Asp Ile Leu Phe Leu Glu Pro Ile Leu Ala Pro Leu Asn Ser Lys Cys

65 70 75 80

Glu Ile Ala Leu Val Ser Glu Ser Met Asp Ile Val Met Asn Glu Ser

85 90 95

Leu Ile Asn Ser Phe Asp Ile Ala Leu Asp Tyr Val Tyr Gly Glu Ala

100 105 110

Lys Arg Ala Tyr Glu Glu Asp Ile Leu Ser His Ile Tyr Gln Tyr Arg

115 120 125

Lys Gly Asn Ala Ile Lys Ser Leu Lys Asp Lys Asn Ile Phe Ile Val

130 135 140

Asp Arg Gly Ile Glu Thr Gly Phe Arg Ala Gly Leu Gly Val Gln Thr

145 150 155 160

Cys Leu Lys Lys Glu Cys Gln Asp Ile Tyr Ile Leu Thr Pro Ile Leu

165 170 175

Ala Gln Asn Val Ala Gln Gly Leu Glu Ser Leu Cys Asp Gly Val Ile

180 185 190

Ser Val Tyr Arg Pro Glu Cys Phe Val Ser Val Glu His His Tyr Lys

195 200 205

Glu Leu Lys Arg Leu Ser Asn Glu Glu Ile Glu Lys Tyr Leu Gly Ala

210 215 220

Asn Asn Ala Pro Asn Leu Lys Lys Glu His

225 230

(2) INFORMATION FOR SEQ ID NO: 160:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 287 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 287

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 160:

Leu Lys Gln Ser Glu Met Ala Met Glu Phe Asn Asp Pro Arg Met Arg

1 5 10 15

Phe Phe Ile Gly Asp Val Arg Asp Leu Glu Arg Leu Asn Tyr Ala Leu

20 25 30

Glu Gly Val Asp Ile Cys Ile His Ala Ala Ala Leu Lys His Val Pro

35 40 45

Ile Ala Glu Tyr Asn Pro Leu Glu Cys Ile Lys Thr Asn Ile Met Gly

50 55 60

Ala Ser Asn Val Ile Asn Ala Cys Leu Lys Asn Glu Ile Ser Gln Val

65 70 75 80

Ile Ala Leu Ser Thr Asp Lys Ala Ala Asn Pro Ile Asn Leu Tyr Gly

85 90 95

Ala Thr Lys Leu Cys Ser Asp Lys Leu Phe Val Ser Ala Asn Asn Phe

100 105 110

Lys Gly Pro Ser Gln Thr Gln Phe Gly Val Val Arg Tyr Gly Asn Val

115 120 125

Val Gly Ser Arg Gly Ser Val Val Pro Phe Phe Lys Lys Leu Val Gln

130 135 140

Asn Lys Ala Ser Glu Ile Pro Ile Thr Asp Ile Arg Met Thr Arg Phe

145 150 155 160

Trp Ile Thr Leu Asp Glu Gly Val Ser Phe Val Leu Lys Ser Leu Lys

165 170 175

Arg Met His Gly Gly Glu Ile Phe Val Pro Lys Ile Pro Ser Met Lys

180 185 190

Met Ile Asp Leu Ala Lys Ala Leu Ala Pro Asn Ile Pro Thr Lys Ile

195 200 205

Ile Gly Ile Arg Pro Gly Glu Lys Leu His Glu Val Met Ile Pro Lys

210 215 220

Asp Glu Ser His Leu Ala Leu Glu Phe Glu Asp Phe Phe Ile Ile Gln

225 230 235 240

Pro Thr Ile Ser Phe Gln Thr Pro Lys Asp Tyr Thr Leu Thr Lys Leu

245 250 255

His Glu Lys Gly Gln Lys Val Ala Pro Asp Phe Glu Tyr Ser Ser His

260 265 270

Thr Asn Asn Gln Trp Leu Glu Pro Asp Asp Leu Leu Lys Leu Leu

275 280 285

(2) INFORMATION FOR SEQ ID NO: 161:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 201 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 201

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 161:

Met Arg Leu His Thr Ala Phe Phe Gly Ile Asn Ser Leu Leu Val Ala

1 5 10 15

Thr Leu Leu Ile Ser Gly Cys Ser Leu Phe Lys Lys Arg Asn Thr Asn

20 25 30

Ala Gln Leu Ile Pro Pro Ser Ala Asn Gly Leu Gln Ala Pro Ile Tyr

35 40 45

Pro Pro Thr Asn Phe Thr Pro Arg Lys Ser Ile Gln Pro Leu Pro Ser

50 55 60

Pro Arg Leu Glu Asn Asn Asp Gln Pro Ile Ile Ser Ser Asn Pro Thr

65 70 75 80

Asn Ala Ile Pro Asn Thr Pro Ile Leu Thr Pro Asn Asn Val Ile Glu

85 90 95

Leu Asn Ala Val Gly Met Gly Val Ala Pro Glu Ser Thr Ile Ser Pro

100 105 110

Ser Gln Ala Leu Ala Leu Ala Lys Arg Ala Ala Ile Val Asp Gly Tyr

115 120 125

Arg Gln Leu Gly Glu Lys Met Tyr Gly Ile Arg Val Asn Ala Gln Asp

130 135 140

Thr Val Lys Asp Met Val Leu Gln Asn Ser Val Ile Lys Thr Arg Val

145 150 155 160

Asn Ala Leu Ile Arg Asn Ala Glu Ile Thr Glu Thr Ile Tyr Lys Asp

165 170 175

Gly Leu Cys Gln Val Ser Met Glu Leu Lys Leu Asp Gly Arg Ile Trp

180 185 190

Tyr Arg Ile Leu Ser Gly Ser Arg Gly

195 200

(2) INFORMATION FOR SEQ ID NO: 162:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 355 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 355

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 162:

Met Ser Tyr Thr Ile Asn Lys Arg Phe Ser Val Gly Val Gly Leu Arg

1 5 10 15

Gly Leu Tyr Ala Thr Gly Ser Phe Asn Asn Thr Val Tyr Val Pro Leu

20 25 30

Glu Gly Ala Ser Val Leu Ser Ala Glu Gln Ile Leu Asn Leu Pro Asn

35 40 45

Asn Val Phe Ala Asp Gln Val Pro Ser Asn Met Met Thr Leu Leu Gly

50 55 60

Asn Ile Gly Tyr Gln Pro Ala Leu Asn Cys Gln Lys Ala Gly Gly Asp

65 70 75 80

Met Ser Asp Gln Ser Cys Gln Glu Phe Tyr Asn Gly Leu Lys Lys Ile

85 90 95

Met Gly Tyr Ser Gly Leu Ile Lys Ala Ser Ala Asn Leu Tyr Gly Thr

100 105 110

Thr Gln Val Val Gln Lys Ser Asn Gly Gln Gly Val Ser Gly Gly Tyr

115 120 125

Arg Val Gly Ser Ser Leu Arg Val Phe Asp His Gly Met Phe Ser Val

130 135 140

Val Tyr Asn Ser Ser Val Thr Phe Asn Met Lys Gly Gly Leu Val Ala

145 150 155 160

Ile Thr Glu Leu Gly Pro Ser Leu Gly Ser Val Leu Thr Lys Gly Ser

165 170 175

Leu Asn Ile Asn Val Ser Leu Pro Gln Thr Leu Ser Leu Ala Tyr Ala

180 185 190

His Gln Phe Phe Lys Asp Arg Leu Arg Val Glu Gly Val Phe Glu Arg

195 200 205

Thr Phe Trp Ser Gln Gly Asn Lys Phe Leu Val Thr Pro Asp Phe Ala

210 215 220

Asn Ala Thr Tyr Lys Gly Leu Ser Gly Thr Val Ala Ser Leu Asp Ser

225 230 235 240

Glu Thr Leu Lys Lys Met Val Gly Leu Ala Asn Phe Lys Ser Val Met

245 250 255

Asn Met Gly Ala Gly Trp Arg Asp Thr Asn Thr Phe Arg Leu Gly Val

260 265 270

Thr Tyr Met Gly Lys Ser Leu Arg Leu Met Gly Ala Ile Asp Tyr Asp

275 280 285

Gln Ala Pro Ser Pro Gln Asp Ala Ile Gly Ile Pro Asp Ser Asn Gly

290 295 300

Tyr Thr Val Ala Phe Gly Thr Lys Tyr Asn Phe Arg Gly Phe Asp Leu

305 310 315 320

Gly Val Ala Gly Ser Phe Thr Phe Lys Ser Asn Arg Ser Ser Leu Tyr

325 330 335

Gln Ser Pro Thr Ile Gly Gln Leu Arg Ile Phe Ser Ala Ser Leu Gly

340 345 350

Tyr Arg Trp

355

(2) INFORMATION FOR SEQ ID NO: 163:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 587 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 587

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 163:

Met Lys Asn Phe Ser Pro Leu Tyr Cys Leu Lys Lys Leu Lys Lys Arg

1 5 10 15

His Leu Ile Ala Leu Ser Leu Pro Leu Leu Ser Tyr Ala Asn Gly Phe

20 25 30

Lys Ile Gln Glu Gln Ser Leu Asn Gly Thr Ala Leu Gly Ser Ala Tyr

35 40 45

Val Ala Gly Ala Arg Gly Ala Asp Ala Ser Phe Tyr Asn Pro Ala Asn

50 55 60

Met Gly Phe Thr Asn Asp Trp Gly Glu Asn Arg Ser Glu Phe Glu Met

65 70 75 80

Thr Thr Thr Val Ile Asn Ile Pro Ala Phe Ser Phe Lys Val Pro Thr

85 90 95

Thr Asn Gln Gly Leu Tyr Ser Val Thr Ser Leu Glu Ile Asp Lys Ser

100 105 110

Gln Gln Asn Ile Leu Gly Ile Ile Asn Thr Ile Gly Leu Gly Asn Ile

115 120 125

Leu Lys Ala Leu Gly Asn Thr Ala Ala Thr Asn Gly Leu Ser Gln Ala

130 135 140

Ile Asn Arg Val Gln Gly Leu Met Asn Leu Thr Asn Gln Lys Val Val

145 150 155 160

Thr Leu Ala Ser Lys Pro Asp Thr Gln Ile Val Asn Gly Trp Thr Gly

165 170 175

Thr Thr Asn Phe Val Leu Pro Lys Phe Phe Tyr Lys Thr Arg Thr His

180 185 190

Asn Gly Phe Thr Phe Gly Gly Ser Phe Thr Ala Pro Ser Gly Leu Gly

195 200 205

Met Lys Trp Asn Gly Lys Gly Gly Glu Phe Leu His Asp Val Phe Ile

210 215 220

Met Met Val Glu Leu Ala Pro Ser Met Ser Tyr Thr Ile Asn Lys Arg

225 230 235 240

Phe Ser Val Gly Val Gly Leu Arg Gly Leu Tyr Ala Thr Gly Ser Phe

245 250 255

Asn Asn Thr Val Tyr Val Pro Leu Glu Gly Ala Ser Val Leu Ser Ala

260 265 270

Glu Gln Ile Leu Asn Leu Pro Asn Asn Val Phe Ala Asp Gln Val Pro

275 280 285

Ser Asn Met Met Thr Leu Leu Gly Asn Ile Gly Tyr Gln Pro Ala Leu

290 295 300

Asn Cys Gln Lys Ala Gly Gly Asp Met Ser Asp Gln Ser Cys Gln Glu

305 310 315 320

Phe Tyr Asn Gly Leu Lys Lys Ile Met Gly Tyr Ser Gly Leu Ile Lys

325 330 335

Ala Ser Ala Asn Leu Tyr Gly Thr Thr Gln Val Val Gln Lys Ser Asn

340 345 350

Gly Gln Gly Val Ser Gly Gly Tyr Arg Val Gly Ser Ser Leu Arg Val

355 360 365

Phe Asp His Gly Met Phe Ser Val Val Tyr Asn Ser Ser Val Thr Phe

370 375 380

Asn Met Lys Gly Gly Leu Val Ala Ile Thr Glu Leu Gly Pro Ser Leu

385 390 395 400

Gly Ser Val Leu Thr Lys Gly Ser Leu Asn Ile Asn Val Ser Leu Pro

405 410 415

Gln Thr Leu Ser Leu Ala Tyr Ala His Gln Phe Phe Lys Asp Arg Leu

420 425 430

Arg Val Glu Gly Val Phe Glu Arg Thr Phe Trp Ser Gln Gly Asn Lys

435 440 445

Phe Leu Val Thr Pro Asp Phe Ala Asn Ala Thr Tyr Lys Gly Leu Ser

450 455 460

Gly Thr Val Ala Ser Leu Asp Ser Glu Thr Leu Lys Lys Met Val Gly

465 470 475 480

Leu Ala Asn Phe Lys Ser Val Met Asn Met Gly Ala Gly Trp Arg Asp

485 490 495

Thr Asn Thr Phe Arg Leu Gly Val Thr Tyr Met Gly Lys Ser Leu Arg

500 505 510

Leu Met Gly Ala Ile Asp Tyr Asp Gln Ala Pro Ser Pro Gln Asp Ala

515 520 525

Ile Gly Ile Pro Asp Ser Asn Gly Tyr Thr Val Ala Phe Gly Thr Lys

530 535 540

Tyr Asn Phe Arg Gly Phe Asp Leu Gly Val Ala Gly Ser Phe Thr Phe

545 550 555 560

Lys Ser Asn Arg Ser Ser Leu Tyr Gln Ser Pro Thr Ile Gly Gln Leu

565 570 575

Arg Ile Phe Ser Ala Ser Leu Gly Tyr Arg Trp

580 585

(2) INFORMATION FOR SEQ ID NO: 164:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 205 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 205

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 164:

Leu Ile Phe Arg Phe Phe Leu Ile Leu Ser Leu Leu Lys Gly Val Leu

1 5 10 15

Leu Ala Lys Lys Asp Trp Asn Phe Phe Lys Pro Leu Glu Pro Thr Lys

20 25 30

Lys Tyr Phe Gly Ser Phe Lys Ile Gly Tyr Leu Tyr Gln His Ala Glu

35 40 45

Thr Thr Lys Arg Phe Pro Ile Arg Pro Lys Asn Arg Pro Pro Ile Leu

50 55 60

Met Asp Lys Ile Tyr His Asp Ala Ser Leu Gly Phe Asp Ala Gly Tyr

65 70 75 80

Val Leu Lys Lys Lys Ala Leu Leu Gly Gly Tyr Leu Asp Ala Gly Met

85 90 95

Gly Asp Ser Tyr Phe Met Ser Ala Gly Leu Val Ala Gly Val Arg Leu

100 105 110

Phe Lys Gly Trp Val Ile Pro Lys Ile Ala Leu Gly Tyr Gln Leu Gln

115 120 125

Ile Leu Gly Ala Lys Ile Asp Lys Tyr Gln Phe Asn Ile Gln Ser Ala

130 135 140

Val Gly Ser Val Gly Leu Phe Phe Asn Ala Ala Lys Asn Phe Gly Leu

145 150 155 160

Ser Ile Glu Ala Arg Gly Gly Ile Pro Phe Tyr Phe Ile Gln Ser Arg

165 170 175

Phe Ser Lys Ala Phe Gly Thr Pro Arg Leu Asn Ile Tyr Ser Val Gly

180 185 190

Ile Thr Phe Thr Phe Tyr Asp Phe Thr Arg Phe Leu Gly

195 200 205

(2) INFORMATION FOR SEQ ID NO: 165:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 253 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 253

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 165:

Leu Trp His Ala Ala Phe Ser Val Gly Glu Trp Gly Trp Asn Gly Asp

1 5 10 15

Glu Ile Pro Tyr Arg Asp Cys Asp Glu Trp Gly Leu Asp Asp Phe Tyr

20 25 30

Gly Val Lys Pro Thr Asp Cys Ala Gly Val Leu Ser Phe Ala Arg Ser

35 40 45

His Arg Arg Gln Asn Gln Ala Val Leu Ser Lys Pro Lys Ser Phe Arg

50 55 60

Met Lys Lys Ile Ala Phe Ile Leu Ala Leu Trp Val Gly Leu Leu Gly

65 70 75 80

Ala Phe Glu Pro Lys Lys Ser His Ile Tyr Phe Gly Ala Met Val Gly

85 90 95

Leu Ala Pro Val Lys Ile Thr Pro Lys Pro Ala Ser Asp Ser Ser Tyr

100 105 110

Thr Ala Phe Leu Trp Gly Ala Lys Gly Gly Tyr Gln Phe Ala Phe Phe

115 120 125

Lys Ala Leu Ala Leu Arg Gly Glu Phe Ser Tyr Leu Met Ala Ile Lys

130 135 140

Pro Thr Ala Leu His Thr Ile Asn Thr Ser Leu Leu Ser Leu Asn Met

145 150 155 160

Asp Val Leu Ser Asp Phe Tyr Thr Tyr Lys Lys Tyr Ser Phe Gly Val

165 170 175

Tyr Gly Gly Leu Gly Ile Gly Tyr Phe Tyr Gln Ser Asn His Leu Gly

180 185 190

Met Lys Asn Ser Ser Phe Met Gly Tyr Asn Gly Leu Phe Asn Val Gly

195 200 205

Leu Gly Ser Thr Ile Asp Arg His His Arg Val Glu Leu Gly Ala Lys

210 215 220

Ile Pro Phe Ser Lys Thr Arg Asn Ser Phe Lys Asn Ser Tyr Phe Leu

225 230 235 240

Glu Ser Val Phe Ile His Ala Ala Tyr Ser Tyr Met Phe

245 250

(2) INFORMATION FOR SEQ ID NO: 166:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 412 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 412

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 166:

Met Glu Ser Val Lys Thr Val Lys Thr Asn Lys Val Gly Lys Asn Thr

1 5 10 15

Glu Thr Ala Asn Thr Glu Ala Ser Lys Glu Thr His Phe Lys Gln Ala

20 25 30

Ser Ala Ile Thr Asn Thr Leu Arg Ser Ile Gly Gly Ile Phe Thr Lys

35 40 45

Ile Ala Lys Lys Val Arg Glu Leu Val Lys Lys His Pro Lys Lys Ser

50 55 60

Ser Val Ala Leu Val Val Leu Thr His Ile Ala Cys Lys Arg Ala Lys

65 70 75 80

Glu Leu Asp Asp Lys Val Gln Asp Lys Ser Lys Gln Ala Glu Lys Glu

85 90 95

Asn Gln Ile Asn Trp Trp Lys Tyr Ser Gly Leu Thr Ile Ala Ala Ser

100 105 110

Leu Leu Leu Ala Ala Cys Ser Thr Gly Asp Ile Asp Lys Gln Ile Glu

115 120 125

Leu Glu Gln Glu Lys Lys Glu Ala Asn Lys Ser Gly Ile Lys Leu Glu

130 135 140

Gln Glu Arg Gln Lys Thr Glu Gln Glu Arg Gln Lys Thr Asn Lys Ser

145 150 155 160

Glu Ile Glu Leu Glu Gln Glu Arg Gln Lys Thr Asn Lys Ser Gly Ile

165 170 175

Glu Leu Ala Asn Ser Gln Ile Lys Ala Glu Gln Glu Arg Gln Lys Thr

180 185 190

Glu Gln Glu Lys Gln Lys Ala Asn Lys Ser Glu Ile Glu Leu Glu Gln

195 200 205

Gln Lys Gln Lys Thr Ile Asn Thr Gln Arg Asp Leu Ile Lys Glu Gln

210 215 220

Lys Asp Phe Ile Lys Glu Thr Glu Gln Asn Cys Gln Glu Lys His Gly

225 230 235 240

Gln Leu Phe Ile Lys Lys Ala Arg Ile Lys Thr Gly Ile Thr Thr Gly

245 250 255

Ile Ala Ile Glu Ile Glu Ala Glu Cys Lys Thr Pro Lys Pro Ala Lys

260 265 270

Thr Asn Gln Thr Pro Ile Gln Pro Lys His Leu Pro Asn Ser Lys Gln

275 280 285

Pro Arg Ser Gln Arg Gly Ser Lys Ala Gln Glu Leu Ile Ala Tyr Leu

290 295 300

Gln Lys Glu Leu Glu Ser Leu Pro Tyr Ser Gln Lys Ala Ile Ala Lys

305 310 315 320

Gln Val Asp Phe Tyr Lys Pro Ser Ser Ile Ala Tyr Leu Glu Leu Asp

325 330 335

Pro Arg Asp Phe Lys Val Thr Glu Glu Trp Gln Lys Glu Asn Leu Lys

340 345 350

Ile Arg Ser Lys Ala Gln Ala Lys Met Leu Glu Met Arg Asn Pro Gln

355 360 365

Ala His Leu Pro Thr Ser Gln Ser Leu Leu Phe Val Gln Lys Ile Phe

370 375 380

Ala Asp Ile Asn Lys Glu Ile Glu Ala Val Ala Asn Thr Glu Lys Lys

385 390 395 400

Thr Glu Lys Ala Gly Tyr Gly Tyr Ser Lys Arg Met

405 410

(2) INFORMATION FOR SEQ ID NO: 167:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 149 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 149

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 167:

Leu Asn Trp Glu His Leu Met Lys Lys Leu Ala Phe Ser Leu Leu Phe

1 5 10 15

Thr Gly Thr Phe Leu Gly Leu Phe Leu Asn Ala Ser Asp Phe Lys Ser

20 25 30

Met Asp Asn Lys Gln Leu Leu Glu Gln Ala Gly Lys Val Ala Pro Ser

35 40 45

Glu Val Pro Glu Phe Arg Thr Glu Val Asn Lys Arg Leu Glu Ala Met

50 55 60

Lys Glu Glu Glu Arg Gln Lys Tyr Lys Ala Asp Phe Lys Lys Ala Met

65 70 75 80

Asp Lys Asn Leu Ala Ser Leu Ser Gln Glu Asp Arg Asn Lys Arg Lys

85 90 95

Lys Glu Ile Leu Glu Val Ile Ala Asn Lys Lys Lys Thr Met Thr Met

100 105 110

Lys Glu Tyr Arg Glu Glu Gly Leu Asp Leu His Asp Cys Ala Cys Glu

115 120 125

Gly Pro Phe His Asp His Glu Lys Lys Gly Gln Lys Gly Lys Lys Pro

130 135 140

Ser His His Lys His

145

(2) INFORMATION FOR SEQ ID NO: 168:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 204 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 204

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 168:

Met Gln Ala Val Ile Leu Ala Asn Gly Glu Phe Pro Lys Ser Lys Lys

1 5 10 15

Cys Leu Asp Ile Leu Gln Asn Ala Pro Phe Leu Ile Ala Cys Asp Gly

20 25 30

Ala Val Ile Ser Leu His Ala Leu Gln Phe Lys Pro Ser Val Val Ile

35 40 45

Gly Asp Leu Asp Ser Ile Asp Ser His Leu Lys Ala Leu Tyr Asn Pro

50 55 60

Ile Arg Val Ser Glu Gln Asp Ser Asn Asp Leu Ser Lys Ala Phe Phe

65 70 75 80

Tyr Ala Leu Asn Arg Gly Cys Asp Asp Phe Ile Phe Leu Gly Leu Asn

85 90 95

Gly Lys Arg Glu Asp His Ala Leu Ala Asn Thr Phe Leu Leu Leu Glu

100 105 110

Tyr Phe Lys Phe Cys Lys Lys Ile Gln Ser Val Ser Asp Tyr Gly Leu

115 120 125

Phe Arg Val Leu Glu Thr Pro Phe Thr Leu Pro Ser Phe Lys Gly Glu

130 135 140

Gln Ile Ser Leu Phe Ser Leu Asp Leu Lys Ala Arg Phe Thr Ser Lys

145 150 155 160

Asn Leu Lys Tyr Pro Leu Lys Asp Leu Arg Leu Lys Thr Leu Phe Ser

165 170 175

Gly Ser Leu Asn Glu Ala Thr Asn His Cys Phe Ser Leu Ser Ser Glu

180 185 190

Pro Lys Ser Val Val Leu Val Tyr Gln Lys Phe Ser

195 200

(2) INFORMATION FOR SEQ ID NO: 169:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 280 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 280

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 169:

Val Phe Asp Ser Leu Gly Gly Phe Leu Gly Tyr Lys Thr Phe Lys Pro

1 5 10 15

Ile Val Asp Lys Val Lys Asn Ile Asn Ala Trp Ile Lys Asn Tyr Asp

20 25 30

Asn Lys Lys Ala Gln Glu Ile Met Gly Phe Ile Glu Asn Pro Thr Pro

35 40 45

Asp Phe Gln Asn Asn Lys Phe Leu Cys Val Leu Asn Arg Gln Gly Thr

50 55 60

Arg His Asn Asn Tyr Leu Gly Leu Thr Ser Thr Asn Leu Leu Ile Gly

65 70 75 80

Ala Ile Tyr Phe Ser Ile Arg His Cys Ile Lys Ala Thr Trp Gln Asn

85 90 95

Asp Arg Asp Gln Phe Tyr Ala Pro Tyr Asp Asp Ala Phe Gln Asp Asp

100 105 110

Ser Glu Phe Lys Asn Asn Cys Leu Ala Phe Met Leu Phe His Thr Gln

115 120 125

Asn Arg Ile Thr Ala Thr Gln Gly Thr Asn His Phe Ile Pro Phe Ser

130 135 140

Glu Asp Glu Val Asp Ser Lys Glu Arg Tyr Leu Ser His Ala Leu Leu

145 150 155 160

Asp Phe Leu Lys Gly Glu Ile Lys Glu Pro Lys Lys Ser Asp Ser Leu

165 170 175

Phe Leu Asn Ala Lys Lys Glu Asn Lys Pro Leu Lys Phe Ser Ser Ser

180 185 190

Ala Ser Lys Val Phe Asp Ala Gly Arg Glu Ile Tyr Arg Tyr Tyr His

195 200 205

Thr Gln Asp Phe Ile His Thr Pro Tyr Asn Ala Asn Ala Ser Leu Tyr

210 215 220

Asp Ile Lys Glu Phe Phe Gln Gly Arg Asn Lys Gln Gly Arg Leu Asn

225 230 235 240

Ser Pro Thr Lys Ala Lys Asp Glu Tyr Tyr Lys Gln Leu Tyr Ala Asn

245 250 255

Leu Gln Tyr Ala Leu Lys Asp Leu Ala Lys Glu Ile Gln Pro Lys Val

260 265 270

Tyr Glu Tyr Gly Phe Leu Arg Glu

275 280

(2) INFORMATION FOR SEQ ID NO: 170:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 309 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 309

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 170:

Cys Asp Arg Ala Ile Pro His Trp Leu Phe Ser Leu Gly Tyr Arg Tyr

1 5 10 15

Pro Pro Pro Leu Lys Pro Thr Asn Ala Phe Asn Leu Glu Val Phe Asp

20 25 30

Ser Leu Gly Gly Phe Leu Gly Tyr Lys Thr Phe Lys Pro Ile Val Asp

35 40 45

Lys Val Lys Asn Ile Asn Ala Trp Ile Lys Asn Tyr Asp Asn Lys Lys

50 55 60

Ala Gln Glu Ile Met Gly Phe Ile Glu Asn Pro Thr Pro Asp Phe Gln

65 70 75 80

Asn Asn Lys Phe Leu Cys Val Leu Asn Arg Gln Gly Thr Arg His Asn

85 90 95

Asn Tyr Leu Gly Leu Thr Ser Thr Asn Leu Leu Ile Gly Ala Ile Tyr

100 105 110

Phe Ser Ile Arg His Cys Ile Lys Ala Thr Trp Gln Asn Asp Arg Asp

115 120 125

Gln Phe Tyr Ala Pro Tyr Asp Asp Ala Phe Gln Asp Asp Ser Glu Phe

130 135 140

Lys Asn Asn Cys Leu Ala Phe Met Leu Phe His Thr Gln Asn Arg Ile

145 150 155 160

Thr Ala Thr Gln Gly Thr Asn His Phe Ile Pro Phe Ser Glu Asp Glu

165 170 175

Val Asp Ser Lys Glu Arg Tyr Leu Ser His Ala Leu Leu Asp Phe Leu

180 185 190

Lys Gly Glu Ile Lys Glu Pro Lys Lys Ser Asp Ser Leu Phe Leu Asn

195 200 205

Ala Lys Lys Glu Asn Lys Pro Leu Lys Phe Ser Ser Ser Ala Ser Lys

210 215 220

Val Phe Asp Ala Gly Arg Glu Ile Tyr Arg Tyr Tyr His Thr Gln Asp

225 230 235 240

Phe Ile His Thr Pro Tyr Asn Ala Asn Ala Ser Leu Tyr Asp Ile Lys

245 250 255

Glu Phe Phe Gln Gly Arg Asn Lys Gln Gly Arg Leu Asn Ser Pro Thr

260 265 270

Lys Ala Lys Asp Glu Tyr Tyr Lys Gln Leu Tyr Ala Asn Leu Gln Tyr

275 280 285

Ala Leu Lys Asp Leu Ala Lys Glu Ile Gln Pro Lys Val Tyr Glu Tyr

290 295 300

Gly Phe Leu Arg Glu

305

(2) INFORMATION FOR SEQ ID NO: 171:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 187 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 187

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 171:

Leu Glu Thr Tyr Ile Ile Asp Ala Asp Asn Ile Asp Gly Asp Leu Phe

1 5 10 15

Phe Tyr Asn Leu Thr Arg Asn Ser Asn Asp Phe Ser Met Leu Pro Val

20 25 30

Phe Glu Leu Asp Arg Ile Ala Gln Lys Ile Arg Asn Ile Leu Lys Lys

35 40 45

His Gly Ser Arg Lys Asp Ile Ile Leu Lys His Asn Glu Ile Lys Glu

50 55 60

Ala Phe Phe Ser Pro Phe Lys Pro Gln Leu Lys Thr Val Gln Val Phe

65 70 75 80

Leu Ser His Ser His Ala Asp Lys Asn Lys Ala Leu Gly Val Lys Asp

85 90 95

Tyr Leu Glu Ser Lys Thr Lys Arg Lys Val Phe Ile Asp Ser Leu Phe

100 105 110

Trp Asp Tyr Lys Asp Asp Val Leu Asn Lys Leu Ala Lys His Asp Asp

115 120 125

Ile Ser Lys Ile Glu Asp Ala Phe Thr Leu Ile Leu Arg Lys Ser Leu

130 135 140

Gln Asp Met Ile Glu Lys Cys Pro Tyr Phe Val Phe Leu Gln Ser Lys

145 150 155 160

Asn Ser Val Ser Asn Gln Gly Leu Ser Arg Ile Thr Tyr Ser Ala Trp

165 170 175

Ile Tyr Glu Glu Leu Lys Ile Ala Ser Phe Tyr

180 185

(2) INFORMATION FOR SEQ ID NO: 172:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 198 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 198

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 172:

Leu Glu Thr Tyr Ile Ile Asp Ala Asp Asn Ile Asp Gly Asp Leu Phe

1 5 10 15

Phe Tyr Asn Leu Thr Arg Asn Ser Asn Asp Phe Ser Met Leu Pro Val

20 25 30

Phe Glu Leu Asp Arg Ile Ala Gln Lys Ile Arg Asn Ile Leu Lys Lys

35 40 45

His Gly Ser Arg Lys Asp Ile Ile Leu Lys His Asn Glu Ile Lys Glu

50 55 60

Ala Phe Phe Ser Pro Phe Lys Pro Gln Leu Lys Thr Val Gln Val Phe

65 70 75 80

Leu Ser His Ser His Ala Asp Lys Asn Lys Ala Leu Gly Val Lys Asp

85 90 95

Tyr Leu Glu Ser Lys Thr Lys Arg Lys Val Phe Ile Asp Ser Leu Phe

100 105 110

Trp Asp Tyr Lys Asp Asp Val Leu Asn Lys Leu Ala Lys His Asp Asp

115 120 125

Ile Ser Lys Ile Glu Asp Ala Phe Thr Leu Ile Leu Arg Lys Ser Leu

130 135 140

Gln Asp Met Ile Glu Lys Cys Pro Tyr Phe Val Phe Leu Gln Ser Lys

145 150 155 160

Asn Ser Val Ser Asn Gln Gly Leu Ser Arg Ile Thr Tyr Ser Ala Trp

165 170 175

Ile Tyr Glu Glu Leu Lys Ile Ala Ser Phe Leu Leu Ala Leu Leu Thr

180 185 190

Arg Val Ala Gln Phe Gln

195

(2) INFORMATION FOR SEQ ID NO: 173:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 189 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 189

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 173:

Met Met Thr Lys Asn Ala Tyr Ala Phe Val Val Ile Glu Lys Ser Ile

1 5 10 15

Met Val Phe Lys Cys Ala Lys Asp Lys Gly Leu Ile Pro Ile Thr Glu

20 25 30

Gly Phe Val Pro Leu Lys Glu Gly Phe Leu Arg Ser Phe Lys Glu Arg

35 40 45

Cys Asn Leu Asp Phe Leu Glu Asn Leu Asp Leu Leu Phe Leu Tyr Asp

50 55 60

Tyr Gln Phe Pro Ser Glu Val Phe Ser Leu Cys Lys Asp Leu Lys Asn

65 70 75 80

Ser Ile Trp Asp Arg Lys Leu Val Val Val Leu Val Glu Ala Leu Glu

85 90 95

Gly Phe Lys Gly Leu Asn Leu Ser Leu Lys Ile Glu Asp Arg His Ser

100 105 110

Asn Ser Leu Gly Asn Gly Val Gln Lys Leu Leu Thr Asn Ala Asp Leu

115 120 125

Gly Ser Asn His Lys Pro Ile Val Ile Asp Ser Met Lys Thr Tyr His

130 135 140

Gln Ser Gln Gln Glu Lys Tyr Lys Arg Glu Arg Gly Glu Thr Leu Glu

145 150 155 160

Val Arg Pro Thr Thr Pro Pro Ser Tyr Gly Gly Gly Ser Ile Arg Ile

165 170 175

Ser Gly Asp Lys Lys Pro Asp Ser Asn Glu Glu Asn Phe

180 185

(2) INFORMATION FOR SEQ ID NO: 174:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 590 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 590

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 174:

Met Lys Ala Ile Lys Ile Leu Leu Ile Met Thr Leu Ser Leu Asn Ala

1 5 10 15

Ile Ser Val Asn Arg Ala Leu Phe Asp Leu Lys Asp Ser Gln Leu Lys

20 25 30

Gly Glu Leu Thr Pro Lys Ile Val Asp Phe Gly Gly Tyr Lys Ser Asn

35 40 45

Thr Thr Glu Trp Gly Ala Thr Ala Leu Asn Tyr Ile Asn Ala Ala Asn

50 55 60

Gly Asp Ala Lys Lys Phe Ser Ala Leu Val Glu Lys Met Arg Phe Asn

65 70 75 80

Ser Gly Ile Leu Gly Asn Phe Arg Ala His Ala His Leu Arg Gln Ala

85 90 95

Leu Lys Leu Gln Lys Asn Leu Lys Tyr Cys Leu Lys Ile Ile Ala Arg

100 105 110

Asp Ser Phe Tyr Ser Tyr Arg Thr Gly Ile Tyr Ile Pro Leu Gly Ile

115 120 125

Ser Leu Lys Asp Gln Lys Thr Ala Gln Lys Met Leu Ala Asp Leu Ser

130 135 140

Val Val Gly Ala Tyr Leu Lys Lys Gln Gln Glu Asn Glu Lys Ala Gln

145 150 155 160

Ser Pro Tyr Tyr Arg Ser Asn Asn Tyr Tyr Asn Ser Tyr Tyr Ser Pro

165 170 175

Tyr Tyr Gly Met Tyr Gly Met Tyr Gly Met Gly Met Tyr Gly Met Tyr

180 185 190

Gly Met Gly Met Tyr Asp Phe Tyr Asp Phe Tyr Asp Gly Met Tyr Gly

195 200 205

Phe Tyr Pro Asn Met Phe Phe Met Met Gln Val Gln Asp Tyr Leu Met

210 215 220

Leu Glu Asn Tyr Met Tyr Ala Leu Asp Gln Glu Glu Ile Leu Asp His

225 230 235 240

Asp Ala Ser Ile Asn Gln Leu Asp Thr Pro Thr Asp Asp Asp Arg Asp

245 250 255

Asp Lys Asp Asp Lys Ser Ser Gln Pro Ala Asn Leu Met Ser Phe Tyr

260 265 270

Arg Asp Pro Lys Phe Ser Lys Asp Ile Gln Thr Asn Arg Leu Asn Ser

275 280 285

Ala Leu Val Asn Leu Asp Asn Ser His Met Leu Lys Asp Asn Ser Leu

290 295 300

Phe His Thr Lys Ala Met Pro Thr Lys Ser Val Asp Ala Ile Thr Ser

305 310 315 320

Gln Ala Lys Glu Leu Asn His Leu Val Gly Gln Ile Lys Glu Met Lys

325 330 335

Gln Asp Gly Ala Ser Pro Asn Lys Ile Asp Ser Val Val Asn Lys Ala

340 345 350

Met Glu Val Arg Asp Lys Leu Asp Asn Asn Leu Asn Gln Leu Asp Asn

355 360 365

Asp Leu Lys Asp Gln Lys Gly Leu Ser Ser Glu Gln Gln Ala Gln Val

370 375 380

Asp Lys Ala Leu Asp Ser Val Gln Gln Leu Ser His Ser Ser Asp Val

385 390 395 400

Val Gly Asn Tyr Leu Asp Gly Ser Leu Lys Ile Asp Gly Asp Asp Arg

405 410 415

Asp Asp Leu Asn Asp Ala Ile Asn Asn Pro Met Gln Gln Pro Ala Gln

420 425 430

Gln Thr Pro Ile Asn Asn Met Asp Asn Thr His Ala Asn Asp Ser Lys

435 440 445

Asp Gln Gly Gly Asn Ala Leu Ile Asn Pro Asn Asn Ala Thr Asn Asp

450 455 460

Asp His Asn Asp Asp His Met Asp Thr Asn Thr Thr Asp Thr Ser Asn

465 470 475 480

Ala Asn Asp Thr Pro Thr Asp Asp Lys Asp Ala Ser Gly Asn Asn Thr

485 490 495

Gly Asp Met Asn Asn Thr Asp Thr Gly Asn Thr Asp Thr Gly Asn Thr

500 505 510

Asp Thr Gly Asn Thr Asp Asp Met Ser Asn Met Asn Asn Gly Asn Asp

515 520 525

Asp Thr Gly Asn Thr Asn Asp Asp Met Gly Asn Ser Asn Asp Met Gly

530 535 540

Asp Asp Met Asn Asn Ala Asn Asp Met Asn Asp Asp Met Gly Asn Ser

545 550 555 560

Asn Asp Asp Met Gly Asp Met Gly Asp Met Asn Asp Asp Met Gly Gly

565 570 575

Asp Met Gly Asp Met Gly Asp Met Gly Gly Asp Met Gly Asn

580 585 590

(2) INFORMATION FOR SEQ ID NO: 175:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 195 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 195

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 175:

Leu Asn Leu Arg Leu Ala Gly Ala Ser Val Leu Thr Ala Cys Val Phe

1 5 10 15

Ser Gly Cys Phe Phe Leu Lys Met Phe Asp Lys Lys Leu Ser Ser Asn

20 25 30

Asp Trp His Ile Gln Lys Val Glu Met Asn His Gln Val Tyr Asp Ile

35 40 45

Glu Thr Met Leu Ala Asp Ser Ala Phe Arg Glu His Glu Glu Glu Gln

50 55 60

Asp Ser Ser Leu Asn Thr Ala Leu Pro Glu Asp Lys Thr Ala Ile Glu

65 70 75 80

Ala Lys Glu Gln Glu Gln Lys Glu Lys Arg Lys His Trp Tyr Glu Leu

85 90 95

Phe Lys Lys Lys Pro Lys Pro Lys Ser Ser Met Gly Glu Phe Val Phe

100 105 110

Asp Gln Lys Glu Asn Arg Ile Tyr Gly Lys Gly Tyr Cys Asn Arg Tyr

115 120 125

Phe Ala Ser Tyr Thr Trp Gln Gly Asp Arg His Ile Ala Ile Glu Asp

130 135 140

Ser Gly Ile Ser Arg Lys Val Cys Arg Asp Glu His Leu Met Ala Phe

145 150 155 160

Glu Leu Glu Phe Met Glu Asn Phe Lys Gly Asn Phe Ala Val Thr Lys

165 170 175

Gly Lys Asp Thr Leu Ile Leu Asp Asn Gln Lys Met Lys Ile Tyr Leu

180 185 190

Lys Thr Pro

195

(2) INFORMATION FOR SEQ ID NO: 176:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 744 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 744

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 176:

Met Leu Lys Leu Ala Ser Lys Thr Ile Cys Leu Ser Leu Ile Ser Ser

1 5 10 15

Phe Thr Ala Val Glu Ala Phe Gln Lys His Gln Lys Asp Gly Phe Phe

20 25 30

Ile Glu Ala Gly Phe Glu Thr Gly Leu Leu Gln Gly Thr Gln Thr Gln

35 40 45

Glu Gln Thr Ile Ala Thr Thr Gln Glu Lys Pro Lys Pro Lys Pro Lys

50 55 60

Pro Lys Pro Ile Thr Pro Gln Ser Thr Tyr Gly Lys Tyr Tyr Ile Ser

65 70 75 80

Gln Ser Thr Ile Leu Lys Asn Ala Thr Glu Leu Phe Ala Glu Asp Asn

85 90 95

Ile Thr Asn Leu Thr Phe Tyr Ser Gln Asn Pro Val Tyr Val Thr Ala

100 105 110

Tyr Asn Gln Glu Ser Ala Glu Glu Ala Gly Tyr Gly Asn Asn Ser Leu

115 120 125

Ile Met Ile Gln Asn Phe Leu Pro Tyr Asn Leu Asn Asn Ile Glu Leu

130 135 140

Ser Tyr Thr Asp Asp Gln Gly Asn Val Val Ser Leu Gly Val Ile Glu

145 150 155 160

Thr Ile Pro Lys Gln Ser Gln Ile Ile Leu Pro Ala Ser Leu Phe Asn

165 170 175

Asp Pro Gln Leu Asn Ala Asp Gly Phe Gln Gln Leu Gln Thr Asn Thr

180 185 190

Thr Arg Phe Ser Asp Ala Ser Thr Gln Asn Leu Phe Asn Lys Leu Ser

195 200 205

Lys Val Thr Thr Asn Leu Gln Met Thr Tyr Ile Asn Tyr Asn Gln Phe

210 215 220

Ser Ser Gly Asn Gly Ser Gly Ser Lys Pro Pro Cys Pro Pro Tyr Glu

225 230 235 240

Asn Gln Ala Asn Cys Val Ala Lys Val Pro Pro Phe Thr Ser Gln Asp

245 250 255

Ala Lys Asn Leu Thr Asn Leu Met Leu Asn Met Met Ala Val Phe Asp

260 265 270

Ser Lys Ser Trp Glu Asp Ala Val Leu Asn Ala Pro Phe Gln Phe Ser

275 280 285

Asp Asn Asn Leu Ser Ala Pro Cys Tyr Ser Asp Tyr Leu Thr Cys Val

290 295 300

Asn Pro Tyr Asn Asp Gly Leu Val Asp Pro Lys Leu Ile Ala Lys Asn

305 310 315 320

Lys Gly Asp Glu Tyr Asn Ile Glu Asn Gly Gln Thr Gly Ser Val Ile

325 330 335

Leu Thr Pro Gln Asp Val Ile Tyr Ser Tyr Arg Val Ala Asn Asn Ile

340 345 350

Tyr Val Asn Leu Leu Pro Thr Arg Gly Gly Asp Leu Gly Leu Gly Ser

355 360 365

Gln Tyr Gly Gly Pro Asn Gly Pro Gly Asp Asp Gly Thr Asn Phe Gly

370 375 380

Ala Leu Gly Ile Leu Ser Pro Phe Leu Asp Pro Glu Ile Leu Phe Gly

385 390 395 400

Lys Glu Leu Asn Lys Val Ala Ile Met Gln Leu Arg Asp Ile Ile His

405 410 415

Glu Tyr Gly His Thr Leu Gly Tyr Thr His Asn Gly Asn Met Thr Tyr

420 425 430

Gln Arg Val Arg Met Cys Glu Glu Asn Asn Gly Pro Glu Glu Arg Cys

435 440 445

Gln Gly Gly Arg Ile Glu Gln Val Asp Gly Lys Glu Val Gln Val Phe

450 455 460

Asp Asn Gly His Glu Val Arg Asp Thr Asp Gly Ser Thr Tyr Asp Val

465 470 475 480

Cys Ser Arg Phe Lys Asp Lys Pro Tyr Thr Ala Gly Ser Tyr Pro Asn

485 490 495

Ser Ile Tyr Thr Asp Cys Ser Gln Val Pro Ala Gly Leu Ile Gly Val

500 505 510

Thr Ser Ala Val Trp Gln Gln Leu Ile Asp Gln Asn Ala Leu Pro Val

515 520 525

Asp Phe Thr Asn Leu Ser Ser Gln Thr Asn Tyr Leu Asn Ala Ser Leu

530 535 540

Asn Thr Gln Asp Phe Ala Thr Thr Met Leu Ser Ala Ile Ser Gln Ser

545 550 555 560

Leu Ser Ser Ser Lys Ser Ser Ala Thr Thr Tyr Arg Thr Ser Lys Thr

565 570 575

Ser Arg Pro Phe Gly Ala Pro Leu Leu Gly Val Asn Leu Lys Met Gly

580 585 590

Tyr Gln Lys Tyr Phe Asn Asp Tyr Leu Gly Leu Ser Ser Tyr Gly Ile

595 600 605

Ile Lys Tyr Asn Tyr Ala Gln Ala Asn Asn Glu Lys Ile Gln Gln Leu

610 615 620

Ser Tyr Gly Val Gly Met Asp Val Leu Phe Asp Phe Ile Thr Asn Tyr

625 630 635 640

Thr Asn Glu Lys Asn Pro Lys Ser Asn Leu Thr Lys Lys Val Phe Thr

645 650 655

Ser Ser Leu Gly Val Phe Gly Gly Leu Arg Gly Leu Tyr Asn Ser Tyr

660 665 670

Tyr Leu Leu Asn Gln Tyr Lys Gly Ser Gly Asn Leu Asn Val Thr Gly

675 680 685

Gly Leu Asn Tyr Arg Tyr Lys His Ser Lys Tyr Ser Ile Gly Ile Ser

690 695 700

Val Pro Leu Val Gln Leu Lys Ser Arg Ile Val Ser Ser Asp Gly Ala

705 710 715 720

Tyr Thr Asn Ser Ile Thr Leu Asn Glu Gly Gly Ser His Phe Lys Val

725 730 735

Phe Phe Asn Tyr Gly Trp Ile Phe

740

(2) INFORMATION FOR SEQ ID NO: 177:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 529 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 529

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 177:

Met Thr Tyr Ile Asn Tyr Asn Gln Phe Ser Ser Gly Asn Gly Ser Gly

1 5 10 15

Ser Lys Pro Pro Cys Pro Pro Tyr Glu Asn Gln Ala Asn Cys Val Ala

20 25 30

Lys Val Pro Pro Phe Thr Ser Gln Asp Ala Lys Asn Leu Thr Asn Leu

35 40 45

Met Leu Asn Met Met Ala Val Phe Asp Ser Lys Ser Trp Glu Asp Ala

50 55 60

Val Leu Asn Ala Pro Phe Gln Phe Ser Asp Asn Asn Leu Ser Ala Pro

65 70 75 80

Cys Tyr Ser Asp Tyr Leu Thr Cys Val Asn Pro Tyr Asn Asp Gly Leu

85 90 95

Val Asp Pro Lys Leu Ile Ala Lys Asn Lys Gly Asp Glu Tyr Asn Ile

100 105 110

Glu Asn Gly Gln Thr Gly Ser Val Ile Leu Thr Pro Gln Asp Val Ile

115 120 125

Tyr Ser Tyr Arg Val Ala Asn Asn Ile Tyr Val Asn Leu Leu Pro Thr

130 135 140

Arg Gly Gly Asp Leu Gly Leu Gly Ser Gln Tyr Gly Gly Pro Asn Gly

145 150 155 160

Pro Gly Asp Asp Gly Thr Asn Phe Gly Ala Leu Gly Ile Leu Ser Pro

165 170 175

Phe Leu Asp Pro Glu Ile Leu Phe Gly Lys Glu Leu Asn Lys Val Ala

180 185 190

Ile Met Gln Leu Arg Asp Ile Ile His Glu Tyr Gly His Thr Leu Gly

195 200 205

Tyr Thr His Asn Gly Asn Met Thr Tyr Gln Arg Val Arg Met Cys Glu

210 215 220

Glu Asn Asn Gly Pro Glu Glu Arg Cys Gln Gly Gly Arg Ile Glu Gln

225 230 235 240

Val Asp Gly Lys Glu Val Gln Val Phe Asp Asn Gly His Glu Val Arg

245 250 255

Asp Thr Asp Gly Ser Thr Tyr Asp Val Cys Ser Arg Phe Lys Asp Lys

260 265 270

Pro Tyr Thr Ala Gly Ser Tyr Pro Asn Ser Ile Tyr Thr Asp Cys Ser

275 280 285

Gln Val Pro Ala Gly Leu Ile Gly Val Thr Ser Ala Val Trp Gln Gln

290 295 300

Leu Ile Asp Gln Asn Ala Leu Pro Val Asp Phe Thr Asn Leu Ser Ser

305 310 315 320

Gln Thr Asn Tyr Leu Asn Ala Ser Leu Asn Thr Gln Asp Phe Ala Thr

325 330 335

Thr Met Leu Ser Ala Ile Ser Gln Ser Leu Ser Ser Ser Lys Ser Ser

340 345 350

Ala Thr Thr Tyr Arg Thr Ser Lys Thr Ser Arg Pro Phe Gly Ala Pro

355 360 365

Leu Leu Gly Val Asn Leu Lys Met Gly Tyr Gln Lys Tyr Phe Asn Asp

370 375 380

Tyr Leu Gly Leu Ser Ser Tyr Gly Ile Ile Lys Tyr Asn Tyr Ala Gln

385 390 395 400

Ala Asn Asn Glu Lys Ile Gln Gln Leu Ser Tyr Gly Val Gly Met Asp

405 410 415

Val Leu Phe Asp Phe Ile Thr Asn Tyr Thr Asn Glu Lys Asn Pro Lys

420 425 430

Ser Asn Leu Thr Lys Lys Val Phe Thr Ser Ser Leu Gly Val Phe Gly

435 440 445

Gly Leu Arg Gly Leu Tyr Asn Ser Tyr Tyr Leu Leu Asn Gln Tyr Lys

450 455 460

Gly Ser Gly Asn Leu Asn Val Thr Gly Gly Leu Asn Tyr Arg Tyr Lys

465 470 475 480

His Ser Lys Tyr Ser Ile Gly Ile Ser Val Pro Leu Val Gln Leu Lys

485 490 495

Ser Arg Ile Val Ser Ser Asp Gly Ala Tyr Thr Asn Ser Ile Thr Leu

500 505 510

Asn Glu Gly Gly Ser His Phe Lys Val Phe Phe Asn Tyr Gly Trp Ile

515 520 525

Phe

(2) INFORMATION FOR SEQ ID NO: 178:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 187 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 187

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 178:

Leu Gly Cys Val Ser Met Thr Leu Gly Ile Asp Glu Ala Gly Arg Gly

1 5 10 15

Cys Leu Ala Gly Ser Leu Phe Val Ala Gly Val Val Cys Asn Glu Lys

20 25 30

Ile Ala Leu Glu Phe Leu Lys Met Gly Leu Lys Asp Ser Lys Lys Leu

35 40 45

Ser Pro Lys Lys Arg Phe Phe Leu Glu Asp Lys Ile Lys Thr His Gly

50 55 60

Glu Val Gly Phe Phe Val Val Lys Lys Ser Ala Asn Glu Ile Asp His

65 70 75 80

Leu Gly Leu Gly Ala Cys Leu Lys Leu Ala Ile Glu Glu Ile Val Glu

85 90 95

Asn Gly Cys Ser Leu Ala Asn Glu Ile Lys Ile Asp Gly Asn Thr Ala

100 105 110

Phe Gly Leu Asn Lys Arg Tyr Pro Asn Ile Gln Thr Ile Ile Lys Gly

115 120 125

Asp Glu Thr Ile Ala Gln Ile Ala Met Ala Ser Val Leu Ala Lys Ala

130 135 140

Ser Lys Asp Arg Glu Met Leu Glu Leu His Ala Leu Phe Lys Glu Tyr

145 150 155 160

Gly Trp Asp Lys Asn Cys Gly Tyr Gly Thr Lys Gln His Ile Glu Ala

165 170 175

Ile Asn Lys Leu Gly Ala Thr Leu Ser Ser Ala

180 185

(2) INFORMATION FOR SEQ ID NO: 179:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 204 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 204

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 179:

Met Thr Leu Gly Ile Asp Glu Ala Gly Arg Gly Cys Leu Ala Gly Ser

1 5 10 15

Leu Phe Val Ala Gly Val Val Cys Asn Glu Lys Ile Ala Leu Glu Phe

20 25 30

Leu Lys Met Gly Leu Lys Asp Ser Lys Lys Leu Ser Pro Lys Lys Arg

35 40 45

Phe Phe Leu Glu Asp Lys Ile Lys Thr His Gly Glu Val Gly Phe Phe

50 55 60

Val Val Lys Lys Ser Ala Asn Glu Ile Asp His Leu Gly Leu Gly Ala

65 70 75 80

Cys Leu Lys Leu Ala Ile Glu Glu Ile Val Glu Asn Gly Cys Ser Leu

85 90 95

Ala Asn Glu Ile Lys Ile Asp Gly Asn Thr Ala Phe Gly Leu Asn Lys

100 105 110

Arg Tyr Pro Asn Ile Gln Thr Ile Ile Lys Gly Asp Glu Thr Ile Ala

115 120 125

Gln Ile Ala Met Ala Ser Val Leu Ala Lys Ala Ser Lys Asp Arg Glu

130 135 140

Met Leu Glu Leu His Ala Leu Phe Lys Glu Tyr Gly Trp Asp Lys Asn

145 150 155 160

Cys Gly Tyr Gly Thr Lys Gln His Ile Glu Ala Ile Asn Lys Leu Gly

165 170 175

Ala Thr Pro Phe His Arg His Ser Phe Thr Leu Lys Asn Arg Ile Leu

180 185 190

Asn Pro Lys Leu Leu Glu Val Glu Gln Arg Leu Val

195 200

(2) INFORMATION FOR SEQ ID NO: 180:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 192 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 192

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 180:

Met Asn Ala Leu Lys Lys Leu Ser Phe Cys Ala Leu Leu Ser Leu Gly

1 5 10 15

Leu Phe Ala Gln Thr Val His Ala Gln His Leu Lys Asp Thr Ile Asn

20 25 30

Tyr Pro Asp Trp Leu Lys Ile Asn Leu Phe Asp Lys Lys Asn Pro Pro

35 40 45

Asn Gln Tyr Val Gly Ser Ala Ser Ile Ser Gly Lys Arg Asn Asp Phe

50 55 60

Tyr Ser Asn Tyr Ile Pro Tyr Asp Asp Lys Leu Pro Pro Glu Lys Asn

65 70 75 80

Ala Glu Glu Ile Ala Leu Leu Arg Ala Arg Met Asn Ala Tyr Ser Thr

85 90 95

Leu Glu Ser Ala Leu Leu Thr Lys Met Cys Asn Arg Ile Val Lys Ala

100 105 110

Leu Gln Val Lys Asn Asn Val Ile Ser His Leu Phe Gly Phe Val Asp

115 120 125

Phe Leu Thr Ser Lys Ser Ile Leu Ala Lys Arg Phe Val Asp Thr Thr

130 135 140

Asn His Arg Val Tyr Val Met Val Gln Phe Pro Phe Ile Gln Pro Glu

145 150 155 160

Asp Leu Ile Ala Tyr Phe Lys Ala Lys Arg Ile Asp Leu Ser Leu Ala

165 170 175

Ser Ala Thr Asn Leu Ser Ala Ile Leu Asn Lys Ala Leu Phe His Leu

180 185 190

(2) INFORMATION FOR SEQ ID NO: 181:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 86 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 86

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 181:

Met Asn Ala Leu Lys Lys Leu Ser Phe Cys Ala Leu Leu Ser Leu Gly

1 5 10 15

Leu Phe Ala Gln Thr Val His Ala Gln His Leu Lys Asp Thr Ile Asn

20 25 30

Tyr Pro Asp Trp Leu Lys Ile Asn Leu Phe Asp Lys Lys Asn Pro Pro

35 40 45

Asn Gln Tyr Val Gly Ser Ala Ser Ile Ser Gly Lys Arg Asn Asp Phe

50 55 60

Tyr Ser Asn Tyr Ile Pro Tyr Asp Asp Lys Leu Pro Pro Glu Arg Thr

65 70 75 80

Leu Lys Lys Ser Leu Phe

85

(2) INFORMATION FOR SEQ ID NO: 182:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 75 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 75

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 182:

Leu Lys Ile Leu Thr Leu Phe Leu Ile Gly Leu Asn Ala Leu Phe Ala

1 5 10 15

Leu Asp Leu Asn Ala Leu Lys Thr Glu Ile Lys Glu Thr Tyr Leu Lys

20 25 30

Glu Tyr Lys Asp Leu Lys Leu Glu Ile Glu Thr Ile Asn Leu Glu Ile

35 40 45

Pro Glu Arg Phe Ser His Ala Ser Ile Leu Ser Tyr Glu Leu Asn Ala

50 55 60

Ser Asn Lys Leu Lys Lys Asp Gly Ser Cys Phe

65 70 75

(2) INFORMATION FOR SEQ ID NO: 183:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 211 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 211

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 183:

Met Phe Ser Ile Ile Leu Gly Gly Gly Gly Gly Asn Thr Pro Cys Gly

1 5 10 15

Leu Thr Trp Gln His Phe Lys Leu Gly Asp Leu Phe Glu Ile Glu Lys

20 25 30

Thr Leu Ser Phe Asn Lys Asp Ala Leu Thr Gln Gly Gln Asp Tyr Asp

35 40 45

Tyr Ile Thr Arg Thr Ser Gln Asn Gln Gly Val Leu Gln Thr Thr Gly

50 55 60

Phe Val Asn Ala Glu Asn Leu Asn Pro Pro Phe Thr Trp Ser Leu Gly

65 70 75 80

Leu Leu Gln Met Asp Phe Phe Tyr Arg Lys Lys Ser Trp Tyr Ala Gly

85 90 95

Gln Phe Met Arg Lys Ile Thr Pro Lys Thr Glu Ile Lys Asn Lys Ile

100 105 110

Asn Ser Arg Ile Ala His Tyr Phe Thr Thr Leu Leu Asn Ala Leu Lys

115 120 125

Arg Pro Leu Leu Ser Val Leu Val Arg Asp Ile Asp Lys Thr Phe Arg

130 135 140

Glu Gln Lys Ile Gln Leu Pro Leu Lys Pro Thr Ala Lys Thr Gln Ser

145 150 155 160

Leu Asp Gly Ile Asp Phe Asp Phe Met His Thr Leu Ile Asn Ala Leu

165 170 175

Met Lys Gln Thr Ile Gln Gly Val Val Gln Tyr Cys Asp Ala Lys Ile

180 185 190

Gln Ala Thr Lys Glu Val Ile Ser Gln Glu Thr Pro Ile Gln Lys Asp

195 200 205

Ser leu phe

210

(2) INFORMATION FOR SEQ ID NO: 184:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 406 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 406

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 184:

Val Ile Gly Pro Leu Ser Ser Gln Leu Asn Ala Ile Lys Trp Gly Glu

1 5 10 15

Phe Lys Leu Gly Asp Leu Phe Glu Ala Ser Asn Gly Asp Phe Asp Ile

20 25 30

Gln Lys Arg His Ile Asn His Lys Gly Glu Phe Val Ile Thr Ala Gly

35 40 45

Leu Ser Asn Asn Gly Val Leu Gly Gln Ser Asp Ile Lys Ala Lys Val

50 55 60

Phe Glu Ser His Thr Ile Thr Ile Asp Met Phe Gly Cys Ala Phe Tyr

65 70 75 80

Arg Ser Phe Ala Tyr Lys Met Val Thr His Ala Arg Val Phe Ser Leu

85 90 95

Lys Pro Lys Phe Glu Ile Asn His Lys Ile Gly Leu Phe Leu Ser Thr

100 105 110

Leu Phe Phe Gly Tyr His Lys Lys Phe Gly Tyr Glu Asn Met Cys Ser

115 120 125

Trp Ala Lys Ile Lys Asn Asp Lys Val Ile Leu Pro Leu Lys Pro Thr

130 135 140

Ala Asn Thr Gln Thr Leu Glu Gly Ile Asp Phe Asp Phe Met Glu Lys

145 150 155 160

Phe Ile Ala Glu Leu Glu Gln Cys Arg Leu Ala Glu Leu Gln Ala Tyr

165 170 175

Leu Lys Ala Thr Gly Leu Glu Asn Thr Thr Leu Ser Asn Asp Glu Glu

180 185 190

Asn Ala Leu Asn Val Phe Asn Asn Ser Gly Gly Gly Gly Gly Asn Thr

195 200 205

Pro Cys Gly Leu Thr Trp Gln His Phe Lys Leu Gly Asp Leu Phe Glu

210 215 220

Ile Glu Lys Thr Leu Ser Phe Asn Lys Asp Ala Leu Thr Gln Gly Gln

225 230 235 240

Asp Tyr Asp Tyr Ile Thr Arg Thr Ser Gln Asn Gln Gly Val Leu Gln

245 250 255

Thr Thr Gly Phe Val Asn Ala Glu Asn Leu Asn Pro Pro Phe Thr Trp

260 265 270

Ser Leu Gly Leu Leu Gln Met Asp Phe Phe Tyr Arg Lys Lys Ser Trp

275 280 285

Tyr Ala Gly Gln Phe Met Arg Lys Ile Thr Pro Lys Thr Glu Ile Lys

290 295 300

Asn Lys Ile Asn Ser Arg Ile Ala His Tyr Phe Thr Thr Leu Leu Asn

305 310 315 320

Ala Leu Lys Arg Pro Leu Leu Ser Val Leu Val Arg Asp Ile Asp Lys

325 330 335

Thr Phe Arg Glu Gln Lys Ile Gln Leu Pro Leu Lys Pro Thr Ala Lys

340 345 350

Thr Gln Ser Leu Asp Gly Ile Asp Phe Asp Phe Met His Thr Leu Ile

355 360 365

Asn Ala Leu Met Lys Gln Thr Ile Gln Gly Val Val Gln Tyr Cys Asp

370 375 380

Ala Lys Ile Gln Ala Thr Lys Glu Val Ile Ser Gln Glu Thr Pro Ile

385 390 395 400

Gln Lys Asp Ser Leu Phe

405

(2) INFORMATION FOR SEQ ID NO: 185:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 275 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 275

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 185:

Met Ser Lys Ser Leu Tyr Gln Thr Leu Asn Val Ser Glu Asn Ala Ser

1 5 10 15

Gln Asp Glu Ile Lys Lys Ser Tyr Arg Arg Leu Ala Arg Gln Tyr His

20 25 30

Pro Asp Leu Asn Lys Thr Lys Glu Ala Glu Glu Lys Phe Lys Glu Ile

35 40 45

Asn Ala Ala Tyr Glu Ile Leu Ser Asp Glu Glu Lys Arg Arg Gln Tyr

50 55 60

Asp Gln Phe Gly Asp Asn Met Phe Gly Gly Gln Asn Phe Ser Asp Phe

65 70 75 80

Ala Arg Ser Arg Gly Pro Ser Glu Asp Leu Asp Asp Ile Leu Ser Ser

85 90 95

Ile Phe Gly Lys Gly Gly Phe Ser Gln Arg Phe Ser Gln Asn Ser Gln

100 105 110

Gly Phe Ser Gly Phe Asn Phe Ser Asn Phe Ala Pro Glu Asn Leu Asp

115 120 125

Val Thr Ala Ile Leu Asn Val Ser Val Leu Asp Thr Leu Leu Gly Asn

130 135 140

Lys Lys Gln Val Ser Val Asn Asn Glu Thr Phe Ser Leu Lys Ile Pro

145 150 155 160

Ile Gly Val Glu Glu Gly Glu Lys Ile Arg Val Arg Asn Lys Gly Lys

165 170 175

Met Gly Arg Thr Gly Arg Gly Asp Leu Leu Leu Gln Ile His Ile Glu

180 185 190

Glu Asp Glu Met Tyr Arg Arg Glu Lys Asp Asp Ile Ile Gln Ile Phe

195 200 205

Asp Leu Pro Leu Lys Thr Ala Leu Phe Gly Gly Lys Ile Glu Ile Ala

210 215 220

Thr Trp His Lys Thr Leu Thr Leu Thr Ile Pro Pro Asn Thr Lys Ala

225 230 235 240

Met Gln Lys Phe Arg Ile Lys Asp Lys Gly Ile Lys Ser Arg Lys Thr

245 250 255

Ser His Val Gly Asp Cys Ile Ala Ser Ser Phe Asp Leu Leu Lys Leu

260 265 270

Lys Arg Phe

275

(2) INFORMATION FOR SEQ ID NO: 186:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 278 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 278

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 186:

Met Ser Lys Ser Leu Tyr Gln Thr Leu Asn Val Ser Glu Asn Ala Ser

1 5 10 15

Gln Asp Glu Ile Lys Lys Ser Tyr Arg Arg Leu Ala Arg Gln Tyr His

20 25 30

Pro Asp Leu Asn Lys Thr Lys Glu Ala Glu Glu Lys Phe Lys Glu Ile

35 40 45

Asn Ala Ala Tyr Glu Ile Leu Ser Asp Glu Glu Lys Arg Arg Gln Tyr

50 55 60

Asp Gln Phe Gly Asp Asn Met Phe Gly Gly Gln Asn Phe Ser Asp Phe

65 70 75 80

Ala Arg Ser Arg Gly Pro Ser Glu Asp Leu Asp Asp Ile Leu Ser Ser

85 90 95

Ile Phe Gly Lys Gly Gly Phe Ser Gln Arg Phe Ser Gln Asn Ser Gln

100 105 110

Gly Phe Ser Gly Phe Asn Phe Ser Asn Phe Ala Pro Glu Asn Leu Asp

115 120 125

Val Thr Ala Ile Leu Asn Val Ser Val Leu Asp Thr Leu Leu Gly Asn

130 135 140

Lys Lys Gln Val Ser Val Asn Asn Glu Thr Phe Ser Leu Lys Ile Pro

145 150 155 160

Ile Gly Val Glu Glu Gly Glu Lys Ile Arg Val Arg Asn Lys Gly Lys

165 170 175

Met Gly Arg Thr Gly Arg Gly Asp Leu Leu Leu Gln Ile His Ile Glu

180 185 190

Glu Asp Glu Met Tyr Arg Arg Glu Lys Asp Asp Ile Ile Gln Ile Phe

195 200 205

Asp Leu Pro Leu Lys Thr Ala Leu Phe Gly Gly Lys Ile Glu Ile Ala

210 215 220

Thr Trp His Lys Thr Leu Thr Leu Thr Ile Pro Pro Asn Thr Lys Ala

225 230 235 240

Met Gln Lys Phe Arg Ile Lys Asp Lys Gly Ile Lys Ser Arg Lys Thr

245 250 255

Ser His Val Gly Asp Cys Ile Ala Ser Ser Phe Asp Leu Pro Lys Ile

260 265 270

Glu Thr Leu Leu Met Ser

275

(2) INFORMATION FOR SEQ ID NO: 187:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 232 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 232

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 187:

Val Val Gln Lys Phe Asn Phe Tyr Lys Thr Gly Gly Met Arg Leu Lys

1 5 10 15

His Phe Lys Thr Phe Leu Phe Ile Thr Met Ala Val Ile Val Ile Gly

20 25 30

Thr Gly Cys Ala Asn Lys Lys Lys Lys Lys Asp Glu Tyr Asn Lys Pro

35 40 45

Ala Ile Phe Trp Tyr Gln Gly Ile Leu Arg Glu Ile Leu Phe Ala Asn

50 55 60

Leu Glu Thr Ala Asp Asn Tyr Tyr Ser Ser Leu Gln Ser Glu His Ile

65 70 75 80

Asn Ser Pro Leu Val Pro Glu Ala Met Leu Ala Leu Gly Gln Ala His

85 90 95

Met Lys Lys Lys Glu Tyr Val Leu Ala Ser Phe Tyr Phe Asp Glu Tyr

100 105 110

Ile Lys Arg Phe Gly Thr Lys Asp Asn Val Asp Tyr Leu Thr Phe Leu

115 120 125

Lys Leu Gln Ser His Tyr Tyr Ala Phe Lys Asn His Ser Lys Asp Gln

130 135 140

Glu Phe Ile Ser Asn Ser Ile Val Ser Leu Gly Glu Phe Ile Glu Lys

145 150 155 160

Tyr Pro Asn Ser Arg Tyr Arg Pro Tyr Val Glu Tyr Met Gln Ile Lys

165 170 175

Phe Ile Leu Gly Gln Asn Glu Leu Asn Arg Ala Ile Ala Asn Val Tyr

180 185 190

Lys Lys Arg His Lys Pro Glu Gly Val Lys Arg Tyr Leu Glu Arg Ile

195 200 205

Asp Glu Thr Leu Glu Lys Glu Thr Lys Pro Lys Pro Ser His Met Pro

210 215 220

Trp Tyr Val Leu Ile Phe Asp Trp

225 230

(2) INFORMATION FOR SEQ ID NO: 188:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 114 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 114

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 188:

Met Arg Phe Leu Asn Asn Lys His Arg Glu Lys Gly Leu Lys Ala Glu

1 5 10 15

Glu Glu Ala Cys Gly Phe Leu Lys Thr Leu Gly Phe Glu Met Ile Glu

20 25 30

Arg Asn Phe Phe Ser Gln Phe Gly Glu Ile Asp Ile Ile Ala Leu Lys

35 40 45

Lys Gly Val Leu His Phe Ile Glu Val Lys Ser Gly Glu Asn Phe Asp

50 55 60

Pro Ile Tyr Ala Ile Thr Pro Ser Lys Leu Lys Lys Met Ile Lys Thr

65 70 75 80

Ile Arg Cys Tyr Leu Ser Gln Lys Asp Pro Asn Ser Asp Phe Cys Ile

85 90 95

Asp Ala Leu Ile Val Lys Asn Gly Lys Phe Glu Leu Leu Glu Asn Ile

100 105 110

Thro phe

(2) INFORMATION FOR SEQ ID NO: 189:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 101 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 101

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 189:

Met Gly Ser Ile Gly Ala Met Thr Lys Gly Ser Ser Asp Arg Tyr Phe

1 5 10 15

Gln Glu Gly Val Ala Ser Glu Lys Leu Val Pro Glu Gly Ile Glu Gly

20 25 30

Arg Val Pro Tyr Arg Gly Lys Val Ser Asp Met Ile Phe Gln Leu Val

35 40 45

Gly Gly Val Arg Ser Ser Met Gly Tyr Gln Gly Ala Lys Asn Ile Leu

50 55 60

Glu Leu Tyr Gln Asn Ala Glu Phe Val Glu Ile Thr Ser Ala Gly Leu

65 70 75 80

Lys Lys Ser His Val His Gly Val Asp Ile Thr Lys Glu Ala Pro Asn

85 90 95

Ile Met Gly Glu Phe

100

(2) INFORMATION FOR SEQ ID NO: 190:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 481 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 481

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 190:

Met Arg Ile Leu Gln Arg Ala Leu Thr Phe Glu Asp Val Leu Met Val

1 5 10 15

Pro Arg Lys Ser Ser Val Leu Pro Lys Asp Val Ser Leu Lys Ser Arg

20 25 30

Leu Thr Lys Asn Ile Gly Leu Asn Ile Pro Phe Ile Ser Ala Ala Met

35 40 45

Asp Thr Val Thr Glu His Lys Thr Ala Ile Ala Met Ala Arg Leu Gly

50 55 60

Gly Ile Gly Ile Val His Lys Asn Met Asp Ile Gln Thr Gln Val Lys

65 70 75 80

Glu Ile Thr Lys Val Lys Lys Ser Glu Ser Gly Val Ile Asn Asp Pro

85 90 95

Ile Phe Ile His Ala His Arg Thr Leu Ala Asp Ala Lys Val Ile Thr

100 105 110

Asp Asn Tyr Lys Ile Ser Gly Val Pro Val Val Asp Asp Lys Gly Leu

115 120 125

Leu Ile Gly Ile Leu Thr Asn Arg Asp Val Arg Phe Glu Thr Asp Leu

130 135 140

Ser Lys Lys Val Gly Asp Val Met Thr Lys Met Pro Leu Val Thr Ala

145 150 155 160

His Val Gly Ile Ser Leu Asp Glu Ala Ser Asp Leu Met His Lys His

165 170 175

Lys Ile Glu Lys Leu Pro Ile Val Asp Lys Asp Asn Val Leu Lys Gly

180 185 190

Leu Ile Thr Ile Lys Asp Ile Gln Lys Arg Ile Glu Tyr Pro Glu Ala

195 200 205

Asn Lys Asp Asp Phe Gly Arg Leu Arg Val Gly Ala Ala Ile Gly Val

210 215 220

Gly Gln Leu Asp Arg Ala Glu Met Leu Val Lys Ala Gly Val Asp Ala

225 230 235 240

Leu Val Leu Asp Ser Ala His Gly His Ser Ala Asn Ile Leu His Thr

245 250 255

Leu Glu Glu Ile Lys Lys Ser Leu Val Val Asp Val Ile Val Gly Asn

260 265 270

Val Val Thr Lys Glu Ala Thr Ser Asp Leu Ile Ser Ala Gly Ala Asp

275 280 285

Ala Val Lys Val Gly Ile Gly Pro Gly Ser Ile Cys Thr Thr Arg Ile

290 295 300

Val Ala Gly Val Gly Met Pro Gln Val Ser Ala Ile Asp Asn Cys Val

305 310 315 320

Glu Val Ala Ser Lys Phe Asp Ile Pro Val Ile Ala Asp Gly Gly Ile

325 330 335

Arg Tyr Ser Gly Asp Val Ala Lys Ala Leu Ala Leu Gly Ala Ser Ser

340 345 350

Val Met Ile Gly Ser Leu Leu Ala Gly Thr Glu Glu Ser Pro Gly Asp

355 360 365

Phe Met Ile Tyr Gln Gly Arg Gln Tyr Lys Ser Tyr Arg Gly Met Gly

370 375 380

Ser Ile Gly Ala Met Thr Lys Gly Ser Ser Asp Arg Tyr Phe Gln Glu

385 390 395 400

Gly Val Ala Ser Glu Lys Leu Val Pro Glu Gly Ile Glu Gly Arg Val

405 410 415

Pro Tyr Arg Gly Lys Val Ser Asp Met Ile Phe Gln Leu Val Gly Gly

420 425 430

Val Arg Ser Ser Met Gly Tyr Gln Gly Ala Lys Asn Ile Leu Glu Leu

435 440 445

Tyr Gln Asn Ala Glu Phe Val Glu Ile Thr Ser Ala Gly Leu Lys Glu

450 455 460

Ser His Val His Gly Val Asp Ile Thr Lys Glu Ala Pro Asn Tyr Tyr

465 470 475 480

Gly

(2) INFORMATION FOR SEQ ID NO: 191:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 204 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 204

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 191:

Met Gln Gly Phe Leu Leu Gln Thr Gln Ser Ile Arg Asp Glu Asp Leu

1 5 10 15

Ile Val His Val Leu Thr Lys Asn Gln Leu Lys Thr Leu Tyr Arg Phe

20 25 30

Tyr Gly Lys Arg His Ser Val Leu Asn Val Gly Arg Lys Ile Asp Phe

35 40 45

Glu Glu Glu Asn Asp Asp Lys Phe Leu Pro Lys Leu Arg Asn Ile Leu

50 55 60

His Leu Gly Tyr Ile Trp Glu Arg Glu Met Glu Arg Leu Phe Phe Trp

65 70 75 80

Gln Arg Phe Cys Ala Leu Leu Phe Lys His Leu Glu Gly Val His Ser

85 90 95

Leu Asp Ser Ile Tyr Phe Asp Thr Leu Asp Asp Gly Ala Ser Lys Leu

100 105 110

Ser Lys Gln His Pro Leu Arg Val Ile Leu Glu Met Tyr Ala Val Leu

115 120 125

Leu Asn Phe Glu Gly Arg Leu Gln Ser Tyr Asn Ser Cys Phe Leu Cys

130 135 140

Asp Ala Lys Leu Glu Arg Ser Val Ala Leu Ala Gln Gly Phe Ile Leu

145 150 155 160

Ala His Pro Ser Cys Leu Lys Ala Lys Ser Leu Asp Leu Glu Lys Ile

165 170 175

Gln Ala Phe Phe Arg Thr Gln Ser Thr Ile Asp Leu Glu Thr Glu Glu

180 185 190

Val Glu Glu Leu Trp Arg Thr Leu Asn Leu Gly Phe

195 200

(2) INFORMATION FOR SEQ ID NO: 192:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 82 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 82

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 192:

Met Gly Val Gly Arg Val Gly Asn Met Ala Leu Leu Ala Cys Ala Gly

1 5 10 15

Pro Met Gly Ile Gly Ala Ile Ala Ile Ala Ile Asn Gly Gly Arg Gln

20 25 30

Arg Ser Arg Met Leu Val Val Asp Ile Asp Asp Lys Arg Leu Glu Gln

35 40 45

Val Gln Lys Met Leu Pro Gly Asn Trp Arg Pro Val Thr Ala Leu Ser

50 55 60

Trp Cys Leu Cys Ile Pro Lys Arg Gly Ala Ile Arg Ala Arg Cys Cys

65 70 75 80

Glu arg

(2) INFORMATION FOR SEQ ID NO: 193:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 67 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 67

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 193:

Leu Ser Gly Thr Ala Val Ser Cys Arg Cys Thr Cys Arg Ile Gln Leu

1 5 10 15

Val Leu Val Arg Thr Ser Ile Pro Val Val Ile Gly Cys Ser Cys Pro

20 25 30

Phe Leu Ser Ser Ile Gly Phe Thr Thr Gly Thr His Gln Ser Pro Val

35 40 45

Lys Arg Cys Gly Val Asn Ala Gly Lys Thr Pro Ser Lys Lys His Leu

50 55 60

His Leu Asn

65

(2) INFORMATION FOR SEQ ID NO: 194:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 114 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 114

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 194:

Val Trp Leu Ala Ala Leu Gly Phe Leu Ile Thr Ala Val Gly Leu Pro

1 5 10 15

Val Ile Thr Val Ile Ala Leu Ala Lys Val Gly Gly Ser Ser Thr Pro

20 25 30

Ser Ala Ile Arg Ser Ala Gly Met Pro Ala Ala Cys Trp Arg Arg Ser

35 40 45

Ala Thr Trp Arg Ser Ala Arg Cys Ser Pro Phe Arg Ala Pro Pro Arg

50 55 60

Cys Pro Ser Lys Val Ser Val Val Pro Leu Leu Gly Glu Glu Ala Ala

65 70 75 80

Arg Arg Cys Ser Ser Thr Ala Trp Arg Thr Ser Ser Ser Pro Trp Pro

85 90 95

Ser Pro Ser Thr Pro Val Ala Cys Trp Thr Pro Ser Asp Ala Ser Ser

100 105 110

Pro arg

(2) INFORMATION FOR SEQ ID NO: 195:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 195:

TATACCATGG TGGGCGCTAA 20

(2) INFORMATION FOR SEQ ID NO: 196:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 23

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 196:

ATGAATTCGA GTAAGGATTT TTG 23

(2) INFORMATION FOR SEQ ID NO: 197:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 22

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 197:

TTAACCATGG TGAAAAGCGA TA 22

(2) INFORMATION FOR SEQ ID NO: 198:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 23

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 198:

TAGAATTCGC ATAACGATCA ATC 23

(2) INFORMATION FOR SEQ ID NO: 199:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 22

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 199:

ATATCCATGG TGAGTTTGAT GA 22

(2) INFORMATION FOR SEQ ID NO: 200:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 200:

ATGAATTCAA TTTTTTATTT TGCCA 25

(2) INFORMATION FOR SEQ ID NO: 201:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 21

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 201:

AATTCCATGG TGGGGGCTAT G 21

(2) INFORMATION FOR SEQ ID NO: 202:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 23

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 202:

ATGAATTCTC GATAGCCAAA ATC 23

(2) INFORMATION FOR SEQ ID NO: 203:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 203:

AATTCCATGG TGCATAACTT CCATT 25

(2) INFORMATION FOR SEQ ID NO: 204:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 204:

AAGAATTCTC TAGCATCCAA ATGGA 25

(2) INFORMATION FOR SEQ ID NO: 205:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 24

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 205:

ATTTCCATGG TCATGTCTCA TATT 24

(2) INFORMATION FOR SEQ ID NO: 206:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 23

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 206:

ATGAATTCCA TCTTTTATTC CAC 23

(2) INFORMATION FOR SEQ ID NO: 207:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 27

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 207:

AACCATGGTG ATTTTAAGCA TTGAAAG 27

(2) INFORMATION FOR SEQ ID NO: 208:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 28

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 208:

AAGAATTCCA CTCAAAATTT TTTAACAG 28

(2) INFORMATION FOR SEQ ID NO: 209:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 209:

GATCATCCAT ATGTTATCTT CTAAT 25

(2) INFORMATION FOR SEQ ID NO: 210:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 23

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 210:

TGAATTCAAC CATTTTAACC CTG 23

(2) INFORMATION FOR SEQ ID NO: 211:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 27

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 211:

TATACCATGG TGAAATTTTT TCTTTTA 27

(2) INFORMATION FOR SEQ ID NO: 212:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 212:

AGAATTCAAT TGCGTCTTGT AAAAG 25

(2) INFORMATION FOR SEQ ID NO: 213:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 24

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 213:

TATACCATGG TGATGGACAA ACTC 24

(2) INFORMATION FOR SEQ ID NO: 214:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 23

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 214:

ATGAATTCCC ACTTGGGGCG ATA 23

(2) INFORMATION FOR SEQ ID NO: 215:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 215:

TTATGGATCC AAACCAATTA AAACT 25

(2) INFORMATION FOR SEQ ID NO: 216:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 23

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 216:

TATCTCGAGT TATAGAGAAG GGC 23

(2) INFORMATION FOR SEQ ID NO: 217:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 22

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 217:

TTAACCATGG TGAAAAGCGA TA 22

(2) INFORMATION FOR SEQ ID NO: 218:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 24

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 218:

TAGAATTCGC CTCTAAAACT TTAG 24

(2) INFORMATION FOR SEQ ID NO: 219:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 22

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 219:

TTAACCATGG TGAAAAGCGA TA 22

(2) INFORMATION FOR SEQ ID NO: 220:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 23

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 220:

TAGAATTCGC ATAACGATCA ATC 23

(2) INFORMATION FOR SEQ ID NO: 221:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 22

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 221:

ATATCCATGG TGAGTTTGAT GA 22

(2) INFORMATION FOR SEQ ID NO: 222:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 222:

ATGAATTCAA TTTTTTATTT TGCCA 25

(2) INFORMATION FOR SEQ ID NO: 223:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 23

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 223:

AATTCCATGG CTATCCAAAT CCG 23

(2) INFORMATION FOR SEQ ID NO: 224:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 224:

ATGAATTCGC CAAAATCGTA GTATT 25

(2) INFORMATION FOR SEQ ID NO: 225:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 24

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 225:

GATACCATGG AATTTATGAA AAAG 24

(2) INFORMATION FOR SEQ ID NO: 226:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 226:

TGAATTCGAA AAAGTGTAGT TATAC 25

(2) INFORMATION FOR SEQ ID NO: 227:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 19

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 227:

CCCTTCATTT TAGAAATCG 19

(2) INFORMATION FOR SEQ ID NO: 228:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 228:

ATTTCAACCA ATTCAATGCG 20

(2) INFORMATION FOR SEQ ID NO: 229:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 229:

GCCCCTTTTG ATTTGAAGCT 20

(2) INFORMATION FOR SEQ ID NO: 230:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 22

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 230:

TCGCTCCAAG ATACCAAGAA GT 22

(2) INFORMATION FOR SEQ ID NO: 231:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 22

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 231:

CTTGAATTAG GGGCAAAGAT CG 22

(2) INFORMATION FOR SEQ ID NO: 232:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 22

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 232:

ATGCGTTTTT ACCCAAAGAA GT 22

(2) INFORMATION FOR SEQ ID NO: 233:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 22

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 233:

ATAACGCCAC TTCCTTATTG GT 22

(2) INFORMATION FOR SEQ ID NO: 234:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 19

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 234:

CTTTGGGTAA AAACGCATC 19

(2) INFORMATION FOR SEQ ID NO: 235:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 235:

CGATCTTTGA TCCTAATTCA 20

(2) INFORMATION FOR SEQ ID NO: 236:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 19

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 236:

ATCAAGTTGC CTATGCTGA 19

(2) INFORMATION FOR SEQ ID NO: 237:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 22

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 237:

TTGAACACTT TTGATTATGC GG 22

(2) INFORMATION FOR SEQ ID NO: 238:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 23

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 238:

GGATTATGCG ATTGTTTTAC AAG 23

(2) INFORMATION FOR SEQ ID NO: 239:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 21

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 239:

GTCTTTAGCA AAAATGGCGT C 21

(2) INFORMATION FOR SEQ ID NO: 240:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 21

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 240:

AATGAGCGTA AGAGAGCCTT C 21

(2) INFORMATION FOR SEQ ID NO: 241:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 18

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 241:

CTTATGGGGG TATTGTCA 18

(2) INFORMATION FOR SEQ ID NO: 242:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 18

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 242:

AGCATGTGGG TATCCAGC 18

(2) INFORMATION FOR SEQ ID NO: 243:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 19

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 243:

AGGTTGTTGC CTAAAGACT 19

(2) INFORMATION FOR SEQ ID NO: 244:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 18

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 244:

CTGCCTCCAC CTTTGATC 18

(2) INFORMATION FOR SEQ ID NO: 245:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 19

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 245:

ACCAATATCA ATTGGCACT 19

(2) INFORMATION FOR SEQ ID NO: 246:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 18

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 246:

ACTTGGAAAA GCTCTGCA 18

(2) INFORMATION FOR SEQ ID NO: 247:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 19

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 247:

CTTGCTTGTC ATATCTAGC 19

(2) INFORMATION FOR SEQ ID NO: 248:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 18

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 248:

GTTGAAGTGT TGGTGCTA 18

(2) INFORMATION FOR SEQ ID NO: 249:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 22

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 249:

CAAGCAAGTG GTTTGGTTTT AG 22

(2) INFORMATION FOR SEQ ID NO: 250:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 22

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 250:

TGGAAAGAGC AAATCATTGA AG 22

(2) INFORMATION FOR SEQ ID NO: 251:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 21

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 251:

GCCCATAATC AAAAAGCCCA T 21

(2) INFORMATION FOR SEQ ID NO: 252:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 24

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 252:

CTAAAACCAA ACCACTTGCT TGTC 24

(2) INFORMATION FOR SEQ ID NO: 253:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 16

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 253:

GTAAAACGAC GGCCAG 16

(2) INFORMATION FOR SEQ ID NO: 254:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 17

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 254:

CAGGAAACAG CTATGAC 17

(2) INFORMATION FOR SEQ ID NO: 255:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 21

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 255:

ATCTTACCTA TCACCTCAAA T 21

(2) INFORMATION FOR SEQ ID NO: 256:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 21

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 256:

AGACAGCAAC ATCTTTGTGA A 21

(2) INFORMATION FOR SEQ ID NO: 257:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 50 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 257:

CGCGGATCCA TATGGCTGAA AAAACGCCTT TTTTTAAAAC TAAAAACCAC 50

(2) INFORMATION FOR SEQ ID NO: 258:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 34 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 34

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 258:

CCGGAATTCA TCAGTATTCA ATGGGAATAA AGCC 34

(2) INFORMATION FOR SEQ ID NO: 259:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 50 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 259:

CGCGGATCCA TATGAAAGAA GAAGAAAAAG AAGAAAAAAA GACAGAAAGG 50

(2) INFORMATION FOR SEQ ID NO: 260:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 37 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 37

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 260:

CCGGAATTCG CTTAAAAGAA AATAGTCCCC CAAACGC 37

(2) INFORMATION FOR SEQ ID NO: 261:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 43 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 43

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 261:

CGCGGATCCA TATGAAAGAG GTCATTCCCA CCCCTTCAAC CCC 43

(2) INFORMATION FOR SEQ ID NO: 262:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 36

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 262:

CCGGAATTCA TATAAATATC ATATAGGCAG AAAAAC 36

(2) INFORMATION FOR SEQ ID NO: 263:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 37 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 37

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 263:

CGCGGATCCA TATGGAGGCA GAGCTTGATG AAAAATC 37

(2) INFORMATION FOR SEQ ID NO: 264:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 36

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 264:

CCGGAATTCG ATTGATTTTG TCAAATCTAA AATCCC 36

(2) INFORMATION FOR SEQ ID NO: 265:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 265:

TATTATACAT ATGGAAGAAG ATGGG 25

(2) INFORMATION FOR SEQ ID NO: 266:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 23

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 266:

TAATCTCGAG TTTAGAAGGC GTA 23

(2) INFORMATION FOR SEQ ID NO: 267:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 267:

TTATATTCAT ATGGAAGACG ATGGC 25

(2) INFORMATION FOR SEQ ID NO: 268:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 24

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 268:

AATTCTCGAG CCTCTTTATA AGCC 24

(2) INFORMATION FOR SEQ ID NO: 269:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 46 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 46

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 269:

CGCGGATCCA TATGGTAGAA GCCTTTCAAA AACACCAAAA AGACGG 46

(2) INFORMATION FOR SEQ ID NO: 270:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 32

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 270:

CCGGAATTCG GAGCCAATAG GGAGCTAAAG CC 32

(2) INFORMATION FOR SEQ ID NO: 271:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 31

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 271:

CGGGATCCGA AGGTGATGGT GTTTATATAG G 31

(2) INFORMATION FOR SEQ ID NO: 272:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 32

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 272:

CGCATATGGA AGGTGATGGT GTTTATATAG GG 32

(2) INFORMATION FOR SEQ ID NO: 273:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 37 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 37

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 273:

GCGAATTCTC ACTCTTTCCA ATAGTTTGCT GCAGAGC 37

(2) INFORMATION FOR SEQ ID NO: 274:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 37 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 37

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 274:

CCGGAATTCT TAATCCCGTT TCAAATGGTA ATAAAGG 37

(2) INFORMATION FOR SEQ ID NO: 275:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Helicobacter pylori

(ix) FEATURE:

(A) NAME / KEY: misc_feature

(B) LOCATION 1 ... 36

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 275:

GCGAATTCCC TTTTATTTAA AAAGTGTAGT TATACC 36

Claims (99)

An isolated nucleic acid comprising a nucleotide sequence encoding a Helicobacter pilori polypeptide that is at least about 60% homologous to an amino acid sequence selected from the group consisting of SEQ ID NO: 98 to SEQ ID NO: 194. An isolated nucleic acid comprising a nucleotide sequence encoding a Helicobacter pilori polypeptide selected from the group consisting of SEQ ID NOs: 98 to 194. An isolated nucleic acid or complement thereof encoding a Helicobacter pilori polypeptide comprising a nucleotide sequence that is at least about 60% homologous to a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 97. The isolated nucleic acid or complement thereof of claim 1, comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 97. An isolated nucleic acid molecule encoding a Helicobacter pylori polypeptide or its complement comprising a nucleotide sequence that hybridizes to a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1 to 97 under stringent hybridization conditions. An isolated nucleic acid or complement thereof comprising a nucleotide sequence of 8 or more nucleotides in length that hybridizes to a nucleic acid having a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1 to 97 under stringent hybridization conditions. SEQ ID NOs: 63, 7, 8, 9, 13, 14, 23, 24, 27, 28, 50, 51, 61, 79, 80, 84, 85, 91, 94, 5, 11, 26, 36, 42, 52 , 22, 29, 30, 65, 66, 48, 49, 17, 18, 19, 43, 44, 38, 39, 1, 2, 6, 34, 35, 60, 69 and 83 , Isolated nucleic acid or complement thereof comprising a nucleotide sequence encoding a Helicobacter Philoly cell envelope polypeptide or fragment thereof. The isolated nucleic acid or complement thereof of claim 7, wherein the Helicobacter philoly cell envelope polypeptide or fragment thereof is a Helicobacter phyllori flagella binding polypeptide or fragment thereof encoded by a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 63. 9. 8. The Helicobacter pilori inner membrane of claim 7, wherein the Helicobacter pili cell envelope polypeptide or fragment thereof is encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 48, 49, 17, 18, 19, 43, 44, 38, and 39. Isolated nucleic acid or complement thereof that is a polypeptide or fragment thereof. The Helicobacter pilori polypeptide of claim 9, wherein the Helicobacter pilori inner membrane polypeptide or fragment thereof is encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 48, 49, 17, 18, 19, 43, and 44. Or an isolated nucleic acid or a complement thereof that is a fragment thereof. The method according to claim 7, wherein the Helicobacter Philoly cell envelope polypeptide or fragment thereof is SEQ ID NO: 7, 8, 9, 13, 14, 23, 24, 27, 28, 50, 51, 61, 79, 80, 84, 85, Isolated nucleic acid, or a helicobacter pylori outer membrane polypeptide or fragment thereof encoded by a nucleic acid selected from the group consisting of 91, 94, 5, 11, 26, 36, 42, 52, 22, 29, 30, 65, and 66 Complementary. 12. The method of claim 11, wherein the Helicobacter pylori outer membrane polypeptide or fragment thereof is SEQ ID NO: 7, 8, 9, 11, 13, 14, 23, 24, 26, 27, 28, 36, 42, 50, 51, 52, 61 , Isolated nucleic acid or complement thereof, which is a Helicobacter pili polypeptide or fragment thereof having a terminal phenylalanine residue encoded by a nucleic acid selected from the group consisting of 79, 80, 84, 85, 91 and 94. 13. The Helicobacter pilori as claimed in claim 12, wherein the Helicobacter pilori outer membrane polypeptide or fragment thereof has a C terminal tyrosine cluster and a terminal phenylalanine residue encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 11, 26, 36, 42 and 52. Isolated nucleic acid or complement thereof that is a polypeptide or fragment thereof. SEQ ID NOs: 160, 104, 105, 106, 110, 111, 120, 121, 124, 125, 147, 148, 158, 176, 177, 181, 182, 188, 191, 102, 108, 123, 133, 139, 149 , 119, 126, 127, 162, 163, 145, 146, 114, 115, 116, 140, 141, 135, 136, 98, 99, 103, 131, 132, 157, 166 and 180 An isolated nucleic acid comprising a nucleotide sequence encoding a Helicobacter pili cell envelope polypeptide or fragment thereof. 15. The isolated nucleic acid of claim 14, wherein said Helicobacter philoly cell envelope polypeptide or fragment thereof is a Helicobacter phyllori flagella binding polypeptide or fragment thereof comprising the amino acid sequence of SEQ ID NO: 160. 15. The method of claim 14, wherein the Helicobacter Philolyll cell envelope polypeptide or fragment thereof is a Helicobacter Philolylium inner membrane polypeptide or fragment thereof selected from the group consisting of SEQ ID NOs: 145, 146, 114, 115, 116, 140, 141, 135 and 136 Isolated nucleic acid. 17. The isolation according to claim 16, wherein said Helicobacter pilori inner membrane polypeptide or fragment thereof is a Helicobacter pilori polypeptide or fragment thereof related to transport, selected from the group consisting of SEQ ID NOs: 145, 146, 114, 115, 116, 140 and 141. Nucleic acid. The method according to claim 14, wherein the Helicobacter Philoly cell envelope polypeptide or fragment thereof is SEQ ID NO: 104, 105, 106, 110, 111, 120, 121, 124, 125, 147, 148, 158, 176, 177, 181, 182, 188, 191, 102, 108, 123, 133, 139, 149, 119, 126, 127, 162, and 163 an isolated nucleic acid that is a Helicobacter pylori outer membrane polypeptide or fragment thereof. 19. The method of claim 18, wherein the Helicobacter pylori outer membrane polypeptide or fragment thereof is SEQ ID NO: 104, 105, 106, 108, 110, 111, 120, 121, 123, 124, 125, 133, 139, 147, 148, 149, 158 , 176, 177, 181, 182, 188, and 191, an isolated nucleic acid that is a Helicobacter pylori polypeptide or fragment thereof having a terminal phenylalanine residue. 20. The Helicobacter pilori polypeptide or fragment thereof according to claim 19, wherein the Helicobacter pilori outer membrane polypeptide or fragment thereof is selected from the group consisting of SEQ ID NOs: 108, 123, 133, 139 and 149. Phosphorus isolated nucleic acid. An isolated nucleic acid or complement thereof comprising a nucleotide sequence encoding a Helicobacter pylori cytoplasmic polypeptide or a fragment thereof selected from the group consisting of SEQ ID NOs: 57, 58, 86, 87, 88, 89, 92, and 93. The isolated nucleic acid or complement thereof of claim 21, wherein said Helicobacter pilori cytoplasmic polypeptide or fragment thereof is a Helicobacter pilori polypeptide or fragment thereof involved in mRNA translation. The isolated nucleic acid of claim 21, wherein the Helicobacter pilori cytoplasmic polypeptide or fragment thereof is a Helicobacter pilori polypeptide or fragment thereof that is involved in genome replication, transcription, recombination and repair, or the nucleic acid selected from the group consisting of SEQ ID NOs: 86 and 87 His complement. An isolated nucleic acid comprising a nucleotide sequence encoding a Helicobacter pilori cytoplasmic polypeptide or a fragment thereof selected from the group consisting of SEQ ID NOs: 154, 155, 183, 184, 185, 186, 189 and 190. The isolated nucleic acid of claim 24, wherein the Helicobacter pilori cytoplasmic polypeptide or fragment thereof is a Helicobacter pilori polypeptide or fragment thereof that is involved in mRNA translation selected from the group consisting of SEQ ID NOs: 154 and 155. The isolated nucleic acid of claim 24, wherein the Helicobacter pilori cytoplasmic polypeptide or fragment thereof is a Helicobacter pilori polypeptide or fragment thereof that is involved in genomic replication, transcription, recombination and repair selected from the group consisting of SEQ ID NOs: 183 and 184. SEQ ID NO: 3, 4, 10, 12, 20, 25, 31, 32, 45, 46, 53, 64, 67, 70, 77, 78, comprising a nucleotide sequence encoding a Helicobacter pylori secreting polypeptide or fragment thereof An isolated nucleic acid or its complement selected from the group consisting of 81, 82, 90, 95, and 97. Helicobacter Phil selected from the group consisting of SEQ ID NOs: 100, 101, 107, 109, 117, 122, 128, 129, 142, 143, 150, 161, 164, 167, 174, 175, 178, 179, 187, 192 and 194 An isolated nucleic acid comprising a nucleotide sequence encoding a Laurie secreting polypeptide or fragment thereof. SEQ ID NO: 15, 16, 21, 33, 37, 40, 41, 47, 54, 55, 56, 59, 62, 68, 71, 72, comprising a nucleotide sequence encoding a Helicobacter pili cell polypeptide or fragment thereof Isolated nucleic acid or complement thereof selected from the group consisting of 73, 74, 75, 76 and 96. Helicobacter Phil selected from the group consisting of SEQ ID NOs: 112, 113, 118, 130, 134, 137, 138, 144, 151, 152, 153, 156, 159, 165, 168, 169, 170, 171, 172, 173 and 193 An isolated nucleic acid comprising a nucleotide sequence encoding a Lori cell polypeptide or fragment thereof. A probe comprising a nucleotide sequence consisting of 8 or more nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1 to 97 or its complement. A recombinant expression vector comprising the nucleic acid of any one of claims 1-7, 14, 21, 24, 27-30 operably linked to a transcriptional regulatory component. A cell comprising the recombinant expression vector of claim 32. A method for producing a Helicobacter pylori polypeptide comprising culturing the cells of claim 33 under conditions in which the polypeptide can be expressed. 35. The method of claim 34, further comprising purifying the polypeptide from the cell. (a) contacting the sample with the nucleic acid of claim 6 or 31 to form a hybrid between the probe and the helicobacter nucleic acid in the sample; And (b) detecting the hybrid formed in step (a), wherein the detection of the hybrid indicates the presence of Helicobacter nucleic acid in the sample. An isolated Helicobacter pylori polypeptide comprising an amino acid sequence that is at least about 60% homologous to a Helicobacter pylori polypeptide selected from the group consisting of SEQ ID NOs: 98 to 194. An isolated Helicobacter pylori polypeptide encoded by a nucleic acid comprising a nucleotide sequence that is at least about 60% homologous to a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 97. The isolated Helicobacter pylori polypeptide of claim 38, wherein said polypeptide is encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 97. An isolated Helicobacter pylori polypeptide encoded by a nucleic acid hybridizing to a nucleic acid selected from the group consisting of SEQ ID NOs: 1 to 97 or its complement under stringent hybridization conditions. An isolated Helicobacter pylori polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 97 to 194. SEQ ID NOs: 160, 104, 105, 106, 110, 111, 120, 121, 124, 125, 147, 148, 158, 176, 177, 181, 182, 188, 191, 102, 108, 123, 133, 139, 149 , 119, 126, 127, 162, 163, 145, 146, 114, 115, 116, 140, 141, 135, 136, 98, 99, 103, 131, 132, 157, 166 and 180 Isolated Helicobacter Philoly cell envelope polypeptide or fragment thereof. 43. The isolated polypeptide of claim 42, wherein said Helicobacter Philolyll cell envelope polypeptide or fragment thereof is a Helicobacter Philly flagella flagella binding polypeptide or fragment thereof comprising the amino acid sequence of SEQ ID NO: 160. 44. The method according to claim 43, wherein the Helicobacter Philolyll cell envelope polypeptide or fragment thereof is a Helicobacter Philolyli inner membrane polypeptide or fragment thereof selected from the group consisting of SEQ ID NOs: 145, 146, 114, 115, 116, 140, 141, 135 and 136 Isolated polypeptide. 45. The isolation of claim 44, wherein said Helicobacter pylori inner membrane polypeptide or fragment thereof is a Helicobacter pylori polypeptide or fragment thereof related to transport, selected from the group consisting of SEQ ID NOs: 145, 146, 114, 115, 116, 140, and 141. Polypeptides. The method of claim 43, wherein the Helicobacter Philolyll cell envelope polypeptide or fragment thereof is SEQ ID NO: 104, 105, 106, 110, 111, 120, 121, 124, 125, 147, 148, 158, 176, 177, 181, 182, 188, 191, 102, 108, 123, 133, 139, 149, 119, 126, 127, 162, and 163 an isolated polypeptide that is a Helicobacter Philoyl outer membrane polypeptide or a fragment thereof. 47. The method of claim 46, wherein the Helicobacter pylori outer membrane polypeptide or fragment thereof is SEQ ID NO: 104, 105, 106, 108, 110, 111, 120, 121, 123, 124, 125, 133, 139, 147, 148, 149, 158 , 176, 177, 181, 182, 188, and 191, an isolated polypeptide that is a Helicobacter pylori polypeptide or fragment thereof having a terminal phenylalanine residue. 48. The Helicobacter pylori polypeptide or fragment thereof according to claim 47, wherein the Helicobacter pylori outer membrane polypeptide or fragment thereof is selected from the group consisting of SEQ ID NOs: 108, 123, 133, 139 and 149. Phosphorus isolated polypeptide. SEQ ID NOs: 63, 7, 8, 9, 13, 14, 23, 24, 27, 28, 50, 51, 61, 79, 80, 84, 85, 91, 94, 5, 11, 26, 36, 42, 52 , 22, 29, 30, 65, 66, 48, 49, 17, 18, 19, 43, 44, 38, 39, 1, 2, 6, 34, 35, 60, 69 and 83 An isolated Helicobacter Philoly cell envelope polypeptide or fragment thereof encoded by a nucleic acid. The isolated polypeptide of claim 49, wherein the Helicobacter philoly cell envelope polypeptide or fragment thereof is a Helicobacter phyllori flagella binding polypeptide or fragment thereof encoded by a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 63. 51. 50. The Helicobacter pylori inner membrane of claim 49, wherein said Helicobacter pili cell envelope polypeptide or fragment thereof is encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 48, 49, 17, 18, 19, 43, 44, 38, and 39 An isolated polypeptide that is a polypeptide or fragment thereof. 52. The Helicobacter pilori polypeptide according to claim 51, wherein said Helicobacter pilori inner membrane polypeptide or fragment thereof is encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 48, 49, 17, 18, 19, 43, and 44. Or an isolated polypeptide thereof. 50. The method of claim 49, wherein the Helicobacter Philoly cell envelope polypeptide or fragment thereof is SEQ ID NO: 7, 8, 9, 13, 14, 23, 24, 27, 28, 50, 51, 61, 79, 80, 84, 85, An isolated polypeptide that is a Helicobacter pylori outer membrane polypeptide or fragment thereof encoded by a nucleic acid selected from the group consisting of 91, 94, 5, 11, 26, 36, 42, 52, 22, 29, 30, 65 and 66. 55. The method of claim 53, wherein the Helicobacter pylori outer membrane polypeptide or fragment thereof is SEQ ID NO: 7, 8, 9, 11, 13, 14, 23, 24, 26, 27, 28, 36, 42, 50, 51, 52, 61 , An isolated polypeptide that is a Helicobacter pili polypeptide or fragment thereof having a terminal phenylalanine residue encoded by a nucleic acid selected from the group consisting of 79, 80, 84, 85, 91, and 94. 55. The Helicobacter pylori of claim 54, wherein the Helicobacter pylori outer membrane polypeptide or fragment thereof has a C-terminal tyrosine cluster and a terminal phenylalanine residue encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 11, 26, 36, 42, and 52. An isolated polypeptide that is a polypeptide or fragment thereof. An isolated Helicobacter pylori cytoplasmic polypeptide or a fragment thereof selected from the group consisting of SEQ ID NOs: 154, 155, 183, 184, 185, 186, 189 and 190. The isolated polypeptide of claim 56, wherein the Helicobacter pilori cytoplasmic polypeptide or fragment thereof is a Helicobacter pilori polypeptide or fragment thereof that is involved in mRNA translation selected from the group consisting of SEQ ID NOs: 154 and 155. The isolated polypeptide of claim 56, wherein the Helicobacter pilori cytoplasmic polypeptide or fragment thereof is a Helicobacter pilori polypeptide or fragment thereof that is involved in genomic replication, transcription, recombination, and repair selected from the group consisting of SEQ ID NOs: 183 and 184. 60. An isolated Helicobacter pylori cytoplasmic polypeptide encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 57, 58, 86, 87, 88, 89, 92, and 93 or fragments thereof. 60. The isolated polypeptide of claim 59 wherein the Helicobacter pilori cytoplasmic polypeptide or fragment thereof is a Helicobacter pilori polypeptide or fragment thereof that is involved in mRNA translation encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 57 and 58. 60. The Helicobacter pilori polypeptide or fragment thereof according to claim 59, wherein the Helicobacter pilori cytoplasmic polypeptide or fragment thereof is encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 86 and 87; Phosphorus isolated polypeptide. Isolated 112, 113, 118, 130, 134, 137, 138, 144, 151, 152, 153, 156, 159, 165, 168, 169, 170, 171, 172, 173 and 193 Helicobacter pylori cell polypeptide or fragment thereof. To a nucleic acid selected from the group consisting of SEQ ID NOs: 15, 16, 21, 33, 37, 40, 41, 47, 54, 55, 56, 59, 62, 68, 71, 72, 73, 74, 75, 76, and 96 An isolated Helicobacter Philoly cell polypeptide or fragment thereof encoded by. Isolated 100, 101, 107, 109, 117, 122, 128, 129, 142, 143, 150, 161, 164, 167, 174, 175, 178, 179, 187, 192 and 194 Helicobacter Philoly secreting polypeptide or fragment thereof. To a nucleic acid selected from the group consisting of SEQ ID NOs: 3, 4, 10, 12, 20, 25, 31, 32, 45, 46, 53, 64, 67, 70, 77, 78, 81, 82, 90, 95, and 97 An isolated Helicobacter Philoly secreting polypeptide or fragment thereof encoded by. A fusion protein comprising a Helicobacter pilori polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 98 to 194 operably linked to a non-Helicobacter pilori polypeptide. A vaccine formulation for the prophylaxis or treatment of Helicobacter pylori infection comprising an effective amount of at least one isolated nucleic acid according to any one of claims 1 to 7, 14, 21, 24, 27 to 30. Helicobacter pylori infection comprising an effective amount of one or more Helicobacter pylori polypeptides or fragments of any one of claims 37, 38, 40-42, 49, 56, 59, 62-65. Vaccine preparations for prophylaxis or treatment. The vaccine formulation of claim 67 further comprising a pharmaceutically acceptable carrier. The vaccine formulation of claim 68 further comprising a pharmaceutically acceptable carrier. The vaccine formulation of claim 69 wherein the pharmaceutically acceptable carrier comprises an adjuvant. The vaccine formulation of claim 70 wherein the pharmaceutically acceptable carrier comprises an adjuvant. The vaccine formulation of claim 69 wherein the pharmaceutically acceptable carrier comprises a delivery system. The vaccine formulation of claim 70 wherein the pharmaceutically acceptable carrier comprises a delivery system. The vaccine formulation of claim 73, wherein the delivery system comprises a live vector. 75. The vaccine formulation of claim 74, wherein the delivery system comprises a live vector. 76. The vaccine formulation of claim 75 wherein the live vector is a bacterium or a virus. The vaccine formulation of claim 76 wherein the live vector is a bacterium or a virus. The vaccine formulation of claim 73 wherein the pharmaceutically acceptable carrier further comprises an adjuvant. 75. The vaccine formulation of claim 74, wherein the pharmaceutically acceptable carrier further comprises an adjuvant. Prevention or treatment of a Helicobacter pilori infection comprising an effective amount of at least one isolated nucleic acid encoding a Helicobacter pilori outer membrane polypeptide or fragment thereof selected from the group consisting of SEQ ID NOs: 28, 50, 24, 11, 52, 42 and 79 Vaccine preparations. The vaccine formulation of claim 81 wherein the nucleic acid comprises the nucleotide sequence of SEQ ID NO: 52. A vaccine preparation for the prevention or treatment of Helicobacter pylori infection comprising an effective amount of one or more Helicobacter pylori outer membrane polypeptides or fragments thereof selected from the group consisting of SEQ ID NOs: 125, 147, 121, 108, 149, 139 and 176. 84. The vaccine formulation of claim 83 wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 149. 84. The vaccine formulation of claim 81 or 83 further comprising a pharmaceutically acceptable carrier. 86. The vaccine formulation of claim 85, wherein the pharmaceutically acceptable carrier comprises an adjuvant. 86. The vaccine formulation of claim 85, wherein the pharmaceutically acceptable carrier comprises a delivery system. 88. The vaccine formulation of claim 87 wherein the delivery system comprises a live vector. 89. The vaccine formulation of claim 88, wherein the live vector is a bacterium or a virus. The vaccine formulation of claim 86 wherein the pharmaceutically acceptable carrier further comprises an adjuvant. A method of treating or reducing the risk of infection of a Helicobacter pylori infection of a subject, comprising administering the vaccine formulation of claim 67 to the subject for the treatment or lowering the risk of infection. A method of treating or reducing the risk of infection of a Helicobacter pylori infection in a subject, comprising administering the vaccine formulation of claim 68 to the subject for the treatment or lowering the risk of infection. A method of treating or reducing the risk of infection of a Helicobacter pylori infection in a subject, comprising administering the vaccine formulation of claim 81 to the subject for the treatment or lowering the risk of infection. A method of treating or reducing the risk of infection of a Helicobacter pylori infection in a subject, comprising administering the vaccine formulation of claim 83 to the subject for the treatment or lowering the risk of infection. A method of making a vaccine formulation, comprising mixing the at least one isolated Helicobacter pili polypeptide or fragment thereof selected from the group consisting of SEQ ID NO: 98 to SEQ ID NO: 194 with a pharmaceutically acceptable carrier to form a vaccine formulation. (a) providing at least one isolated Helicobacter Philolyte polypeptide or fragment thereof selected from the group consisting of SEQ ID NO: 98 to SEQ ID NO: 194, and (b) constraining the at least one isolated Helicobacter Philoly polypeptide or fragment thereof Forming a vaccine formulation by mixing with a phase acceptable carrier. (a) culturing the cell under conditions permitting expression of the Helicobacter Philoly polypeptide or fragment thereof selected from the group consisting of SEQ ID NO: 98 to SEQ ID NO: 194, (b) isolating the Helicobacter Philoly polypeptide or fragment thereof from the cell And (c) mixing the at least one isolated Helicobacter pylori polypeptide or fragment thereof with a pharmaceutically acceptable carrier to form a vaccine formulation. A chimera helicobacter pili polypeptide comprising at least two helicobacter pili polypeptides or fragments thereof encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 1 to 97. A chimeric Helicobacter pili polypeptide comprising at least two Helicobacter pili polypeptides or fragments thereof selected from the group consisting of SEQ ID NOs: 98 to 194.